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Abstract 
 
Advanced glycation end products as a biomarker for 
accelerated ocular ageing and glaucoma 
 
Leanne Smewing 
 
 
Advanced glycation end products (AGEs) have a large impact on the healthy 
ageing population and those diagnosed with pathology. Studies have linked 
AGEs to glaucomatous optic neuropathy, however there is little consensus on the 
role AGEs play in glaucoma development. Furthermore, it is known that diet is an 
exogenous source of AGEs, however it is not clear how dietary AGE (dAGE) 
influences tissue-bound levels in the body. The overarching theme of this thesis 
was to assess the impact of AGE level, measured both through diet and tissue-
bound levels in the skin (skin autofluoresence, SAF), on retinal vessels and the 
cornea in healthy participants and patients diagnosed with ocular hypertension 
(OHT), early stage normal-tension glaucoma (NTG) and early stage primary open 
angle glaucoma (POAG). 
 
A UK-specific food frequency questionnaire (FFQ) was developed and found to 
reliable and valid. This newly designed FFQ was subsequently used throughout 
the thesis to measure dAGE. In healthy controls, the contribution of dAGE to 
tissue-bound AGE levels appeared to be minimal. The level of AGE taken in via 
diet was similar between healthy, OHT, NTG and POAG participants. 
 
Interestingly, tissue-bound AGE level (SAF) was found to be 16% higher in NTG 
and 14% higher in POAG than healthy control participants. Adding to the 
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evidence that SAF, as an accessible measure, may be a suitable long-term 
biomarker of glaucoma.  
 
Higher SAF was associated with narrower retinal arteries (CRAE) in a healthy 
population, adding to the evidence that AGEs may be an accessible marker of 
vascular health. The NTG group had a significantly narrower CRAE than healthy 
controls as well as the highest SAF level. Increased SAF was also associated 
with a less viscoelastic, stiffer cornea in the NTG group only. These findings pose 
interesting questions about the possible association of SAF with ocular rigidity 
and subsequent increased susceptibility to IOP or arterial blood supply related 
injury, however larger scale studies are needed before any conclusions could be 
drawn. 
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RGC   Retinal ganglion cell  
RNFL   Retinal nerve fibre layer   
RNS   Reactive nitrogen species 
ROS   Reactive oxygen species 
RPE  Retinal pigment epithelium  
RT  Reaction time  
RVP   Retinal venous pressure  
SAF   Skin auto fluorescence 
SBP  Systolic blood pressure 
SDRA  Sequential and diameter response analysis 
SOD  Superoxide dismutase  
sRAGE Soluble RAGE 
TF  Transferrin 
TM  Trabecular meshwork 
TNF-  Tumour necrosis factor 
UPLC–MS/MS Ultra-performance liquid chromatography tandem mass-spectrometry 
VEGF   Vascular endothelial growth factor  
VCAM1  Vascular cell adhesion molecule 1 
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Advanced glycation end products (AGEs) as a biomarker 
for accelerated ocular ageing and glaucoma 
 
 
 
1.  Introduction  
 
Globally, life expectancy has been rising and over the last two centuries it has 
more than doubled (1).  This rise however, is due to global improvement of health 
rather than an increase in understanding or slowing of the ageing process (1-3). 
Increased age is a significant risk factor for both ocular and systemic disease (4, 
5). Advanced glycation end products (AGEs) are a group of reactive compounds 
which accumulate gradually with age in cells, tissues and blood vessels 
throughout the body where they adversely affect structure and function. A 
sustained exposure to high levels of AGEs has been associated with the 
development of a number of chronic age-related systemic and ocular disorders. 
This body of research will utilise recent advances in technology to explore the 
role that AGEs may play in the acceleration of ocular ageing, as well as in the 
pathogenesis of neurodegenerative disease in the form of glaucomatous optic 
neuropathy (GON).   
 
1.1 Accelerated ageing  
The rate of ageing is not the same in all age matched individuals. The concept of 
accelerated ageing suggests that the presence of a number of specific genetic, 
environmental or systemic risk factors may cumulate to accelerate the ageing 
process in some individuals and lead to the development of age-related disease 
(5-7). Understanding the factors that influence accelerated ageing is vital for both 
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patient care and healthcare systems. As AGEs accumulate with age, the 
relationship between AGEs and accelerated ageing is an interesting one.  
 
1.2  Advanced glycation end products (AGEs)  
AGEs are a diverse group of reactive compounds produced naturally when a 
reducing sugar reacts with proteins, lipids or nucleic acids in a non-enzymatic 
way (8, 9). This reaction can occur endogenously within the body (8), and 
exogenously within food and tobacco (8, 10).  
 
It is the tobacco curing process that promotes the formation of AGEs, 
consequently when smoking tobacco, glycotoxins are directly inhaled into the 
lungs where they then form AGEs (10). Smoking also causes increased oxidative 
stress levels (11), which encourages AGE formation. The relationship between 
AGEs and oxidative stress will be discussed further in Section 1.6.  
 
Foods prepared by high heat cooking methods can promote deterioration 
reactions within the food products, including protein degradation, which can 
subsequently lead to AGE formation (12). The amount of AGE formed is 
dependent on a foods nutrient content and method of cooking; with formation of 
AGEs accelerating with exposure to heat (12-14). The relationship between 
AGEs and foods are discussed further in the ‘Dietary AGE’ Section 1.4.  
 
AGEs accumulate gradually with age in cells, tissues and blood vessels 
throughout the body, where over time they can adversely affect structure and 
function by; binding to specific cell surface receptors, forming covalent cross links 
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on proteins such as collagen, creating reactive oxygen species (ROS), and 
oxidative stress (15-19).  Each form of AGE has a complex structure with some 
displaying fluorescent properties (20). Due to AGEs accumulation in all tissues, 
including the skin, levels of AGE can be detected by skin biopsy and through 
measuring skin auto fluorescence (SAF) (21, 22). Skin biopsy is an invasive 
procedure that allows the collagen to be examined in the laboratory. Recent 
technology advances have produced a non-invasive means to measure AGEs by 
utilising SAF properties of tissue bound AGEs in the skin, examples of this 
include; the AGE Reader (DiagnOptics B.V., Groningen, Netherlands) and the 
TrūAge scanner (Morinda, Long Island City, NY) (21-24).  
 
1.3 Formation of AGEs 
AGE formation within the body is influenced by multiple factors such as levels of 
oxidative stress, blood glucose concentration and conversion and concentration 
of proteins (9). There are multiple mechanisms for the formation of AGEs and 
there are three that have been most studied (25). Firstly, the Maillard reaction 
has been studied since the 1900’s particularly by those interested in food, as the 
products from the Maillard reaction add a desired taste to foods along with a 
brownish colour (26). The two other most researched mechanisms include; the 
polyol pathway (27) and the autoxidation of glucose and peroxidation of lipids into 
dicarbonyls derivatives, by increase in oxidative stress (28). All three 
mechanisms are shown in Figure 1.1.  
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Figure 1.1: Formation of AGEs. Green pathway shows the Maillard reaction, blue pathway shows 
the Polyol pathway and purple pathway shows autoxidation of glucose and peroxidation of lipids 
into dicarbonyls derivatives.   
 
 
 
The Maillard reaction is shown in green in Figure 1.1. The first step of the 
reaction is the formation of a Schiff base which has the general structure shown 
in Figure 1.2; it is formed by glucose reacting with a free amino acid. This occurs 
through the nucleophilic addition of a free amino acid from a protein or DNA to 
glucose (8). This reaction takes place over hours and is concentration dependent; 
a decrease in the concentration of glucose would enable the Schiff base reaction 
to be reversed (15). The formation of more stable Amadori products, also known 
as early glycation products, takes a number of days (29, 30). Although more 
stable than a Schiff base the reaction creating Amadori products is still a 
reversible one (8). Amadori products continue to accumulate over a number of 
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weeks where they undergo intra and intermolecular rearrangements via oxidative 
or non-oxidative pathways to create AGEs. This final stage in the Maillard 
reaction is irreversible (15, 31, 32). 
 
 
 
 
 
 
 
 
 
Figure 1.2 – General structure of a Schiff base 
 
 
The alternative pathways to the Maillard reaction are shown in purple and blue in 
Figure 1.1, these pathways occur at a faster rate than the Maillard reaction (33). 
The purple pathway illustrates the autoxidation of glucose and peroxidation of 
lipids, by increase in oxidative stress, into α-oxaldehydes (glyoxal, methylglyoxal, 
and 3-deoxyglucosone) also known as dicarbonyl derivatives. The reaction of the 
α-oxaldehydes with monoacids then produces AGEs (34). The blue pathway is 
known as the polyol pathway. Here glucose is reduced into sorbitol, which in turn 
converts to fructose which then converts to α-oxaldehydes. In the same 
mechanism as previously the α-oxaldehydes react with monoacids to produce 
AGEs (27).  
 
It can be seen from Figure 1.1 that, as a result of the differing pathways of 
production, there is more than one type of AGE, each with different structure and 
properties. Ahmed (2005) categorised AGEs based on their chemical properties, 
R1 R2 
R3 
C 
N 
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creating three subgroups; fluorescent cross-linking AGEs, non-fluorescent cross-
linking AGEs and non-cross-linking AGEs (30). N-Carboxymethyl-lysine (CML), 
N-Carboxyethyl-lysine (CEL), pentosidine, Methylglyoxal-derived 
hydroimidazolone 1 (MG-H1) and pyrraline are some of the most studied AGEs 
and have been previously used as biomarkers for in vivo formation of AGEs (30, 
35-37). The AGE glucosepane, a lysine-arginine product, as shown in Table 1.1 
is a non-fluorescent cross-linking AGE. Although glucosepane previously has had 
less use as a biomarker compared to other AGEs, it is now thought to be one of 
the most abundant AGEs in human tissues (38, 39) and is becoming more widely 
studied. Table 1.1 shows examples of the AGE types mentioned applied to each 
category.  
 
 
Category AGE 
Fluorescent cross-linking AGEs Pentosidine 
Crossline 
Non-fluorescent cross-linking 
AGEs 
 
Imadazolium dilysine 
Alkyl formyl glycosyl pyrrole 
Arginine–lysine imidazole 
Glucosepane 
Non-cross-linking AGEs 
 
Pyrraline 
N-Carboxymethyl-lysine (CML) 
N-Carboxyethyl-lysine (CEL)  
Methylglyoxal-derived hydroimidazolone 1 (MG-
H1) 
Table 1.1: Table categorising well-known AGEs 
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Meerwalt (2004) used the AGEs pentosidine, carboxymethyl-lysine (CML), and 
carboxyethyl-lysine (CEL) to look at AGE levels within the skin using skin biopsy. 
He showed that the fluorescent AGE pentosidine correlated with the non-
fluorescent skin AGE levels of CML and CEL. From this Meerwalt went on to 
validate skin auto fluorescence as a technique for measuring AGEs (21). The use 
of skin auto fluorescence as a measure of AGE levels is discussed further in the 
methods Section 3.3.2.4. 
 
1.4 Dietary AGE 
Foods are a source of exogenous AGE; AGEs are formed during the heating 
process of food (40, 41). In the past, AGEs derived from diet (dAGEs) were 
disregarded as a contributor to circulating AGE levels as it was thought that the 
absorption into the gastrointestinal system was insignificant. It has been shown 
however in multiple studies that dAGEs could have a substantial influence on the 
body’s AGE level and contribute to pathology (42-48). Diabetes is an example of 
this, higher consumption of dAGE is thought to have a pathogenic significance by 
contributing to insulin resistance (49). Although there is a body of literature 
suggesting dAGEs are a risk factor for increasing circulatory AGE levels, a pilot 
study by Piroddi et al. (2011) contradicts this, having looked at the dAGE CML 
and found it did not contribute to circulating levels of AGE in chronic kidney 
disease patients (50). Further research is needed to precisely define the dAGE 
AGE relationship.  
 
The process of heating foods, comprising of sugars and/or lipids and proteins, 
triggers the Maillard reaction, as described in Section 1.3. There are certain 
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influencing factors that determine the level of AGE within food namely; nutrient 
composition, humidity, pH, temperature, and length of time cooked (40). Low pH 
values are thought to slow the Malliard reaction (40), high AGE values are seen 
for foods cooked at high temperatures as well as by certain cooking methods; 
barbequing, grilling, frying and roasting (dry heat methods) (51). The length of 
time a food is cooked for is relevant too, however the temperature and type of 
cooking method is more significant to the AGE value (14, 36).  
 
The AGE carboxymethyl-lysine (CML) is a key type of dAGE and is fairly stable 
and inert, as such it is commonly used as a dAGE marker (14, 40). Goldberg et 
al. (2004) were the first to produce a table showing AGE content from various 
food groups, with 250 foods measured for CML content (40). Uribarri et al. (2010) 
developed upon this database and measured the CML present in 549 foods (14). 
Since then other dAGE databases have been produced (52), with Scheijen et al. 
(2016) measuring other AGEs in addition to CML (53). Dresden University of 
Technology are developing a large dAGE database which different authors can 
contribute to, it currently has measured values for a wide variety of AGE types 
including: CML, CEL, methylglyoxal, Amadori-Product, pentosidine, pyrraline and 
furosine (45).  
 
Foods such as fruits and vegetables in all of the databases have low AGE values 
recorded. The Goldberg et al. (2004) and Uribarri et al. (2010) databases found 
that foods with a high protein and lipid content have the highest AGE value, as 
illustrated by the fat and meat categories having much higher AGE values than 
other foods. Fats such as cheese have the highest dAGE although generally 
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these are eaten in smaller portions than meats (14, 40). The later developed Hull 
et al. (2012) and Scheijen et al. (2016) databases found that foods with a high 
sugar content such as chocolate, sweets and biscuits had the highest values, 
with these food categories having higher values than meats and cheeses (52, 
53). The differences in CML values for similar foods between the databases is 
thought to be due to a different in analytical measurement methods used (48). 
Table 1.2 is a summary of the published AGE databases.  
 
 
AGE database Type of 
AGE 
measured 
Method of 
measurement 
Units Number of 
foods measured  
Goldberg et al. 
(2004) (40). 
CML ELISA CML kU/100 g 249 
Uribarri et al. 
(2010) (14). 
CML ELISA CML kU/100 g 549 
Hull et al. 
(2012) (52). 
CML UPLC–MS/MS mg CML/100 g 257 
Scheijen et al. 
(2016) (53). 
CML 
CEL 
MG-H1 
UPLC–MS/MS mg CML/100g 
mg CEL/100g 
mg MG-
H1/100g 
190 
Table 1.2: Summary of published AGE databases. CML: carboxymethyl-lysine, CEL: 
carboxyethyl-lysine, MG-H1: 5-hydro-5-methyl-4-imidazolon-2-yl-ornithine, ELISA: Enzyme-linked 
immunosorbent assay, UPLC-MS/MS: Ultra-performance liquid chromatography tandem mass-
spectrometry  
 
 
A food frequency questionnaire (FFQ) is considered one of the most suitable 
methods to measure the intake of a specific nutrient, such as dAGE. FFQ’s are 
discussed further in Section 3.3.2.5 and Section 4.3.2. There are currently very 
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few FFQs specifically designed to target dietary intake of AGEs and there are no 
AGE specific FFQs that have been designed for a UK based population. Indeed, 
the only existing validated AGE specific FFQ is that produced by Luevano-
Contreras et al. (2013); which used the database produced by Uribarri et al. 
(2010) for AGE values, to measure dAGE in diabetic patients (54, 55). The 
Uribarri et al. (2010) database is the database most commonly used in the 
literature and has been used for both FFQ’s and food records (49, 54, 56-58). 
Hull et al. (2012) has been used by a 3-day food record (59), but no FFQ. 
Scheijen et al. (2016) database was used by the Scheijen et al. (2018) study 
which used the Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) 
non-AGE specific FFQ.   
 
When measuring the dAGE intake of two ethnicity groups with type 2 diabetes it 
was found that those with higher dietary intake of saturated fats had a higher 
dAGE level and those with a higher dAGE were more likely to have a moderate-
high cardiovascular disease risk (55). Animal (rodent) studies have shown that a 
diet high in AGE is associated with increased circulating AGE levels as well as; 
atherosclerosis, weight gain, diabetes progression, lower plasma insulin and 
intolerance to glucose (60-62). Uribarri et al. (2003) found that if human 
participants with renal failure were given a low dAGE diet the circulating AGE 
levels decreased (44). Similarly, Vlassara et al. (2002) found that if participants 
diagnosed with type two diabetes were on a reduced dAGE diet for six weeks 
there would be a reduction of both circulating AGE level and reduction in the 
inflammatory markers tumour necrosis factor  (TNF- and vascular cell 
adhesion molecule 1 (VCAM1) (43). In addition, it has been shown that giving a 
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single dietary oral AGE-rich liquid beverage (free from lipids) results in a rise in 
AGE serum levels. This serum AGE was measured 90 minutes after ingestion of 
the AGE beverage. Endothelial function was measured using flow-mediated 
arterial vasodilation, it was found that the AGE-rich beverage caused impairment 
of endothelial function (63). These studies suggest that restriction of dAGE may 
be a favourable approach for reducing the levels of AGE circulating within the 
body. Additionally they demonstrate the association between dAGE and 
circulating AGE level. Despite there being a number of dAGE studies the 
evidence has been questioned due to a lack of high quality randomised trials 
(64). 
 
1.5 Effect of AGEs on cells and tissues 
The accumulation of AGEs is important for the pathogenesis of different 
pathologies of the body (30). Endogenously AGEs are formed and accumulate 
where glycation reactions occur; in both tissues and bodily fluids. The damaging 
effects that AGEs have on tissues are primarily caused by their interference with 
protein function. There are two ways in which these damaging effects occur; one 
involves the cell surface receptor for AGE known as RAGE, the other is 
independent of RAGE, with AGEs causing direct damage to protein structure 
(30).  
 
1.5.1 AGE – RAGE binding mechanism 
AGE-binding receptors (RAGE) are scavenger receptors that mediate 
intracellular signalling (30, 65). They are expressed on a diverse range of cells; 
monocytes, macrophages, smooth muscle cells, vascular endothelial cells, 
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pericytes, podocytes, astrocytes, microglia, Müller, glia and retinal pigmented 
epithelial cells (65, 66). RAGE has the ability to bind non-AGE ligands, causing 
inflammation independent of AGE (67), making RAGE complex in itself.  
 
As shown in Figure 1.3, when an AGE binds to RAGE it causes cellular signalling 
reactions; mitogen-activated protein kinases (MAPKs) and phosphatidylinositol-3 
kinase (PI3-K) are activated, which in turn activate transcription factor kappa B 
(NF-B) (60, 61). NF-B is also activated due to the sudden increase in 
intracellular oxidative stress caused by NAD(P)H oxidase, created in response to 
the binding of AGE to RAGE (62, 63). Once NF-B is activated it triggers the 
nucleus to begin to transcribe genes for; tissue growth factor, thrombomodulin, 
endothelin-1 and VCAM1, as well as cytokines; interleukin 1 (IL-1 interleukin 
6 (IL-6), TNF-(60, 64). RAGE expression is increased by activation of NF-B; 
hence a positive feedback cycle is also present here. Essentially, the AGE-RAGE 
binding mechanism initiates a state of inflammation and oxidative stress. It can 
also disturb the functioning of the vascular endothelium, which normally acts to 
regulate blood flow to ensure it always meets the demand of the tissues, through 
its action on endothelin-1. Oxidative stress and endothelial function are discussed 
further in Sections 1.6 and 1.8.    
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1.5.2 RAGE independent mechanism 
The second mechanism involves AGEs causing direct damage to structure, 
properties and function independent of RAGE mediated events. AGEs can alter 
molecular recognition and protein binding (30, 38). In addition, as mentioned in 
Section 1.3, the AGEs pentosidine, crossline, imadazolium dilysine, alkyl formyl 
glycosyl pyrrole, arginine–lysine imidazole and glucosepane form covalent cross-
links (30, 68). Cross-linking can occur with short-lived molecules, however since 
time is a factor in cross-link formation it is thought that crosslinking occurs more 
often in long-lived proteins (69, 70), such as extracellular proteins collagen and 
AGE 
RAGE 
MAPK PL3-K 
NF-B 
NAD(P)H 
Nucleus 
Generation of pro-
inflammatory cytokines: 
IL-1 
IL-6 
TNF- 
Pro-coagulant state: 
Tissue growth factor 
Thrombomodulin 
 
Vasoconstriction: 
Endothelin-1 
 
Enhanced adhesion 
molecule expression: 
VCAM1 
Oxidative stress 
RAGE 
RAGE 
expression 
Figure 1.3 - AGE-RAGE interaction 
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elastin. The AGE induced cross-link alters the mechanical properties of the 
protein, in collagen these cross-links result in increased stiffness of tissues and 
reduction in elasticity (38, 71, 72). Since normal collagen function is essential for 
organs and tissues throughout the body (19, 73) collagen cross-linking can have 
an adverse effect on physiology. In blood vessels for example, cross-linking 
causes increased stiffness of the protein matrix and decrease elasticity/flexibility, 
which affects cell interactions, as well as cell function and integrity (32, 72-75). 
 
Recent research has found that as a result of their chemical, pro-inflammatory 
and pro-oxidant actions, sustained exposure to high levels of circulating AGEs 
could be a major factor in the development of a number of chronic degenerative 
age-related systemic disorders; diabetes (23), Alzheimer’s disease (76), renal 
disease (77), osteoarthritis (78), atherosclerosis (79, 80), as well as the ocular 
disorders; age-related macular degeneration (AMD) (22, 81), diabetic retinopathy 
(DR) (82, 83), cataract formation (81, 84-86),  primary open angle glaucoma 
(POAG) (20) and other neurodegenerative diseases (76). These links with age-
related disorders make AGEs and their mechanisms of damage an area of 
interest.  
 
1.5.3 Soluble RAGE 
Soluble RAGE (sRAGE) is different to the cell-surface RAGE described in 1.5.1, 
and is considered beneficial. Soluble RAGE contributes to the detoxification of 
AGEs (87). It does this by acting as a ‘decoy’ and competitor to RAGE, blocking 
RAGE-dependent responses (87, 88). It has been shown in a study investigating 
patients with diabetic retinopathy that sRAGE levels were significantly lower in 
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patients non-proliferative and proliferative diabetes compared to healthy controls 
and diabetic patients without retinopathy (88). In addition it has also been shown 
that levels of sRAGE are reduced in patients diagnosed with hypertension (89).  
 
1.6 Oxidative stress  
Oxidative stress is “an imbalance between oxidants and antioxidants in favour of 
the oxidants, potentially leading to damage” (90). Oxidation is the loss of 
electrons during a reaction, carried out by oxidants. Oxidants are products of 
normal cellular metabolism, though in pathological conditions involving 
inflammation and infection oxidants tend to be found in increased amounts. 
Oxidants can be referred to as ‘reactive species’, for example; reactive oxygen 
and nitrogen species (ROS/RNS) (91, 92). They come in two forms, free radical 
and non-radical species and both can be reactive (93). Free radicals are unstable 
molecules which are reactive due to the unpaired electron in their outer orbit (94). 
Free radicals derived from glycation cause oxidation of lipids and DNA as well as 
breaking down proteins (25, 30). Due to the glycation reactions involved in the 
formation of AGEs free radicals are often referred to in AGE literature.  
  
An antioxidant is “any substance that, when present at low concentrations 
compared with that of an oxidisable substrate, significantly delays or inhibits 
oxidation of that substrate” (91). Antioxidants are essentially able to ‘neutralise’ 
free radicals and reactive species as part of the protection mechanism for tissues 
of the body from the damage reactive oxidative species could cause (95, 96). 
Compounds of both oxidant and antioxidant form can be found in human diet 
(97). Vitamins A, C, and E are examples of anti-oxidants derived from foods that 
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are able to neutralise free radicals directly (98). However current clinical research 
on the effectiveness of dietary anti-oxidants at protecting the body is controversial 
as research is contradictory with no clear associations established (99). It has 
however been shown that a balanced diet is healthier than antioxidant 
supplementation (100, 101).  
 
Oxidative stress can cause damage to DNA, proteins, and lipids. It is understood 
that oxidative stress contributes to; atherosclerosis, cardiovascular diseases, 
stroke, diabetes, cancer, rheumatoid arthritis, post-ischaemic perfusion injury, 
age-related neurodegenerative diseases and ageing (93, 96, 102, 103). Oxidative 
stress contributes to neurodegenerative damage via the mechanism of free 
radicals attacking the neural cells (96). The harmful effect the reactive species 
has on cells leads to tissue damage, oxidative injury and ultimately apoptosis (96, 
104).  
 
In more recent years it has been shown that reactive species such as ROS and 
RNS are linked to more than just pathology. They can also act as part of redox 
signalling throughout the body (100). Although generally reactive species are 
thought of as harmful it is not fully understood how damaging they are, as it 
seems to depend upon the circumstances (105). The understanding of oxidative 
stress has principally come through standard laboratory conditions. Laboratory 
conditions are limited in that they may not be related to free radical biology within 
the body (105).  
 
34 
 
Since reactive species are particularly unstable they are challenging to measure 
directly. Oxidative stress biomarkers give an indication of the level of oxidative 
stress present in the body. These biomarkers are molecules that are involved in 
the reactions with reactive oxygen species (106). There are a variety of 
biomarkers that exist, a summary of some commonly used biomarkers are listed 
in Table 1.3.  The molecules; α- tocopherol (vitamin E), ascorbic acid (vitamin C) 
and malondialdehyde each have mechanisms relating to oxidative stress and will 
be used as biomarkers for oxidative stress in this thesis. Each biomarker is 
explained in Section 3.3.2.6.  These are recognised biomarkers of oxidative 
stress in ageing and POAG (107-109) and have been shown to be sensitive to 
variations in AGE levels (110). 
 
 
Oxidants  Descriptor  
Malondialdehyde (MDA) Product of lipid peroxidation 
4-hydroxynonenal (4-HNE) Product of lipid peroxidation 
Acrolein Product of lipid peroxidation 
8‐isoprostane Product of lipid peroxidation 
8-hydroxy-20-deoxyguanosine (8-OH-G) DNA lesion 
Antioxidants Type 
Ascorbic acid (vitamin C) Non-enzymatic antioxidant 
α- tocopherol (vitamin E) Non-enzymatic antioxidant 
Glutathione (GSH) Non-enzymatic antioxidant 
Glutathione peroxidase (GPx) Non-enzymatic antioxidant 
Uric acid Non-enzymatic antioxidant 
Carotenoids Non-enzymatic antioxidant 
Flavonoids Non-enzymatic antioxidant 
Transferrin (TF) Non-enzymatic antioxidant 
Superoxide dismutase (SOD) Enzymatic antioxidant 
Glutathione peroxidase (GPx) Enzymatic antioxidant 
Catalase (CAT) Enzymatic antioxidant 
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Table 1.3: Summary of oxidative stress biomarkers 
 
1.7 AGE and Oxidative stress relationship 
The relationship between AGE levels and oxidative stress is complex, with an 
increase in AGE levels having been shown to be both a cause and an effect of 
elevated oxidative stress (15). Oxidative stress contributes and accelerates the 
process of AGE formation (111). It is produced as a by-product of AGE formation 
and by the AGE-RAGE binding interaction; the interaction causes an intracellular 
generation of free radicals and oxidative stress, as shown in Figure 1.3 (112, 
113). There is a positive feedback cycle between AGEs and oxidative stress; 
hence AGE levels can be influenced by oxidative stress levels and vice versa. 
For this reason it is important to consider the AGE oxidative stress relationship 
when examining the effects of AGEs. 
 
Both AGEs and oxidative stress levels increase with age and are both able to 
cause pathological consequence (8, 45, 114). The majority of the literature 
differentiates between AGEs and oxidative stress, measuring each individually 
while discussing the known connection (8, 45, 115-117). However, there are 
examples in literature which use the terms interchangeably, with some using 
AGEs as biomarkers of oxidative stress (92, 118, 119). Further investigation of 
the AGE oxidative stress relationship may help to clarify if it is acceptable to 
interchange between these terms.  
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1.8 Endothelial function  
The vascular endothelium is a monolayer of cells which lines the inner surface of 
all blood vessel surfaces, acting as the barrier to blood and vessel interactions 
(120-122) see Figure 1.4. It is a multifaceted tissue that maintains vascular 
homeostasis in response to mechanical, chemical and biological stimuli (121, 
123), through regulation of vascular tone, adhesion of cells, prevention of vessel 
wall inflammation, resistance of thrombus formation and resistance to smooth 
muscle cell proliferation (124). One of the fundamental roles of the microvascular 
endothelium is to regulate blood flow to ensure blood supply meets the demand 
of tissues, this is known as autoregulation. The endothelium controls this through 
the balanced secretion of endothelial derived vasoactive factors, the most potent 
of which are endothelin-1 (ET-1) and nitric oxide (NO) (125). ET-1 is a 
vasoconstriction agent and NO a vasodilation agent (126), they act on the 
underlying vascular smooth muscle to regulate blood vessel diameter, hence 
enabling regulation of the amount of blood that reaches a region to ensure supply 
meets demand.  
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Figure 1.4: Diagram representation of a blood vessel. 1: Tunica intima, 2: Tunica media, 3: Tunica 
externa.  
 
Endothelial dysfunction refers to a failure in the ability of the endothelium to 
regulate blood vessel diameter and hence blood flow when the metabolic 
demand of the tissues is high. This is usually due to either decreased NO or 
increased ET-1 production (127). Unable to maintain vascular homeostasis, a 
pro-inflammatory and pro-thrombotic state is more likely, as well as the formation 
of atherosclerotic plaques (123, 128).  A failure to increase blood supply to meet 
metabolic demand can leave the tissues ischaemic and repeated ischaemic 
episodes can cause damage through recurrent ischaemic reperfusion injury. 
Recurrent ischaemic reperfusion injury will be discussed in relation to GON in 
Section 1.13.2.2.  
 
Endothelial function is essential to vascular biology. Endothelial dysfunction has 
been associated with: ageing, smoking, obesity, diabetes, coronary heart 
disease, chronic renal failure, hypercholesterolemia, hypertension, peripheral 
vascular disease, stroke and severe infectious diseases (129-131). Oxidative 
stress, as well as other factors, has also been linked to the cellular imbalance 
which causes endothelial dysfunction (127). 
 
1.9 Relationship between AGEs and endothelial function 
AGEs have an influence on endothelial function. The AGE-RAGE interaction 
produces NFκB which is the transcription factor that causes an increase in ET-1 
levels (132). In addition, AGEs reduce availability and activity of NO (133). Hence 
38 
 
AGE-RAGE interaction has the overall effect of vasoconstriction, because ET-1 
levels are increased and NO levels, as a ‘relaxing factor’, are reduced, resulting 
in a dysfunctional endothelium.  
 
In addition to disturbing vascular endothelial function via the AGE-RAGE 
interaction, AGEs directly alter the functional properties of vessels due to their 
accumulation in vessel tissue (80, 134). Vessel walls are primarily made of 
collagen and elastin (135), as mentioned previously these long-lived proteins are 
susceptible to AGE cross-linking. This cross-linking results in a reduction in blood 
vessel elasticity and increased vascular stiffness (74, 80, 136). Animal studies 
have shown AGE cross-linking to be present on type I collagen, and found that 
increased vasculature stiffness occurs due to cross-links increasing the area of 
extra-cellular matrix (13, 137). In human studies aortic pulse wave velocity has 
been used as a method of measuring vessel stiffness. Semba et al. (2009) found 
a positive correlation between serum levels of CML and vessel stiffness (138), 
and Ueno et al. (2008) found a positive correlation between SAF and vessel 
stiffness (139). Reduced elasticity and increased vascular stiffness can also 
interfere with the ability of the blood vessels to regulate blood supply to meet 
demand, as blood vessel diameter cannot be so easily altered (74). 
 
The apparent associations of AGEs with endothelial dysfunction, oxidative stress 
and vascular stiffness, and the known associations of endothelial dysfunction with 
age-related ocular and systemic disease, raises the question as to whether 
increased AGE levels could be an underlying causative factor for such disease 
states. Exploring this association will be a focus of this PhD research.   
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Indeed, the effect of AGEs on blood vessel function occurs throughout the body, 
including in the ocular vasculature. Reduced function of the ocular blood vessels 
is important as it affects the regulation of blood flow to and within the eye. Altered 
blood flow is a known risk factor for ocular pathology (140) and can also be a 
marker for systemic vascular disease. Hence, increasing our understanding of 
the role that AGEs play in microvascular dysfunction at the ocular level may 
increase our understanding of ocular pathology.  
 
Measurement of microvascular function at the retinal level and examination of 
retinal vascular structure is possible with the Dynamic Retinal Vessel Analyser 
(DVA; IMEDOS GmbH, Jena). As will be explained in Section 3.3.2.2 in a normal 
healthy person heightened metabolic demand triggers the retinal endothelium to 
release additional NO, resulting in vasodilation and consequently increased blood 
flow. The DVA can analyse vessel structure and measure altered retinal vessel 
response to flicker light which is thought to indicate any impaired endothelial 
function (141). Using the non-invasive AGE Reader alongside this will allow the 
comparison of AGE level and retinal endothelial function. This is something which 
has not previously been investigated and may provide insight as to AGEs effect 
on retinal vascular function in healthy ageing and ocular disease. 
  
1.10 Advancing age as a risk factor for ocular disease 
A significant risk factor for both ocular and systemic disease is increased age (4, 
5). The ageing process is multifaceted, usually defined as deterioration of 
structure and function of cells and tissues throughout the body (142). The 
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cumulation of this deterioration causes increased risk of pathology, disease and 
death (143). The ocular cells and tissues are equally as affected by ageing as 
other cells and tissues in the body. Advancing age is a significant risk factor for a 
number of ocular diseases such as cataract (144), AMD (145) and GON (146). Of 
interest to this body of research is the role that ageing plays in the pathogenesis 
of the neurodegenerative disease glaucomatous optic neuropathy. Ageing is a 
risk factor for all neurodegenerative diseases and it is thought to exert its effects 
through mechanisms such as ; increased oxidative stress, mitochondrial 
dysfunction, impaired ability to self-repair; reduced DNA repair and decreased 
tissue regeneration (147). AGEs are associated with oxidative stress and their 
accumulation increases with age; hence AGEs may also be part of a 
neurodegenerative disease mechanism (148, 149). 
 
1.11 The effect of advancing age and AGEs on ocular structures  
The negative effect that physiological ageing has on structures of the eye will be 
discussed individually in this section, although it is important to remember that 
ageing of ocular components is not something that occurs in isolation, changes in 
certain structures has impact on others as a whole system. The structures in 
which AGEs accumulate within the eye will also be discussed.  
 
1.11.1 Sclera 
In spite of it having reduced collagen content, there is increased rigidity and 
stiffness of the sclera with age; it is thought that this rigidity is due to the 
accumulation of non-enzymatic cross-links. Girard et al. (2009) found that 
monkeys of increased age had a significantly stiffer posterior sclera. It is 
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postulated that this increased stiffness may cause overall globe stiffness and 
contribute to optic nerve head damage, contributing to glaucomatous changes 
(150). AGEs accumulate in the sclera (151) and could contribute to the increased 
collagen crosslinking that occurs with age.  
 
 
1.11.2 Cornea 
With physiological ageing the cornea becomes flatter, there is an increase in 
thickness of Descemet’s membrane, decrease in stromal density and a decrease 
in the density of endothelial cells (152-154). In the stroma there is an increase in 
collagen fibrils and collagen cross-linking (155) but no change in the thickness of 
Bowman’s layer with age, however calcific deposits at the periphery of the layer 
become more likely (7). Consequently there is a change in corneal curvature and 
a variation in thickness of structures which results in the cornea becoming stiffer 
(156). Stiffening as a result of collagen cross-linking has been shown to be 
beneficial in the treatment of keratoconus and is thought to be beneficial in 
treating other corneal conditions (157).  
 
It has also been shown that there is an increase in AGEs in the stroma with 
increased age (158). It is thought that collagen modified by AGEs may contribute 
to the reduced corneal flexibility seen with ageing due to encouraging an increase 
in collagen fibrils (159, 160). Hence AGEs may be a contributing factor to the 
reduced corneal viscoelasticity seen with age. There is currently no research 
directly comparing tissue bound AGE levels to corneal viscoelastic properties. 
Corneal viscoelastic properties in relation to GON will be discussed in more detail 
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in Section 1.12 as it is relevant in understanding the mechanisms of 
glaucomatous damage. 
 
 
 
 
1.11.3 Trabecular meshwork 
The shape of the trabecular meshwork changes with physiological ageing; 
becoming shorter with the scleral spur more prominent, the uveal meshwork 
compacted, narrowing of the canal of Schlemm and increased thickening of 
trabeculae (161). There is a decrease in cellularity and absolute cell number with 
age (162). One of the postulated contributors to increased intraocular pressure 
(IOP) with age is that aqueous outflow is reduced and outflow resistance is 
increased (163). This is thought to be due to the changes in structure as well as 
reduction in giant vacuoles and intracellular pores in the canal of Schlemm 
through which aqueous humour passes (164, 165) and an accumulation of 
extracellular materials and changes to the collagen (163, 166, 167). In Section 
1.13.2.2.3 endothelial dysfunction is discussed in relation to GON as an 
imbalance in NO and ET-1 can affect outflow of aqueous humour in the 
trabecular meshwork, any dysfunction located here would ultimately affect IOP. It 
is suggested that AGEs accumulate in the trabecular meshwork (116) and that 
AGEs may induce the oxidative stress thought to contribute to dysfunction. 
 
1.11.4 Ciliary body 
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With increased age the ciliary stroma has an increase in collagen with some 
tissues replaced by collagen and the ciliary processes become shorter and less 
vascular. Similar to the trabecular meshwork, with age the ciliary body loses 
cellularity (7). The ciliary muscle appears to change with a displacement of 
muscle mass (168). As the ciliary body produces aqueous humour which 
ultimately affects IOP its ageing process is important.  
 
1.11.5 Intraocular Lens 
Lens shape and weight alters with physiological age; in adults the lens is more 
oval and heavier than at birth (169). Age related colour changes, yellowing, of the 
lens is a characteristic of cataract. It occurs with age due to lens proteins 
becoming oxidised (7). AGEs accumulate in lens (85) and are linked with the 
formation of cataract (81, 84, 170). The long-lived lens proteins crystallins are a 
site of glycation and cross-linking (170, 171), the modification to crystallin results 
in reduced transparency, and is thought to affect chaperoning and anti-apoptosis, 
resulting in cataract formation (170, 172, 173). The specific AGEs; CML and 
pentosidine have been found at increased levels in lenses with cataract 
compared to those without, with the intensity of brown cataract colour increasing 
with increased AGE level (86). In addition the AGE MG-H1 has been identified as 
a major AGE in human lens proteins (174). The lens capsule has more recently 
been identified as a glycation location, with different AGEs found at higher levels 
in capsules lenses with cataract than those without (171).  
 
1.11.6 Vitreous 
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Ageing causes structural changes in the vitreous gel, including liquefaction and 
posterior vitreous detachment (175). The vitreous gel is comprised of a 
transparent extracellular matrix. Through studying diabetic patients vitreous it has 
been suggested that AGEs have a pathologic role in the degeneration of the 
vitreous (176). 
 
 
 
1.11.7 Retina 
Ageing occurs throughout the layers of the retina, Figure 1.5 shows a cross 
Section of the retinal cells. The RPE will be discussed in the next Section with 
Bruch’s membrane.  As the retina ages the internal limiting membrane thickens 
and gliosis occurs in the peripheral retina (7). The nuclei in the outer nuclear 
layer become displaced, move towards the photoreceptor layer, where their cell 
structure changes, eventually ending in cell death (177). Reduction of rods 
occurs before cones at the macula with age (178). The retina has physiological 
age related peripheral degenerations; typical and reticular peripheral cystoid 
degeneration (179), peripheral chorioretinal atrophy (paving stone degeneration) 
(180), and lattice degeneration (181). Additionally, small masses of degenerate 
cells named Corpora amylacea have been found to be present in autopsied eyes 
in the; retinal nerve fibre layer and optic nerve, optic nerve head, inner plexiform 
layer and inner nuclear layer with increased age (182-184). Corpora amylacea in 
the central nervous system are associated with ageing and neurodegeneration 
(185). AGEs are present in the retina (81), the presence of AGEs in retinal blood 
vessels as will be discussed in Section 1.11.11. 
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Figure 1.5 – Cross section of retinal cells 
 
 
1.11.8 RPE & Bruch’s membrane  
With increased age the retinal pigment epithelium (RPE) begins to change shape, 
this occurs in two distinct regions of the RPE (186). The macula RPE alters by 
narrowing with an increased height, while the peripheral RPE becomes shorter 
and wider (187). With age, the RPE macula cells have increased pigment density 
and irregular pigmentation and in the ageing peripheral RPE vacuoles form (187, 
188). There is also an increase in lipofuscin accumulation in the cytoplasm of 
RPE cells with age (189). It is thought that lipofuscin accumulation in the RPE cell 
may contribute to the mechanism of macular degeneration (190). Drusen are 
found on the inner side of Bruch’s membrane, their accumulation come in 
different forms; hard, soft and confluent. With increased age there is an increase 
in presence of drusen. Soft, confluent and large drusen are seen in greater 
amounts in age-related macular degeneration (191). Bruch's membrane thickens 
with age (192) and also has an accumulation of lipids (such as cholesterol) and 
can also become calcified (193, 194). It is these accumulates that form a barrier 
that is linked with age-related macular degeneration, photoreceptor dysfunction 
and pigment epithelial detachment (193).  
 
AGEs accumulate in increased amounts in the RPE and basement membrane 
with age (81, 195-199), specifically the AGEs CML and pentosidine have been 
found in both the basement membrane and choroid with age (196). AGEs are 
thought to accumulate in the extracellular matrix of Bruch’s altering its physical 
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properties (200). This accumulation of AGEs induces VEGF, inflammation, and 
encourages neovascular AMD (22, 201). 
 
1.11.9 Choroid 
With age the thickness of the choroid does not change (192) but there is a 
decrease in choriocapillary density  (192). With advancements in OCT the 
volume of choriocapillaries can now be measured non-invasively. OCT data has 
also confirmed that choriocapillary density decreases with advancing age (202).   
 
 
1.11.10 ONH 
With physiological ageing there is an increase in the amount of connective tissue 
present in the fibrovascular pial septae of the ONH. This increased thickness 
could impair transmission of essential nutrients and metabolic substances 
between nerve fibres and capillaries (7). Another consequence of physiological 
ageing on the optic nerve head is that cellular and extracellular material can 
collect in optic nerve fibre bundles and meninges (7).   
 
It is the cribriform plates within the lamina cribrosa where AGEs accumulate 
within the ONH (203). It is thought that accumulation in this location may 
contribute to the mechanism of optic neuropathy (204). With age increased 
amounts of collagen cause the structure of the lamina cribrosa to alter, becoming 
stiffer and less resilient (203); when pressure is applied to the lamina cribrosa the 
ability to return to its original shape decreases (205). These age-related collagen 
changes are thought to be linked with age related glaucomatous optic 
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neuropathy. Along with an increase in the amount of collagen present in the 
lamina cribrosa, with age the AGE pentosidine has been found in increased 
amounts (203). The AGE pyrraline has also been located in the; sclera, pia 
matter, cribriform plates, optic nerve connective tissues and around the vessels in 
the optic nerve in donor eyes (204). The potential relationship between AGEs and 
GON is discussed in Section 1.11.4.1.  
 
1.11.11. The retinal vasculature and the influence of AGEs on vascular function  
With physiological ageing the body’s peripheral capillaries have a reduction in 
cellularity (206), hence the retinal microvasculature, as part of this peripheral 
network, also has a decrease in cellularity. Atherosclerotic and hypertensive 
vessel wall changes such as increased vessel wall thickness, are more likely to 
occur with ageing and as such ageing is a risk factor for both hypertension and 
atherosclerosis (7).   
 
Research into the effect of AGE accumulation within blood vessels and tissues in 
cardiovascular disease is increasing as it appears that AGEs are part of the 
disease mechanism (13, 138, 142, 207) and play an important role in 
atherosclerosis (208). With ageing the vessels within the body experience; 
endothelial dysfunction, reduced elasticity, accumulation of collagen and increase 
in intimal medial thickness (thickening of the innermost two layers of artery wall) 
(209, 210). Elasticity of the blood vessels is dependent on the level of collagen 
fibres and collagen cross-links (211). An increase in covalent crosslinks, as a 
result of AGE accumulation causes a reduction in blood vessel elasticity (136), as 
was discussed in Section 1.8. Reddy (2004) using diabetic rats, demonstrated 
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this mechanism (212) and other studies have shown that increased vascular 
stiffness correlates with increased AGE accumulation (13, 138). Furthermore, 
SAF measured by the AGE Reader has been shown to be an independent 
predictor of cardiovascular disease in diabetic, dialysis and coronary heart 
disease participants (139, 213-216).  SAF has also been shown to be a predictor 
for vessel AGE modifications in patients with coronary heart disease (216). 
Specific mechanisms linking AGEs and vascular endothelial function as well as 
vascular stiffness were discussed in Section 1.8.  
 
1.12 Current knowledge of AGEs and Ocular disease  
As explained throughout Section 1.11 AGEs accumulate throughout the 
structures of the eye and it is thought that they may be linked with both 
physiological and pathological age-related changes. There are certain specific 
conditions and structures that have been researched in more detail such as 
diabetic retinopathy, macular degeneration and diabetic keratopathy. The link 
between AGEs and GON is explained in detail in Section 1.13.4. A table 
summary of the AGEs and ocular disease literature can be found in Appendix 
Section 8. 
 
1.12.1 AGEs and Diabetic Retinopathy 
It has been estimated that there are approximately 93 million people worldwide 
with diabetic retinopathy, 17 million with proliferative diabetic retinopathy (217). 
Diabetic retinopathy is characterised by the development of blood vessels which 
are abnormally permeable, have impaired blood flow, basement membrane 
thickening, and ischaemia (218). Diabetic retinopathy is a complicated disease 
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with multiple pathological mechanisms, AGEs and AGE-RAGE interactions are 
thought to be one of these mechanisms (219). The link between hyperglycaemia, 
AGEs and diabetic retinopathy is becoming better understood, it has been shown 
that increased AGE level is correlated with increased diabetic retinopathy injury 
(220), with higher AGE levels found in those with proliferative retinopathy (221-
223). There is also a relationship between increased levels of the AGE CML and 
increased expression of vascular endothelial growth factor (VEGF) (134). In post-
mortem examination of retinas with background diabetic retinopathy and 
proliferative retinopathy both the AGE CML and VEGF were distributed around 
retinal blood vessels (134). The accumulation of AGEs on the endothelial 
membrane causes damage to the structure and function of the retinal vessel wall 
by increasing the permeability leading to vascular leakage (15). In addition, the 
thickening of vessel walls causes ischaemia and occlusion while increase in 
VEGF causes angiogenesis (224, 225).   
 
It has been shown that AGE levels within the skin, particularly CML, are a good 
predictor for diabetic retinopathy (226). It is thought that skin levels of AGEs are 
superior predictors of diabetic retinopathy than HbA1c as they reflect 
hyperglycaemia over a longer time course (83, 227). The advancements in skin 
auto fluorescent technology is important as this may be a future method for 
predicting diabetic retinopathy.   
 
1.12.2 AGEs and Age-related macular degeneration (AMD) 
AMD is a complicated disease thought to occur via multiple pathology 
mechanisms and not only due to ‘normal’ physiologic ageing. The exact aetiology 
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of AMD remains largely unknown, however the degeneration of the macula is 
caused by changes in the retina and choroid due to atrophy, detachment and 
neovascularisation (145).  
 
As mentioned in Section 1.11.8, AGEs accumulate in the RPE and basement 
membrane with age (195-199). AGEs are also found to accumulate within drusen 
(228). The alterations AGEs make to the basement membrane causes changes 
to the RPE proteome; with many proteins losing their physiological structure 
(229). The specific AGEs CML and pentosidine located in the basement 
membrane and choroid are thought to contribute to RPE-basement membrane-
choroid dysfunction (196), as mentioned, we know that Bruch’s membrane 
thickens with age becoming less permeable (192). It is thought that AGE cross-
link accumulation may be the cause of this thickening and decrease in 
permeability (201). As well as AGE contributing to AMD, RAGE accumulates in 
the RPE and photoreceptors of eyes with early AMD and geographic atrophy 
(199). It is thought that the AGE-RAGE interaction is related to photoreceptor 
loss, with NFκB, apoptosis and upregulation of RAGE having been observed in 
RPE cell cultures (199). Lipofuscin seen within drusen reduces the effectiveness 
of lysosomal antioxidant systems (230). The dysfunction of lysosomes has also 
been linked with reactive oxygen species and AGEs (173, 230, 231). Hence 
AGEs are not only located within drusen, but also encourage lysosome 
dysfunction, hence promoting drusen formation.  As AGEs accumulate they 
induce inflammation via VEGF, promoting neovascular AMD (201). Mulder et al. 
(2010) found that there was an increased SAF measured using the AGE Reader 
in Caucasian subjects with neovascular AMD (22). It is thought that AGEs are 
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both formed and deposited with increased AMD (22). It appears that AGEs affect 
the progression of both dry and wet AMD. 
  
1.12.3 AGEs and diabetic keratopathy 
Collagen is the principal structural component in the cornea and as mentioned 
previously in Section 1.4, AGEs are found to accumulate during normal ageing in 
long-lived proteins such as collagen (19). This accumulation of AGEs occurs at 
an accelerated rate in those with diabetes (73, 232). Diabetic corneas have been 
well researched in this area due to this. Sady et al. (1995) showed that the 
specific AGE pentosidine and increased collagen are found in higher amounts in 
diabetic corneas, compared to age-matched healthy controls (232). It has also 
been shown that there is an increase in AGEs in the stroma with increased age 
(158). It is thought that collagen modified by AGEs may contribute to the reduced 
corneal flexibility seen with ageing due to encouraging an increase in collagen 
fibrils (159). Measurement of the AGE CML in diabetic compared to non-diabetic 
corneas, has shown that CML accumulates in the epithelial basement membrane 
of diabetic cornea’s (233). A large accumulation of CML was present in the 
laminin, in the basal lamina (233). As the function of the laminin is to aid 
adhesion and migration it is thought CML reduces adhesion and dispersion of 
corneal epithelial cells and may be relevant in the mechanism of diabetic corneal 
epithliopathy. Kaji et al. (2003) found that accumulation of AGEs and reactive 
oxygen species, products from AGE formation, cause endothelial cell death 
(234). It has also been shown that patients with proliferative diabetes have an 
increased corneal AGE level compared to healthy age-matched controls (82). It is 
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hypothesised that increased corneal AGE level may contribute to the mechanism 
for diabetic keratopathy. 
 
1.13 Glaucoma and the influence of AGEs  
 
1.13.1 Glaucoma background 
Glaucoma is a degenerative optic neuropathy which is characterised by structural 
damage to the ONH and progressive visual field loss (235). Damage to the ONH 
causes retinal ganglion cell (RGC) death which can result in vision loss and 
visual field loss (236). Globally POAG affects over 60 million people, by 2020 it is 
expected that this will have increased to 80 million (237). It is estimated that the 
number of people living with glaucoma in the UK will rise in the coming years. 
Table 1.4 shows UK glaucoma epidemiology. 
   
 
Estimated number of people living with glaucoma  
 
 
2015 
(Population estimate  
65.1 million) 
2020 2025 2030 
Percentage 
change from 
2015 to 
2030 
UNITED 
KINGDOM 
598,560 626,300 655,080 668,400 12% 
Table 1.4: RNIB; key information and statistics (238). 
 
 
GON is commonly classified by: age of onset (acquired/congenital) then further 
classified by aetiology (239, 240). In the early 20th century an advancement in 
methods to view the anterior drainage angle (gonioscopy) enabled a 
differentiation in aetiology; open angle and closed angle glaucoma, each with 
different cause of damage (235, 240). Figure 1.6 shows the classification of 
glaucoma. This study is interested in acquired POAG. 
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Figure 1.6: Classification of glaucoma 
Further clinical separation of POAG patients into ‘high’ IOP and normal tension 
sub-categories has been common practice for many years; however NICE 
guidelines no longer subdivide open angle glaucoma based on IOP. The 
diagnosis ‘chronic open angle glaucoma’ (COAG) is used to describe primary 
open angle glaucoma with both normal and high IOP (241) as shown in Figure 
1.7. This links with recent research which has indicated that glaucoma may be a 
disease continuum, whereby the balance of mechanical factors (IOP) and 
vascular factors vary on an individual basis and therefore suggest that the sub 
divisions; POAG, normal tension glaucoma (NTG) and ocular hypertension 
(OHT), based on the Bedford glaucoma survey in the 1970’s are now outdated to 
describe GON and should be abolished (242-244).  
 
As shown in Figure1.7, OHT is the diagnosis given when there is a repeatable 
high IOP measured with applanation tonometry, with no presence of visual field 
defect or glaucomatous ONH signs (241). The subdivision OHT enables 
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practitioners to distinguish between patients with simply increased IOP from 
those with both increased IOP and glaucomatous changes (245). Although NICE 
guidelines no longer subdivide COAG based on IOP it is important for this body 
of research to distinguish between participants to allow comparison with OHT 
participants. When recruitment for this study opened the NICE guidelines defined 
high IOP as 21mmHg or above, the NICE guidelines changed increasing the IOP 
threshold in November 2017. Current NICE guidelines recommend IOP treatment 
to occur if a patient has an “IOP of 24 mmHg or more” (246). Section 3.1.3 
describes the sub-divisions used throughout this research.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: NICE guideline pathway for OHT and COAG (241). 
 
 
IOP is the most important risk factor for GON however it is not always associated 
with the disease. Knowing that glaucomatous changes can occur in those with 
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normal IOP indicates that more than one mechanism of damage can take place. 
Research into differences between NTG and POAG began in the 1980’s with 
some finding no significant difference between NTG and POAG (247, 248), and 
others finding that although total field loss between POAG and NTG were the 
same, NTG visual field defects were deeper, steeper, more localised and closer 
to fixation than in POAG (249-251). Hence there is still a disagreement in the 
literature as to if visual function differs between NTG and POAG.  
 
1.13.2 Glaucoma pathogenesis  
The exact pathogenesis of POAG is poorly understood, with two main theories, 
namely the mechanical theory and the vascular theory, having been proposed 
and a possible link to accelerated ageing having been made (20). High and 
fluctuating IOP linked with the mechanical theory are known factors affecting 
pathogenesis, it’s thought that changes in vascular function also play a significant 
role (120, 244).  
 
1.13.2.1 Mechanical theory 
Increased IOP has been identified as a cause of retinal ganglion cell death (236, 
252) and the role that elevated IOP may play in the development of GON is the 
central focus of the ‘mechanical theory’; which suggests that high IOP causes 
mechanical strain/pressure on the ONH (253). This strain on the ONH causes 
deformation of the cribriform plates of the lamina cribrosa, activation of glial cells, 
possible compromise of the vasculature and compression of optic nerve fibre 
bundles which ultimately leads to nerve fibre damage (253-255). IOP is a 
clinically modifiable factor and its reduction slows the progression of glaucoma 
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(253, 256). Due to our incomplete understanding of the mechanism of glaucoma, 
current treatment is focused on the reduction of IOP by medical and surgical 
treatment (246, 257, 258). Increased understanding of the other mechanisms in 
glaucoma would potentially enable expansion and improvement of glaucoma 
treatment.  
 
 
 
1.13.2.2 Vascular theory 
The vascular theory proposes that a compromised supply of blood to the optic 
nerve head causes retinal ganglion cell death (255, 259). Blood flow in POAG 
has been widely researched (260-263) and has been linked to increased severity 
of the disease (260, 261, 264). In the retina, reduced retinal arteriolar diameter 
has been found in glaucomatous eyes, compared to healthy controls and OHT 
patients (265). In addition, constriction of retinal arteries located near to the optic 
disc has been shown in POAG and NTG, which also correlated with extent of 
optic nerve head damage (266).  The reduced blood flow observed in 
glaucomatous eyes was previously thought to be a consequence of GON, as 
ganglion cell loss causes a reduction in number of blood vessels (120). However, 
research has shown that reduced blood flow occurs before optic nerve damage 
develops (267-269). In addition, reduced blood flow is linked with disease 
progression (270), leading to the conclusion that reduced blood flow could be a 
mechanism of damage in GON. Over recent years it has emerged that unstable 
blood flow, in the form of altered regulation of blood supply to meet demand, is 
more relevant to GON pathogenesis than a steady, constant reduced blood flow 
58 
 
(271, 272). An example which illustrates this well is multiple sclerosis (MS). MS 
causes a constant reduced blood flow which can cause atrophy, however 
glaucomatous optic nerve head signs such as excavation are not seen (273). 
Unstable blood flow in glaucoma has been hypothesised to result from the 
presence of disturbed autoregulation in these patients, as a result of endothelial 
dysfunction (274) and/or structural vessel wall changes (275). 
 
 
1.13.2.2.1 Autoregulation 
Ocular perfusion pressure (OPP) refers to the force of the blood flow through the 
intraocular vessels (120, 276), calculation shown in Chapter 3, equation 3.2. 
Under normal circumstances, if OPP falls autoregulation commences to make 
sure that adequate ocular perfusion is maintained (276, 277). This regulation 
occurs through automatic modification of vascular resistance i.e. vessel diameter, 
to ensure blood supply meets metabolic demand (276). Autoregulation occurs in 
the retina and ONH and is a neurovascular coupling response. This means that 
when the neural activity of the retina increases, it triggers the retinal vasculature 
to dilate to ensure that blood supply is increased, via the blood-retinal barrier, to 
meet the increased metabolic demand of the neurons. The endothelium plays an 
important role in the autoregulation of blood vessel diameter (120). Dysfunctional 
regulation is linked with endothelial dysfunction which has been shown to be 
associated with systemic factors such as systemic hypertension (278), 
cardiovascular disease (279), plus ocular vascular factors such as reduced OPP 
(279) and vasospasm (280).  
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Autoregulation of the retinal and ONH blood flow is only able to maintain blood 
flow within a certain range of OPPs. If OPP reduces to a level outside the 
capability of autoregulation, blood supply may not be able to be increased to 
meet demand, resulting in damage through ischaemia (276). Alternatively, if OPP 
is reduced to a level within the normal range for autoregulation but the 
mechanism is not functioning correctly, there is also the risk that ischaemic 
damage may occur (276). If blood flow regulation is dysfunctional the ONH is 
vulnerable to periods of ischaemia when demand is high, followed by periods of 
adequate perfusion when demand is low. This instability in blood flow can result 
in ischaemia-reperfusion injury and potentially GON as a consequence. 
Dysfunctional autoregulation is referred to in the literature as vascular 
dysregulation (275) and has been evidenced in glaucoma patients, both systemic 
(281) and ocular (282-285) with increased disturbance in those with NTG (286) 
and progressive GON (287).  
 
1.13.2.2.2 Primary Vascular dysregulation 
Primary vascular dysregulation describes an inherent inappropriate constriction 
(vasospasm) or inadequate dilation response of the microcirculation when 
stimulated which is present in some individuals (273). Within the eye the 
presence of primary vascular dysregulation could affect autoregulation, causing 
unstable blood flow and under/over perfusion to the retina and ONH hence 
increasing the likelihood of damage (273). It has been shown that vasospasm 
decreases OPP through increasing  vascular resistance in the central retinal 
artery of primary vascular dysregulation patients compared to healthy controls 
(288). Primary vascular dysregulation syndrome has been linked with the 
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development of GON (289), with vasospasm shown to alter ocular blood 
circulation in NTG and POAG patients (290, 291). This provides support for the 
role that altered vascular regulation appears to play in the pathogenesis of GON. 
 
1.13.2.2.3 Endothelial dysfunction 
Endothelial dysfunction is introduced and explained in Section 1.8 along with the 
molecules ET-1 and NO. The endothelium is important in the regulation of 
systemic and ocular blood supply. A decrease in the availability of NO and 
increase in ET-1 results in excessive vasoconstriction and as a result, blood flow 
dysregulation (292, 293). As explained above, the endothelium plays an 
important role in the autoregulation of blood supply to meet demand, through the 
release of the vasoactive agents NO and ET-1 that act to increase and decrease 
the diameter of the blood vessels according to metabolic demand.  A dysfunction 
of the endothelium and hence a failure in this autoregulation process can cause 
unstable blood flow to the ONH during periods of high neural activity, increasing 
the likelihood of glaucomatous damage through ischaemia-reperfusion injury 
(273). In NTG and POAG patients, levels of NO in the plasma have been found to 
be at a reduced level compared to healthy controls (294-296). ET-1 in the plasma 
has also been shown to be at higher levels in NTG (297, 298) and POAG patients 
(299, 300). In addition to ET-1 constricting vessels it has also been shown to 
facilitate an increase retinal venous pressure (RVP) (301). High RVP reduces 
perfusion pressure and hence reduces blood flow to ONH; which causes 
glaucomatous damage (301). In addition to indicating dysfunction by measuring 
plasma levels the clinical sign of ONH haemorrhages can be observed by viewing 
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the retina, ONH haemorrhages are associated with autoregulation and instability 
of ONH blood flow (302).  
 
Endothelial dysfunction has been observed in the systemic macro-circulation of 
patients with NTG (256). Although this is important as it supports the vascular 
theory, endothelial dysfunction of the microcirculation is thought to be affected 
prior to macro-circulation (303). As mentioned in Section 1.9, the DVA can 
analyse microvasculature structure and measure altered retinal vessel response 
to flicker light which is thought to indicate any impaired endothelial function (302, 
304). Garhofer et al. (2004) identified that POAG patients have a reduced venous 
dilation response compared to healthy controls (305). Further studies have 
shown that NTG patients have a reduced baseline-corrected flicker response 
(304) and found evidence of vascular dysfunction  in both early-stage POAG and 
NTG compared to healthy controls (243). These associations infer that patients 
with GON have impaired autoregulation due to endothelial dysfunction.   
 
As well as affecting the vasculature, endothelial dysfunction can affect the 
channels in the trabecular meshwork and canal of Schlemm. Endothelial cells line 
the trabecular meshwork channels, as outflow of aqueous humour occurs in the 
trabecular meshwork, any dysfunction located here would ultimately affect IOP 
(255, 293). Interestingly, levels of NO in the aqueous humour have been found to 
be significantly decreased in POAG patients (296) and in a separate study 
endothelin levels were found to be significantly higher than healthy control 
participants (299).  
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1.13.3 Oxidative stress and glaucoma 
As described throughout this glaucoma section, glaucoma is a multifactorial 
disease. Oxidative stress is one factor that has been linked with glaucomatous 
RGC death (236, 306-311). Oxidative stress contributes to neurodegenerative 
damage via the mechanism of free radicals attacking the neural cells (96). The 
harmful effect the reactive species has on cells leads to tissue damage, oxidative 
injury and ultimately apoptosis (96, 104). It is thought that RGCs are susceptible 
to oxidative stress due to their high oxygen consumption (312) and light exposure 
(313).  
 
In addition to affecting RGCs, oxidative stress is also thought to affect IOP. It has 
been shown that glaucoma patients have reduced antioxidant activity in the 
aqueous humour, suggesting increased oxidative stress is present (307, 314, 
315). Increased levels of oxidative stress leads to inflammation, cellular loss and  
impairment and damage to trabecular endothelial cells (306, 316), affecting 
aqueous outflow and ultimately increasing IOP (317-319). As discussed in 
Section 1.13.2.1, increased IOP has been identified as a cause of retinal ganglion 
cell death.  
 
Oxidative stress is also related to the vascular mechanisms of damage linked 
with glaucoma. As explained in 1.13.2.2 recurrent reperfusion injury refers to the 
damage caused to tissue when blood supply returns after a period of ischemia. 
During ischaemia, the absence of oxygen impairs electron transport, resulting in 
unused electrons. When the tissue returns to normal the additional electrons 
react with oxygen which leads to the formation of ROS (320). Astrocytes in the 
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ONH are susceptible to ROS. When activated, the astrocytes produce abnormal 
molecules such as ET-1 and NO which alter the cell environment (321). The 
activation of astrocytes is thought to be one of the mechanisms initiating 
inappropriate apoptosis of RGC’s in glaucoma. In addition, ROS also impact the 
vascular endothelium by promoting endothelial dysfunction through reduction in 
the bioavailability of the vasodilator NO (322). 
 
The antioxidant glutathione (GSH) and total glutathione (t-GSH) in the plasma 
have been shown in glaucoma participants in be lower compared to healthy 
controls, suggesting a depleted antioxidant status, indicative of increased 
oxidative stress (323). A number of other oxidative stress biomarkers have also 
shown depleted antioxidant levels and increased pro-oxidants (107). Levels of 
the biomarker MDA has been found to be significantly correlated with glaucoma 
severity (109, 315). Recent studies have investigated reduction of oxidative 
stress as a possible treatment for glaucoma. The antioxidants alpha-lopoic acid 
delivered through the diet was found to decrease oxidative stress and increase 
protection of RGCs in mice (324). Similarly the antioxidant tempol was found to 
be beneficial in mice, the antioxidant caused a decrease in pro-inflammatory 
cytokines and decrease in decrease in NF-κB activation (325). The results of 
these animal studies suggest that antioxidant treatment may be a strategy for 
glaucoma prevention, although further research is required.   
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1.13.4 AGEs and glaucoma 
The possibility that GON may develop as a manifestation of accelerated ageing 
has been suggested by previous studies (20, 326), and due to the known 
associations between accelerated ageing and AGE accumulation (142, 327), it is 
logical to hypothesise that increased AGE levels may contribute to the 
pathogenesis of glaucoma. To date, there have been few clinical studies that 
have been able to directly explore the relationship between AGEs and the 
development and progression of GON due to methodology restrictions, however 
as previously discussed, a number of the known associates of elevated AGE 
levels, namely increased oxidative stress, vascular dysfunction and altered ocular 
biomechanics, have been previously linked to the pathogenesis of GON. These 
associations and their potential relationship with AGE levels in glaucoma will be 
discussed further in these sections with relevance to the mechanical and vascular 
theories of glaucoma to show how AGEs could be hypothesised to be related 
throughout the glaucoma disease continuum.  
 
1.13.4.1 AGEs in relation to the mechanical theory of GON 
 
1.13.4.1.1 Accumulation of AGEs in the ONH 
As discussed in Section 1.11.10 with age increased amounts of collagen cause 
the structure of the lamina cribrosa to alter, becoming stiffer and less resilient 
(203). These age-related collagen changes are thought to be linked with age 
related GON. As well as increased collagen present in the lamina cribrosa with 
age the AGE pentosidine has been found in increased amounts (203). 
Additionally Amano et al. (2001) investigated optic nerve specimens from diabetic 
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participants and the AGE pyrraline was located in the; sclera, pia matter, 
cribriform plates, optic nerve connective tissues and around the vessels in the 
optic nerve (204). Tezel et al. (2007) measured the accumulation of AGEs (CML) 
in glaucomatous and age-matched control donor eyes and found that there was 
increased AGE and RAGE presence in those with more advanced age and those 
with glaucoma (20). The AGEs were primarily detected in the cribriform plates of 
optic nerve head, while RAGE was seen on the glial cells, mainly the Müller cells 
(20).  It is thought that accumulation of AGEs in this region may have a role in the 
reduced ability of the cribriform plates to withstand strain and the increased 
rigidity of lamina cribrosa (20), leading to susceptibility to mechanical IOP 
induced damage (328).  
 
1.13.4.1.2 Accumulation of AGEs in the trabecular meshwork 
As previously explained in Section 1.5, AGEs accumulate in the extracellular 
matrix of tissues. In the trabecular meshwork the age related changes of the 
extracellular matrix is thought to contribute to increased outflow resistance (329), 
which in turn may contribute to elevated IOP in POAG (328). The decreased 
cellularity and structure changes of the trabecular meshwork may be attributed to 
AGE accumulation(116).  
 
The increased presence of AGEs in glaucomatous tissues and the fact that AGEs 
accumulate with age supports the accelerated ageing theory that GON and the 
ageing process is related (20). 
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1.13.4.1.3 Corneal biomechanics and the relevance of AGEs to glaucoma 
Corneal biomechanics is important as it is thought to be one of the hypotheses 
for why variations in IOP have a damaging effect on some optic nerve heads and 
not others (156). Central corneal thickness (CCT) and the curvature of the cornea 
are measurements known to influence measured IOP; eyes with increased CCT 
or steep corneas have an overestimated IOP, with the opposite true for 
decreased CCT or flat corneas (330). In addition, reduced CCT has been 
identified as an independent risk factor for GON (331, 332). The mechanism that 
causes this increased risk is not understood, although it is thought that improving 
the understanding of corneal biomechanics in eyes with reduced CCT may reveal 
a structural characteristic which makes the ONH more susceptible to damage 
(333).  
 
CCT and corneal curvature are important biomechanical properties however they 
do not entirely explain IOP variations. It’s thought that corneal hysteresis is a 
biomechanical contributor to this variance (156). Corneal hysteresis is an 
assessment of the cornea’s ability to absorb and disperse energy, defined as; the 
difference between inward force to flatten the cornea and outward recovery (334). 
The resistance calculated is in theory related to viscoelastic corneal properties 
(334). The cornea’s viscoelastic behaviour is primarily derived from the stroma, 
and the stiffness that is known to increase with age is due to changes in the 
cornea’s extracellular matrix (328, 335, 336). 
 
Corneal hysteresis in particular is of interest as lower hysteresis has been found 
in patients diagnosed with glaucoma (337), in addition corneal hysteresis has 
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been linked with progressive visual field worsening (337). Prata et al. (2012) 
similarly found that low corneal hysteresis is linked with glaucomatous nerve 
head signs; larger cup to disc ratio and increased cup depth (338), and in those 
with bilateral glaucoma, 75% of participants with lower corneal hysteresis had a 
larger cup to disc ratio (338). As explained in Section 1.11.2, AGEs accumulate in 
the collagen of the stroma with increased age (158) and encourage an increase 
in collagen fibrils (159). Hence it could be hypothesised that AGEs may be a 
contributing factor to the reduced corneal viscoelasticity seen with age and it 
could be further hypothesised that in individuals with elevated AGE levels, this 
age-related reduction in viscoelasticity could occur at an accelerated rate. There 
are no previous studies that have directly assessed the relationship between 
corneal hysteresis or viscoelasticity and tissue-bound AGE levels in healthy 
participants, or those with GON. It is possible that an increased rigidity of the 
extracellular matrix, not only in the cornea, but also throughout the structures of 
the eye, could contribute to overall ocular mechanical rigidity, including lamina 
cribrosa rigidity (338, 339).  
 
The inclusion of OHT participants enabled the relationship of the structural 
properties between POAG, NTG and OHT to be examined. OHT patients have 
been shown to have a higher corneal hysteresis compared to patients with POAG 
and NTG (340). It is hypothesised that this relates to overall rigidity. Corneal 
biomechanic properties measured between groups as well as SAF will allow 
examination between altered rigidity and AGE level.  
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1.13.4.2 AGEs in relation to the vascular theory of GON 
 
1.13.4.2.1 AGEs and endothelial dysfunction 
The relationship between AGEs and endothelial dysfunction is explained 
previously in Section 1.8 with regard to specifically how AGEs create an 
imbalance in ET-1 and NO. In glaucoma research it has been reported there is an 
imbalance of ET-1 and NO (294, 296, 300). The associations between 
endothelial dysfunction and glaucoma were explained in more detail in Section 
1.13.2.2.3. The exact relationship between AGE levels and microvascular 
endothelial function in healthy ageing and GON has however not previously been 
explored. It is possible that AGEs could potentially represent an underlying 
causative factor for retinal vascular dysfunction and hence could be suggested to 
contribute to the development of GON. The measurements taken by the DVA will 
help to indicate any impaired vascular endothelial function. 
 
1.13.4.2.2 AGEs and structural alterations in the vasculature  
As explained in Section 1.11.11 as part of the normal ageing process the vessels 
within the body experience; endothelial dysfunction, reduced elasticity, 
accumulation of collagen and increase in intimal medial thickness (209, 210). 
Elasticity of the blood vessels is dependent on the level of collagen fibres and 
collagen cross-links (211). AGE accumulation causes an increase in collagen 
covalent crosslinks (341), as a result there is an increase in stiffness of arteries 
(342).  AGE accumulation also causes an increase in cross-links within elastin 
which also causes a reduction in blood vessel elasticity (136, 342). As discussed 
in Section 1.8 Reddy (2004) using diabetic rats, demonstrated this mechanism 
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(212) and other studies have shown that increased vascular stiffness correlates 
with increased AGE accumulation (13, 138). Stiffness of arteries is a recognised 
risk factor for cardiovascular diseases (343). Increased systemic arterial stiffness 
has been shown in diabetic patients with glaucoma (344) and Mroczkowska et al. 
(2013) found evidence of vascular dysfunction in both POAG and NTG (243). 
However the relationship between increased vascular stiffness and glaucoma 
remains controversial as other studies have found relationships but none of which 
are statistically significant (345, 346). Altered dynamic retinal vessel function has 
been hypothesised to be linked to increased arterial stiffness and altered retinal 
vessel calibres infer an alteration in stiffness (304). Structural alterations in the 
retinal vessels will be analysed using the StaticVesselMap2 software (see 
Section 3.2.2.2.2).  
 
1.13.5 AGEs measured with SAF in glaucoma 
Only a few studies have used the AGE Reader (DiagnOptics B.V., Groningen, 
The Netherlands) and SAF in relation to glaucoma. The Schweitzer et al. (2018) 
study recruited 424 healthy controls and 31 POAG participants and found that 
high SAF was independently associated with an greater risk of glaucoma (115), 
they used SAF as a measurement of AGE level. A research group in Japan is 
also using SAF in glaucoma research (118, 119), however they use SAF as a 
biomarker of oxidative stress and not AGEs.  
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1.13.6 Summary of the potential mechanisms by which AGEs may link to 
glaucoma pathogenesis 
The relationship of AGEs with the tissues associated with glaucoma and 
evidence from oxidative stress suggest the association between AGEs and 
glaucoma require further investigation. The accumulation of AGEs and RAGE 
detected in glaucomatous retina and ONH’s as well as AGEs accumulation in the 
collagen of the cornea presents the theory that AGE accumulation in these 
structures may be linked with the mechanical theory of GON. AGE accumulation 
in blood vessels as well as their negative effect on vascular function links AGE 
accumulation with the vascular theory of GON. No one has yet directly explored 
retinal vascular structure and function relationship with AGEs. The DVA and 
StaticVesselMap2 will help to build a picture of how AGEs may be linked with the 
vascular theory of GON. As the degree of mechanical and vascular involvement 
is thought to differ between POAG, NTG and OHT patients, evaluation of AGE 
levels between groups may improve understanding of the role AGEs play in 
GON. Any role AGEs do have could potentially be altered by advice about 
reduction of dietary AGEs if these are also found to be associated.  
 
1.14 Strategies to reduce AGE level 
 
It has been evidenced that AGEs have a strong pathological significance.  As 
such research has been conducted with the aim of modifying/reducing AGE level, 
both exogenous and endogenous. 
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1.14.1 Restriction of dietary AGEs 
As shown in Table 1.2 there are databases which have measured levels of AGEs 
within foods. Using these databases multiple studies have investigated the effect 
of AGEs on diet, predominantly using ‘high’ and ‘low’ AGE diets then measuring 
the resultant circulating AGE level, oxidative stress biomarkers and inflammation 
biomarkers. These studies are discussed in Section 1.4 and also listed in a Table 
summary in Appendix 9. It is generally considered that a reduction in dietary AGE 
level is beneficial to circulatory levels, however how this translates to tissue 
bound levels is not known.  
 
1.14.2 Exercise and AGEs 
Initial exercise AGE studies used animals, predominantly exercise trained rats, 
and with increased exercise there was decreased advanced glycation (347, 348). 
There are a few exercise AGE studies in humans. A study by Goon et al. (2009) 
found that participants performing tai chi twice a week had reduced plasma AGE 
levels and reduced levels of plasma MDA compared to the matched sedentary 
participants (349). In a different study the AGE CML was measured in relation to 
activity measured by a pedometer. It was found that serum levels of CML 
decreased with increased number of steps, this correlation was significant (350). 
The results of a study by Habacuc Macías-Cervantes et al. (2014) however found 
that exercise alone did not reduce serum AGE level, restriction of dAGE did 
reduce serum levels of AGE and when this was combined with exercise there 
was an improvement lipid profile (351). 
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1.14.3 Pharmacological Interventions and AGEs 
Pharmacological interventions to reduce AGEs have been studied, they include 
agents that target AGE formation and reduce crosslinks as well as agents that 
block AGE-RAGE reactions (8). A few specific drugs have been studied in 
relation to AGEs. The drug metformin reduced serum levels of AGE in women 
diagnosed with polycystic ovary disease (352) and that the lipase inhibitor Orlistat 
also reduced serum AGE levels in women with polycystic ovary disease (353). In 
a group of diabetic patients with kidney disease it was found that the drug 
candersatan reduced CML levels measured from patient’s urine (354).   
 
As explained in Section 1.5.3, soluble RAGE (sRAGE) is different to the cell-
surface RAGE and is considered beneficial. Pharmacological agents have been 
studied in relation to regulating sRAGE. In a study using rats inhibiting the 
angiotensin-converting enzyme (ACE) resulted in increased expression of 
sRAGE (355). A relationship has been found between plasma levels of sRAGE 
and coronary artery calcium, with increased sRAGE inversely associated with 
coronary atherosclerosis (356). An atherosclerosis study found that the insulin 
sensitising thiazolidinedione medications increased levels of sRAGE (357). It is 
thought therefore that thiazolidinedione medications may be promising for 
regulating sRAGE (355). The pharmacological agents being researched are in 
the early stages of being trialled (358, 359), therefore effective safe treatments 
are not yet available to prescribe to patients.   
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2.  Research rationale  
 
AGEs are complex compounds with a potentially large impact both on the healthy 
ageing population and those diagnosed with pathology. Enhancing our 
understanding of the role that AGEs may play in accelerating the development of 
GON has the potential to offer additional insight into GON pathogenesis. 
 
Total tissue-bound AGE level in the body includes AGEs produced 
endogenously, via normal glycation reactions occurring within the body, and the 
AGEs that are taken in exogenously, mainly through diet or smoking (as 
discussed in Sections 1.2 and 1.4). Measurement of tissue-bound AGE levels via 
skin auto-fluorescence does not allow the relative contribution of exogenous 
(dietary) and endogenous sources of AGE to be determined, which can make 
targeted treatment difficult. Dietary AGE intake represents a potentially modifiable 
target (360), however there is currently no UK specific AGE FFQ to measure 
dietary AGE intake (14, 56). Through the design of a specific and targeted FFQ, 
this research will investigate the contribution of dietary AGE to tissue-bound AGE 
levels with the aim of evaluating the viability of dietary treatment as an option to 
reduce the overall levels of AGE in the body and potentially reduce the 
development of age-related disease such as glaucoma. 
 
When considering the influence that AGEs may have on the development of age-
related disease, it is important to also take into consideration oxidative stress. 
Evidence suggests that oxidative stress is also part of the normal ageing process 
(114), in addition to this there is a complex relationship between AGE levels and 
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oxidative stress levels in the body. Indeed, an increase in AGE levels is both a 
cause and an effect of elevated oxidative stress (9), with oxidative stress 
accelerating AGE formation and the production of free radicals, as well as being 
produced as a by-product of AGE formation and AGE-RAGE binding interaction 
(see Section 1.7) (112, 113). AGEs are considered to be pro-oxidant substances, 
due to their formation increasing the cellular level of oxidative stress (361, 362).  
 
To date, few studies have explored the possibility that AGEs may be an 
underlying causative factor for GON (20, 115, 204). It could be hypothesised that 
increased accumulation of AGEs could be the underlying causative factor for a 
number of the known pathological associations of GON and ultimately contribute 
towards its development in some individuals through acceleration of the ageing 
process. Establishing an association between AGE levels and these parameters 
in POAG, NTG and OHT patients therefore could increase our understanding of 
the pathogenesis of GON and potentially allow a new biomarker for accelerated 
ocular ageing, in the form of tissue-bound AGE levels to be realised. This 
evaluation is interesting as POAG, NTG and OHT are thought to have differing 
levels of vascular and mechanical involvement.  
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2.1 Research aims 
 
 To develop and validate an AGE specific semi-quantitative FFQ. 
 
 To determine whether dietary AGE intake and circulating oxidative stress 
levels are associated with tissue-bound AGE levels (SAF) in a healthy 
ageing population as well as to explore the influence of BMI, smoking 
history, alcohol consumption, body fat percentage and blood pressure on 
oxidative stress, SAF and dAGE, in the same population. 
 
 To determine whether tissue bound and dietary AGE levels are elevated in 
POAG and NTG in comparison to age-matched OHT patients and healthy 
controls. Oxidative stress levels will be compared as a possible influencing 
factor. 
 
 To determine how tissue-bound AGE levels are associated with static and 
dynamic retinal vessel parameters and corneal viscoelasticity in a healthy 
ageing population.   
 
 To evaluate whether level of tissue bound AGEs (SAF) relates to static 
and dynamic retinal vessel structure and function and corneal 
viscoelasticity in POAG, NTG and OHT patients. 
 
 To explore whether dynamic retinal vascular parameters are related to 
corneal viscoelastic parameters in HC, OHT, NTG and POAG patients.  
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3. Participants and Methods 
 
3.1 Recruitment  
 
All participants for the studies that make up this programme of work were 
recruited using convenience sampling. The study’s inclusion and exclusion 
criteria indicated which potential participants to approach. Written informed 
consent was received from all participants prior to study enrolment, and all study 
procedures were designed and conducted in accordance with the tenets of the 
Declaration of Helsinki. Four different participant groups were recruited for this 
study; healthy control, early POAG, early NTG and OHT.  
 
The study design ensured that the recruiter did not apply undue pressure. In 
particular, it was ensured participants were fully aware that there was no personal 
benefit in terms of specialist care. As a registered health professional, the ability 
to judge capacity to provide valid consent is a familiar challenge, as the ethical 
principles of giving informed consent are core to professional optometric practice. 
  
3.1.1 Participant recruitment  
3.1.1.1 Recruitment of participants with early stage Primary Open Angle 
Glaucoma, early stage Normal Tension Glaucoma and Ocular Hypertension 
POAG, NTG and OHT participants were identified through their attendance at 
their routine outpatient’s appointment at Derriford Royal Eye Infirmary (REI). 
Participants that fit the study inclusion/exclusion criteria were identified by Mr 
Adam Booth FRCOphth PhD (Consultant Ophthalmic and Glaucoma Surgeon at 
the REI, Derriford Hospital, Plymouth) or a member of his team, and provided 
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with information about the study. If willing, suitable participants were either 
referred directly for further information and given a copy of the patient information 
sheet (Appendix 2.3 and 2.5), or asked whether they were happy for their contact 
details to be passed on and to be contacted at a later date. 
  
3.1.1.2 Recruitment of healthy control participants 
Some healthy control participants self-presented for involvement in the study 
following advertisement and promotion of the study within and around Plymouth 
University and through our Centre for Eyecare Excellence (CEE). In addition 
some suitable friends and relatives of the glaucoma or OHT participants also self-
presented for involvement. After confirmation that the participant met the 
inclusion/exclusion criteria they were provided with the information sheet 
(Appendix 2.1).  
 
Active recruitment of healthy control participants was also carried out through 
CEE at Plymouth University. Any patient who appeared to fit the 
inclusion/exclusion criteria for the study was given the opportunity to participate. 
They were provided with verbal information about the study and given the 
participant information sheet to review after their routine eye examinations. In 
addition, CEE patients who had consented to being contacted for research 
purposes were contacted if they fit the study criteria. These participants were 
informed about the study and if interested, provided with an information sheet by 
post inviting them to participate. The participants were given time to consider 
their involvement in the study.  
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3.1.2 Consent 
Fully informed written consent was obtained at the outset of the study, in 
accordance with the principles of the Declaration of Helsinki (363) and Good 
Clinical Practice (GCP) (364). Persons who were deemed vulnerable or unable to 
give fully informed consent were not invited to take part. Participants were 
informed of their right to withdraw at any time, and no coercion or undue 
influence was used to encourage participation. A copy of the consent form can be 
found in Appendix 2. 
 
3.1.3 Inclusion criteria for all study groups  
• All participants had to be 50 years or older and have completed a 
comprehensive eye exam in the last two years.    
• Informed and written content was required for participation in the study and all 
participants had to have the capacity to give informed consent themselves.  
• All participants had to have adequate understanding of English language to be 
able to comprehend the oral and written instructions.  
• All participants had to be able to complete a 12-hour overnight fast, which 
includes no alcohol or caffeine.   
 
3.1.3.1 Definition of Ocular Hypertension (OHT)  
For the purposes of this study OHT was defined as intraocular pressure (IOP) 
above 21 mmHg with no significant visual field defect and no signs of optic nerve 
head damage. Central corneal thickness was required to be less than or equal to 
600 μm. Only reliable visual field results, with <20% fixation losses and <33% 
false positive and false negative responses were considered. The diagnosis of 
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OHT according to these criteria was made by Mr Adam Booth or one of his 
ophthalmology team.   
 
3.1.3.2 Definition of early stage Normal Tension Glaucoma (NTG): 
NTG patients were required to be in the early stage of their disease process and 
were only included if they met the definition outlined; for the purposes of this 
study early stage NTG was defined as patients with IOP equal to or below 21 
mmHg, with a mild glaucomatous visual field defect and/or optic nerve heads 
changes indicative of glaucoma. A mild glaucomatous visual field defect was 
defined as a Mean Deviation (MD) between 0 and - 6.00 dB along with either a 
Glaucoma Hemifield Test “outside normal limits” and/or a pattern standard 
deviation with p-value <0.05. Only reliable visual field plots, with <20% fixation 
losses and <33% false positive and false negative responses were considered. 
The diagnosis of NTG according to these criteria was made by Mr Adam Booth or 
one of his ophthalmology team.  
 
3.1.3.3 Definition of early stage Primary Open Angle Glaucoma (POAG)  
POAG patients were required to be in the early stage of their disease process 
and were only be included if they met the definition outlined; for the purposes of 
this study early stage POAG was defined as intraocular pressure above 21 
mmHg with a mild glaucomatous visual field defect and/or optic nerve head 
changes indicative of glaucoma. A mild glaucomatous visual field defect was 
defined as detailed for NTG participants as above. The diagnosis of POAG 
according to these criteria was made by Mr Adam Booth or one of his 
ophthalmology team.   
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3.1.4 Exclusion criteria 
Participants younger than 50 years were excluded, and there was no upper limit 
for age. This criterion was set since glaucoma is an age-related condition and 
has an older patient population (365).  
Participants were excluded if they were smokers or had a positive diagnosis of 
severe cardio- or cerebro-vascular disease such as coronary artery disease, 
heart failure, arrhythmia, angina, stroke, transient ischaemic attacks, peripheral 
vascular disease, severe dyslipidaemia, diabetes, as well as other metabolic 
disorders. Any individuals suffering from chronic systemic diseases known to 
influence oxidative stress or taking cardiovascular preventative medication, 
hormone replacement therapy or antioxidant supplements were also not included. 
The previous lists of exclusions from the study are due to the possible effects on 
AGE level, oxidative stress and vascular function. 
 
Participants with symptomatic cataract and/or cataract of grade 3.0 or above 
according to the Lens Opacities Classification System III (LOCS III) were 
excluded from the study because of the potential influences that cataract may 
have on the accurate conduction of DVA analysis. Due to the flicker light used in 
DVA testing any patients with photosensitive epilepsy were excluded from the 
examination.  
 
All of the healthy control participants were screened for glaucoma and other 
ocular disease and were excluded if any signs consistent with glaucomatous 
optic neuropathy, ocular hypertension or retinal disease found. The glaucoma 
patient group were also be screened for ocular disease other than glaucoma and 
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excluded if any other ocular disease was revealed. The glaucoma patients were 
required to be in the early stage of their disease process as the DVA analyses 
the microvasculature and in vascular disease microcirculation is believed to be 
affected earlier than macro-circulation (303, 304). In addition it is known that 
ocular blood flow decreases in glaucoma with increased damage (120), hence 
investigation of the blood vessels prior to any damage is necessary to investigate 
any underlying causative factor. Recruitment of patients in the early stage of their 
disease process also enabled progression follow up to be possible.   
 
A finger prick test was used prior to blood sampling to ensure the participant did 
not have high glucose levels. Normal blood sugar glucose levels after fasting 
were considered to be: 3.5–5.5 mmol/l, prediabetics/impaired glucose tolerance: 
5.6-7.0 mmol/l and diagnosis of diabetes: more than 7.0 mmol/l. If the participant 
had a fasting glucose level of 7.0 mmol/l or above they were be excluded from 
the study due to the already established link between diabetes and AGE levels. 
In addition their GP was informed of their high fasting glucose level.  
 
Potential participants incapable of giving informed consent due to reduced 
capacity, problems with communication or language that prevents that patient 
from fully understanding the procedure and nature of the study were excluded. 
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3.2 Ethical approval 
 
Ethical approval was received from the Health Research Authority (HRA), 
Plymouth Hospitals R & D department and Plymouth University Ethics Committee 
(Appendix 1). Written informed consent was received from all participants before 
participating in the study and all procedures were designed and conducted in 
accordance with the tenets of the Declaration of Helsinki.  
 
3.3 Methods 
 
All techniques described in this chapter were performed by the author, including 
phlebotomy and blood sample analyses. Prior to commencing recruitment full 
training was received for all techniques to ensure reliability of data collection. 
Phlebotomy training took place at Derriford hospital and lab analysis training 
provided by Dr Desley White. 
 
This programme of research will address six aims (Chapters four to nine). The 
methodology that will be implemented in this research is summarised in this 
section to provide an overview of techniques. All of the investigative techniques 
that form part of this research are detailed in Table 3.1.  
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Purpose 
 
Technique 
Ocular  
Assessment of ocular vascular 
function and structure 
Dynamic Retinal Vessel Analyser 
(DVA) 
Assessment of corneal biomechanics Corvis ST 
Systemic 
Measure height Stadiometer 
Measure weight and body fat 
percentage 
Tanita body composition analyser 
Measure blood pressure  Scian LD578 
Measure blood glucose  Freestyle Optium Neo glucose monitor 
Measurement of tissue-bound AGE AGE Reader 
Measure dietary AGE level Food Frequency Questionnaire (FFQ) 
Plasma analysis – Fasted venous blood sample 
Biomarker for oxidative stress Plasma levels of malondialdehyde 
(MDA) 
Indicators of antioxidant status Plasma levels of vitamin E 
Indicators of antioxidant status Plasma levels of ascorbate 
Table 3.1: Summary of the investigative techniques conducted in this research. 
 
 
 
3.3.1 Visit routine/procedures 
The procedures and visit routine are detailed in each participant information 
sheet (Appendix 2). The different techniques used to address each aim are 
stated in each individual chapter. The recruitment and clinical tests for all groups 
were recruited and measured simultaneously with no one group set of data 
collected first. 
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3.3.2 Specific methods 
3.3.2.1 General investigations 
A demographic questionnaire was used for all participants to collect information 
such as; date of birth, gender, ethnicity, education, smoking history, alcohol 
consumption, general and ocular health history as well as current medication. As 
well as providing this data, the demographic questionnaire also served as a 
‘check’ to ensure each participant met the inclusion/exclusion criteria. Data such 
as height, weight, body mass index (BMI) were collected and used to build a 
picture of overall health as well as aiding the match between healthy control 
participants and OHT, NTG and POAG participants.   
 
Height was measured in meters using a stadiometer. Participants removed their 
shoes and socks and were asked to stand with their feet flat on the floor and to 
stand tall. Weight was measured in kg, patients were asked to remove heavy 
items. Weight, basal metabolic rate (BMR), and body fat percentage were 
measured using the Tanita body composition analyser (TBF-300 MA). BMI was 
calculated by; Dividing the participant’s weight in kilograms by their height in 
metres, and then dividing the answer by the participant height again.  
Blood pressure was measured using a digital blood pressure monitor, Scian 
LD578 (GF Health Products., Atlanta, USA). The cuff size chosen for the 
measurement met the arm diameter requirements. A finger prick blood sugar test 
was performed prior to obtaining the blood sample to ensure normal fasting blood 
glucose levels. As mentioned previously (section 3.1.4), high glucose levels (7.0 
mmol/l or more) resulted in exclusion. A fasting venous blood sample was 
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obtained to enable the measurement of oxidative stress biomarkers, venesection 
and sample handling is described in Section 3.3.2.6.1.  
All healthy control participants and OHT, NTG and POAG participants had the 
health of their eyes examined and vision measured by the principal investigator 
(LS). Proxymetacaine 0.5% (Bausch & Lomb minims) drops were inserted and 
Goldmann tonometry performed. Tropicamide 0.5% (Bausch & Lomb minims) 
drops were inserted for pupil dilation which was required for dynamic and static 
vessel analysis with the DVA.  
 
Results from these general and ocular health investigations were used for 
vascular calculations. Mean arterial blood pressure (MABP) was calculated using 
the blood pressure results, shown in equation 3.1. Ocular perfusion pressure 
(OPP) was calculated using MABP and IOP result, shown in equation 3.2.  
 
 
MABP = 
𝟐
𝟑
 DBP +  
𝟏
𝟑
 SBP 
Equation 3.1: MABP: mean arterial blood pressure, DBP: diastolic blood pressure, SBP: systolic 
blood pressure 
 
OPP = 
𝟐
𝟑
  MABP - IOP 
Equation 3.2: OPP: Ocular perfusion pressure, MABP: mean arterial blood pressure, IOP: 
intraocular pressure 
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3.3.2.2 Dynamic retinal vascular function (DVA) 
The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) 
was used to assess both dynamic and static retinal vessel function. The DVA is a 
non-invasive device that evaluates the dynamic behaviour of retinal vessels 
through the continuous measurement of vessel diameter changes in response to 
flicker light provocation (366, 367). Dynamic retinal vessel parameters 
determined were baseline diameter fluctuation (BDF), baseline corrected flicker 
response (BFR), maximum vessel diameter, minimum vessel diameter, reaction 
time, percentage dilation and percentage constriction response. The DVA has 
been widely used as a measure of retinal microvascular function in both healthy 
ageing and ocular and systemic disease research (243, 368-370). Static retinal 
vessel parameters were measured using the VesselMap2 software on the DVA 
device. Measured parameters included central retinal artery equivalent (CRAE), 
central retinal vein equivalent (CRVE) diameters and arterio-venous ratio (AV 
ratio) (371).   
 
The DVA device comprises a fundus camera (FF450, Zeiss Jena, Germany), a 
digital high-resolution charged coupling device (CCD) camera, CCD video 
camera, a computer with analysis software and a printer (Figure 3.1) (366, 372). 
An additional green (red-free) filter is inserted for dynamic retinal vessel analysis 
as this provides contrast for vessel visualisation (366). This filter is removed for 
static vessel analysis.  
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Figure 3.1 - The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena) 
 
 
3.3.2.2.1 Technical specifications  
The DVA and static VesselMap2 technical specifications are summarised in 
Table 3.2. As well as being non-invasive the DVA has high reproducibility (373), 
low variability (374), while allowing different vessel segments of artery and vein to 
be measured simultaneously. However, the DVA has shortcomings; it relies on 
the participant being able to hold stable fixation for 350 seconds, clear media to 
ensure sufficient image quality. Dynamic vessel analysis requires full pupil 
dilation, and the calculations performed by the software assume that the eye is 
emmetropic. The VesselMap2 software is non-invasive and requires the 
participant to fixate for a short period of time (approximately 1 minute).  The 
vessel diameter for Vessel Map2 is measured in units (MU) (372), in Gullstrand’s 
‘normal eye’ 1 MU is also defined as 1 μm (375).  
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Table 3.2: Technical specifications of the DVA and Static VesselMap2 (372). 
 
3.3.2.2.2 Measurement of dynamic retinal vessel function 
The DVA uses flicker light to instigate a vessel response and assess dynamic 
retinal vessel function (376). Flicker light increases the neural activity of the 
retina, which in turn increases the metabolic demand of the retina (377, 378). In a 
healthy person this heightened metabolic demand triggers the retinal endothelium 
to release more nitric oxide (NO) which causes vasodilation and consequently 
increases blood flow to meet the increased demand (379), as Figure 3.2 
illustrates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Parameter 
 
DVA value Static VesselMap2 
value 
Spatial resolution 10 μm 10 μm 
Scaling factor 12.3 µm/Pixel * 7 >= ~ 85 
µm 
5.35 µm/Pixel * 7 >= ~ 
40 µm 
Image field angle 30 degrees 50 degrees 
Measuring time 350 seconds (although 
can be up to 10 min) 
2 min 
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Increased metabolic demand of 
the photoreceptors 
(Triggering neurovascular coupling response) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Pathway response to flicker light 
 
This process is referred to as neurovascular coupling, see section 1.13.2.2.1. 
Flicker light as a stimulus is useful as it has the ability to stimulate the retina 
without involving any other vascular/microvascular bed. When normally 
functioning, both arteries and veins respond to flicker light with dilation. The 
arterial response is typically more marked than veins. Furthermore, whilst the 
arteries react almost instantly, the venous response is delayed several seconds 
(380, 381).  
 
Flicker light 
12.5Hz 
Increased neural 
activity  
Retinal endothelium 
triggers increase in NO 
Vasodilation 
Increased blood flow 
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The DVA uses a flicker frequency of 12.5 Hz; this is within the maximum 
sensitivity (10-20 Hz) for the human visual system (380) and has been shown to 
be a suitable frequency for stimulation of retinal vessels (371, 376, 380, 381).  
The duration of exposure to flicker is 20 seconds as the maximum vessel reaction 
has been shown to occur during this time (380). After the 20 second flicker ends 
vasodilation ceases and vasoconstriction begins. During the baseline that follows 
the end of the flicker there has been shown to be an overshoot period that lasts 
6-10 seconds. Between 10-40 seconds after flicker has ceased the vessels will 
be at their minimum diameter, after which the vessel diameter returns to baseline 
(376, 380).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Dynamic profile of an individual’s artery and vein response.  
 
 
The camera is positioned to provide the optimal illumination and the participant is 
directed to fixate on a fixation needle. This needle can be moved to enable a 
centre view of the area of interest. The real time video monitor allows vessel 
selection where the practitioner deems most appropriate, see Figure 3.4. From 
this area a section of retinal artery and vein approximately 1 to 1.5 disc diameters 
 
 
 
 
 
 
 
 
 
 
Baseline 
BDF 
Time (seconds) 
91 
 
Fixation needle  
Section of 
retinal artery  
Section of retinal 
vein 
away from the ONH and approximately half a disc diameter in length was 
selected, tortuous vessels, vessels with crossings and vessels very close to one 
another were avoided as per the recommendation outlined by Imedos (372, 382, 
383).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Vessel selection for DVA measurement.  
 
 
The diameter of the vessel is calculated by an algorithm within the system which 
detects differences in reflectance. The selected portions of artery and vein 
automatically begin to be measured once the vessel selection is completed. Each 
selected vessel’s diameter is continuously monitored during the procedure (total 
of 350 seconds). The first 50 seconds of baseline measurement are conducted in 
apparent constant illumination (25 Hz).  This is followed by three flicker cycles 
(12.5 Hz) with 80 seconds of recovery (25 Hz) between each cycle, as shown in 
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Figure 3.5. This length of test and inclusion of three flicker cycles was designed 
to enable the calculation of an average vessel response within an acceptable 
testing time length (376).   
 
Figure 3.5: Visual display of measurement cycles during DVA testing 
 
 
 
The procedure outlined above is in accordance with established protocols for 
carrying out assessments with the DVA (382, 384). Before testing began 
systemic blood pressure and pulse rate was measured. All participants were 
instructed to avoid alcohol, tobacco, nicotine, extreme exercise, unnecessary 
sleep deprivation, caffeine containing products or any dietary 
supplements/vitamins 12 hours prior to the study session due to their possible 
effect on retinal blood vessel function (382). However, they were asked to 
maintain normal eating habits as fasting can cause abnormal vascular activity 
(385). As mentioned previously in the exclusion criteria 3.1.4, participants taking 
vasoactive systemic drugs were excluded.  
 
3.3.2.2.3 DVA dynamic output and parameters  
The DVA algorithm calculates a baseline measurement, the results are based on 
this and expressed as percentage to baseline (141). The DVA software can 
analyse the dynamic response profile, and this output has been used by multiple 
 
 
 
 
 
 
350  
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baseline 
20sec
Flicker 
80 sec 
Recovery 
20sec
Flicker 
80 sec 
Recovery 
20sec
Flicker 
80 sec 
Recovery 
0  50  70  150  170  250  270  
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studies (386-389). However the DVA software averages all three cycles in 
combination such that responses from individual cycles cannot be distinguished. 
It also makes its calculation of maximum vessel diameter using an average of the 
vessel diameter in the last three seconds of flicker and first three seconds post 
flicker (17-23 seconds) Therefore using this method alone individuals who reach 
maximum dilation outside of this specified time window would have their dilatory 
response underestimated (390).  In addition, the DVA software does not consider 
the baseline fluctuation of vessels diameter (BDF) that occurs in a normal resting 
state. This fluctuation is physiological and occurs due to arterial pulsation and 
vascular tone (384). Baseline corrected flicker response (BFR) is a calculation 
that accounts for BDF, it uses dilation amplitude (DA) and subtracts BFR to give 
BDF. This equation was established by Nagel et al. (2004) and has been used in 
other research using the DVA (243, 384, 390). For this reason, this thesis has not 
used the DVA software calculations.  
 
Sequential and diameter response analysis (SDRA) was developed by Heitmar et 
al. (2010), it uses raw data from the DVA, which allows BDF, DA and BFR to be 
calculated in addition to percentage dilation and constriction (141, 390, 391). In a 
similar manner to SDRA, this thesis uses the raw data from the DVA to calculate 
the relevant parameters, see Table 3.3 
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Parameter 
 
Description 
Baseline diameter 
fluctuation (BDF) 
The maximum range in vessel diameter 
during first 30 seconds of baseline readings 
(difference between max diameter and min 
diameter at baseline) 
Dilation amplitude (DA) Amplitude of the dilation response;  
difference between the maximum and minimum 
diameter (DA = MD – MC). 
Baseline corrected flicker 
response (BFR) 
Change in vessel diameter after  
considering the baseline diameter fluctuation 
(BFR = DA – BDF).  
Maximum percentage 
dilation (MD%) 
The percentage change in vessel diameter from 
baseline to maximum following flicker onset  
Reaction time (RT) Time taken to reach maximum diameter after 
flicker onset. 
Minimum percentage 
constriction (MC%) 
The smallest vessel diameter below baseline 
following cessation of flicker  
Constriction time (CT) Time taken to reach the point of maximum 
constriction following flicker cessation. 
Table 3.3: Parameters calculated from raw data used for analysis of DVA response used in this 
thesis 
 
 
The window of measurement for maximum percentage dilation was chosen to 
begin at 30 seconds, as the flicker commenced, and ended 10 seconds after 
flicker cessation to allow delayed dilation responses to be measured. Figure 3.3 
is an example of a participant’s dynamic profile, the maximum dilation for the vein 
response is during flicker, however the artery maximum dilation response is 
delayed. Minimum percentage constriction was measured from flicker cessation 
at 50 seconds, until 90 seconds. Again, setting a wider window allowed any 
delayed response to be recorded. 
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Figure 3.6: Dynamic retinal vessel analysis profile with parameters used labelled.  
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The three measurement cycles outputted from the DVA raw data were assessed 
for quality, the cycles were reviewed individually and graded for 
inclusion/exclusion. Firstly, the raw data was checked and any cycle with a large 
number of missing values was excluded, this was checked both by looking at the 
list of data and visually at the cycles produced. Figure 3.7 is an example of three 
reviewed cycles; cycle 1 and 3 would be included, however cycle 2 has missing 
data at 30, 45 and 65 seconds. Due to the number of missing values the second 
cycle would therefore be excluded.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Shows the three stimulation cycles for the selected artery and vein. In this example 
based on missing readings cycle 2 would be excluded and cycle 1 and 3 included.  
 
 
 
 
Cycle 2 artery Cycle 2 vein 
Cycle 1 artery Cycle 1 vein 
Cycle 3 artery Cycle 3 vein 
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Image noise artefact Measurement ‘jump’ to neighbouring vessel 
During the dynamic retinal vessel analysis trace artefacts can occur due to 
effects such as image noise, blinking, poor image quality, head or eye movement, 
change in illumination, and the measurement ‘jumping’ to a neighbouring vessel 
(392). Examples of common artefacts are shown in Figures 3.8 and 3.9. Cycles 
with a large number of artefacts were excluded.  
 
 
 
 
 
 
 
 
Figure 3.8: Illustration of common artefacts seen in the dynamic ‘real time’ trace 
 
 
 
Figure 3.9: The dynamic vessel trace of a participant in the first 14 seconds of measurement and 
the artefacts present.  
 
In addition to checking for missing values and artefacts in the ‘real time’ trace the 
data was smoothed over the whole 350 seconds to check once more for any 
artefacts or errors. Figure 3.10 and 3.11 show examples of a trace that would and 
would not be included.  
Image noise 
artefact 
Gaps in data due to blinking 
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Figure 3.10: Example of a real time trace with data that would be included 
 
 
 
 
 
 
 
Figure 3.11: Example of a real time trace with data that would be excluded 
 
 
3.3.2.2.4 Measurement of static retinal vessel parameters 
The VesselMap2 software (ImedosSystems, Jena, Germany) enables the retinal 
vasculature structure to be examined and evaluated (393). Static vessel analysis 
requires a disc centred red free fundus image. Insufficient image quality can 
result in errors when analysing, hence the device was set up to ensure optimal 
illumination and focused to produce the best possible images. Once the 
participant and equipment were in position 3-5 monochromatic disc centred 
fundus images were taken, the three best images were chosen to be analysed 
using the VesselMap2 software. Three images were taken as eye movements 
can cause vessel diameter variation as can pulse waves, the images taken were 
analysed and the average used to allow for this (375, 384).  
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Figure 3.12: Vessel Map 2 analysis of vessels 
 
 
 
Once the image was selected the ONH was manually marked with a 
superimposed ring. From this ring two additional superimposed rings were 
automatically generated by the software, with the first concentric ring 0.5 disc 
diameters (DD) away from the edge of the ONH, and the second 1DD away 
(394). The grader was then required to manually select all arteries and veins 
segments within the outer ring section, see Figure 3.12. The software 
automatically prevents selecting vessels 45 μm and smaller as vessels this size 
can be neglected (395), this is due to vessels this size having insufficient vessel 
edge resolution to be measured accurately (396). In accordance with the 
guidelines set out by the software manufacturers, the grader, who was the 
primary investigator, manually checked the vessel selections, ensuring that all 
branched vessels had the ‘branches’ selected and not the ‘trunk’ as well as 
ensuring each vessel has only been selected once. Once the vessels had been 
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selected the programme automatically included each vessel’s diameter to its 
Parr-Hubbard calculation and output CRAE, CRVE and AVR (393, 394), 
discussed further in section 3.3.2.2.5. As mentioned, the vessel selection was 
completed on each of the 3 images and the 3 sets of data output were averaged.  
 
Subjective assessment of AVR has traditionally been used by practitioners to 
assess static retinal vessel parameters, however  semi-automated analysis of 
AVR has been shown to be more reproducible, sensitive, specific and less 
observer-dependent (397). The parameters CRAE and CRVE are being 
increasingly used in research. Narrowing of CRAE is anticipated as part of the 
normal ageing process, as narrowing of arteries with age occurs throughout the 
body. However reduced CRAE has also been found to be associated with 
systemic hypertension (396, 398, 399) as well as kidney disease and heart 
disease (400, 401). Furthermore, an increase in CRVE has been found to be 
associated with obesity, dyslipidaemia, markers of vascular endothelial 
dysfunction (398, 402) and also associated with vascular dementia (403), 
diabetes (398, 404), cardiovascular disease and stroke (401, 405). 
 
CRAE and CRVE have also been linked with ocular diseases. An increase in 
CRVE has been linked with incidence of proliferative retinopathy, and an increase 
of both CRAE and CRVE linked with progression of retinopathy in type one 
diabetics (406). Age-related macular degeneration is associated with increased 
CRVE (407) and narrowing of CRAE is associated with POAG, however it is not 
known if this narrowing is a cause or result of neurone loss (265). As such, 
participants recruited for this research were required to be in the early stage of 
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their disease process. Although AVR is more familiar in optometric practice, it is 
ambiguous in that an alteration in the diameter of the artery and or an alteration 
in the diameter of the vein can each cause an altered AVR. CRAE and CRVE 
provide much more information on the state of the retinal vasculature and have 
therefore been shown to be more profound biomarkers for systemic and ocular 
disease.  
 
3.3.2.2.5 DVA static output and parameters  
Semi-automated measurement of retinal artery and vein diameters is being 
increasingly used in vascular research. The static VesselMap2 software 
calculates AVR, CRAE and CRVE using the disc centred red-free fundus 
photograph and manually selected vessels, described above, with the Parr-
Hubbard formula (396).  
 
The Parr-Hubbard formula combines the vessel diameter measurements taken 
from the concentric ring to create an estimate of the larger trunk diameters. 
These trunks are then combined to give a single estimation for artery and vein; 
CRAE and CRVE (393, 396, 397). The Knudtson formula is the alternative 
method used by some semi-automated software (408). Unlike the Parr-Hubbard 
formula the Knudtson formula is based upon selection of the 6 largest arteries 
and veins within the concentric measurement ring. Both of these formulas are 
effective hence choice between the two is not imperative so long as the same 
formula is applied throughout (394). The VesselMap2 software uses the Parr-
Hubbard formula hence this formula was used throughout this thesis.  
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The static output from the Vesselmap2 software is shown in Figure 3.13. It shows 
in the bottom left table the AVR, CRAE and CRVE for each image analysed. The 
three images for CRAE and CRVE are plotted on a graph, red cross for CRAE 
and blue cross for CRVE. In this example the three measurements are close to 
one another and this is reflected in the graph.  
 
 
Figure 3.13: Static vessel analysis results sheet from Vesselmap2 software 
 
Within this research CRAE and CRVE was used to assess vascular diameter 
changes in healthy ageing population as well as examining the narrowing or 
widening that takes place in the NTG, POAG and OHT groups. 
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3.3.2.3 Measurement of corneal parameters 
The viscoelastic properties of the cornea was assessed using the Corvis ST 
(Oculus; Optikgeräte GmbH, Wetzlar, Germany) (Figure 3.14). The Corvis ST is a 
noncontact tonometry system integrated with an ultra-high speed Scheimpflug 
camera which allows dynamic real-time inspection of the corneal deformation 
process; speed of deformation and corneal deformation amplitude as well as 
measuring IOP and central corneal thickness (CCT) (409, 410). Full list of 
parameters measured by the Corvis ST is listed in Appendix 7.  The parameters 
measured by the Corvis ST are linked with corneal biomechanics, an area of 
interest in relation to both AGEs and glaucomatous optic neuropathy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.14: Corvis ST (Oculus; Optikgerate GmbH, Wetzlar) 
 
The ultra-high speed Scheimpflug camera has a resolution of 640 x 480 pixels 
and frame rate of 4,330 images per second. The corneal deformation recorded 
with this camera is over 8.5mm horizontal coverage of the central cornea. The 
pachymeter used for measuring CCT has a measurement range of 200-1,200 μm 
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and uses corneal section images taken (without ‘air-pulse’ effect) (410, 411). The 
non-contact tonometer has a measurement range 6-60 mmHg (411). The 
tonometer air puff is applied to the corneal apex while the camera records the air-
pulse reaction of the cornea i.e. the cornea moving inwards and recovery 
outwards (409, 411). The Corvis-ST’s accuracy has been shown to be 
comparable with the gold standard equivalent techniques for IOP and CCT 
measurement (410).  
 
The Ocular response analyser (ORA) is also a non-contact tonometer and it 
measures two corneal biomechanical parameters. The parameter corneal 
hysteresis is used to represent corneal viscoelasticity and the parameter corneal 
resistance factor to indicate the degree of elastic resistance (334). Unlike the 
ORA the Corvis ST measures the deflection behaviour of the cornea as it 
deforms rather than describe a specific biomechanical characteristic (412). A 
previous study by Matsuura et al. (2016) found statistically significant correlations 
between Corvis ST parameters and ORA measurements, however these 
correlations were not strong (413). It is thought that this may be due to the Corvis 
ST measuring further parameters which may reflect features of corneal 
biomechanics not measured by the two ORA biomechanical measurements 
(413).    
 
 
 
 
 
105 
 
3.3.2.3.1 Corvis ST output and parameters  
The Corvis ST uses the captured sequence of images of the corneal deformation 
to calculate a range of parameters, the parameters used in this thesis are listed in  
Table 3.4 and Figure 3.15 shows the corneal deformation during the Corvis ST 
measurement.  
 
Table 3.4: Corvis ST parameters with descriptions. A1: first applanation 1, A2: second 
applanation. 
 
 
 
 
 
 
 
 
 
 
Parameter 
 
Description 
Time A1 (ms) Measures the time from the initiation of the air puff to the 
first inward corneal movement 
Time A2 (ms) Measures the time to second applanation / outward 
corneal movement 
Velocity A1 (m/s) Velocity of corneal surface movement at the first 
applanation 
Velocity A2 (m/s) Velocity of corneal surface movement at the second 
applanation 
Deformation 
amplitude A1 (mm) 
The magnitude of the movement of the corneal surface 
at the first applanation 
Deformation  
amplitude A2 (mm) 
The magnitude of the movement of the corneal apex at 
the second applanation 
Highest deformation 
amplitude (mm) 
The magnitude of the movement of the corneal surface 
at the highest concavity 
Highest concavity 
time (ms) 
Time from the initiation of the air puff to the highest 
concavity of the deformation of cornea 
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Figure 3.15: shows the corneal deformation during the Corvis ST measurement. (A) shows an 
image prior to air puff applanation, (B) shows an image in the first applanation, (C) shows an 
image at the highest concavity, and (D) shows an image in the second applanation (414).  
 
 
 
 
 
 
107 
 
3.3.2.4 Measurement of AGE levels 
 
As explained in Section 1.2 due to AGEs accumulation in the skin, tissue-bound 
AGE levels can be detected by skin biopsy. Although skin biopsy has been 
shown to be an accurate means of determining AGE levels, it is an invasive 
technique. The AGE Reader (DiagnOptics B.V., Groningen, The Netherlands) is 
a device which utilises the fluorescent properties of tissue-bound AGEs in the 
skin to provide a measurement of skin autofluorescence (SAF), which has been 
proposed as a marker for tissue-bound AGE levels (23). The AGE Reader is a 
non-invasive device, which has been suggested to provide a low cost, fast, and 
reproducible means of determining tissue-bound AGE levels in the body (21-23). 
In addition the AGE Reader has been validated and is comparable to skin 
biopsies (21).  
 
The protocol used for the AGE Reader is based upon the manufacturer’s 
instructions and previous research using the AGE Reader (21, 23). Each 
participant had the inside of their forearm measured for the assessment of SAF. 
The reader was set to take three measurements with the forearm repositioned for 
each repeated measurement. The average of the three SAF readings was 
recorded as well as average skin reflectance value. Self-tanning agents, sun 
cream and body lotion/moisturising cream were not permitted as they affect the 
SAF reading (415). As part of the appointment reminder participants were told to 
avoid all creams and lotions on their forearms. Noordzij et al. (2011) found that 
sun cream and self-tanning agents gave an SAF increase of >100% and body 
lotion increased SAF by 18% (415). They established that the hydration state of 
the skin did not influence SAF (415).  
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Figure 3.16: AGE Reader (DiagnOptics B.V., Groningen, The Netherlands)  
 
 
 
The AGE Reader as seen in Figure 3.16 is 280 mm wide, 150 mm deep with a 
height of 115mm. At the top of the machine there is a 4 cm2 window in the 
silicone mat through which the UV-A light is transmitted to enable direct 
illumination of the participant’s skin once the participants arm is resting on the 
silicone mat. The AGE reader contains an excitation light source which emits UV-
A light with a peak wavelength of 375 nm which excites the fluorescent AGEs in 
the skin, these AGEs have a fluorescence range of 300–420 nm. The 
autofluorescent light from the skin is then measured by the integrated 
spectrometer which has a detection range of 300–600 nm (416). The AGE 
Reader acquires 50 scans, each scan approximately 200 ms, dependent on skin 
reflectance, is used to create each measurement.  Each SAF measure takes 
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approximately 30 seconds, as mentioned this process is repeated three times as 
part of the software’s triple measurement programme, with the participant’s arm 
being repositioned, hence measuring a different section of skin after each 
measurement. The results are automatically displayed once the measurement is 
completed (see Figure 3.17 for patient measurement set up and Figure 3.18 for 
an example output). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 – Participant having SAF measured with AGE Reader  
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Figure 3.18: AGE Reader measurement report (417) 
 
 
The automatic calculation for SAF by the software corrects for light absorption, 
the result is a ratio between emitted light intensity (per nm) and excitation light 
intensity (per nm) multiplied by 100, with the result in arbitrary units (22, 23). 
 
Meerwaldt et al. (2004) validated the AGE reader by comparing SAF to skin 
biopsy assays in non-pigmented skin, SAF was found to be related to skin AGE 
accumulation (21, 418). Skin with darker pigmentation gives a lower SAF result. 
This has in the past resulted in studies excluding participants with dark skin 
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pigmentation from SAF studies (22, 419). Koetsier et al. (2010) validated a new 
algorithm which enabled SAF to be assessed in pigmented skin (Fitzpatrick skin 
colour classes 1-4) (419). Skin reflectance <6% (Fitzpatrick skin colour classes 5 
and 6) do not give the required reflectance, lower reflectance leads to a warning 
that the signals are too small to permit a valid analysis (416, 417, 419).  
 
Repeated SAF readings on the same day showed the AGE reader to have an 
error of approximately 5% (21). McIntyre et al. (2011) when repeating 10 SAF 
measures using the AGE reader that there was a variation of 7%. This result was 
obtained on a single patient by a single operator (420). Ideally there should be no 
variation of the equipment used on the same day with the same method of use; 
however a small degree of error such as this has been deemed acceptable.  
 
3.3.2.5 Measurement of dietary AGEs 
In this thesis, an assessment of dietary AGE intake over the previous 12 months 
was made using a FFQ that was designed specifically to assess dietary AGE 
levels in a UK population for the purposes of this research. This questionnaire 
was administered to all participants with the aim of providing an estimate of AGE 
consumption through diet (see Figure 3.19, full FFQ in Appendix 4.1).  
 
These is no single method to collect a participants nutritional status accurately as 
all measurements of food intake have an element of error (421). All methods are 
equally limited in that participants tend to under-report actual consumption and 
some also report what they consider as ‘healthier food’ rather than their true food 
consumption (34). FFQ was the method chosen for evaluating dietary AGE intake 
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in this research as it is suitable for large sample sizes, straightforward for 
participants to complete and is inexpensive (34, 54, 422). Additionally, FFQ’s are 
beneficial when aiming to measure a specific nutritional intake (423, 424), hence 
making FFQ a good choice for measuring dietary AGE.  
 
 
 
Table 3.5 Advantages and disadvantages of different dietary assessment methods  
 
Dietary 
assessment 
method 
Advantages Disadvantages 
Retrospective methods 
24 hour recall Long-term memory not 
required, small respondent 
burden, actual intake over 
the last 24 hours, relatively 
detailed intake data. 
Requires accurate memory of 
last 24 hours, if only 24 hours 
would not be representative – 
often multiple days required, 
time-consuming, moderate 
respondent burden. 
Food frequency 
questionnaire 
(FFQ) 
Useful for large sample 
sizes, cost effective, simple 
to complete/ small 
respondent burden, portion 
size can estimated to make 
the FFQ semi quantitative. 
Long-term memory required, 
requires accurate 
interpretation - ideally with 
computer software, requires 
accurate long-term recall, and 
is reliant on the participant 
having literacy and numeric 
ability. 
Non retrospective methods 
Weighed food 
records 
Actual intake recorded, 
detailed dietary intake data, 
no recall bias/no long-term 
memory required. 
Not suitable for large-scale 
studies, large respondent 
burden, time-consuming, 
multiple days required to 
assess usual intake 
Food record 
with estimated 
weights 
Actual intake recorded, 
relatively detailed dietary 
intake data, no recall 
bias/no long-term memory 
required. 
Not suitable for large-scale 
studies, relatively large 
respondent burden, time-
consuming,  multiple days 
required to assess usual 
intake 
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Figure 3.19 – Image of pages 1-4 of FFQ  
 
The only existing validated AGE specific FFQ is that produced by Luevano-
Contreras et al. (2013), the FFQ however was designed for use on diabetic 
patients in the USA. Luevano-Contreras describes in her validation paper that 
before being used in another population the FFQ requires further validation, due 
to the subjects having diabetes and there being a mean age of 56.6 years. 
Unfortunately further validation has not taken place (54). In its current format this 
FFQ does not therefore transfer well to UK based, non-diabetic populations, 
consequently the Luevano-Contreras FFQ was not appropriate to the population 
in this study and a new, targeted FFQ was developed.  
Validation of a newly designed FFQ is important to ensure that the nutrient, 
dietary AGEs, is measured correctly (425) as incorrect information could result in 
false associations (426).  The design and validation of this FFQ is discussed in 
full in Chapter 4.  
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3.3.2.6 Measurement of oxidative stress 
Plasma levels of malondialdehyde (MDA), alpha tocopherol (vitamin E) and 
ascorbate (vitamin C) were measured as biomarkers of oxidative stress. As 
explained in Section 1.6. these are recognised biomarkers of oxidative stress in 
ageing and POAG (107-109) and have been shown to be sensitive to variations 
in AGE levels (110). The relationship between AGE levels and oxidative stress is 
complex, with an increase in AGE levels having been shown to be both a cause 
and an effect of elevated oxidative stress (15).  
 
3.3.2.6.1 Venesection and sample handling 
The laboratory used for blood sampling and analysis is a Containment Level 2 
biosafety level environment, which follows University of Plymouth Codes of 
Practice for Control of Hazardous Substances, in line with the Control of 
Substances Hazardous to Health (COSHH) Regulations 2002. Blood and plasma 
processing and sample preparation were carried out in a level 2 biosafety cabinet 
which is serviced annually. COSHH regulations were followed for the disposal of 
potentially infectious waste. Blood cells were not used or stored, they were 
destroyed in line with COSHH regulations. Plasma samples were stored in a -80 
freezer until analysis took place. The plasma samples remaining after the end of 
processing were destroyed in line with COSHH regulations. All relevant material 
was disposed of with respect for the donor of the sample. 
 
Three 3 mL lithium heparin vacutainers, green top tubes as shown in Figure 3.20, 
were used to collect the blood samples. These were spun in a centrifuge at 20G 
for 20 minutes at 4°C. The separated plasma was then pipetted into serum tubes, 
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see Figure 3.21, ready for freezing. Two batches were created, with each batch 
stored in a different freezer at -80°C. Storing the samples in parallel follows the 
Human Tissues Act licence. Once samples from all participant groups were 
collected the analysis began. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 - 3 mL blood collection   Figure 3.21 - Serum tubes  
lithium heparin tubes        
 
 
3.3.2.6.2 Biochemical analyses 
Biochemical analysis of oxidative stress biomarkers was carried out by the 
primary investigator (LS). Samples from each group of participants were 
analysed once all data collection had ended.  
 
Ascorbic acid (vitamin C) is an essential nutrient. It is able to protect plasma lipids 
against oxidative damage from free radicals (427). The water soluble antioxidant 
ascorbate was measured by validated high performance liquid chromatography 
(HPLC) methods routinely used in the laboratory. Ascorbate was measured by 
the HPLC electrochemical method of Mitton and Trevithick (1994) (428), see 
Appendix 5.1 for method detail. The method allows the measurement of both 
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reduced and total ascorbate, from which the amount of oxidised ascorbate was 
calculated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.22 HPLC machine used to measure ascorbate (vitamin C). 
 
MDA was measured as an index of free radical activity and free radical damage. 
The rationale and methodology for this is that free radicals may oxidatively 
damage protein, phospholipid and DNA forming MDA. Hence MDA is a sensitive 
and robust marker of lipid peroxidation (429). For more than 30 years MDA has 
been used as a biomarker for lipid oxidation (430). MDA has been used as an 
oxidative stress biomarker in previous studies investigating glaucoma (109, 315) 
and it has also been shown to be sensitive to variations in AGE levels (110). 
MDA is routinely measured by reacting it with thiobarbituric acid which, under 
appropriate conditions, converts MDA to products which can be measured by 
HPLC. MDA was measured in the laboratory by the validated HPLC with 
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fluorescence detection method of Agarwal and Chase (2002) (431), see 
Appendix 5.2 for method detail. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.23. HPLC machine used to measure MDA 
 
The phospholipid bilayer molecules that make up the cell membrane are 
vulnerable to free radicals as they have an unpaired electron. The free radical will 
attempt to take an electron from the cell membrane molecule in the process of 
oxidation.  Vitamin E is a lipid soluble antioxidant, its role is to scavenge free 
radicals and donate an electron. This process protects the cell from any damage 
the free radical would have caused (432). Vitamin E occurs in eight forms, alpha 
tocopherol is the main lipid soluble antioxidant found in the plasma (433). For 
plasma vitamin E (α-tocopherol), the method is based on Julianto et al (1999) 
(434), using UV/vis HPLC detection, see Appendix 5.3 for method detail. Vitamin 
E plasma levels indicate the levels in cell membranes, where it protects against 
oxidative damage (433). 
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Figure 3.24. HPLC machine used to measure alpha-tocopherol (vitamin E) 
 
 
The methods described throughout this chapter have each been chosen to meet 
the five aims (Chapters four to nine). Each method used will be listed in the 
Chapters which follow. 
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4. Validation of a specifically designed semi-quantitative 
food frequency questionnaire (FFQ) 
 
 
4.1 Abstract 
Purpose: To design and validate a UK-specific food frequency questionnaire 
(FFQ) for use in advanced glycation end product (AGE) research and assess its 
validity and reliability. In addition this study aims to compare the different 
databases available to calculate dietary AGE. 
 
Methods: The newly designed FFQ was completed by 70 healthy participants and 
compared to plasma carboxymethyl-lysine (CML) levels and the outcome from a 
4-day weighed food record (4-day FR). Reliability of the FFQ was assessed in a 
sub-sample of the participants through the completion of a second FFQ one 
month after the first.   
 
Results: A relationship was found between dietary AGE (dAGE) values measured 
with the FFQ and that of the 4-day FR (n = 10, r = 0.894, p = <0.001, 95% 
bootstrap confidence interval 0.669 to 0.996). No significant relationship was 
found between dietary CML levels calculated from the FFQ and the plasma CML 
levels for 2 of the 3 dAGE databases used, a weak negative correlation was 
found between plasma CML level and dietary CML calculated with the Uribarri et 
al. (2010) database (n = 70, r = -0.256, p = 0.038, 95% bootstrap confidence 
interval -0.014 to -0.477). There was no significant difference in the dAGE values 
calculated across the two repeated FFQs (n = 20, p = 0.544).  
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Conclusion: The UK-specific semi-quantitative FFQ developed to measure dAGE 
was found to produce valid results when compared to a 4-day FR and to be 
reliable across completions. We were unable to validate the FFQ against the 
objective plasma CML-AGE measurement, however this could be due to the 
methodology used. The comparisons between databases suggests that they are 
more in line with each another than previously thought. 
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4.2 Introduction  
AGEs are a group of reactive compounds with chemical, pro-inflammatory and 
pro-oxidant actions. They accumulate with age in cells and tissues throughout the 
body where they contribute to an acceleration of the ageing process by adversely 
affecting structure and function.  AGEs exert their effects through binding to 
specific cell surface receptors, forming covalent cross links on proteins such as 
collagen and generating reactive oxygen species (ROS) and oxidative stress (15-
18). 
 
Strong associations have been demonstrated between elevated AGE levels and 
diabetes. Formation of AGEs is accelerated in hyperglycaemic conditions, and 
increased accumulation of AGEs has been associated with the occurrence and 
severity of diabetic complications (15, 23, 435), including diabetic retinopathy (82, 
83).  Independent of diabetes, it is also thought that sustained exposure to a high 
levels of circulating AGEs could be a major factor in the development of age-
related degenerative disorders such as Alzheimer’s disease (76), renal disease 
(77), osteoarthritis (78), atherosclerosis (79), as well as a number of ocular age-
related disorders such as age-related macular degeneration (22, 81), cataract 
(81, 84-86) and primary open angle glaucoma (20). 
 
Foods are an exogenous source of AGE, (40) and it has been shown that dietary 
AGEs (dAGEs) can influence the body’s total AGE level and contribute to 
pathology in a similar manner to endogenous AGEs (42-47, 64). A high dAGE 
intake has been shown to increase oxidative stress, inflammation and endothelial 
dysfunction (64, 436, 437). It has been well evidenced in diabetes that dAGEs 
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have a pathogenic significance. Cardiovascular risk factors have been shown to 
be increased in the presence of high intake of dAGE in patients with diabetes (43, 
438), and dAGEs are thought to contribute to insulin resistance (49). In addition it 
has been shown that patients with type 2 diabetes who have restricted dAGE 
consumption have lower levels of oxidative stress and inflammation, suggesting 
dAGE intake could act as a modifiable target (439). The evidence in this regard 
has been questioned due to a lack of high quality randomised trials (64). 
However, a meta-analysis of randomised controlled trials investigating a diet low 
in dAGE on cardiometabolic parameters had similar results to previous dAGE 
research, in that a lower dAGE intake was found to be beneficial (437).  
 
There is no gold standard method to determine a participants dAGE status, as all 
measures of dietary intake are known to carry an element of error (421, 440). 
Previous studies measuring dAGE have primarily used food frequency 
questionnaires (FFQs) and food records (FRs) (14, 54, 56). FRs have the 
advantage of not being retrospective and allowing portion size to be measured 
precisely (441, 442). In contrast, FFQs are suitable for large samples, 
straightforward to complete, and inexpensive (34, 54, 422, 442, 443). For 
measurement of a specific nutrient intake, such as dAGE, FFQs are considered 
to be most beneficial (423, 424, 441). To ensure that FFQ estimates of dAGE are 
representative of the population being investigated, the FFQ needs to be targeted 
to the food culture and preparation methods of the specific country or region (56). 
There is currently no UK specific FFQ to measure dAGE intake. 
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The AGE carboxymethyl-lysine (CML) has previously been used as a marker of 
dAGE (14, 40). The choice of CML as a dAGE biomarker is likely to be due to it 
being one of the wider studied AGEs as well as it being fairly stable and inert 
(14). However, it is known that other types of AGEs are present in foods (53, 
444). Additionally the published associations between elevated AGE levels and 
pathology incorporate multiple types of AGEs and not one individual type (23, 76, 
78, 435). In order to determine dAGE intake from the responses to a FFQ or FR, 
one needs to have knowledge of the relative AGE content of the listed foods.  
There are three different databases available that have calculated and listed the 
level of CML in foods (Uribarri et al. (2010) (14), Hull et al. (2012) (52) and 
Scheijen et al. (2016) (53)), with one of these databases (Scheijen) also listing 
the levels of  two additional methylglyoxal AGE derivatives (carboxyethyl-lysine 
(CEL) and 5-hydro-5-methyl-4-imidazolon-2-yl-ornithine (MG-H1)). Interestingly, 
the CML results of similar foods from each database differs from one another, 
this is thought to be due to a difference in the analytical methods used (53). The 
Uribarri et al. (2010) database uses an enzyme-linked immunosorbent assay 
(ELISA) method using a monoclonal anti-CML antibody, and Hull et al. (2012) 
and Scheijen et al. (2016) use ultra-performance liquid chromatography tandem 
mass-spectrometry (UPLC–MS/MS). This inconsistency makes the decision of 
which database to use for determining dAGE intake problematic, as outlined in 
detail in Section 1.4. 
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4.2.1 Aim 
The aim of this study was to design and validate a UK-specific FFQ for use in 
AGE research. In addition, this study aims to assess the reliability of the newly 
developed FFQ and to compare the dAGE outputs calculated using the three 
different databases. 
 
4.2.2 Hypothesis 
The newly designed FFQ will be related to plasma-CML level and 4-day food 
records and will be reliable. Dietary CML levels will be comparable between the 
Hull and Scheijen databases which use the same analytic method, but will not be 
comparable to the Uribarri database which uses a different analytical method.  
 
4.2.3 Validity, repeatability and reliability 
In this study, validity will be the term used to describe the probability that the 
method (the semi-quantitative FFQ) accurately measures dAGE (445). 
Repeatability is an evaluation of the variation in repeated measurements taken 
under the same conditions (446). Reliability is how consistent a result is when 
measured under the same conditions. Repeatability and reliability are often 
interchanged in the literature due to their similar definition (54, 447, 448). The test 
re-test of the FFQ in this study will be referred to as reliability, referring to the 
consistency of the FFQ to produce repeatable estimates of dAGE intake. 
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4.3 Methods 
4.3.1 Participants 
Convenience sampling was used to recruit participants who were eligible 
according to the inclusion and exclusion criteria for healthy ageing participants as 
detailed in Section 3.1.3. and Section 3.1.4. Due to the established link between 
diabetes and AGEs (449, 450), participants diagnosed with diabetes or 
participants found to have a high fasting glucose level were excluded from the 
study, as were current smokers, and previous smokers who quit less than 15 
years ago due to the link between AGEs and tobacco (10). Participants who 
reported a major change to their diet over the last 12 months were excluded.  
 
4.3.2 Development of the semi-quantitative FFQ 
A total of 178 foods and drink choices were included in the semi-quantitative FFQ 
that was designed for use in this research (Appendix 4.1). Although this may 
seem lengthy compared to an average FFQ (79 foods) (443), an increased 
number of food choices was also used by Luevano-Contreras et al. (2013) for an 
AGE specific FFQ (130 foods used) (54). The foods were listed individually, 
rather than in groups, as AGE values can differ greatly with different 
temperatures and cooking methods, this therefore was reflected in the number of 
food choices within the FFQ. For example rather than ‘beef’ listed once there was 
a recorded section for: roast beef, pan fried steak, grilled steak, stewed beef, stir 
fried steak strips, meatballs, fried burger, fast food burger, beef mince browned 
and other beef to reflect the relative difference in AGE levels. Using the Uribarri 
database for example, a pan fried steak would have a value of 22,630 CML 
kU/portion and stewed beef only 2391 CML kU/portion. This method of listing 
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foods rather than grouping is known to possibly cause participants to 
overestimate intake due to some people unintentionally ‘double counting’ certain 
foods (451).  
 
Careful consideration was given to the order in which the food and drink 
categories where inserted into the FFQ, as it is well known that errors are often 
made at the beginning of a FFQ and the format can initially be confusing to 
participants new to FFQs (443). The first section of the newly designed FFQ 
therefore focused on drinks, as drinks are known to have low AGE values (14, 
52, 53) and any errors would have a low impact on the dAGE result calculated 
from the FFQ. Dairy and meat sections followed this, as they are thought to have 
high AGE content and are therefore of most interest (14, 52, 53). According to 
Cade et al (2001), placing food groups of high interest in the middle to early 
sections of the FFQ allows the important information to be collected at a point 
where the participant understands the FFQ format, but before any fatigue or 
boredom sets in (443).  
 
Participants were required to indicate the frequencies at which they consume the 
various listed foods. The frequency options were based on the frequencies used 
in the European Prospective Investigation into Cancer (EPIC) FFQ (452). An 
example of the frequencies is shown in Figure 4.1. The full FFQ can be found in 
Appendix Section 4. 
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Figure 4.1: An example of a food listed and its frequencies displayed in the FFQ.  
 
The FFQ required participants to also consider portion size, to allow the most 
accurate AGE calculation, making this a semi-quantitative FFQ (453). The 
average portion size stated next to each food was based on the food standards 
agency portion sizes (454). Portion pictures were included at the beginning of the 
questionnaire, and the plate and cup used for these photographs was shown to 
the participants to ensure the most accurate recalled portion reporting possible 
(455-457). It has been suggested that photographs improve reliability of portion 
estimates (458). The pictures of the portion sizes concentrated on foods with a 
high protein and lipid content, as these are the foods which are thought to have 
the highest AGE value and therefore required the most accurate responses (14).  
 
All of the available databases that list the AGE content of foods were developed 
in different countries, the lists of foods measured and cooking methods reflect 
these cultural variations (14, 52, 53). It was therefore not possible to directly 
insert these listed foods and cooking methods into this new FFQ as they would 
not easily be translated by a UK population. In the development of this new FFQ 
therefore, all foods and cooking methods were ‘translated’ to traditional cooking 
method descriptions for the UK. Certain foods not eaten in the UK were omitted, 
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for example pop tarts. In addition, some foods commonly eaten in the UK were 
added, for example battered cod.  All adjustments to the list of foods excluded 
and included in the FFQ were approved by a registered dietitian. In addition to 
adjusting foods, space in the FFQ was added to allow participants to list any 
foods they eat which had not already been named. The addition of space to 
record other foods allowed a complete report of all foods eaten by participants.  
 
4.3.2.1 Procedure for completion of the FFQ 
Prior to data collection, the FFQ was piloted with 12 people to ensure it was easy 
to fill out and follow. The pilot study raised the issue that the columns showing 
foods eaten per month, week and day were difficult to separate from each other. 
Colour was added to help address this difficulty. There was also a query about 
the portion size of cheese, e.g. “how big is 30 g of cheese?”. An additional portion 
page was added at the end of the questionnaire to illustrate visually some other 
general portion sizes, such as 250 ml displayed in a mug and cup, 30 g 
cornflakes, 30 g of cheddar cheese as well as some other foods (see Appendix 
Section 4). These photos were taken on the same plate as previous portion 
photos. No queries about the names of foods or cooking methods were raised 
from these pilot questionnaires. All adjustments to the FFQ design were 
approved by a registered dietitian. 
 
Every study participant completed the FFQ, it was interview-administered with 
questions and prompts made by the primary-investigator throughout the 
questionnaire. This was appropriate as there were some open questions 
throughout the questionnaire; it also allowed the participant to raise any queries 
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about nutrient details and for these to be addressed, as well as helping to ensure 
accurate portion size was recorded where possible to add to the reliability of the 
resulting data (425, 459). A flow chart of food prompts used is detailed in 
Appendix 4.2. 
 
4.3.2.2 Calculation of dAGE from the FFQ   
It is standard practice when investigating diet to use a FFQ in conjunction with 
analysis software which can calculate nutrient content (460, 461). For example, a 
study that was part of EPIC-Norfolk study used a 130 item semi quantitative FFQ 
and the dietary assessment software FETA (FFQ EPIC Tool for Analysis) (462). 
There is currently no software which can calculate or analyse dAGE values. The 
FFQ responses were recorded and calculated using Microsoft Excel (Seattle, 
WA, USA).  
 
The dAGE consumption value was calculated by totalling the dAGE value for 
each food and portion selected in the FFQ and scaled up to its relative frequency 
eaten over the year. For example (using the Uribarri database) a 30 g portion of 
cheddar cheese has a dAGE value of 1657 CML kU; if a participant reported 
eating cheese twice a week then 1657 x 104 = 172328 CML kU is the dAGE 
value for cheese eaten in a year. The dAGE value was assigned using the three 
databases which have measured AGE content in foods (and drinks). These 
databases were introduced in Section 1.4 and the three that were used in this 
study to calculate dAGE were the Uribarri database, which measures CML in 549 
foods (14), Hull database, which measures CML in 257 foods  (52), and the 
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Scheijen database which measures the AGEs; CML, CEL and MG-H1 in 190 
foods (53), (see Table 2 in Section 1.4) 
 
As mentioned in Section 1.4 Dresden University of Technology are developing a 
large dAGE database which different authors can contribute to (444). It includes a 
wide variety of AGEs including; CML, CEL, methylglyoxal, amadori-product, 
pentosidine, pyrraline, furosine, however this database is not complete and has 
limited AGEs measured for certain food groups compared to others, for example 
the ‘milk and milk products’ section has values for seven types of AGEs, whereas 
‘meats’ only have one type of AGE measured (444). For this reason this 
database was not included in this study.  
 
Of the three databases, the Uribarri database lists the most foods and is the 
database most commonly used in the literature (49, 54, 56-58). Hence, to ensure 
findings were comparable to previous literature, the Uribarri database was the 
principal database used in this study to calculate dAGE. Despite the large 
number of FFQ studies using the Uribarri database however, its calculations are 
not without criticism. As shown in Table 2 in Section 1.4, ELISA is the method 
used by Uribarri to measure AGE in foods. Hull and Scheijen use the validated 
method UPLC MS/MS, which has increased sensitivity (463). The immunoassay 
ELISA method used by Uribarri has not been validated and as such, it has been 
suggested that its analysis may be misleading (51, 53, 463, 464). As previously 
described by Poulsen et al. (2013) the Uribarri database uses different units to 
the UPLC MS/MS databases, making comparison between databases particularly 
difficult (51). Scheijen compared its newly developed database to Uribarri by 
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comparing which food groups were generally considered to have ‘high’ AGE 
levels (53), however they were unable to make any calculations or analysis from 
this. In this study, participants’ FFQ responses were used with each database 
individually, allowing dAGE calculated from each database to be directly 
compared, despite unit differences.  
 
The dAGE value of the foods listed in the newly designed FFQ was assigned 
using the AGE values calculated from each database (14, 52, 53). All foods 
without a value listed had their dAGE value assigned by using the next most 
similar food, for example, apple crumble was assigned with the dAGE value of 
apple pie. The databases considered agree with one another in that fruits, 
vegetables and drinks have low or negligible values. However, the CML results of 
similar foods from each database differ; cheese, oil, butter and meats have a high 
dAGE value with Uribarri and low with Hull and Scheijen. Biscuits, chocolate and 
cereals had a high dAGE value with Hull and Scheijen, and low with Uribarri. As 
stated previously, these discrepancies are thought to be due to the different 
measurement methods used (53). There is currently no guidance as to which of 
the available databases should be used for calculation of dAGE.  
 
4.3.3 Validation 
The newly designed semi-quantitative FFQ was validated against plasma CML 
levels and results from a 4-day food record (FR). Using FRs is an accepted 
method for validating a FFQ (443, 465) and ELISA is a method widely used to 
measure AGEs from serum and plasma samples (43, 466-469).  
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4.3.3.1 Enzyme-linked immunosorbent assay (ELISA) 
A 3 mL lithium heparin vacutainer was used to collect a blood sample; this was 
then spun in a centrifuge at 20 G for 10 minutes at 4°C. The separated plasma 
was pipetted into serum tubes and stored in a freezer at -80°C. Analysis of the 
samples began once all samples were obtained. ELISA analysis was carried out 
by Dr Desley White.  
 
The plasma samples were measured by a direct double antibody (monoclonal 
CML antibody and polyclonal biotin-labelled secondary antibody) sandwich 
ELISA kit which analysed the presence of the CML-AGE (469). The human CML-
AGE ELISA commercial kit was from MyBioSource (MBS263691, San Diego, CA, 
USA) and was used according to the manufacturer’s instructions. 
  
4.3.3.2. 4-day food records (FR) 
Using weighed food records in a sub-sample of the main study participants is an 
accepted method for validation of a FFQ (54, 465). The length of days used for a 
FR can range from 24 hours to 16 days, the number of days chosen should be 
sufficient to represent average nutrient intake (470). It is considered that 3 days is 
the minimum number of days to be representative (191). Multiple consecutive 
days, more than four, can result in poor compliance (471) and it has been shown 
that in 7-day weighed FRs the later days are less likely to comply, instead 
recording foods retrospectively (472). For this reason it was decided that a 4-day 
food record would be used and that the days did not have to be consecutive. 
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Prior to completing the 4-day FR, training was given to each participant in the 
form of written and verbal instructions. The food diary was given to the 
participants approximately 1 month after the FFQ was administered (Appendix 5).  
The 4-day records consisted of three weekdays and one weekend day to obtain 
an accurate reflection of participants diet over the week (473, 474). Participants 
were instructed that food/drink items and portions should be recorded in a real 
time and that they should not modify their dietary habits and the food choices just 
because they are being recorded. Participants were asked to avoid recording at 
times of any unusual fasting or feasting, for example birthdays, as any highly 
atypical intake would affect the mean total of the 4-day FR (475). 
 
Digital kitchen scales (Colour match digital scale, Milton Keynes, UK) were 
loaned to participants to allow all food and drink to be measured accurately. The 
dAGE intake was calculated using the same database values used to calculate 
dAGE for the FFQ. The dAGE results from the 4-day FR were averaged to give 
the average daily dAGE value.  
 
4.3.4 Reliability 
To assess the reliability of the FFQ (FFQ1) a second FFQ (FFQ2) was 
administered approximately 1 month after the first. The one month interval made 
it unlikely that initial responses could be remembered, but also made it unlikely 
that substantive changes in diet had taken place (443, 476).  
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4.3.5 Database Comparison 
Annual dAGE intake was calculated from the FFQ responses using the 
corresponding food values from each of the three databases (Uribarri CML, Hull 
CML, Scheijen CML, Scheijen CEL and Scheijen MG-H1) in order to determine if 
the relative calculations were comparable.  
 
4.3.6 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and through inspection of quantile-
quantile (QQ) plots. The Mann-Whitney U test was used to test for differences in 
the demographic data.  
 
P values of less than 0.05 were considered statistically significant.  
There was a mix of parametric and non-parametric distributions in the different 
groups of participants. For non-parametric data median and interquartile range 
should be reported (477), however, for consistency in the tables in this Chapter 
and throughout this thesis mean and standard deviation have been reported. 
Tables reporting the median and interquartile range for all non-parametric data 
can be found in Appendix 10.1. 
 
4.3.6.1 Validity 
Due to nonparametric distribution Spearman’s rank correlation was used to 
analyse the association between FFQ1 and plasma CML levels in order to 
evaluate its validity. This analysis was carried out separately for each dAGE 
database under consideration, namely: Uribari, Hull and Scheijen. 
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Pearson’s correlation was used to analyse the association between FFQ1 and 
the 4-day FR, in order to evaluate its validity. This analysis was carried out using 
the principal database (Uribarri). The use of one database was chosen as the 
FFQ validation was centred upon participants’ dietary responses, and hence the 
relative associations would be the same with whichever database values were 
used. In order to visualise the differences between dAGE calculated using the 
FFQ and that calculated from the 4-day FR, a Bland-Altman plot with 95% limits 
of agreement was also constructed (478).  
 
4.3.6.2 Reliability 
Reliability of the FFQ using the principal database (Uribarri) was analysed using 
Pearson’s correlation and intraclass correlation coefficient (ICC). An ICC of 0.60 
or below would be considered low, and  0.8 or above would be considered to 
have good reliability (446). To visualise the difference between FFQ1 and FFQ2, 
a Bland-Altman plot with 95% limits of agreement was constructed.  
 
4.3.6.3 Database Comparison 
Spearman’s rank correlation was used to analyse the association between each 
dAGE value calculated by the databases under consideration, namely: Uribari, 
Hull and Scheijen. 
 
4.3.6.4 Power Calculation 
Sample size for FFQ validation using CML-plasma levels was determined using 
G*Power 3 programme (Heinrich-Heine, Universität Düsseldorf). In order to 
achieve 80% power at the 5% alpha level with a medium effect size of 0.3, 64 
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participants would be required. To account for unusable data an allowance was 
made and a sample size of 71 participants was chosen.  
 
Sample size for FFQ reliability and validation using the weighed FR was 
determined using G*Power 3 programme (Heinrich-Heine, Unversität Düsseldorf) 
using data from previous research which also assessed FFQ reliability and 
validated a FFQ using FR to measure AGE in the diet (54). In order to achieve 
80% power at the 5% alpha level a sample size of 14 was required. To account 
for unusable data an allowance was made and a sample size of 20 participants 
was chosen.  
 
4.4 Results 
A total of 70 participants were recruited for this study. All 70 participants 
completed the newly designed FFQ and had their plasma CML levels measured. 
10 of the 70 participants additionally completed the 4-day weighed food diary. 20 
out of the 70 participants were asked to complete a second FFQ for evaluation of 
reliability. The characteristics of the participant group with mean and standard 
deviation are detailed in Table 4.1. 
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Table 4.1: Mean and standard deviation of participant group characteristics (n = 70) * P < 0.05, ** 
P < 0.001 difference between M: males and F: females.   
 
 
 
Variable Mean  ± SD 
Gender (n) 
Male 
Female 
 
23 
47 
Age (years) 60.84 ± 9.54 
Ethnicity (n) 
Caucasian 
White other 
Mixed white/Asian 
Mixed white/black Caribbean 
Indian 
 
64 
2 
1 
2 
1 
Body mass index (BMI) 26.11 ± 4.56 
Basal metabolic rate (BMR) (kcal) All: 1445 ± 230 
M: 1666 ± 212,   F: 1337 ± 149 ** 
Body fat percentage (%) 31.74 ± 8.77 
M: 23.32 ± 6.34,  F: 35.86 ± 6.56 ** 
Fat mass (Kg) 23.69 ± 9.84 
M: 19.74 ± 8.28,  F: 25.62 ± 10.04 * 
SBP 129.24 ± 17.25 
DBP 81.16 ± 10.20 
Alcohol units per week 6.21 ± 6.56 
Smoking history (n) 
Non-smoker 
Previous smoker, quit >20yrs ago 
Previous smoker, quit >15yrs ago 
 
44 
25 
1 
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4.4.1 Validity of the FFQ 
4.4.1.1 FFQ vs. Plasma CML levels 
No significant correlations existed between the dAGE values calculated from the 
FFQ and plasma CML for two out of the three databases (Hull and Scheijen). 
Spearman’s correlation did however show a weak negative relationship between 
the average CML kU/day calculated from the FFQ responses using the Uribarri 
database and plasma CML (n = 70, r = -0.256, p = 0.038, 95% bootstrap 
confidence interval -0.014 to -0.477) (Figure 4.2) (Table 4.2).  
 
Table 4.2: Mean, standard deviation and Spearman’s correlations between plasma CML and 
dAGEs calculated with each database. *p < 0.05  
 
 
 
 
 
 
 
 
 
 
 
Mean SD Spearman’s correlation coefficients (R values) 
 Uribarri 
(average CML 
kU/day) 
Hull CML 
(average mg 
CML/day) 
Scheijen 
CML 
(average 
mg 
CML/day) 
Scheijen 
CEL 
(average mg 
CEL/day) 
Scheijen 
MG-H1 
(average mg 
MG-H1/day) 
Plasma 
CML  
(ng/ml) 
101.91 ± 28.81 -0.256 
p = 0.038* 
0.079 
p = 0.526 
0.080 
p = 0.523 
-0.029 
p = 0.817 
0.068 
p = 0.590 
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Figure 4.2: Negative relationship between the average CML kU/day calculated from the FFQ 
responses and plasma CML ng/ml (n = 70, r = -0.256, p = 0.038, 95% CI -0.014 to -0.477). The 
dashed grey line represents the line of best fit.  
 
 
4.4.1.2 FFQ vs. 4-day food record 
Pearson’s correlation showed a strong relationship (n = 10, r = 0.894, p = < 
0.001, 95% bootstrap confidence interval 0.669 to 0.996) between the average 
CML kU/day calculated from the FFQ using the Uribarri database and that 
calculated from the 4-day food record (Figure 4.3). 
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Figure 4.3: Relationship between FFQ1 and 4-day FR using the Uribarri database to calculate 
dAGE (n = 10, r = 0.894, p = < 0.001, 95% CI 0.669 to 0.996). The dashed grey line represents 
the line of equality (1:1).  
 
 
The Bland–Altman plot in Figure 4.4 shows the level of agreement between the 
dietary CML level calculated with the FFQ and that calculated with the 4-day FR, 
with the 95% limits of agreement calculated. There was good agreement between 
the two measures and no evidence of proportional bias, however this is based 
upon a small number of participants (n=10).    
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Figure 4.4: Agreement between FFQ1 and 4-day FR using the principal database. The red line 
shows the mean difference and green lines the 95% (1.96 ± SD) limits of agreement between and 
4-day FR for dAGE (n=10).  
 
 
4.4.2 Reliability of the FFQ 
Pearson’s correlation showed a strong association between dAGE value 
calculated with FFQ1 and FFQ2, (n = 20, r = 0.934, p = < 0.001, 95% bootstrap 
confidence interval 0.75 to 0.973), (Figure 4.5). There was no significant 
difference between the mean and standard deviations of the calculated dAGE 
values for FFQ1 and FFQ2 (Table 4.3, t-test; p = 0.544). In addition the FFQ had 
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an ICC (2 way mixed) of 0.965 with 95% a confidence interval of 0.913 to 0.986. 
The Bland–Altman plot in Figure 4.6 shows the mean difference between FFQ1 
and FFQ2 with the 95% limits of agreement calculated. There was good 
agreement and no evidence of proportional bias. 
 
Table 4.3: Means, standard deviation, Pearson’s correlation and ICC between FFQ1 and FFQ2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FFQ reliability 
 
 Mean 
(average  
CML kU/day) 
Standard 
deviation 
 
Pearson’s 
correlation 
(R values) 
ICC 
FFQ1 23011 ± 8115 0.934 0.965 
FFQ2 22758 ± 9881 
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Figure 4.5: Relationship between FFQ1 and FFQ2 using the Uribarri database to calculate dAGE 
(n = 20, r = 0.934, p = < 0.001, 95% CI 0.75 to 0.973). The dashed grey line represents the line of 
equality (1:1). 
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Figure 4.6: Agreement between FFQ1 and FFQ2 using the principal database. The red line shows 
the mean difference and green lines the 95% (1.96 ± SD) limits of agreement between FFQ1 and 
FFQ2 for dAGE (n = 20). . 
 
In Figure 4.6 the Bland-Altman plot indicates heteroscedasticity. For this reason, 
the Bland–Altman plot was repeated using dAGE data which had been log 
transformed. This repeat log transformed plot is shown in Figure 4.7. There was 
no evidence of proportional bias.    
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Figure 4.7: Agreement between LogFFQ1 and LogFFQ2 using the principal database. The red 
line shows the mean difference and green lines the 95% (1.96 ± SD) limits of agreement between 
LogFFQ1 and LogFFQ2 for dAGE (n = 20).  
 
4.4.3 Database comparison 
Strong/moderate correlations were found between each of the FFQ calculated 
dAGEs from each database, with one exception. No correlation was found 
between the dAGE calculated from the FFQ using the Uribarri CML database and 
that calculated with the Scheijen MG-H1 database. The mean and standard 
deviations of the calculated dAGE values, as well as the correlations between the 
databases are shown in Table 4.4.  
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Table 4.4: Means, standard deviation and Spearman’s correlations between dAGEs for each 
database measured with FFQ1 (n = 70). *p < 0.05. **p < 0.01.  
 
4.5 Discussion 
The aim of this study was to design and validate a new UK-specific FFQ for use 
in research. It is thought that the FFQ designed in this study is the first UK 
specific FFQ to measure dAGE intake and the first to directly compare dAGE 
values calculated from a range of databases.  
 
Careful consideration was given to the design of this FFQ to ensure it targeted 
food products known to have high AGE values and to ensure maximum reliability 
of responses. It is important that any newly designed FFQ undergoes validation 
against other known measures of the dietary target and that its measures are 
reliable.  
 
4.5.1 Validity of the FFQ 
Strong agreement was found between the dietary CML levels calculated using 
the FFQ (Uribarri database) and those calculated from the 4-day FR. Using food 
records is an established method for validating FFQs (425) and has been used 
    Spearman’s correlation coefficients (R) 
 
 
Mean Standard 
deviation 
1 2 3 4 5 
1. Uribarri  
(average CML kU/day) 
20534.94 ± 8981. 31  0.274* 0.337** 0.525** 0.176 
2. Hull CML  
(average mg CML/day) 
5.99 ± 2.25   0.745** 0.705** 0.771** 
3. Scheijen-CML  
(average mg CML/day) 
3.98 ± 1.59    0.740** 0.731** 
4. Scheijen-CEL   
(average mg CEL/day) 
3.07 ± 1.04     0.764** 
5. Scheijen-MGH1   
(average mg MG-H1/day) 
30.20 ± 9.93      
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by multiple studies as a means of validating  newly designed FFQs (54, 425, 479, 
480). This finding suggests that the FFQ developed in this study is valid in its 
measurement of dAGE. Looking at the data, there was one extreme value where 
the 4-day FR result was much lower than the FFQ result, which goes against the 
trend. Interestingly this participant’s FFQ showed good agreement on repeat, 
suggesting perhaps the participant modified their eating habits for the 4-day FR, 
or that the four days they recorded were over a period of irregularly low dAGE 
consumption. This sort of variation is recognised in regard to weighed food 
records, since it is known that participants tend to underestimate food intake in 
this style of reporting (481, 482). Macdiarmid and Blundell (1998) found that 
underestimating food intake is most prevalent in overweight and obese 
participants, with women more likely to underestimate intake than men (482). 
Interestingly the individual with this extreme value was a woman and had a BMI 
of 41, classed as very obese.  
 
Consideration should be given to the fact that the comparison of the dietary CML 
levels calculated from the newly designed FFQ and the 4-day FR in this study 
was based on the data obtained from 10 participants. Weighed food records and 
diaries place a high level of burden on the individual and FRs are known to only 
be suitable for small sample studies (471).  Sample sizes of the order used in this 
study are considered acceptable for FFQ validation and these numbers are 
comparable to other validation FFQ studies (54, 443), the EPIC study for 
example, which had a cohort of 25,000 had 179 participants complete a 7-day 
food diary (483).  
 
148 
 
Interestingly, despite good agreement between the FFQ and 4-day FR output, no 
strong relationships were found between dietary CML calculated with the FFQ 
and CML-AGE plasma level.  In fact, a weak negative relationship was found to 
exist between CML-AGE plasma level (ng/ml) and CML calculated from the newly 
designed FFQ (Uribarri database). Two previous studies have found no 
association between dietary and circulating CML-AGE levels (50, 484). However, 
the majority of the literature suggests that there is an association between dAGE 
intake and circulating AGE levels (45, 437, 485-488). There are no previous 
studies which report a negative correlation between CML-AGE plasma level and 
dAGE. The ELISA kit used for this study had unfortunately not been validated, 
and the standards provided with the kit were not in the same range as the results. 
If pre-tests had been carried out this may have been able to be accounted for, as 
plasma samples could have been diluted to be in the same range as the 
standards. Due to the limited number of pre-set wells in the kit this was not 
possible.  It has to be considered that this could have impacted the results and 
may explain why the CML-AGE plasma level in this study is not consistent with 
the previous literature. This finding therefore needs to be considered with caution. 
 
 
4.5.2 Reliability 
Assessing the reliability of any newly designed FFQ is considered to be a 
standard requirement (443, 448, 476, 489). Strong agreement was demonstrated 
between the first completion of the newly designed FFQ (FFQ1) and the second 
completion, one month later (FFQ2), suggesting that the newly designed FFQ is 
reliable. Review of the Bland-Altman plots indicates there was no proportional 
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bias and no consistent trend that one FFQ measured dAGE levels that were 
higher than the other, with there being an equal number of points above and 
below the mean. There is an indication on the Bland-Altman plot, Figure 4.6, that 
the data is skewed, showing heteroscedasticity, in that higher values calculated 
by the FFQ have slightly increased variability. This would suggest that the FFQ is 
less reliable when measuring high dAGE values. It is common for nutritional data 
in Bland-Altman plots to be skewed (490) since intake will be above zero. In 
addition it is common that those with higher intakes will appear relatively more 
variable. The non-uniform variability in Figure 4.6 can be overcome by using 
logarithms of the data for each method (447, 491). Figure 4.7 shows the Bland-
Altman plot using the log-transformed data, the heteroscedasticity is no longer 
present. FFQ1 and FFQ2 agree with each other and as shown in Figure 4.7 and 
are approximately +/- 0.3 log units, which corresponds to be within a factor of 2, 
approximately.  
 
4.5.3 Database Comparison 
There is currently no guidance or gold standard on which of the available 
databases should be used as a reference for calculation of dAGE levels, 
furthermore the databases are known to have dAGE measurement differences.   
As described in Section 4.3.4 the calculation of dAGE from the FFQ responses, 
using the values provided within each individual database in this study has 
allowed the first direct comparison of the database outputs, despite there being 
unit differences between them.  Perhaps, unexpectedly, poor agreement was 
found between the CML levels calculated from the FFQ using all three of the 
available dAGE databases (Uribarri, Hull and Scheijen). These correlations are 
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likely to exist in part due to the fact they are measuring the same type of AGE, 
despite the measuring techniques having been different. This suggests that the 
databases may be more in line with each another when measuring the same 
AGE than previously thought by Poulsen et al. (2013) and Scheijen et al. (2016) 
(51, 53).  
 
The Scheijen database, alongside CML, also provides values for the AGEs CEL 
and MG-H1. Interestingly, the CEL levels calculated from the FFQ with the 
Scheijen database, showed good agreement with the CML levels for each of the 
other databases. It is known that CML and CEL are similar to one another (492), 
this can be evidenced when comparing the chemical structures of CML and CEL, 
since they only differ by a methyl group (see Figure 4.8). The strong correlations 
between CEL and CML values from each database suggests that these AGEs 
are found in close association in foods. 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Chemical structure of AGEs: N-carboxymethyllysine: CML, N-carboxyethyllysine: CEL.  
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Figure 4.9: Chemical structure of AGEs: 5-hydro-5-methyl-4-imidazolon-2-yl-ornithine: MG-H1 
 
MG-H1 has a different chemical structure to CEL and CML, as shown in Figure 
4.9. MG-H1 levels calculated from the FFQ using the Scheijen database, were 
found to have good agreement with the CEL and CML levels calculated from the 
same Scheijen database and that calculated from the Hull database, however no 
relationship was found between MG-H1 and CML calculated using the Uribarri 
database. It may be that this reflects the difference in measurement techniques 
since MG-H1 levels correlated with all AGEs measured by UPLC MS/MS but not 
ELISA.  
 
The three types of AGEs measured by Scheijen: CML, CEL and MG-H1 all had 
different values for foods within the database, for example, Kellogs rice crispies, 
CML = 0.59, CEL = 0.47, MG-H1 = 14.70. Despite the within database 
differences in food values, strong correlations existed between each of the 
different annual AGE calculated intakes. This emphasises the importance of 
considering the diet as a whole.  
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4.6 Conclusion: 
The UK-specific semi-quantitative FFQ developed to measure dAGE was found 
to produce valid results when compared to a 4-day FR and to be reliable on two 
completions; this indicates that it is a useful tool for estimating dAGE in a UK 
population. We were however unable to validate the FFQ against the objective 
plasma CML-AGE measurement and the reasons behind this require further 
research, but could relate to the measurement technique used. The comparisons 
between databases suggests that they are more in line with each another than 
previously thought. The choice of database should therefore be based upon 
which is most relevant to the population, and has enough foods measured to 
ensure minimal instances of assigning ‘assumed values’ to foods with no 
assigned measured value. The strong correlations found between the three 
different types of AGEs measured by Schejien (CML, CEL and MG-H1) suggests 
that when considering diet as a whole, an individual dAGE may be sufficient to 
give a representation as to if a person has a high or low AGE diet. 
 
The UK-specific semi-quantitative FFQ developed to measure dAGE was found 
to produce valid results when compared to a 4-day FR and to be reliable across 
completions. The comparisons between databases suggests that they are more 
in line with each another than previously thought. 
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4.7 Limitations: 
FFQs and FRs are limited in that one cannot be certain that participants have not 
misreported their diet. It is possible that both methods of collecting a participant’s 
dietary status could be equally flawed. 
 
The Plasma AGE-CML ELISA kit used was not validated and produced results 
which did not agree with the previous research. The standards given with this kit 
were not in the same range as the measurements found, this will have impacted 
the results. In future research plasma AGE-CML will be carried out using the 
UPLC–MS/MS method. 
 
Although this study identifies relationships between variables it cannot identify 
causative factors.  
 
4.8 Future work: 
Further validation of the FFQ by using UPLC-MS/MS to measure CML in the 
plasma.  
 
This is the first UK-specific semi-quantitative FFQ for the measurement of 
dAGEs, with increased use further validation and review should take place. 
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5. The relationship between dietary AGE intake, skin 
autofluorescence and circulating oxidative stress levels in a 
healthy ageing population. 
 
5.1 Abstract 
 
Purpose: To determine how dAGE intake influences tissue-bound AGE level 
(SAF) in a healthy ageing population, as well as to determine how circulating 
oxidative stress levels relate to SAF and dAGE. The relative influence that a 
variety of demographic parameters may have on these measures were also 
assessed. 
 
Methods: Skin autofluorescence (SAF) as a measure of tissue-bound AGE level 
was measured in 68 healthy participants and compared to dAGE measured by 
FFQ. Fasting venous blood samples were obtained to enable the measurement 
of oxidative stress biomarkers. 
 
Results: A positive relationship between SAF and dAGE (MG-H1) was calculated 
from the Scheijen database (n = 68, r = 0.319, p = 0.008, 95% CI 0.099 to 0.511). 
Spearman’s correlation showed a positive relationship between SAF and the 
oxidative stress biomarker alpha tocopherol (n = 68, r = 0.252, p = 0.044, 95% CI 
0.007 to 0.463). When MG-H1 and alpha-tocopherol were included in a multiple 
linear regression along with relevant demographic variables they were not found 
to be significant predictors of SAF; age was the single best predictor (p = 
<0.001), followed by BMI (p = 0.008). 
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Conclusion: The contribution of dietary AGE to tissue-bound AGE levels 
appeared to be minimal. This unexpected finding requires further investigation, 
which will be aided by the development of new AGE databases. No statistically 
significant associations between oxidative stress biomarkers and dAGE were 
found. AGEs measured by SAF and the circulating oxidative stress biomarkers 
measured in this study were not closely related. This suggests that the two 
measures should be considered alongside each other, rather than 
interchangeably and that the output from the AGE Reader, SAF, should not 
simply be considered as a marker of oxidative stress. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
156 
 
5.2 Background 
Foods are a known exogenous source of AGEs (40), and dAGEs have been 
shown to influence the body’s total AGE level (see Section 4.2). It is understood 
that approximately a third of dietary AGEs consumed are absorbed through the 
digestive tract, then circulate in the body (493). It is not currently known if dAGEs 
accumulate in tissues or if they cause biological consequence (51). It has 
however been suggested that after urinary excretion a proportion of dAGEs 
remain in the body (494) and rodent studies have evidenced that CML-rich diets 
result in accumulation in tissues (495-497). Dietary AGE intake represents a 
potentially modifiable target (360), hence this is an area of interest.  
 
AGEs are known to accumulate in cells and tissues throughout the body, 
however the amount of AGEs that are contributed exogenously from the diet 
versus those that produced endogenously is unclear. Measuring tissue-bound 
AGE levels is thought to give an indication of the total AGE levels in the body. 
The contribution of dAGE to tissue-bound AGE levels has not been widely 
researched due to difficulties in assessing human tissue (493). As explained in 
Section 3.3.2.4., the AGE reader provides a measurement of skin 
autofluorescence (SAF) which has been proposed as a marker for tissue-bound 
AGE levels (21, 23).  
 
Using the AGE-reader, Klenovics et al. (2014) found that infants had a higher 
SAF if they were formula fed compared to breast fed infants (498), Nongnuch et 
al. (2015) measured SAF levels in haemodialysis patients and found those with a 
vegetarian diet had a lower SAF level (499), Botros et al. (2017) found that SAF 
157 
 
and coffee intake positively correlated with one another (500), and Kellow et al. 
(2017) measured SAF in a group of healthy adults and found those with a higher 
intake of meat products had a higher SAF level. None of these studies used an 
AGE specific FFQ or AGE database to calculate dAGE consumption. A recent 
study by Hörner et al. (2018) used a FFQ to measure dAGE in a group of 
hemodialysis patients and found that SAF did not correlate with dAGE intake 
(501). 
 
SAF, by its nature, can only measure the level of fluorescent AGEs in the skin; 
examples of fluorescent AGEs include pentosidine and crossline, the previously 
discussed AGEs CML, CEL and MG-H1 do not fluoresce. The lack of 
fluorescence of all types of AGEs is therefore considered a limitation of SAF and 
consequently of the AGE-reader (37, 502). However, Meerwaldt et al. (2004) did 
show that levels of fluorescent and non-fluorescent AGEs do correlate with one 
another, suggesting that SAF could in fact be a marker of total AGE in the skin 
(21). Another consideration with SAF readings is that other molecules in the skin 
fluoresce as well as AGEs, examples include porphyrins (organic compounds) 
and redox regulated fluorophores such as nicotinamide adenine dinucleotide and 
flavin adenine dinucleotide (502, 503). While this is important to consider, Smit et 
al. (2010) found that approximately 75% of the SAF variance was due to 
variability of the AGE pentosidine, confirmed by skin biopsies (33). 
 
In a similar manner to AGEs, oxidative stress develops as part of the body’s 
normal metabolism and is linked with ageing (114). This supports the notion that 
ageing is multifactorial (114, 504). When considering the influence that AGEs 
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may have on the development of age-related disease, it is important to take into 
consideration the complex relationship between AGE levels and oxidative stress 
levels in the body. Indeed, endogenous AGE formation is accelerated by 
increased levels of oxidative stress and blood glucose (9). Increase in AGE levels 
is both a cause and an effect of elevated oxidative stress (11), with oxidative 
stress accelerating AGE formation and the production of free radicals, as well as 
being produced as a by-product of AGE formation and AGE-RAGE binding 
interaction (see Section 1.7) (112, 113). AGEs are considered to be pro-oxidant 
substances, because their formation increases the cellular level of oxidative 
stress (361, 362). It has been found that serum CML levels correlate with the 
ELISA measured oxidative stress biomarker 8-isoprostane (45). It has been 
suggested that dAGEs are directly associated with oxidative stress as a low-AGE 
diet resulted in a significant reduction in 8-isoprostanes and vascular cell 
adhesion molecule one (VCAM-1) (505). In addition it has been found that dAGE 
intake weakly positively correlates with the inflammation marker high sensitivity 
C-Reactive Protein (hsCRP) (45). Although statistically significant results have 
been reported the proposed risk of dAGEs to health has been questioned, since 
the results of these studies have been described as low grade evidence (493). 
 
As described in Section 1.7, the vast majority of the literature differentiates 
between AGEs and oxidative stress, measuring each individually while 
discussing the known complex relationship (8, 45, 115-117). However, there are 
examples in the literature which use the terms interchangeably, with some using 
AGEs as biomarkers of oxidative stress (92, 118, 119), suggesting that the two 
are perhaps measurements of the same thing. Understanding the relationship 
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between circulating oxidative stress markers and AGE levels could help increase 
understanding of which may be the primary influence and whether they are 
measures of the same thing, or should be considered, and potentially targeted, 
individually.  
 
Increased body mass index (BMI) is known to result in increased oxidative stress 
(506) as well as smoking (507) and alcohol (508). Kellow et al. (2017) found that 
increased age, smoking and BMI correlated with increased SAF (494). These 
demographic, general health parameters are known associates of the AGEs and 
oxidative stress and therefore need to be considered. Understanding which 
parameters influence AGE and oxidative stress levels in healthy participants 
could help increase understanding as to the demographic factors that accelerate 
the physiological ageing process. It is also important to identify possible 
confounders in this healthy population before examining participants with 
pathology.   
 
5.2.1 Aims 
To determine whether dietary AGE intake is associated with tissue-bound AGE 
levels (SAF) in a healthy ageing population, to determine whether circulating 
oxidative stress levels relate to tissue-bound AGE levels (SAF) and dAGE in a 
healthy ageing population and to explore the influence of BMI, smoking history, 
alcohol consumption, body fat percentage and blood pressure on oxidative 
stress, SAF and dAGE, in the same population.   
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5.2.2 Hypothesis 
Dietary AGE intake will be associated with SAF in healthy controls, and both 
dAGE and SAF will relate to the measured oxidative stress biomarkers. 
 
5.3 Methods 
The methodology that will be used in this study is summarised here; more 
detailed information on the specifics of each technique can be found in Chapter 
3. 
 
5.3.1 Participants  
Convenience sampling was used to recruit participants who were eligible 
according to the inclusion and exclusion criteria for healthy ageing participants as 
detailed in Section 3.1.3. and Section 3.1.4. Due to the established link between 
diabetes and AGEs (449, 450), participants diagnosed with diabetes, or 
participants found to have a high fasting glucose level were excluded from the 
study, as were current smokers, and previous smokers who quit less than 15 
years ago due to the link between AGEs and tobacco (10).  
 
5.3.2 General health investigations 
As described in 3.3.2.1, height was measured in meters using a stadiometer, 
weight was measured in kg and from these measurements BMI was calculated. 
Weight, basal metabolic rate (BMR), and body fat percentage were measured 
using the Tanita body composition analyser (TBF-300 MA). Blood pressure was 
measured and a fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers in plasma. Three oxidative stress 
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biomarkers were used, the non-enzymatic antioxidants ascorbate (vitamin C) and 
alpha tocopherol (a form of vitamin E) and the product of lipid peroxidation 
malondialdehyde (MDA). Each biomarker is described in Section 3.3.2.6. A 
normal range for ascorbate levels would be 30 to 150 µM (509) and MDA 
range 0.36 and 1.24 µM, and (429). There is currently no established normal 
range for plasma alpha tocopherol concentration, however the mean plasma 
alpha tocopherol concentration is 32.5 µM for adults aged 19-64, in the UK (454) 
 
5.3.3 Skin autofluorescence (SAF) 
The measurement of tissue-bound AGE levels was obtained using the AGE 
Reader (DiagnOptics B.V., Groningen, The Netherlands). The AGE Reader is a 
non-invasive device, which provides a low cost, fast, and reproducible means of 
determining AGE levels in the body through utilisation and measurement of the 
fluorescent properties of tissue-bound AGEs in the skin (21-23). Specific detail on 
the AGE reader and its protocol can be found in Chapter 3, Section 3.3.2.4.  
 
5.3.4 Dietary AGE, semi-quantitative FFQ 
An assessment of dietary AGE intake over the last year was made using a semi-
quantitative FFQ that was designed specifically to assess dietary AGE levels in a 
UK population for the purposes of this research (Chapter 4, Appendix 4.1). The 
FFQ was administered to all participants. The results from the FFQ were 
calculated with each of the databases described in Chapter 4.  
As explained previously in Section 4.3.1, use of all of the different AGE 
databases available in this study enabled the measurement of dietary intake of 
CEL and MG-H1 in addition to CML from the FFQ responses. It is important to 
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note that CML, CEL and MG-H1 do not fluoresce (510), hence the FFQ 
measures different types of AGEs to the AGE-reader. Furthermore, it is thought 
that the fluorescent AGE pentosidine may have only a minor role in the Maillard 
reaction within foods (511). 
 
5.3.5 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and visual inspection of the QQ 
plots. P values of less than 0.05 were considered significant.  
 
5.3.5.1 SAF and dAGE 
Spearman’s rank correlation was used to analyse the association between SAF 
and dAGE. This analysis was carried out separately for each dAGE database 
under consideration, namely: Uribari et al. (2010), Hull et al. (2012) and Scheijen 
et al. (2016). 
 
5.3.5.2 Relationship between oxidative stress, SAF and dAGE 
Spearman’s rank correlation was used to analyse the association between 
oxidative stress and SAF. This analysis was carried out separately for each 
oxidative stress biomarker, namely: ascorbate (vitamin C), malondialdehyde 
(MDA) and alpha tocopherol (form of vitamin E). 
Spearman’s rank correlation was used to analyse the association between 
oxidative stress and dAGE. This analysis was carried out for each oxidative 
stress biomarker and each dAGE database. 
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5.3.5.3 Relationship between demographic variables, SAF, dAGE and oxidative 
stress 
Mann-Whitney U test and Kruskal-Wallis test were used to analyse the 
demographic data.  
Spearman’s rank correlation was used to assess the relationship between SAF 
and each clinical measure namely: blood pressure, BMI, BMR, body fat 
percentage, fat mass as well as dietary AGE, and oxidative stress biomarkers.  
The same statistical analyses were repeated for dAGE database and each 
oxidative stress parameter. 
Any significant correlations were entered into a stepwise forward and backward 
multiple linear regression to further assess the influence of different variables on 
SAF.  
 
5.3.5.4 Power calculation 
Sample size was determined using G*Power 3 programme (Heinrich-Heine, 
Universität Düsseldorf). In order to achieve 80% power at the 5% alpha level with 
a medium effect size of 0.3, 64 participants would be required. To account for 
unusable data an allowance was made and a sample size of 71 participants was 
chosen.  
 
5.4 Results  
A total of 70 participants were recruited, 68 of which were eligible for the study. 
The 68 eligible participants were free of acute or chronic diseases, including 
diabetes, with the exception of controlled hypertension. Participants who reported 
a major change to their diet over the last 12 months were excluded. The 
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characteristics of the participant group with mean and standard deviation are 
detailed in Table 5.1.   
 
 Table 5.1: Mean and standard deviation of participant group characteristics. AU: arbitrary units. 
* P < 0.05, ** P < 0.001 difference between M: males and F: females.   
 
Variable Mean ± SD 
Gender (n) 
Male 
Female 
 
22 
46 
Age (years) 60.84 ± 9.67 
Ethnicity (n) 
Caucasian 
White other 
Mixed white/Asian 
Mixed white/black Caribbean 
Indian 
 
62 
2 
1 
2 
1 
Body mass index (BMI) 26.12 ± 4.62 
Basal metabolic rate (BMR) (kcal) All: 1444 ± 232 
M: 1667 ± 217,   F: 1338 ± 150 ** 
Body fat percentage (%) All: 31.75 ± 8.73 
M: 23.41 ± 6.51,  F: 35.74 ± 6.59 ** 
Fat mass (kg) All: 23.73 ± 9.94 
M: 19.88 ± 8.44,  F: 25.57 ± 10.15 * 
Systolic blood pressure (SBP) (mmHg) 129.54 ± 17.36 
Diastolic blood pressure (DBP) 
(mmHg) 
81.18 ± 10.29 
Alcohol units per week 6.07 ± 6.59 
Smoking history (n) 
Non-smoker 
Previous smoker, quit >20yrs ago 
Previous smoker, quit >15yrs ago 
 
43 
24 
1 
Skin autofluorescence (SAF) (AU) 2.24 ± 0.39 
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The characteristic BMR (kcal) was significantly higher in males, both body fat 
percentage and fat mass measurements were significantly higher in females. All 
other characteristics were not statistically different between genders. Figure 3.17, 
Chapter 3 shows the AGE Reader measurement report displayed after an AGE 
reading and visually displays what a ‘normal’ SAF reading would be depending 
on age of the participant. The reference values used in the graph are from mean 
SAF data for age from Koetsier et al. (2010) (512). The average SAF value for 
the average age of 61 would be 2.25 AU. 
 
5.4.1 SAF and dAGE 
Spearman’s correlation showed a positive relationship between SAF and dAGE 
(MG-H1) calculated from the Scheijen database (n = 68, r = 0.319, p = 0.008, 
95% bootstrap confidence interval 0.099 to 0.511) (Figure 5.1). No significant 
correlations existed between the other dAGE values calculated from the FFQ 
responses (Uribarri CML, Hull CML, Scheijen CML and CEL) and SAF (Table 
5.2). 
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Figure 5.1: Positive relationship between SAF and dAGE MG-H1 calculated from the FFQ 
responses using the Scheijen et al. (2016) database (n = 68, r = 0.319, p = 0.008, 95% CI 0.099 
to 0.511). 
 
 
 
Table 5.2: Mean, standard deviation and Spearman’s correlations between SAF (AU) and dAGEs 
calculated with each database. *p<0.05  
 
 
 
Mean SD Spearman’s correlation coefficients (R values) 
 Uribarri 
(average CML 
kU/day) 
Hull CML 
(average mg 
CML/day) 
Scheijen 
CML 
(average mg 
CML/day) 
Scheijen 
CEL 
(average mg 
CEL/day) 
Scheijen    
MG-H1 
(average mg MG-
H1/day) 
SAF  2.24 ± 0.39 0.075  
p = 0.545 
0.210 
p = 0.085 
0.190 
p = 0.120 
0.175 
p = 0.153 
0.319 
p = 0.008* 
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5.4.2. Oxidative stress, SAF and dAGE 
5.4.2.1 Relationship between oxidative stress and SAF 
Spearman’s correlation showed a positive relationship between SAF and the 
oxidative stress biomarker alpha tocopherol (n = 68, r = 0.252, p = 0.044, 95% 
bootstrap confidence interval 0.007 to 0.463) (Figure 5.2). No significant 
correlations existed between MDA and SAF or ascorbate and SAF (Table 5.3). 
 
 
Table 5.3: Mean, standard deviation and Spearman’s correlations between SAF (AU) and each 
oxidative stress biomarker: ascorbate (vitamin C), malondialdehyde (MDA) and alpha tocopherol 
(form of vitamin E). *p<0.05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
Ascorbate (µM) 50.41 ± 18.52 -0.207,  p = 0.093 
MDA (µM) 0.61 ± 0.19 0.072,  p = 0.570 
Alpha tocopherol 
(µM) 
43.68 ± 16.01 0.252,  p = 0.044*  
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Figure 5.2: Weak positive relationship between alpha tocopherol (µM) and SAF (AU) (n = 68, r = 
0.252, p = 0.044, 95% CI 0.007 to 0.463).  
 
 
5.4.2.2 Relationship between oxidative stress and dAGE 
No statistically significant correlations existed between the oxidative stress 
biomarkers (ascorbate, MDA and alpha tocopherol) and dAGEs derived from any 
of the databases.  
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5.4.3. Relationship between demographic variables, SAF, dAGE and oxidative 
stress 
5.4.3.1 Relationship between demographic variables and SAF 
Spearman’s correlation showed a strong positive relationship between increased 
age and SAF (n = 68, r = 0.420, p = <0.001, 95% bootstrap confidence interval 
0.182 to 0.613) (Figure 5.3). No statistically significant correlations existed 
between any other demographic variables and SAF.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3: Positive relationship between age (years) and SAF (AU) (n = 68, r = 0.420, p = 
<0.001, 95% CI 0.182 to 0.613).  
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The demographic history of previous smokers who had quit more than 15 years 
ago, and participants who had ‘never’ smoked, were analysed to detect if there 
was a difference related to SAF. There was no significant difference (p = 0.788). 
In a similar manner alcohol units consumed per week were assessed. Nine 
participants did not drink alcohol, 53 drank a low to moderate amount of units (1-
14 units per week) and 6 participants drank 15 or more units, classified as high 
consumption due to it being above the UK recommended units consumed per 
week (513). There was no significant difference in SAF level between the 
different alcohol consumption groups (Kruskal-Wallis; p = 0.616). 
 
An incidental finding regarding reflectance, a measurement obtained from the 
AGE-reader when measuring SAF, was discovered during data analysis. 
Reflectance was found to correlate with BMI (R = 0.244, p = 0.044, 95% 
bootstrap confidence interval -0.001 to 0.473), body fat percentage (R = 0.311, p 
= 0.01, 95% bootstrap confidence interval 0.057 to 0.530), and fat mass (R = 
0.268, p = 0.027, 95% bootstrap confidence interval 0.020 to 0.502). 
     
5.4.3.2 Relationship between demographic variables and dAGE 
No statistically significant correlations existed between the demographic variables 
and different measured dAGEs. 
 
5.4.3.3 Relationship between demographic variables and oxidative stress 
Spearman’s correlation showed a negative relationship between ascorbate and 
BMI (n = 68, r = -0.345, p = 0.004, 95% bootstrap confidence interval -0.115 to -
0.535) (Figure 5.4) and negative relationship between ascorbate and BMR (n = 
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68, r = -0.328, p = 0.007, 95% bootstrap confidence interval -0.108 to -0.517) 
(Figure 5.5). No statistically significant correlations were found between any other 
demographic variables and oxidative stress biomarkers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: Negative relationship between ascorbate (µM) and BMI (n = 68, r = -0.345, p = 0.004, 
95% bootstrap confidence interval -0.115 to -0.535).  
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Figure 5.5: Negative relationship between ascorbate (µM) and BMR (kcal) (n = 68, r = -0.328, p = 
0.007, 95% bootstrap confidence interval -0.108 to -0.517).   
 
 
5.4.4. Multiple linear regression 
Considering all findings together, within the variables considered (dAGE, 
oxidative stress markers and demographic parameters), there were three 
variables which correlated with SAF, the demographic parameter age as well as 
the dAGE MG-H1 and oxidative stress biomarker alpha tocopherol. Table 5.4 
summarises all of the variables which correlated with SAF.  
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Table 5.4: Mean, standard deviation and Spearman’s correlations between all parameters which 
correlated with SAF. 
 
Forwards stepwise and backwards multiple linear regression analysis was 
performed to determine the factors that had the most influence on SAF. The 
independent variables included were those which had previously correlated with 
SAF: age, dAGE MG-H1 and alpha tocopherol. BMI did not correlate with SAF (n 
= 68, r = 0.173, p = 0.159, 95% bootstrap confidence interval -0.065 to 0.381), 
however BMI was included since the literature suggests that it is a confounding 
variable (494).   
 
Age was the single best predictor (p = <0.001), followed by BMI (p = 0.008). 
These findings were also found to be true in the backwards model. 
 
 
 
 
 
Variable 
 
 
 
Mean 
 
 
Standard 
deviation 
 
Spearman’s correlation coefficients 
R values P values 95% bootstrap 
confidence 
interval 
Age (years) 60.84 ± 9.67 0.435 p<0.001 0.205 to 0.620 
Dietary AGE 
MG-H1  
(average mg MG-
H1/day) 
30.26 ± 9.66 0.333 0.007 0.105 to 0.550 
Alpha 
tocopherol  
(µM) 
43.68 ± 16.01 0.252 0.044 0.034 to 0.461 
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5.5 Discussion 
The aim of this study was to determine how dAGE intake relates to SAF in a 
healthy ageing population, as well as to determine whether circulating oxidative 
stress biomarker levels relate to SAF and dAGE and the relative influence that a 
variety of demographic parameters may have on these measures. We believe 
that this is the first study to examine the influence of dAGE on tissue-bound AGE 
(SAF) levels using a specifically designed FFQ for measuring dAGE with different 
databases.   
 
5.5.1 SAF and dAGE 
A positive relationship was found in this study between the dAGE MG-H1 and 
SAF, however no relationship was found between SAF and dietary intake of CML 
and CEL. As explained in Section 5.2 only a few studies have previously 
assessed the relationship between dAGE and SAF. Only one of these studies 
used an AGE specific FFQ to calculate dAGE consumption, Hörner et al. (2018) 
in a group of haemodialysis patients found that SAF did not correlate with dAGE 
intake. The FFQ used by Hörner et al. (2018) only used the Uribarri database, 
hence could only measure the dAGE CML (501). Lack of correlation between the 
dAGE CML and the results of this study agree with one another. No previous 
studies have examined the relationship between CEL and MG-H1 and SAF.  
 
MG-H1 is known to be a major type of AGE (514), although CML is currently the 
favoured dAGE marker, the result from this study supports the notion that 
databases should expand and examine multiple types AGEs in the diet. The 
weak correlation between MG-H1 and SAF suggests that MG-H1 absorbed from 
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the diet may be accumulating in the tissues. The lack of relationship between 
dietary CML and CEL and SAF suggests that these dAGEs may not contribute, or 
contribute only to a low extent, to tissue-bound AGE levels. The difference 
between the types of dAGEs may be due to reactivity or structural differences 
(see Figure 4.8 and Figure 4.9). CML and CEL can bind to RAGE when in an 
embedded peptidic structure (515), however when considering free CML and 
CEL it has been suggested that they do not readily bind to RAGE, whereas free 
MG-H1 does (492, 516). These differences in reactivity with RAGE suggests that 
circulating levels of MG-H1 may be more likely to react and therefore be less 
likely to be excreted from the body and potentially more likely to accumulate in 
the tissues. This difference in reactivity between types of dAGEs could indicate 
possible differing pathological effects which would be important to consider.  
 
Important to note is that whilst the correlation between MG-H1 and SAF was 
moderate, when MG-H1 was included in the multiple linear regression it was not 
a significant predictor of SAF. This supports the theory that AGEs formed 
endogenously create the largest burden on the tissues of the body, and that diet 
makes only a minor contribution to overall tissue-bound levels. Further research 
is required to assess if dAGE restriction is a viable treatment option to reduce 
tissue-bound AGE levels.  
 
5.5.2 Relationship between oxidative stress, SAF and dAGE  
As explained in Section 5.2, when considering AGEs, it is important to take into 
consideration the complex relationship between AGE and oxidative stress levels 
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in the body. Increased understanding is needed to establish if they are measures 
of the same thing, or should be considered, and potentially targeted, individually.  
 
In an environment of increased oxidative stress it would be expected that the 
oxidant MDA would be increased and the antioxidants ascorbate and alpha 
tocopherol decreased (103). There are only a few studies directly comparing 
oxidative stress biomarkers and SAF. Hartog et al. (2006) measured vitamin C 
(ascorbate) and vitamin E plasma levels in renal transplant recipients and found 
that increased SAF was related to decreased plasma vitamin C levels and no 
association was found between SAF and vitamin E (517). Himori et al. (2016) 
found that the oxidative stress biomarker 8-hydroxy-2’- deoxyguanosine did not 
correlate with SAF (119). The oxidative stress biomarker alpha tocopherol in this 
study was found to weakly positively correlate with SAF and borderline significant 
(p = 0.044). Both ascorbate and MDA were found not to correlate with SAF. The 
lack of correlation of MDA and ascorbate with SAF may be attributed to the 
participants being healthy and not being in a state of oxidative stress. Indeed, 
MDA and ascorbate levels were within a healthy normal range, and the 
antioxidant alpha tocopherol levels were above normal (429, 454, 509). In 
addition oxidative stress biomarkers are short-term measures, providing only a 
measurement for that moment in time whereas the tissue-bound SAF measure is 
thought to indicate longer-term tissue damage (418).  
 
. 
Both ascorbate and alpha tocopherol are thought to be appropriate oxidative 
stress biomarkers (518). Frei (1989) proposed that ascorbate is the most 
effective antioxidant present in the plasma and is vital in the protection against 
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oxidative stress (427). Low levels of ascorbate have been linked with AGEs and 
AGE inhibitors such as aminoguanidine (519) as well as being linked to 
endothelial dysfunction (520, 521). Alpha tocopherol has also been shown to 
regulate inflammation related to neurodegeneration in Alzheimer's disease (522, 
523). 
 
.As explained in 3.3.2.6.2, alpha tocopherol is one of the eight forms of vitamin E 
and is the main lipid soluble antioxidant found in the plasma (433). The mean UK 
plasma alpha tocopherol concentration is 32.5 µmol/L for adults aged 19-64 
(454), as shown in Table 5.1 the adults in this study (mean age 61) had mean 
alpha tocopherol of 43.68 ± 16.01 µmol/L. This higher mean may be in part due 
to a ‘healthy volunteer effect’, in that the inclusion/exclusion criteria and protocol 
of this study is likely to have attracted a healthier volunteer sample (524, 525). 
Nevertheless, the finding of a positive correlation between alpha tocopherol and 
SAF in this study was not expected. Indeed, as alpha tocopherol is a lipid soluble 
antioxidant, higher levels are considered to be beneficial, as alpha tocopherol has 
been shown to inhibit low density lipoprotein oxidation and inhibit glycation (526-
528). Culbertson et al. (2003) used a novel AGE inhibitor, 6-
dimethylaminopyridoxamine (dmaPM) which was pharmacologically designed to 
scavenge free radicals in a similar manner to non-enzymatic antioxidants, such 
as alpha tocoperol. Interestingly, they similarly found an unexpected result, as 
dmaPM (antioxidant) increased the levels of pentosidine (fluorescent AGE) (529). 
The similarities in unexpected results could however be coincidence, as the 
theory of an antioxidant encouraging AGE formation opposes the previous 
literature.  Indeed, it should also be considered that the positive correlation 
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between alpha tocopherol and SAF found in this study was only weak (R = 0.252, 
p = 0.044) and when put through multiple regression analysis alpha tocopherol 
was not found to be a predictor of SAF.  
 
Previous research has used the AGE reader’s SAF measure as a biomarker for 
oxidative stress (118, 119). The AGE reader has not been validated or developed 
to measure oxidative stress. Oxidative stress is particularly challenging to 
measure as reactive species are unstable, oxidative stress biomarkers are used 
to give an indication of the level within the body. As mentioned above the 
recognised oxidative stress markers ascorbate and MDA did not correlate with 
SAF and alpha tocopherol had a weak positive correlation. These results suggest 
that SAF may not be a suitable biomarker of oxidative stress and helps to clarify 
that it is not acceptable to interchange between oxidative stress and AGE (SAF) 
level, since although related, they appear to measure different things. 
 
With regard to dAGE, none of the oxidative stress biomarkers tested in the study 
related to dAGE however previous studies have suggested that increased intake 
of dAGEs is directly linked to oxidative stress in mice and humans (45, 57, 505, 
530). The markers of oxidative stress used in these studies however were: CML, 
MG derivatives, hsCRP, VCAM-1, plasma 8-isoprostane and fibrinogen. Although 
relevant, CML is a type of AGE, MG a precursor to AGE formation, hsCRP and 
VCAM-1 are considered inflammation markers, and fibrinogen is a coagulation 
factor. The only specific oxidative stress biomarker measured in previous studies 
was plasma level of 8‐isoprostane, which is a product of lipid peroxidation (531). 
MDA was chosen as a biomarker in this thesis as it has been linked with AGEs 
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(110) as well as glaucoma, with increased levels of MDA having been associated 
with glaucoma (108) and glaucoma severity (107, 109, 315). Since both MDA and 
8‐isoprostane are products of lipid peroxidation it was expected that MDA would 
also correlate with dAGE, however this was not the case. This difference in 
findings may in part be related to the way in which dAGE was measured between 
the studies however, rather than oxidative stress biomarker differences. 
Methodology differences can make study findings more difficult to compare.  
 
5.5.3 Demographic variables with SAF, dAGE and oxidative stress 
No meaningful relationships were found in this study between dAGEs and any of 
the different demographic variables measured. Hörner et al. (2018) presented 
similar results suggesting the lack of a meaningful association between 
measurements such as BMI and dAGE (501).  
 
Both age and BMI were found to be statistically significant predictors of SAF in 
this study. The strong correlation between age and SAF was an expected finding 
as it is known that AGEs accumulate with age (494, 500, 532).There are 
conflicting conclusions in previous research regarding the correlation between 
SAF and BMI. Some studies have found that in healthy adults BMI and SAF do 
not correlate (498, 500, 533), and others have found statistically significant 
correlations (494, 532, 534). However Corstjens et al. (2008) found that BMI was 
only significantly related to SAF in healthy adults under the age of 40 (532). 
Indeed, this may explain the lack of a correlation found in this study as all 
recruited participants were aged 50 or older. Higher BMI and BMR in this study 
were also related to lower ascorbate levels and in an environment of increased 
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oxidative stress it would be expected that ascorbate, as an antioxidant would be 
at a decreased level (103). These results support the already established 
relationship between oxidative stress and increased BMI and obesity (506, 535, 
536), with Kimmons et al. (2006) similarly finding that ascorbate levels were lower 
obese participants (537).  
 
No relationship was found between SAF, smoking history and alcohol intake in 
this study, or between circulating oxidative stress markers and these parameters. 
Tobacco smoke can increase oxidative stress and is a known exogenous source 
of AGEs (10, 507, 538). It has previously been shown that smoking and smoking 
history are positively correlated with increased SAF (512, 533, 534). However, 
the finding that SAF was not at a higher level in the previous smoker participants 
compared to ‘never’ smoked participants in this study is consistent with previous 
research by van Waateringe et al. (2017) who found that smoking cessation had 
a reversible effect on SAF level. After approximately 15 years of smoking 
cessation SAF levels are thought to be comparable to ‘never’ smokers (539). All 
of the participants who were ‘previous smokers’ in this study had been non-
smokers for a minimum of 15 years, with the majority having not smoked for 20 or 
more years (see Table 5.1). In a similar manner the finding that there was no 
significant correlation between circulating oxidative stress biomarkers and 
smoking history is consistent, since it had been such a long period of smoking 
cessation (540). The lack of relationship between alcohol consumption and SAF 
is also in accordance with the previous literature; Jochemsen et al. (2009) found 
alcohol consumption not to be correlated with SAF (541). In addition the different 
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AGE databases agree with one another, estimating alcohol intake to be of either 
little or no value (14, 53).  
 
As previously stated in Section 3.3.2.4 the AGE reader is able to measure 
pigmented skin ranging from 1 to 4 in the Fitzpatrick skin colour classification. It is 
unable to read darker skin pigment classifications 5 and 6.  As shown in Table 
5.1 the majority of participants in this study were Caucasian or ‘white other’. This 
reflects the population in the South West of England where 95% of the population 
describe themselves as ‘White British’ or ‘White other’ (542). All participants who 
volunteered for this study had their AGE reading successfully measured, this 
included participants who described their ethnicity as ‘Indian’ and ‘Mixed 
white/black Caribbean’ whose characteristics would usually be linked to 
Fitzpatrick class 5 (416, 543). This suggests reflectance thought to be associated 
with certain ethnicities and the capabilities of the AGE reader should be 
reviewed. Due to the low number of participants with darker skin pigmentation in 
this study the relationship between ethnicity, skin reflectance and SAF could not 
be determined.  
 
An incidental finding regarding reflectance, an additional output from the AGE-
reader when measuring SAF, was revealed during data analysis. Reflectance 
positively correlated with body fat percentage, fat mass and BMI. Fat cells 
(adipocytes) aggregate to form adipose tissue. Bashkatov et al. (2005) measured 
human subcutaneous adipose tissue and found it to have a spectral range from 
400 to 1500 nm (544). As explained in Section 3.3.2.4 the AGE reader emits UV-
A light with a peak wavelength of 375 nm to excite the fluorescent AGEs in the 
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skin. Since these wavelengths do not overlap the adipocytes should not be 
excited. However results from this study show a correlation between the 
demographic variables body fat percentage, fat mass and BMI with skin 
reflectance. Reflectance is not a parameter usually reported by studies using the 
AGE reader, hence this correlation has not previously been reported. This 
relationship requires further investigation since reflectance is part of the SAF 
calculation. A possible relationship could therefore impact and influence SAF 
readings.  
 
5.6 Conclusion 
This study suggests that the contribution of dietary AGE to tissue-bound AGE 
levels may be minimal. This however requires further investigation, this will be 
aided by the development of new AGE databases, expanding with more types of 
AGEs measured than in the past (444).  
 
The relationship between oxidative stress and AGEs was investigated. No 
associations between oxidative stress biomarkers and dAGE were found. The 
oxidative stress biomarker alpha tocopherol weakly correlated with SAF, this was 
however in the opposite way than was hypothesised and therefore requires 
further investigation before the relevance and insight that could be gained from 
this finding can be determined. The results suggest that tissue-bound AGEs 
measured by SAF and the circulating oxidative stress biomarkers measured in 
this study are not closely related. For this reason the AGE reader, SAF, should 
not simply be used as a marker for oxidative stress and instead the two 
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measures should be used alongside each other, rather than interchangeably in 
place of each other. 
 
5.7 Limitations 
Plasma CML (ng/ml) was not included in this chapter. Statistical analyses were 
performed to investigate the relationships between plasma CML and SAF, 
demographic parameters, dAGE and oxidative stress biomarkers. No 
relationships were found between plasma CML and any of these listed 
parameters. We believe that this may be due to the standards given with the 
ELISA kit not being in the same range as the measurements found which 
impacted the results. 
 
As mentioned in Section 5.2 the AGE reader is only able to measure fluorescent 
AGEs. None of the dAGEs calculated from the databases available have 
fluorescent properties. It has however been shown that fluorescent AGEs 
positively correlate with other non-fluorescent AGEs (21), as part of validation of 
the AGE reader. In addition, other molecules in the skin are known to fluoresce 
and influence SAF measurement. 
 
FFQs are heavily reliant on accurate responses from the participant. This is a 
limitation of all FFQ based studies.  
 
This study did not measure the levels of AGEs excreted by the body in the urine. 
This data would have enabled a calculation of the amount of dAGEs absorbed in 
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the body. It would be interesting to know if amount of dAGE absorbed relates to 
SAF.  
 
5.8 Future work 
To measure dAGE intake, dAGE excretion, and SAF to assess if absorption is 
associated with tissue-bound AGE levels. Since the AGE reader was able to 
successfully measure SAF readings in participants whose characteristics would 
be linked to Fitzpatrick class 5 further research is required to better understand 
the capabilities of the AGE reader and establish which ethnicity groups can be 
measured accurately. Further investigation into how body fat percentage and fat 
mass impact SAF measurements is also required.  
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6.0 AGE levels in early stage POAG, NTG and OHT patients 
 
6.1 Abstract 
Purpose: To determine whether tissue bound and dietary AGE levels are 
elevated in POAG and NTG in comparison to age-matched OHT patients and 
healthy controls. Oxidative stress levels were considered as a possible 
influencing factor.   
 
Methods: Skin autofluorescence (SAF) as a measurement of tissue-bound AGE 
level was measured in 33 healthy control participants, 16 OHT, 12 NTG and 32 
POAG patients. A fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers. 
 
Results: SAF was significantly higher in NTG and POAG compared to healthy 
controls (p = 0.005). Furthermore, POAG patients had a lower ascorbate (p = 
<0.001) and alpha tocopherol (p = <0.001) level than healthy controls. There was 
no statistically significant difference in dAGE value between the groups nor 
between contributing factors such as BMI and blood pressure.  
 
Conclusion: AGE (SAF) level was significantly higher in NTG and POAG 
compared to healthy controls. This finding adds to the evidence that SAF, as an 
accessible measure, may be a suitable long-term biomarker of glaucoma. 
Patients with POAG exhibited lower levels of the antioxidants ascorbate and 
alpha tocopherol compared to OHT and healthy controls, suggesting oxidation 
inhibition. Dietary AGE intake was similar between healthy controls, OHT, NTG 
and POAG patients. 
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6.2 Background 
 
AGEs are known to accumulate in and around the ONH with the specific AGE 
pentosidine having been found in increased amounts in cribriform plates of the 
lamina cribrosa (203) and the specific AGE pyrraline being found in the sclera, 
pia matter, cribriform plates, optic nerve connective tissues and around the 
vessels in the optic nerve (204). It is hypothesised that AGE accumulation in and 
around the ONH may contribute to the mechanism of GON (204). Indeed, Tezel 
et al. (2007) measured the accumulation of the specific AGE CML in 
glaucomatous and age-matched control donor eyes, and found an increase in 
AGE and RAGE in those with glaucoma (20). The AGEs were primarily detected 
in the cribriform plates of the optic nerve head, while RAGE was seen on glial 
cells, mainly the Müller cells (20). It is thought that AGEs may be responsible for 
the reduced ability of the cribriform plates to withstand strain, increased rigidity of 
lamina cribrosa (20) and may also impair the ONH vasculature. The increased 
presence of AGEs in glaucomatous tissues and AGEs accumulation with age 
supports the accelerated ageing theory of glaucomatous optic neuropathy 
development (20).  
 
As well as accumulating in the ONH AGEs affect vascular function in the eye by 
creating crosslinks in the vessel wall collagen causing stiffening (136, 341, 342) 
and by creating an imbalance in ET-1 and NO (132, 133) promoting endothelial 
dysfunction. The cumulative effect is that accumulation of AGEs in blood vessels 
negatively affects vessel structure and function. This is relevant as compromised 
or variable supply of blood to the optic nerve head causes retinal ganglion cell 
death (255, 259). Blood flow regulation in GON has been widely researched 
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(260-263) and has been linked to increased severity of the disease (260, 261, 
264).  
 
To date, only a few studies have been able to explore the possibility that AGEs 
may be an underlying causative factor for GON. In addition to the study by Tezel 
et al. (2007), which used healthy control and glaucoma donor eyes (20), Moschos 
et al. (2017) measured two RAGE gene polymorphisms in POAG patients and 
healthy controls. The results showed that the gene and allele frequencies were 
not significantly different between the groups, suggesting that RAGE 
polymorphisms are not associated with POAG susceptibility (545). A study by 
Hondur et al. (2017) examined AGE levels in the serum of glaucoma patients and 
found AGE levels were higher than in control patients, however this study did not 
state the type of AGE measured by ELISA, hence this result should be viewed 
with caution (546). The other three studies examining AGE in glaucoma have 
used the AGE-reader (DiagnOptics B.V., Groningen, The Netherlands) to 
measure AGE level (SAF). A recent study by Schweitzer et al. (2018) measured 
SAF in 31 open angle glaucoma patients, and found that SAF level was higher in 
glaucoma patients than healthy controls (115). The other two studies were 
conducted by the same research group; the first examined patients with NTG and 
found that there was no significant difference in SAF levels between NTG and 
healthy controls, but did report that SAF was correlated with circumpapillary 
retinal nerve fibre layer thickness and visual field mean deviation (119). The 
second study similarly found no significant difference in SAF level between OAG 
patients and healthy controls (118). 
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It is known that a proportion of OHT participants are likely to develop POAG. The 
Ocular Hypertension Treatment Study (OHTS) recruited 1,636 participants and 
over a 5 year follow up found that 4.4% of the treated group and 9.5% of the 
observation group went on to develop POAG (547). Age is an independent risk 
factor for OHT participants developing glaucoma (548, 549). It is this link with 
ageing as well as the known links with glaucoma that makes AGE levels in OHT 
patients an area of interest. Indeed, in addition to this, OHT patients are 
interesting as a large proportion of them do not develop POAG. Understanding if 
AGEs are at similar levels or not to POAG may aid understanding as to why 
many OHT do not develop POAG.  
 
6.2.1 Aims 
To determine whether tissue bound and dietary AGE levels are elevated in early 
stage POAG and NTG in comparison to age-matched OHT patients and healthy 
controls. Oxidative stress levels will be compared as a possible influencing factor.   
 
6.2.2 Hypothesis 
Tissue bound AGE (SAF) level and dAGE intake will be higher in the glaucoma 
groups than OHT and control groups. Oxidative stress marker MDA will be 
higher, and antioxidants ascorbate and alpha tocopherol lower in glaucoma 
groups compared to OHT and control groups.  
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6.3 Methods 
The methodology used in this study is summarised here; more detailed 
information on the specifics of each technique can be found in Chapter 3. 
 
6.3.1 Participants  
Convenience sampling was used to recruit participants who were eligible 
according to the study’s inclusion and exclusion criteria, the inclusion criteria for 
participants are detailed in section 3.1.3, exclusion detailed in section 3.1.4. Due 
to the established link between diabetes and AGEs (449, 450) participants 
diagnosed with diabetes, and participants found to have a high fasting glucose 
level, were excluded from the study, as were current smokers, and previous 
smokers who quit less than 15 years ago due to the link between AGEs and 
tobacco (10). POAG, NTG and OHT participants were identified through their 
attendance at routine outpatient appointments at Derriford REI.  
6.3.2 General investigations  
As described in 3.3.2.1, height was measured in meters using a stadiometer, 
weight was measured in kg and from these measurements BMI was calculated. 
Weight, basal metabolic rate (BMR), and body fat percentage were measured 
using the Tanita body composition analyser (TBF-300 MA). Blood pressure was 
measured and a fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers. Three oxidative stress biomarkers 
were used, the non-enzymatic antioxidants ascorbate (vitamin C) and alpha 
tocopherol (form of vitamin E) and the product of lipid peroxidation 
malondialdehyde (MDA). Each biomarker is described in Section 3.3.2.6. 
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Oxidative stress is linked with glaucoma and is thought to be a contributing factor 
to glaucomatous RGC death (306-309). RGCs are understood to be susceptible 
to oxidative stress due to their high oxygen consumption (312) and light exposure 
(313). MDA has been identified as one of the best circulating oxidative stress 
biomarkers and is commonly used in glaucoma research (550). Oxidative stress 
and AGEs accompany one another, AGE levels can be influenced by oxidative 
stress levels and vice versa. Previous chapters have assessed the AGE oxidative 
stress relationship in healthy controls, the results suggest that AGEs measured 
by SAF and the circulating oxidative stress biomarkers MDA, ascorbate and 
alpha tocopherol are not closely related. Although oxidative stress is not thought 
to be the primary influence on AGEs its contribution still needs to be considered. 
Each biomarker is described in Section 3.3.2.6 and method for analysis 
described in Appendix 6. 
 
6.3.3 Skin autofluorescence (SAF) 
The measurement of tissue-bound AGE levels was obtained using the AGE 
Reader (DiagnOptics B.V., Groningen, The Netherlands). The AGE Reader is a 
non-invasive device, which provides a low cost, fast, and reproducible means of 
determining AGE levels in the body through utilisation and measurement of the 
fluorescent properties of tissue-bound AGEs in the skin (21-23). Specific detail on 
the AGE reader and its protocol can be found in Chapter 3, section 3.3.2.4.  
 
6.3.4 Dietary AGE, semi-quantitative FFQ 
An assessment of dietary AGE intake over the last year was made using a semi-
quantitative FFQ that was designed specifically to assess dietary AGE levels in a 
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UK population for the purposes of this research. The FFQ design and delivery is 
discussed in Chapter 4. The FFQ was administered to all participants. The results 
from the FFQ were calculated with each of the databases described in Chapter 4.  
As explained previously in Section 4.3.1, use of all of the different AGE 
databases available in this study enabled the measurement of dietary intake of 
CEL and MG-H1 in addition to CML from the FFQ responses. It is important to 
note that CML, CEL and MG-H1 do not fluoresce (510), hence the FFQ 
measures different types of AGEs to the AGE-reader. 
 
6.3.5 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and visual inspection of the QQ 
plots.  P values of less than 0.05 were considered significant.  
 
6.3.5.1 General characteristics between groups 
Mann-Whitney U test was used to analyse the demographic data. An ANOVA 
was used to compare the results of general investigations, namely: gender, age, 
BMI, SBP, DBP, IOP, MABP and OPP between the four groups (POAG, NTG, 
OHT and HC).  
 
6.3.5.2 SAF, dAGE and oxidative stress between groups 
An ANOVA was used to compare the SAF level between groups, followed by the 
post-hoc analysis Scheffe. An ANOVA was then used to compare dAGE between 
groups and oxidative stress between groups.  
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Parameters identified as different between groups were entered into a correlation 
with SAF, to examine any possible relationship between SAF and oxidative 
stress. 
 
6.3.5.3 Power calculation 
The sample size was determined using data from previous research which also 
measured tissue-bound AGE level using AGE Reader between healthy and 
disease groups (83). In order to achieve 80% power at the 5% alpha level a 
sample size of 37 per group was required (NTG, POAG, OHT and controls). To 
account for unusable data an allowance was made and a sample size of 40 
participants was chosen per group. 
 
6.4 Results  
 
A total of 32 POAG, 12 NTG, 16 OHT and 33 healthy control participants were 
recruited and eligible for the study. These recruitment numbers are below 
intended target; this was due to recruitment difficulties of finding participants that 
met the strict inclusion criteria. Post-hoc power calculation using G*Power 3 
programme (Heinrich-Heine, Universität Düsseldorf) revealed a 66% power at a 
5% alpha level. The number of participants recruited were sufficient to obtain 
significant results.  
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6.4.1 Group characteristics 
There were no significant differences in age, BMI, systemic blood pressure, IOP, 
MABP and OPP between the four groups (p > 0.05). The characteristics of the 
participant group with mean and standard deviation are detailed in Table 6.1. It 
was expected that there would not be a significant difference in IOP between the 
groups since the OHT, POAG and NTG patients were all taking their prescribed 
IOP lowering treatment as normal. There was no significant difference between 
the NTG and POAG group’s visual field mean deviation. 
 
Table 6.1: Summary of mean and standard deviation of participant characteristics for the study 
groups. P<0.05 is considered a significant difference. BMI: body mass index, SBP: systolic blood 
pressure, DBP: diastolic blood pressure, IOP: intraocular pressure, MABP: mean arterial blood 
pressure, OPP: ocular perfusion pressure, was subsequently calculated using MABP and IOP 
values, MD: mean deviation from visual field data collected from REI appointment, OHT MD 
added for reference in brackets.  
 
 
 
Variable HC OHT NTG POAG ANOVA 
p value 
N 33 16 12 32  
Gender  F:22 M:11 F:7 M:9 F:5 M:7 F:14 M:18  
Age (years) 65.97 ±9.43 65.94 ±8.10 72.17 ±7.16 67.72 ±7.398 0.146 
BMI 25.62 ±3.36 26.48 ±4.58 26.60 ±4.39 26.26 ±4.32 0.844 
SBP (mmHg) 134.82 ±16.93 139.56 ±16.84 140.17 ±17.35 140.00 ±19.16 0.625 
DBP (mmHg) 80.67 ±10.17 85.38 ±9.28 81.33 ±9.56 84.91 ±9.56 0.252 
IOP (mmHg) 16.39 ±2.72 18.00 ±3.16 14.83 ±3.16 16.71 ±3.93 0.099 
MABP (mmHg) 98.72 ±11.11 103.44 ±10.68 100.94 ±10.79 103.27 ±11.38 0.340 
OPP 49.63 ±7.91 50.96 ±9.16 52.46 ±7.07 52.17 ±9.36 0.623 
MD (dB)  (-0.19 ±0.95) -3.62 ±1.32 -3.95 ±1.72  
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6.4.2 SAF  
A significant difference was found between groups with regard to SAF (p = 0.005, 
Table 6.2). Post-hoc testing found SAF to be significantly higher in the POAG and 
NTG patients than in healthy controls (POAG p = 0.018, NTG p = 0.05).  SAF 
level in the OHT patients was not significantly different to healthy controls or to 
the glaucoma groups (p>0.05).   
 
Table 6.2: Difference in mean SAF between groups. SAF: Skin autofluorescence, AU: arbitrary 
units. P<0.05 is considered significant.  
 
 
6.4.3 Dietary AGE  
No significant differences were found between groups with regard to any of the 
dAGE values calculated using FFQ responses (p > 0.05, Table 6.3). In addition, 
no significant relationships were present between the dAGE calculated for each 
database with SAF for each group (p = >0.05) 
 
 
 
 
 
 
 
 HC (1) OHT (2) NTG (3) POAG 
(4) 
ANOVA  
p value 
Post-hoc 
SAF 
(AU) 
2.19 ±0.39 2.44 ±0.42 2.6 ±0.39 2.54 ±0.45 0.005 3, 4 > 1 
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Table 6.3: Difference in mean dAGE between groups (± standard deviation). dAGE: dietary 
advanced glycation end-products. P<0.05 is considered a significant difference. Uribarri CML 
(average CML kU/day), Hull CML (average mg CML/day), Scheijen CML (average mg CML/day), 
Scheijen CEL (average mg CEL/day)m Scheijen MG-H1 (average mg MG-H1/day).  
 
 
6.4.4 Oxidative stress biomarkers  
A significant difference was found between groups with each of the oxidative 
stress biomarkers measured (see Table 6.4). Post-hoc testing found the 
antioxidant ascorbate to be significantly lower in POAG compared to all other 
groups. In addition, post-hoc testing found that alpha tocopherol was lower in the 
POAG group compared to HC and OHT groups, and not significantly different to 
NTG. The ANOVA showed a significant difference in MDA between the groups, 
however the post-hoc tests did not confirm this, with the tests between groups not 
significant (p > 0.05). 
 HC OHT NTG POAG ANOVA 
p value 
Uribarri 
CML  
18560 ±6672 19485 ±5963 19899 ±6849 22837 ±15733 0.430 
Hull CML  5.66 ±1.61 6.72 ±2.05 6.13 ±1.83 6.45 ±1.99 0.213 
Scheijen 
CML  
4.03 ±1.53 4.07 ±2.05 3.23 ±0.65 3.69 ±1.17 0.330 
Scheijen 
CEL  
3.03 ±0.89 2.99 ±1.04 2.98 ±0.83 3.12 ±0.91 0.954 
Scheijen 
MG-H1  
30.52 ±9.45 30.86 ±12.91 27.72 ±6.40 32.83 ±10.24 0.497 
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Table 6.4: Difference in mean oxidative stress biomarker levels between groups (± standard 
deviation). P<0.05 is considered a significant difference. Ascorbate (uM), MDA (uM), Alpha 
tocopherol (umol/L). 
 
Pearson’s correlation between SAF and ascorbate in the POAG group (r = -
0.130, p = 0.226, 95% bootstrap confidence interval -0.336 to 0.087), and 
between SAF and alpha tocopherol in the POAG and NTG groups (r = 0.149, p = 
0.163, 95% bootstrap confidence interval -0.064 to 0.351) were not statistically 
significant. Hence, there was no significant relationship between reduced levels 
of antioxidants and SAF.  
 
6.5 Discussion  
The aim of this study was to determine if both tissue-bound AGE levels (SAF) 
and dAGE were different in POAG, NTG, OHT and healthy control participants. 
Oxidative stress was also assessed due to the known links with AGEs and 
glaucoma. It is thought that this is the first study to examine dAGE and tissue-
bound AGE (SAF) levels in OHT, NTG, POAG patients in conjunction with each 
other.  
 
 
 HC (1) OHT (2) NTG (3) POAG (4) ANOVA 
p value 
Post-
hoc 
Ascorbate  54.14 
±18.44 
62.69 
±11.37 
52.81 
±11.85 
30.83 
±10.85 
<0.001 4 < 1,2,3 
MDA  6.43  
±1.85 
7.88 
±2.75 
5.36 
±1.16 
6.09 
±2.73 
  0.034  
Alpha 
tocopherol  
42.31 
±15.98 
41.66 
±6.46 
37.85 
±5.36 
29.44 
±8.91 
<0.001 4 < 1,2 
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6.5.1 SAF  
POAG and NTG patients were found to have a significantly higher SAF level 
compared to healthy controls. These results are in agreement with the previously 
published study by Schweitzer et al. (2018) which found SAF was higher in OAG 
patients that controls (115), and also agrees with the Tezel et al. (2007) which 
found accumulation of the AGE CML and RAGE in glaucomatous compared to 
control donor eyes (20). The result of the study does differ to the two studies by 
Himori et al., in which SAF was not significantly different between OAG patients 
and healthy controls (118, 119). The results of the Himori et al. studies may have 
been impacted by the inclusion of participants with diabetes in the healthy control 
group.  
 
This study recruited OHT patients in addition to glaucoma patients. Interestingly 
the mean SAF level for OHT patients was above healthy control levels and below 
both glaucoma groups. This result does to some extent match what is known 
about OHT patients in that they do not have a signs of pathology, yet are at 
increased risk of ONH damage compared to healthy individuals. A long-term 
follow-up study would aid understanding as to if SAF is linked with OHT patients 
progression to glaucoma.  
 
Although there are many similarities between NTG and POAG it is thought that 
there are differing levels of vascular and mechanical involvement (551). Although 
vascular dysregulation has been identified in individuals with POAG, it is not 
traditionally considered a primary cause, as opposed to in NTG, where it is 
thought to be a more significant part of glaucomatous development and 
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progression (552, 553). On the other hand, IOP, is not considered a primary 
causative factor in NTG (554), but is strongly linked with the mechanical theory of 
POAG development, with higher IOP associated with POAG development and 
progression (552, 555, 556). In more recent years, rather than segregating POAG 
and NTG, it has been proposed that open angle glaucoma should be thought of 
as a disease continuum (242, 244), with the relative influences of mechanical and 
vascular factors varying on an individual basis. Indeed, it has previously been 
shown that both early stage POAG and early stage NTG patients can have 
similar ocular and systemic circulation altercations (243). The results of this study 
found that both NTG and POAG patients had a significantly higher SAF 
compared to healthy controls. In addition the SAF result between NTG and 
POAG was not statistically different to one another.  
 
In a similar manner to OAG disease continuum theory it may be that the extent to 
which AGEs affect the different structures related to mechanical involvement and 
vascular function differs in different patients. It may also be that AGEs equally 
affect mechanical and vascular function and are hence a factor in both POAG 
and NTG pathogenesis. Since SAF is raised in both POAG and NTG a reduction 
in AGE level would likely be beneficial for both forms of OAG.  
 
6.5.2 Dietary AGE  
There was no difference in dAGE intake between the groups. This was the case 
for each of the dAGEs calculated using FFQ responses with each of the different 
AGE databases available. This result indicates that the patients diagnosed with 
glaucoma recruited for this study had a similar dAGE intake to healthy controls, 
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suggesting that dAGE intake is not a causative factor in glaucoma onset. It 
should however be noted that this estimation of dAGE is a short-term indicator as 
the FFQ estimates intake over the previous 12 months. Current dAGE research is 
focused on only short-term effects (54) as this is what is feasible to measure with 
dietary recall methods (425). It could however be that a sustained high diet of 
dAGE over many years could have an influence, or could contribute in part to 
elevated tissue bound AGE levels. Further research is required to understand if 
long-term restriction of dAGE is in anyway beneficial.  
 
6.5.3 Oxidative stress 
The antioxidant alpha tocopherol was found to be at reduced levels in POAG 
patients compared to HC and OHT in this study. Furthermore, levels of the 
antioxidant ascorbate were found to be reduced in POAG compared to all other 
groups. This reduced antioxidant level agrees with the findings of Gherghel et al. 
(2005) who found that the antioxidant glutathione was reduced in POAG 
compared to healthy controls (323). The reduced levels of circulating ascorbate 
and alpha tocopherol may be due to a higher rate of oxidative reactions, however 
if this was the case it would be expected that levels of the oxidant MDA would be 
increased. MDA has been used in multiple glaucoma studies to measure 
oxidative stress (550). It was expected that MDA levels would be significantly 
higher in the glaucoma groups compared to OHT and healthy controls based on 
previous literature, however this was not the case. The lack of result with MDA 
could be related to a difference in glaucoma severity between this study and 
previous POAG MDA studies, as this study only included patients with early 
stage glaucoma. This notion could not be verified as the previous studies 
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measuring circulating levels of MDA in POAG have not specified how 
advanced/the progression of POAG in their participants. Each did however state 
that having glaucomatous visual field loss was part of the inclusion criteria (108, 
557-559).  
 
The lack of correlation between reduced antioxidant levels and SAF supports the 
conclusion of Chapter 5 that AGEs measured by SAF are not closely related to 
circulating oxidative stress biomarkers. This suggests that a higher SAF in 
glaucoma patients may be independent of oxidative stress levels.  
 
6.6 Conclusion  
SAF was significantly higher in patients with NTG and POAG compared to 
healthy controls. This finding adds to the evidence that SAF, as an accessible 
measure, may be a suitable long-term biomarker of glaucoma. Understanding if 
AGEs influence vascular parameters more than structural parameters of tissues 
is not yet established. Dietary AGE intake was similar between healthy controls, 
OHT, NTG and POAG patients. Patients with POAG exhibited lower levels of the 
antioxidants ascorbate and alpha tocopherol compared to OHT and healthy 
controls, suggesting oxidation inhibition. There was however no increased level 
of MDA. 
 
 6.7 Limitations  
The sample size recruited was lower than the target sample size, this potentially 
limits the conclusions drawn from this study. The challenge with recruitment of 
early stage glaucoma participants and OHT participants was due to the strict 
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inclusion/exclusion criteria. These criteria however were necessary to avoid any 
other influences on AGE level, e.g. if smokers were included this may have 
masked any other relationships. In addition the recruitment between glaucoma 
groups was not even, with fewer NTG patients recruited. The number recruited 
participants however was able to provide statistically significant results.  
 
6.8 Future work 
To assess if baseline AGE (SAF) levels are associated with an increased rate of 
progression in NTG and POAG patients. In addition, to determine whether SAF 
levels are associated with OHT progression to develop POAG.  
To assess if long-term restriction of dAGE is beneficial in terms of glaucoma 
progression. 
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7. The relationship between tissue-bound AGE levels (SAF), 
retinal vessel structure and function and corneal 
viscoelastic properties in a healthy ageing population 
 
7.1 Abstract 
Purpose: To determine how SAF is associated with static and dynamic retinal 
vessel parameters as well as corneal viscoelasticity, in a healthy ageing 
population.  
 
Methods: Skin autofluorescence (SAF) as a measurement of tissue-bound AGE 
level was measured in 60 healthy participants and compared to dynamic and 
static vessel parameters measured by the Dynamic Retinal Vessel Analyser 
(DVA; IMEDOS GmbH, Jena, Germany) and corneal viscoelasticity measured by 
the Corvis ST (Oculus; Optikgeräte GmbH, Wetzlar, Germany). A fasting venous 
blood sample was obtained to enable the measurement of oxidative stress 
biomarkers. 
 
Results: Central retinal artery equivalent diameter (CRAE) was found to be 
negatively associated with SAF (r = -0.313, p = 0.015, 95% CI -0.077 to -0.512) 
and positively associated with circulating levels of the antioxidant ascorbate (r = 
0.258, p = 0.048, 95% CI 0.004 to 0.473). This association was further assessed 
with forwards and backwards multiple regression analysis, the independent 
variables included were CRAE, age, ascorbate, BMI, BMR and MG-H1. The 
model revealed that age (p = <0.001), BMI (p = 0.010) and CRAE (p = 0.015) 
were significantly associated with SAF. These findings were also found to be true 
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in the backwards model. No statistically significant relationships existed between 
SAF and dynamic retinal parameters or corneal viscoelastic parameters. 
 
Conclusion: Higher levels of tissue-bound AGE (SAF) are associated with 
narrower retinal arteries in a healthy population. This finding adds to the evidence 
that AGEs are an accessible marker of vascular health. Increased levels of 
ascorbate were associated with wider retinal arteries, this supports the notion that 
diet derived antioxidants may have a protective effect. In this healthy population 
SAF was not found to be associated with dynamic vessel parameters or corneal 
viscoelastic parameters.  
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7.2 Background 
 
In the eye the earliest signs of age-related change are often alterations in 
structure and function of the transparent structures, such as the lens and cornea 
(158, 560-562) and the microvascular blood supply to the retina and optic nerve 
(563-566). These age-related changes have been linked to a number of disease 
states (562, 565, 566). Determining whether AGE levels are influencing the 
structure and function of these components of the eye will be a focus of this 
study. The relationship between ageing, AGEs and cataract formation in the lens 
is well established (see Section 1.11.5), and will not be discussed in this Chapter 
(7, 81, 84, 170, 171). In the cornea it is known that there is an increase AGEs in 
the stroma with increased age (158), and it is thought that the modification to 
collagen contributes to the reduced flexibility seen with age (159, 160). 
Accumulation of AGEs has been shown to disturb the structure of blood vessels 
by altering the extra-cellular matrix and blood vessel function via the AGE-RAGE 
reaction (13, 138, 142, 207, 342). Altered retinal vessel structure and function 
has previously been linked to a number of ocular and systemic disease states, 
including cardiovascular disease, Alzheimer’s disease, diabetes, obesity, 
hypertension, hyperlipidaemia, AMD and glaucoma  (243, 368-370). 
 
There are no previous studies that have explored whether tissue-bound AGE 
levels are directly associated with retinal vessel structure and function. 
Establishing this relationship across a healthy ageing population is the first step 
to increasing our understanding of the impact that AGE accumulation in tissues 
may be having on the microvasculature and hence the potential contribution it 
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could make to the pathogenesis of diseases with a vascular origin. The potential 
association between AGEs and vascular function is important as altered retinal 
vascular function has been linked with ocular pathology (140, 281).   
 
The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) 
has been used as a measure of retinal microvascular function in both healthy 
ageing and ocular and systemic disease research (243, 368-370). The DVA uses 
luminance flicker light to instigate vessel response and assess dynamic retinal 
vessel function (376). In a normal healthy person this heightened metabolic 
demand causes the retinal endothelium to release additional NO, resulting in 
vasodilation and consequently increased blood flow (379) (see Section 3.3.2.2). 
A failure to observe this vasodilation response has been linked to the presence of 
vascular endothelial dysfunction (304) or perhaps to an increase in vascular 
stiffness (342).  
 
Although the association between AGE level and retinal vessel structure and 
function has not previously been explored there are a number of studies that 
have linked AGEs to alterations in blood vessel structure and function at the 
systemic level. AGEs and the AGE-RAGE interaction for example has been 
shown to cause an increase in ET-1 levels (132) and reduced bioavailability and 
activity of NO (133), with the overall effect of vasoconstriction and a disturbance 
in the regulatory function of the endothelium. Furthermore, the AGE-RAGE 
interaction has been linked to endothelial cell hyperpermeability which can 
eventually lead to impairment of the blood-retinal barrier (567). In addition, as 
explained in Section 1.5, AGEs have also been shown to cause direct damage to 
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the systemic vasculature by forming covalent cross-links in the long-lived proteins 
of extracellular matrix, such as collagen and elastin in blood vessels (74, 568). 
These AGE induced cross-links alter the mechanical properties of the protein, 
resulting in increased vessel stiffness, increased vessel wall thickness, increased 
rigidity and reduced elasticity (38, 71, 72, 75, 136). Finally, a study by Yoshioka 
(2018) examined the maximum intima–media thickness (IMT) of the carotid artery 
in diabetic participants and found that increased SAF was associated with 
increased IMT (569). All of these findings indicate that AGE accumulation has the 
potential to influence blood vessel structure and the ability of blood vessels to 
regulate blood flow to ensure supply meets demand, with the potential effect of 
putting tissues at risk of ischaemic-hypoxic damage (570, 571).  
 
As previously mentioned it has been shown that there is an increase in AGEs in 
the corneal stroma with increased age (2). There are however no previous 
studies that have explored whether AGE levels are directly associated with 
corneal viscoelasticity. A recent study by Bekmez and Kocaturk (2018) used the 
ORA to measure corneal biomechanics in diabetic patients and healthy controls 
and found that mean corneal hysteresis was lower in diabetic patients than 
healthy controls. They go on to explain that “We do not know ‘how and why’ 
diabetes affects corneal biomechanical measurements. It may be related to 
glucose level or something else possibly affecting the elasticity or viscosity of the 
cornea.” (572). Since AGE levels are known to be increased in diabetic patients 
(69, 573) it may be that increased an AGE level is altering corneal mechanical 
properties.  
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We hypothesise that AGEs may be a contributing factor to the reduced corneal 
viscoelasticity seen with age and that in individuals with elevated AGE levels, this 
age-related reduction in viscoelasticity could occur at an accelerated rate. 
Establishing this relationship across a healthy ageing population is the first step 
to increasing our understanding of the impact that AGE accumulation may be 
having and the potential contribution to the pathogenesis of diseases. The 
viscoelastic biomechanics of the cornea has been linked with glaucoma (337, 
574). In addition, it has previously been suggested by Kotecha et al. (2007) that 
the biomechanical properties of the cornea may indicate overall globe mechanics, 
indicating stiffness of structures that cannot easily be measured (156).  
 
7.2.1 Aims 
To determine how tissue-bound AGE levels are associated with static and 
dynamic retinal vessel parameters and corneal viscoelasticity in a healthy ageing 
population.   
 
7.2.2 Hypothesis 
Retinal microvasculature structure and function will be associated with tissue-
bound AGE levels (SAF), with increased SAF having a negative impact on the 
microvasculature. Corneal viscoelasticity will be related to AGEs, with an 
increased AGE level resulting in reduced elasticity.  
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7.3 Methods 
The methodology that will be used in this study is summarised here; more 
detailed information on the specifics of each technique can be found in Chapter 
3. 
 
7.3.1 Participants  
Convenience sampling was used to recruit participants who were eligible 
according to the inclusion and exclusion criteria for healthy ageing participants as 
detailed in section 3.1.3. and section 3.1.4. Due to the established link between 
diabetes and AGEs (449, 450) participants diagnosed with diabetes or 
participants found to have a high fasting glucose level were excluded from the 
study, as were current smokers, and previous smokers who quit less than 15 
years ago due to the link between AGEs and tobacco (10).  
 
A total of 71 participants were recruited, 60 of which were eligible for the study. 
One participant was excluded due to a diagnosis of arrhythmia between 
recruitment and study appointment. A second was excluded due to them 
revealing that although they quit smoking tobacco 15 years ago they continue to 
smoke non-tobacco products. A third participant was excluded due to use of fake 
tanning agent. As explained in section 3.3.2.2.3, the DVA raw data was assessed 
for quality. A further eight participants were excluded due to DVA cycles not 
meeting the quality criteria.  
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7.3.2 General investigations  
Participant’s eyes were examined with visual acuity recorded as well as a slit 
lamp exam: anterior eye health examined, angles graded with Van Herick 
technique and posterior pole assessed.  Proxymetacaine 0.5% drops were 
inserted, Goldmann tonometry performed and tropicamide 0.5% drops inserted 
for pupil dilation. 
 
As described in 3.3.2.1, height was measured in meters using a stadiometer, 
weight was measured in kg and from these measurements BMI was calculated. 
Weight, basal metabolic rate (BMR), and body fat percentage were measured 
using the Tanita body composition analyser (TBF-300 MA). Blood pressure was 
measured and a fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers.  
 
In Chapter 5 the relationship between tissue-bound AGEs and oxidative stress 
was examined. The results suggested that tissue-bound AGEs and the circulating 
oxidative stress biomarkers used in this study cannot be used interchangeably, 
although there is clear evidence from the literature that AGEs and oxidative 
stress have a complex relationship and therefore it was decided that for this study 
oxidative stress markers would also be considered. Three oxidative stress 
biomarkers were used: ascorbate, MDA and alpha tocopherol. Each biomarker is 
described in section 3.3.2.6. Oxidative stress markers were measured due to 
their known associations with AGEs. 
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7.3.3 Dynamic Retinal Vessel Analyser (DVA) 
The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) 
was used to assess both dynamic and static retinal vessel function. It is a non-
invasive device, with high reproducibility (373) and low variability (374). Specific 
detail on the DVA and its protocol for both dynamic and static measurements can 
be found in Section 3.3.2.2.  
 
The dynamic parameters calculated from the raw data included: baseline 
diameter fluctuation (BDF), dilation amplitude (DA), baseline corrected flicker 
response (BFR), maximum percentage dilation (MD%), reaction time (RT), 
minimum percentage constriction (MC%), constriction time (CT) for artery and 
vein. For full list of descriptions of these parameters see Table 3.4 in Section 
3.3.2.2. Particpants were asked to maintain normal eating habits before DVA 
measurement as fasting can cause abnormal vascular activity (385).  
 
The VesselMap2 software (ImedosSystems, Jena, Germany) was used to enable 
the retinal vasculature structure to be examined and evaluated (393). The static 
VesselMap2 software calculates central retinal artery equivalent (CRAE) and 
central retinal vein equivalent (CRVE) using the disc centred red-free fundus 
photograph and manually selected vessels, described in Section 3.3.2.2.  
 
7.3.4 Corvis ST 
The viscoelastic properties of the cornea were assessed using the Corvis ST 
(Oculus; Optikgeräte GmbH, Wetzlar, Germany). The Corvis ST is a noncontact 
tonometry system, for specific detail see Section 3.3.2.3. The parameters used: 
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first applanation time, second applanation time, velocity of corneal surface 
movement at the first applanation, velocity of corneal surface movement at 
second applanation, deformation amplitude at first applanation, deformation 
amplitude at second applanation, highest deformation amplitude, corneal highest 
concavity and highest concavity time. Corvis measurements were taken for each 
eye of each participant.  
 
7.3.5 Skin autofluorescence (SAF) 
The measurement of tissue-bound AGE levels was obtained using the AGE 
Reader (DiagnOptics B.V., Groningen, The Netherlands). The AGE Reader is a 
non-invasive device, which provides a low cost, fast, and reproducible means of 
determining AGE levels in the body through utilisation and measurement of the 
fluorescent properties of tissue-bound AGEs in the skin (21-23). Specific detail on 
the AGE reader and its protocol can be found in Section 3.3.2.4. 
 
7.3.6 Dietary AGE, semi-quantitative FFQ 
An assessment of dietary AGE intake over the last year was made using a semi-
quantitative FFQ that was designed specifically to assess dietary AGE levels in a 
UK population for the purposes of this research. The FFQ design and delivery is 
discussed in Chapter 4. The FFQ was administered to all participants. The results 
from the FFQ were calculated with each of the databases described in Chapter 4.  
The results of Chapter 5 suggested that the contribution of dietary AGE to tissue-
bound AGE levels is minimal, and that further investigation is required to 
understand which, if any, types of AGEs are impacting tissue-bound levels. MG-
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H1 appears to be the dAGE most likely to impact tissue-bound AGE levels, for 
this reason MG-H1 was the dAGE included in this study. 
 
7.3.7 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and visual inspection of the QQ 
plots. P values of less than 0.05 were considered significant. 
Mann-Whitney U test was used to check for differences in categorical data.   
 
7.3.7.1 Relationship between retinal vessel structure and function parameters 
and SAF  
Spearman’s rank correlation was used to analyse the association between each 
dynamic retinal vessel parameter, namely: BDF, DA, BFR, MD%, RT, MC% and 
CT for artery and vein with SAF.   
Spearman’s rank correlation was used to analyse the association between each 
structural static retinal vessel parameter, namely: CRAE and CRVE with SAF. 
 
Parameters found to correlate with SAF were entered into a stepwise forward and 
backward multiple linear regression was used to further assess the influence of 
different variables on SAF. Age and BMI were included in the multiple regression 
since in Chapter 5 it was found they influence SAF, the dAGE MG-H1 as a 
possible relevant form of dAGE. Due to oxidative stress having previously been 
shown to be both a cause and an effect of increased AGE formation (see Section 
1.7) oxidative stress biomarkers were also included in the multiple linear 
regression.  
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7.3.7.2 Relationship between corneal viscoelasticity and SAF 
Spearman’s rank correlation was used to analyse the association between each 
corneal parameter, namely: first and second applanation time, velocity of corneal 
surface movement at the first and second applanation, deformation amplitude at 
first and second applanation, highest deformation amplitude and time of highest 
concavity with SAF.  
 
7.3.7.3 Power Calculation 
Sample size was determined using G*Power 3 programme (Heinrich-Heine, 
Universität Düsseldorf). In order to achieve 80% power at the 5% alpha level with 
a medium effect size of 0.3, 64 participants would be required. To account for 
unusable data an allowance was made and a sample size of 71 participants was 
chosen. 
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7.4 Results  
All 60 eligible participants were free of acute or chronic diseases, including 
diabetes, with the exception of controlled hypertension. The characteristics of the 
participant group with mean and standard deviation are detailed in Table 7.1.  
Collectively the participants blood pressure fell within normal limits, as described 
by the World Health Organisation & International Society of Hypertension 
guidelines (SBP: 120-129, DBP: 80-84) (575). The group were overweight, with a 
mean BMI of 26 ± 4 kg/m2.   
 
 
Table 7.1: Mean and standard deviation of participant group characteristics. AU: arbitrary units.  
 
 
 
 
 
Variable Mean  ± SD 
Gender (n)  Male 
                    Female 
17 
43 
Age (years) 60.02 ± 8.86 
Body mass index (BMI) 26.29 ± 4.84 
Systolic blood pressure (SBP) (mmHg) 129.12 ± 17.23 
Diastolic blood pressure (DBP) (mmHg) 80.57 ± 10.28 
Mean arterial blood pressure (MABP) 96.75 ± 11.27 
Intraocular pressure (IOP) (mmHg) 15.70 ± 3.21 
Ocular perfusion pressure (OPP) 48.79 ± 7.79 
Skin autofluorescence (SAF) (AU) 2.22 ± 0.36 
Ascorbate (μM) 51.41 ± 18.31 
Malondialdehyde (MDA) (μM) 6.23 ± 1.91 
Alpha tocopherol (µM) 43.12 ± 16.10 
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7.4.1 Dynamic retinal vessel analysis 
No statistically significant correlations were found between any of the dynamic 
retinal vessel parameters (artery and vein) and SAF as shown in Table’s 7.2 and 
7.3. 
 
 
 
Table 7.2: Artery dynamic parameters, mean, standard deviation and spearman’s correlation with 
SAF. AU: arbitrary units, BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: 
baseline corrected flicker response, MD%: maximum percentage dilation, RT: reaction time, 
MC%: minimum percentage constriction, CT: constriction time.  
 
 
 
 
 
 
 
 
 
Artery  
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
BDF 2.32 ± 1.21  0.007,  p = 0.956 
DA 4.51 ± 3.20 0.144,  p = 0.272 
BFR 2.24 ± 2.50 0.165,  p = 0.207  
MD % 2.89 ± 2.27 0.131,  p = 0.319 
RT (secs) 15.31 ± 5.41 -0.033,  p = 0.803 
MC % 1.61 ± 1.63 0.123,  p = 0.349 
CT (secs) 22.85 ± 7.82 0.215,  p = 0.098 
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Table 7.3: Vein dynamic parameters, mean, standard deviation and spearman’s correlation with 
SAF. AU: arbitrary units, BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: 
baseline corrected flicker response, MD%: maximum percentage dilation, RT: reaction time, 
MC%: minimum percentage constriction, CT: constriction time.  
 
 
7.4.2 Static retinal vessel analysis 
Table 7.4 shows the mean, standard deviation of the static retinal parameters. 
Spearman’s rank correlation showed a negative relationship between SAF and 
CRAE (r = -0.313, p = 0.015, 95% bootstrap confidence interval -0.077 to -0.512), 
Figure 7.1. There was no statistically significant association between CRVE and 
SAF (r = 0.061, p = 0.641, 95% bootstrap confidence interval -0.204 to 0.302). 
 
 
 
 
 
Vein 
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
BDF 2.34 ± 1.51 -0.140,  p = 0.287 
DA 5.55 ± 2.81 -0.075,  p = 0.570 
BFR 3.21 ± 1.87 0.008,  p = 0.950  
MD % 4.57 ± 2.11 -0.098,  p = 0.458 
RT (secs) 18.47 ± 3.07 -0.004,  p = 0.978 
MC % 0.991 ± 1.26 0.015,  p = 0.912 
CT (secs) 31.07 ± 7.31 -0.147,  p = 0.262 
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Table 7.4: Static vessel parameters, mean, standard deviation and Spearman’s correlation with 
SAF. AU: arbitrary units, CRAE: central retinal artery equivalent, CRVE: central retinal vein 
equivalent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.1: Relationship between Skin autofluorescence (SAF) (AU) and central retinal artery 
equivalent (CRAE) (MU) (n = 60, r = -0.313, p = 0.015, 95% CI -0.077 to -0.512). 
Static 
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
CRAE 180.95 ± 18.36 -0.313,  p = 0.015 
CRVE 210.80 ± 17.57 0.061,  p = 0.641 
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Spearman’s rank correlation also showed a positive relationship between CRAE 
and ascorbate (r = 0.258, p = 0.048, 95% bootstrap confidence interval 0.004 to 
0.473), Figure 7.2, there was no statistically significant association between 
ascorbate and CRVE (r = 0.123, p = 0.354, 95% bootstrap confidence interval -
0.145 to 0.364). There and no association between static vascular parameters 
and MDA or alpha tocopherol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Relationship between Ascorbate (µM) and central retinal artery equivalent (CRAE) 
(MU)   (n = 60, r = 0.123, p = 0.354, 95% CI -0.145 to 0.364). 
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The association between SAF and CRAE was further assessed with forwards 
and backwards multiple regression analysis, the independent variables included 
were CRAE, age, ascorbate, BMI, BMR and MG-H1. The model revealed that 
age (p = <0.001), BMI (p = 0.010) and CRAE (p = 0.015) were significantly 
associated to SAF. These findings were also found to be true in the backwards 
model.   
 
7.4.3 Corvis ST analysis 
Spearman’s Rank revealed no statistically significant correlations between any of 
the corneal parameters and SAF, as shown in Table 7.5. 
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Table 7.5: Corneal viscoelastic parameters, mean, standard deviation and spearman’s correlation 
with SAF. AU: arbitrary units, Time A1: first applanation time, Time A2: second applanation time, 
Velocity A1: velocity of corneal surface movement at the first applanation, Velocity A2: velocity of 
corneal surface movement at second applanation, Deformation amp. A1: deformation amplitude 
at first applanation, Deformation amp. A2: deformation amplitude at second applanation, Highest 
deformation amp: highest deformation amplitude.  
 
 
 
 
 
 
 
Corneal 
parameters 
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
Time A1 (ms) 7.33 ± 0.31 0.140,  p = 0.394 
Time A2 (ms) 21.83 ± 0.45 -0.105,  p = 0.526 
Velocity A1 (m/s) 0.15 ± 0.02 -0.227,  p = 0.165  
Velocity A2 (m/s) -0.27 ± 0.03 0.290,  p = 0.074 
Deformation amp. 
A1 (mm) 
0.13 ± 0.13 0.033,  p = 0.840 
Deformation amp. 
A2 (mm) 
0.44 ± 0.44 0.113,  p = 0.492 
Highest 
deformation amp. 
(mm) 
1.09 ± 0.10 -0.265,  p = 0.103 
Highest 
concavity time 
(ms) 
16.47 ± 0.50 0.012,  p = 0.942 
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7.5 Discussion  
The aim of this study was to determine if SAF is associated with static and 
dynamic retinal vessel parameters and corneal viscoelasticity in a healthy ageing 
population. It is thought that this is the first study to compare SAF levels with 
these retinal vessel and corneal parameters in a healthy ageing population.   
 
7.5.1 Relationship between retinal vessel structure and function and SAF  
Higher SAF levels were found to be associated with narrower retinal arteries in 
this healthy ageing population. Narrowing of microvascular arteries is part of the 
normal ageing process (576), but the influence of tissue-bound AGE (SAF) levels 
on this finding has not been previously explored. At the macrovascular level 
however, increased SAF has been associated with increased maximum IMT of 
the carotid artery in diabetic patients (569). It is thought that the microvasculature 
is affected earlier than the macrovasculature (304, 577), hence SAF may be 
associated with IMT of retinal vessels. AGEs are known to increase cross-links in 
the proteins of the extra-cellular matrix of blood vessels (74, 136, 568). This 
accumulation may contribute to thickening of the inner layers of the artery wall 
and could be a possible explanation for why a narrower CRAE was associated 
with SAF. It is worth noting that changes to retinal vessels are likely to be 
multifactorial, and although this study has identified a relationship between SAF 
and CRAE it cannot ascertain if AGEs are indeed a causative factor in retinal 
artery narrowing.  
 
An increase in CRVE has been associated with obesity, dyslipidaemia and 
markers of vascular endothelial dysfunction (398, 402). As the AGE-RAGE 
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interaction disrupts endothelial function (132, 133), it was hypothesised that 
increased SAF level may be related to increased CRVE. However in contrast to 
CRAE, no statistically significant relationship was found between CRVE and SAF. 
This could be related to structural component differences between arteries and 
veins, whereby arteries have a thicker tunica media and increased collagen and 
elastin in comparison to veins, since they have more extracellular matrix (578). 
As explained previously AGEs form covalent cross-links in the collagen and 
elastin of the extracellular matrix (74, 568). The structure of the arteries may 
therefore be more susceptible to AGE crosslinking than the vein (216).  
 
A positive correlation was found in this study between the antioxidant ascorbate 
and CRAE, suggesting that lower antioxidant levels are associated with narrower 
retinal artery diameters. An increased ascorbate level suggests that ascorbate 
has not had to scavenge free radicals, hence there is not an environment of 
oxidative stress (103). Therefore the lack of relationship with MDA is consistent, 
as MDA is a lipid peroxidation product present in environments of increased 
oxidative stress. It has previously been proposed that ascorbate is the most 
effective non-enzymatic antioxidant present in the plasma (427), this may explain 
why only ascorbate and not alpha tocopherol correlated with CRAE. Ascorbate, 
as a diet derived antioxidant is considered to have a protective effect (579), this 
appears to be evidenced here with increased ascorbate correlating with a wider 
CRAE.  
 
No statistically significant correlations existed between any of the dynamic 
vascular function parameters and SAF or oxidative stress. This suggests that the 
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AGE and oxidative stress levels are not affecting retinal microvascular function in 
the healthy population examined in this study. This however may be related to 
the fact this healthy ageing group do not have a high AGE level, hence the AGE 
related associated effects not present. Previously Seshadri et al. (2015) found 
that the non-enzymatic antioxidant GSH did correlate with retinal microvascular 
dynamic responses and suggested that this was due to increased levels of 
oxidative stress impairing endothelium‐dependent dilation (370). Since ascorbate 
and alpha tocopherol are both non-enzymatic antioxidants (92), it was 
hypothesised that the GSH correlation would be replicated, however this was not 
the case. One possible explanation for the difference is that ascorbate and alpha 
tocopherol levels in the healthy participants in this study were above or within 
normal range (454, 509), indicating that oxidative stress was not present, hence 
may explain why oxidative stress associated effects were not present. In addition, 
it is worth noting that GSH has a large range in what is considered normal values 
in the literature (150-1500 µM). Rossi et al. (2002) described difficulties in the 
measurement of GSH and concluded that most published data may be affected 
by multiple artefacts (580), this may have impacted the Seshadri et al. (2015) 
results and may also add to why there is a difference between Seshadri et al. 
(2015) results and those from this study.  
 
7.5.2 Relationship between corneal viscoelasticity and SAF  
There were no statistically significant correlations between the corneal 
viscoelastic parameters measured and SAF. This suggests that the AGE levels 
may not be related to corneal viscoelasticity in the healthy population examined 
in this study. It may also be related to the fact this healthy ageing group do not 
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have a high AGE level, hence the AGE related associated changes may not be 
present. The recruited participants in this study were aged 50 to 90 years, it was 
noted that the older participants free from any general health conditions had a 
lower AGE level than expected for their age, for example a participant aged 90 
had a SAF of 2.80 AU, which would be approximately normal for an 80 year old. 
It was anticipated that recruiting participants in the age range of 50 to 90 would 
give differing results, however this was not the case. Future studies examining 
SAF and corneal viscoelasticity would benefit from recruiting a larger age range, 
to enable a larger range of SAF and viscoelasticity results.    
 
 7.5.3 Possible healthy volunteer effect 
The mean SAF of this healthy group of participants was 2.22 ± 0.36. This result is 
lower than expected, since a study with a healthy participant group of similar 
mean age had a mean SAF of 2.46 ± 0.57 (420). Indeed the mean SAF of a 
study by Kellow et al. (2017) was closer at 2.10 ± 0.60, however the average age 
of the group was considerably younger (47 years) (494). This suggests that the 
group recruited in this study has possibly been subject to a healthy volunteer 
effect. This may help to explain why there are no adverse associations with 
vascular or corneal parameters that would be expected to be affected by 
increased AGE level. In addition the standard deviation of SAF measures was 
low, this low variability of the data means that there are no particularly high or low 
AGE values in this data. Low variance is possibly problematic here as the lack of 
association may be due more to the fact participants have a normal AGE level 
and little AGE effect rather than there truly being no association between AGEs 
and the retinal vasculature and cornea.  
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7.6 Conclusion 
Higher levels of tissue-bound AGE (SAF) are associated with narrower retinal 
arteries in a healthy population. This finding adds to the evidence that AGEs are 
an accessible marker of vascular health. Increased levels of ascorbate were 
associated with wider retinal arteries, this supports previous literature that diet 
derived antioxidants may have a protective effect (579). In this healthy population 
SAF was not found to be associated with dynamic vessel parameters or corneal 
viscoelastic parameters. This suggests that AGE levels may not be related to 
dynamic vessel parameters or corneal viscoelasticity, although it should be 
considered that this recruited healthy group had a lower mean SAF than 
expected.  
 
7.7 Limitations 
By excluding all disease linked to AGEs the resultant group of participants were 
particularly healthy and as a result had a lower SAF level than was expected for 
mean age.  
 
7.8 Future work 
Having a wider age range would enable a better comparison of corneal elasticity. 
The relationship between corneal viscoelasticity and SAF should be further 
assessed with participants with a wider age range. In addition the use the ORA in 
conjunction with the Corvis ST and AGE-reader to enable examination of corneal 
hysteresis and corneal resistance factors relationship with SAF. 
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8.0 The relationship between tissue bound AGE levels, static 
and dynamic retinal vessel structure and function, and 
corneal viscoelasticity in POAG, NTG and OHT patients 
 
 
8.1 Abstract 
 
Purpose: To evaluate how tissue bound AGE level (SAF) relates to static and 
dynamic retinal vessel structure and function and corneal viscoelasticity in 
POAG, NTG and OHT patients. 
 
Methods: 33 healthy control (HC) participants, 16 OHT, 12 NTG and 32 POAG 
patients had skin autofluoresence (SAF) measured using the AGE Reader 
(DiagnOptics B.V., Groningen, The Netherlands), static and dynamic retinal 
vessel structure and function evaluated using the Dynamic Retinal Vessel 
Analyser (DVA; IMEDOS GmbH, Jena, Germany) and corneal viscoelasticity 
measured using the Corvis ST (Oculus; Optikgeräte GmbH, Wetzlar, Germany). 
 
Results: Increased SAF was found to correlate with a decrease in corneal 
viscoelasticity velocity A1 (m/s) (r = -0.748, p = 0.033, 95% CI -0.838 to 0.102) 
and reduced deformation amplitude at A1 (r = -0.714, p = 0.047, 95% CI -0.115 to 
-0.997) in NTG patients. There were no significant differences with OHT or POAG 
patients. No significant relationships were found between dynamic and static 
retinal vascular parameters and SAF for any group, however NTG patients were 
found to have a significantly smaller static CRAE diameter (p=0.048) than healthy 
controls.  
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Conclusion: Ageing is a multifactorial process and similarly glaucoma is thought 
to be influenced by multiple factors. In the NTG group a less viscoelastic, stiffer 
cornea was related to increased SAF level. There was no significant relationship 
in the OHT or POAG groups. There were no statistically significant relationships 
between SAF and dynamic and static vascular parameters in any groups, 
however CRAE was found to be narrowest in the NTG group.  
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8.2 Background 
In Chapter 6 SAF was shown to be significantly higher in NTG and POAG 
patients compared to healthy controls. This finding adds to the evidence that 
SAF, as an accessible measure, may be a suitable long-term biomarker of 
glaucoma. To establish how AGEs may contribute to glaucoma pathogenesis it is 
important to establish the structures they may be affecting. This evaluation is 
particularly interesting as POAG, NTG and OHT are thought to have differing 
levels of vascular and mechanical involvement.  
 
Studies investigating the vascular effects of AGEs have linked increased AGE 
levels to vascular stiffness and endothelial dysfunction, both of which have also 
been linked to glaucoma pathogenesis (243, 304, 328, 344, 345). AGEs are 
thought to cause increased vessel stiffness due to increased cross-linking (136), 
and to contribute to endothelial dysfunction by increasing ET-1 levels (132) and 
reducing availability and activity of NO (133). A decrease in the availability of NO 
and an increase in ET-1 can result in excessive vasoconstriction and subsequent 
blood flow dysregulation (292, 293). Interestingly, in NTG and POAG patients, 
levels of NO in the plasma have been found to be at a reduced level compared to 
healthy controls (294-296), and levels of ET-1 have been shown to be at higher 
levels in NTG (297, 298) and POAG patients (299, 300). It is therefore of interest 
to explore whether a relationship between vascular parameters and SAF is 
evident within these patient groups due to the known underlying AGE 
mechanism.  
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Hysteresis is a viscoelastic property of the cornea; it describes the difference 
between behaviour in ‘loading’ and ‘unloading’ conditions (574). A lower corneal 
hysteresis (less viscoelastic cornea) has been found in patients diagnosed with 
glaucoma; in addition, a lower corneal hysteresis has been linked with 
progressive visual field worsening (337, 581, 582). Prata et al. (2012) found that 
low corneal hysteresis is linked with glaucomatous nerve head signs such as 
larger cup to disc ratio and increased cup depth, and in those with bilateral 
glaucoma, 75% of participants with lower corneal hysteresis had a larger cup to 
disc ratio (338). Murphy et al. (2017) examined corneal hysteresis in patients with 
glaucoma, OHT and glaucoma-like optic discs and found corneal hysteresis to be 
higher (more viscoelastic) in OHT and glaucoma-like discs compared to 
glaucoma, suggesting that increased viscoelasticity of the cornea may have a 
beneficial, protective role against glaucoma (340).   
 
As previously mentioned it has been shown that there is an increase in AGEs in 
the corneal stroma with increased age (2). Chapter 7 explored whether AGE 
levels were directly associated with corneal viscoelasticity in healthy control 
participants, and the results showed no significant relationship. This result 
however may have been influenced by a healthy volunteer effect. No previous 
studies have directly linked AGE (SAF) level and corneal viscoelasticity in OHT, 
NTG and POAG patients.  
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8.2.1 Aims 
To evaluate whether level of tissue bound AGEs (SAF) relates to static and 
dynamic retinal vessel structure and function and corneal viscoelasticity in 
POAG, NTG and OHT patients. 
 
8.2.2 Hypothesis 
Tissue bound AGE (SAF) level will be associated with static and dynamic vessel 
parameters and corneal viscoelasticity parameters in NTG, POAG, OHT groups.  
 
8.3 Methods 
The methodology used in this study is summarised here; more detailed 
information on the specifics of each technique can be found in Chapter 3. 
 
8.3.1 Participants  
Convenience sampling was used to recruit participants who were eligible 
according to the study’s inclusion and exclusion criteria. The inclusion criteria for 
participants are detailed in section 3.1.3, exclusion detailed in section 3.1.4. Due 
to the established link between diabetes and AGEs (449, 450) participants 
diagnosed with diabetes or participants found to have a high fasting glucose level 
were excluded from the study, as were current smokers, and previous smokers 
who quit less than 15 years ago due to the link between AGEs and tobacco (10). 
POAG, NTG and OHT participants were identified through their attendance at 
routine outpatient appointments at Derriford REI.  
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IOP lowering medication was not an exclusion factor for this study as diagnosed 
early stage glaucoma or OHT patients were required. With this in mind, it should 
be noted that some participants were prescribed a beta-blocker or combination 
drop which contained a beta-blocker, this applied to 18 of the recruited 
participants (OHT: n = 2, NTG: n = 3, POAG: n = 13). It is possible that 
vasoactive eye-drops influence retinal blood vessel parameters (583-585), 
however AGE level would likely be unaffected. In addition participants were 
asked to refrain from using their drops on the morning of the study.  
 
8.3.2 General investigations  
As described in 3.3.2.1, height was measured in meters using a stadiometer, 
weight was measured in kg and from these measurements BMI was calculated. 
Weight, basal metabolic rate (BMR), and body fat percentage were measured 
using the Tanita body composition analyser (TBF-300 MA). Blood pressure was 
measured and a fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers. Three oxidative stress biomarkers 
were used, the non-enzymatic antioxidants ascorbate (vitamin C) and alpha 
tocopherol (form of vitamin E) and the product of lipid peroxidation 
malondialdehyde (MDA). Each biomarker is described in Section 3.3.2.6. 
 
8.3.3 Dynamic Retinal Vessel Analyser (DVA) 
The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) 
was used to assess both dynamic and static retinal vessel function. It is a non-
invasive device, with high reproducibility (373) and low variability (374). Specific 
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detail on the DVA and its protocol for both dynamic and static measurments can 
be found in Section 3.3.2.2.  
 
The dynamic parameters calculated from the raw data included: baseline 
diameter fluctuation (BDF), dilation amplitude (DA), baseline corrected flicker 
response (BFR), maximum percentage dilation (MD%), reaction time (RT), 
minimum percentage constriction (MC%), constriction time (CT) for artery and 
vein. For full list of descriptions of these parameters see Table 3.3 in Section 
3.3.2.2. Pariticpants were asked to maintain normal eating habits before DVA 
measurement as fasting can cause abnormal vascular activity (385).  
 
The VesselMap2 software (ImedosSystems, Jena, Germany) was used to enable 
the retinal vasculature structure to be examined and evaluated (393). The static 
VesselMap2 software calculates central retinal artery equivalent (CRAE) and 
central retinal vein equivalent (CRVE) using the disc centred red-free fundus 
photograph and manually selected vessels, described in Section 3.3.2.2.  
 
8.3.4 Corvis ST 
The viscoelastic properties of the cornea were assessed using the Corvis ST 
(Oculus; Optikgeräte GmbH, Wetzlar, Germany). The Corvis ST is a noncontact 
tonometer system, for specific detail see Section 3.3.2.3. The parameters used: 
first applanation time (time A1), second applanation time (time A2), velocity of 
corneal surface movement at the first applanation (velocity A1), velocity of 
corneal surface movement at second applanation (velocity A2), deformation 
amplitude at first applanation (deformation amplitude A1), deformation amplitude 
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at second applanation (deformation amplitude A2), highest deformation 
amplitude, and highest concavity time. Corvis measurements were taken for each 
eye of each participant.  
 
8.3.5 Skin autofluorescence (SAF) 
The measurement of tissue-bound AGE levels was obtained using the AGE 
Reader (DiagnOptics B.V., Groningen, The Netherlands). The AGE Reader is a 
non-invasive device, which provides a low cost, fast, and reproducible means of 
determining AGE levels in the body through utilisation and measurement of the 
fluorescent properties of tissue-bound AGEs in the skin (21-23). Specific detail on 
the AGE reader and its protocol can be found in Section 3.3.2.4. 
 
8.3.6 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and visual inspection of the QQ 
plots. P values of less than 0.05 were considered significant.  
 
8.3.6.1 General characteristics between groups 
Mann-Whitney U test was used to analyse the demographic data. A one-way 
ANOVA was used to compare the results of general investigations between the 
groups.  
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8.3.6.2 SAF associated with vascular parameters 
Vascular parameters, both from retinal artery and vein, were entered into a 
Pearson’s correlation with SAF, to examine any possible relationships.  
 
8.3.6.3 Static vessel parameters between groups 
A one-way ANOVA was used to compare the static retinal vessel parameters, 
namely: CRAE and CRVE followed by the post-hoc analysis Scheffe.  
 
8.3.6.4 SAF associated with corneal parameters 
Corneal parameters were entered into a Pearson’s correlation with SAF, to 
examine any possible relationships.  
 
8.3.6.5 Relationship between corneal parameters in the groups  
An ANOVA was used to compare the corneal parameters measured by the 
Corvis ST between the groups, followed by the post-hoc analysis Scheffe. 
 
8.3.6.6 Power calculation 
The sample size was determined using data from previous research which also 
measured tissue-bound AGE level using AGE Reader between healthy and 
disease groups (83). In order to achieve 80% power at the 5% alpha level a 
sample size of 37 per group was required (NTG, POAG, OHT and controls). To 
account for unusable data an allowance was made and a sample size of 40 
participants was chosen per group. 
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8.4 Results  
A total of 32 POAG, 12 NTG, 16 OHT and 33 healthy control participants were 
recruited and eligible for the study.   
 
8.4.1 Group characteristics 
There were no significant differences in age, BMI, systemic blood pressure, IOP, 
MABP and OPP between the four groups (p > 0.05). The characteristics of the 
participant group with mean and standard deviation are detailed in Table 8.1. It 
was expected that there would not be a significant difference in IOP between the 
groups since the OHT, POAG and NTG patients were all taking their prescribed 
IOP lowering treatment as normal.  
 
Table 8.1: Summary of mean and standard deviation of participant characteristics for the study 
groups. P<0.05 is considered a significant difference. BMI: body mass index, SBP: systolic blood 
pressure, DBP: diastolic blood pressure, IOP: intraocular pressure, CDR: cup to disc ratio, CCT: 
central corneal thickness, MABP: mean arterial blood pressure, OPP: ocular perfusion pressure, 
was subsequently calculated using MABP and IOP values. MD: mean deviation from visual field 
data collected from REI appointment, OHT MD added for reference in brackets.  
Variable HC (1) OHT (2) NTG (3) POAG (4) ANOVA 
p value 
N 33 16 12 32  
Gender F:22 M:11 F:7 M:9 F:5 M:7 F:14 M:18  
Age (years) 65.97 ±9.43 65.94 ±8.10 72.17 ±7.16 67.72 ±7.398 0.146 
BMI 25.62 ±3.36 26.48 ±4.58 26.60 ±4.39 26.26 ±4.32 0.844 
SBP (mmHg) 134.82 ±16.93 139.56 ±16.84 140.17 ±17.35 140.00 ±19.16 0.625 
DBP (mmHg) 80.67 ±10.17 85.38 ±9.28 81.33 ±9.56 84.91 ±9.56 0.252 
IOP (mmHg) 16.39 ±2.72 18.00 ±3.16 14.83 ±3.16 16.71 ±3.93 0.099 
MABP (mmHg) 98.72 ±11.11 103.44 ±10.68 100.94 ±10.79 103.27 ±11.38 0.340 
OPP 49.63 ±7.91 50.96 ±9.16 52.46 ±7.07 52.17 ±9.36 0.623 
MD (dB)  (-0.19 ±0.95) -3.62 ±1.32 -3.95 ±1.72  
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As shown in Chapter 6 a significant difference was found between groups with 
regard to SAF (p = 0.005, Table 6.2). Post-hoc testing found SAF to be 
significantly higher in the POAG and NTG patients than in healthy controls 
(POAG p = 0.018, NTG p = 0.05).  SAF level in the OHT patients was not 
significantly different to healthy controls or to the glaucoma groups (p>0.05).   
 
Copy of Table 6.2 from Chapter 6: Difference in mean SAF between groups (± standard 
deviation). SAF: skin autofluorescence, AU: arbitrary units. P<0.05 is considered significant.  
 
 
 
8.4.2 Dynamic retinal vessel analysis 
8.4.2.1 Relationship between SAF and dynamic retinal artery parameters 
In Chapter 7 Table 7.2 and 7.3 show that there were no statistically significant 
correlations between SAF and any of the dynamic retinal vessel parameters 
(artery and vein) in healthy control participants. Table 8.2 shows the mean and 
standard deviation for the retinal artery dynamic parameters of each group. Table 
8.3 shows the correlations between SAF and each dynamic retinal artery 
parameter, no statistically significant relationships were detected (all p > 0.05).  
 
 
 
 HC (1) OHT (2) NTG (3) POAG (4) ANOVA  
p value 
Post-
hoc 
SAF 
(AU) 
2.19 ±0.39 2.44 ±0.42 2.6 ±0.39 2.54 ±0.45 0.005 3, 4 > 1 
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Table 8.2: Mean and SD of artery dynamic parameters, BDF: baseline diameter fluctuation, DA: 
dilation amplitude, BFR: baseline corrected flicker response, MD%: maximum percentage dilation, 
RT: reaction time, MC%: minimum percentage constriction, CT: constriction time.  
 
 
 
Table 8.3: Artery dynamic parameters Pearson’s correlation with SAF. AU: arbitrary units, BDF: 
baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected flicker response, 
MD%: maximum percentage dilation, RT: reaction time, MC%: minimum percentage constriction, 
CT: constriction time.  
 
Artery OHT NTG POAG 
BDF 2.42 ± 1.31 4.77 ± 4.04 3.11 ± 2.21 
DA 5.53 ± 3.08 5.59 ± 3.59 4.96 ± 7.96 
BFR 3.12 ± 2.55 1.46 ± 2.05 2.02 ± 2.05 
MD% 3.27 ± 3.03 3.58 ± 4.30 2.87 ± 2.48 
RT (secs) 15.22 ± 4.59 19.55 ± 5.67 14.69 ± 9.56 
MC% 2.27 ± 2.02 2.16 ± 1.67 2.31 ± 2.90 
CT (secs) 26.26 ± 8.55 21.09 ± 9.82 24.57 ± 7.49 
Artery  
 
 Pearson’s correlation coefficients (R values) 
 SAF (AU) 
OHT NTG POAG 
BDF 0.386, p = 0.155 -0.444, p = 0.171 0.032, p = 0.867 
DA -0.023, p = 0.935 -0.441, p = 0.174 -0.080, p = 0.676 
BFR -0.226, p = 0.418 -0.096, p = 0.778 -0.110, p = 0.563 
MD % -0.428, p = 0.112 -0.448, p = 0.167 -0.107, p = 0.575 
RT (secs) 0.211, p = 0.450 -0.107, p = 0.754 -0.129, p = 0.497 
MC % 0.306, p = 0.107 0.089, p = 0.795 -0.031, p = 0.870 
CT (secs) 0.048, p = 0.865 -0.413, p = 0.207 -0.107, p = 0.572 
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8.4.2.2 Relationship between SAF and dynamic retinal vein parameters 
Table 8.4 shows the mean and standard deviation for the retinal vein dynamic 
parameters of each group. Table 8.5 shows the correlations between SAF and 
each dynamic vein artery parameter, no significant relationships existed (all p > 
0.05).  
 
 
Table 8.4: Mean and SD of vein dynamic parameters, BFR: baseline diameter fluctuation, DA: 
dilation amplitude, BRF: baseline corrected flicker response, MD%: maximum percentage dilation, 
RT: reaction time, MC%: minimum percentage constriction, CT: constriction time.  
 
Vein OHT  NTG  POAG  
BDF 2.66 ±1.92 3.83 ±2.29 3.11 ±2.21 
DA 5.76 ±3.60 5.89 ±3.79 4.92 ±2.28 
BFR 3.35 ±2.79 2.54 ±2.63 2.54 ±1.86 
MD% 4.54 ±2.86 5.55 ±3.79 4.36 ±2.13 
RT (secs) 16.80 ±3.91 19.73 ±2.80 19.53 ±3.21 
MC% 1.22 ±1.42 0.65 ±1.43 0.97 ±1.47 
CT (secs) 26.11 ±8.55 30.00 ±10.43 32.56 ±6.32 
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Table 8.5: Vein dynamic parameters Pearson’s correlation with SAF. AU: arbitrary units, BDF: 
baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected flicker response, 
MD%: maximum percentage dilation, RT: reaction time, MC%: minimum percentage constriction, 
CT: constriction time.  
 
8.4.3 Static retinal vessel analysis 
Chapter 7 showed a negative relationship between SAF and CRAE (r = -0.313, p 
= 0.015, 95% bootstrap confidence interval -0.077 to -0.512), with no statistically 
significant association between CRVE and SAF (r = 0.061, p = 0.641, 95% 
bootstrap confidence interval -0.204 to 0.302) in healthy control participants. 
Table 8.7 shows the lack of significant correlation between SAF and static 
parameters in OHT, NTG and POAG patients. Figure 8.1 demonstrates the trend 
in association between CRAE and the groups when considered together.  
 
 
 
Vein 
 
Pearson’s correlation coefficients (R values) 
 SAF (AU) 
OHT NTG POAG 
BDF 0.151, p = 0.592 -0.376, p = 0.254 0.068, p = 0.723 
DA -0.156, p = 0.578 -0.262, p = 0.437 -0.043, p = 0.820 
BFR -0.390, p = 0.151 -0.140, p = 0.682 -0.137, p = 0.470 
MD % -0.320, p = 0.245 -0.220, p = 0.516 -0.035, p = 0.854 
RT (secs) -0.366, p = 0.181 0.156, p = 0.647 0.060, p = 0.753 
MC % 0.247, p = 0.374 -0.137, p = 0.687 -0.049, p = 0.798 
CT (secs) -0.293, p = 0.290 0.032, p = 0.926 -0.010, p = 0.957 
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Table 8.6: Central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) 
mean and standard deviation. 
 
 
 
Table 8.7: Central retinal artery equivalent (CRAE) and central retinal vein equivalent (CRVE) 
correlations with SAF. P<0.05 is considered a significant difference. 
 
 
When comparing CRAE and CRVE across the study groups the artery static 
parameter CRAE was significantly different between groups (ANOVA p = 0.024), 
post hoc testing revealed that NTG patients have a lower CRAE than HC (p = 
0.048). No significant difference was found between CRVE in the study groups 
(ANOVA p>0.05). 
 
 
 
 
 
Static HC  OHT  NTG  POAG  
CRAE 180.18 
±20.81 
175.64 
±17.94 
164.61 
±11.51 
171.56 
±17.97 
CRVE 210.67 
±19.27 
204.22 
±20.84 
206.83 
±18.86 
214.59  
±2.28 
Static 
 
Pearson’s correlation coefficients (R values) 
 SAF (AU) 
OHT NTG POAG 
CRAE -0.161, p = 0.567 0.349, p = 0.267 0.112, p = 0.548 
CRVE 0.018, p = 0.949 0.012, p = 0.971 -0.028, p = 0.883 
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Figure 8.1: Relationship between skin autofluorescence (SAF) (AU) and central retinal artery 
equivalent (CRAE) (MU) in each group.  
 
 
8.4.4 Corvis ST analysis 
The corneal viscoelasticity velocity A1 (m/s) significantly correlated with SAF (r = 
-0.748, p = 0.033, 95% bootstrap confidence interval -0.838 to 0.102) in the NTG 
group. As SAF increased, the velocity at A1 was slower, however as shown by 
the confidence interval, due to the low participant number we cannot be confident 
in this result. Deformation amplitude at A1 was also found to correlate with SAF 
in the NTG group (r = -0.714, p = 0.047, 95% bootstrap confidence interval -0.115 
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to -0.997). With increased SAF there was a decreased deformation amplitude, 
with the cornea becoming less deformed on A1.  
 
An ANOVA comparison of means revealed that there was no significant 
difference between the groups for velocity A1 and deformation amplitude A1 (P > 
0.05). The parameter CCT was however found to be different between the groups 
(ANOVA p = 0.011), post hoc testing revealed that NTG (p = 0.046) and POAG (p 
= 0.022) patients have a lower CCT than HC. 
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Table 8.8: Mean and SD of corneal viscoelastic parameters. Time A1: first applanation time, Time 
A2: second applanation time, Velocity A1: velocity of corneal surface movement at the first 
applanation, Velocity A2: velocity of corneal surface movement at second applanation, 
Deformation amp. A1: deformation amplitude at first applanation, Deformation amp. A2: 
deformation amplitude at second applanation, Highest deformation amp: highest deformation 
amplitude, CCT: central corneal thickness. 
 
 
 
 
 
 
 
 
 
 
 
 
Corneal 
viscoelasticity 
HC  OHT  NTG  POAG  
N 33 13 8 28 
Time A1 (ms) 7.33 ±0.37 7.45 ±0.30 7.18 ±0.18 7.34 ±0.25 
Time A2 (ms) 21.95 ±0.44 21.66 ±0.48 22.03 ±0.28 21.67 ±0.44 
Velocity A1 
(m/s) 
0.15 ±0.02 0.13 ±0.03 0.16 ±0.01 0.15 ±0.02 
Velocity A2 
(m/s) 
-0.26 ±0.03 -0.26 ±0.02 -0.28 ±0.02 -0.27 ±2.48 
Deformation 
amp. A1 (mm) 
0.13 ±0.01 0.13 ±0.01 0.13 ±0.01 0.13 ±0.01 
Deformation 
amp. A2 (mm) 
0.44 ±0.07 0.44 ±0.08 0.45 ±0.08 0.42 ±0.05 
Highest 
deformation 
amp. (mm) 
1.09 ±0.11 1.07 ±0.12 1.10 ±0.06 1.09 ±0.09 
Highest 
concavity time 
(ms) 
16.52 ±0.51 16.42 ±0.54 16.45 ±0.39 16.41 ±0.59 
CCT (μm) 555 ±34.34 550 ±21.22 527 ±45.39 526 ±36.62 
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Table 8.9: Corneal viscoelastic parameters correlation with SAF. AU: arbitrary units, Time A1: first 
applanation time, Time A2: second applanation time, Velocity A1: velocity of corneal surface 
movement at the first applanation, Velocity A2: velocity of corneal surface movement at second 
applanation, Deformation amp. A1: deformation amplitude at first applanation, Deformation amp. 
A2: deformation amplitude at second applanation, Highest deformation amp: highest deformation 
amplitude, CCT: central corneal thickness. 
 
 
 
 
 
Corneal 
parameters 
 
Pearson’s correlation coefficients (R values) 
 SAF (AU) 
OHT NTG POAG 
Time A1 (ms) 0.550, p = 0.053 0.000, p = 0.999 -0.181, p = 0.367 
Time A2 (ms) -0.484, p = 0.093 0.003, p = 0.993 0.314, p = 0.110 
Velocity A1 (m/s) -0.414, p = 0.159 -0.748, p = 0.033* 0.234, p = 0.240 
Velocity A2 (m/s) 0.424, p = 0.148 0.334,  p = 0.419 0.303, p = 0.882 
Deformation amp. 
A1 (mm) 
0.115, p = 0.708 -0.714, p = 0.047* -0.032, p = 0.872 
Deformation amp. 
A2 (mm) 
0.129, p = 0.675 -0.609, p = 0.109 0.105, p = 0.601 
Highest 
deformation amp. 
(mm) 
-0.167, p = 0.587 -0.652,  p = 0.080 0.201, p = 0.316 
Highest 
concavity time 
(ms) 
0.090, p = 0.770 -0.183, p = 0.664 -0.078, p = 0.698 
 CCT (μm) -0.086, p = 0.779 0.488, p = 0.220 0.011, p = 0.958 
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Figure 8.2 demonstrates the lack of relationship between CCT and the groups 
when considered together. Pearson’s correlation, including all groups showed no 
significant relationship between SAF and CCT (r = -0.005, p = 0.968, 95% 
bootstrap confidence interval -0.252 to 0.239), Figure 8.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2: Relationship between Skin autofluorescence (SAF) (AU) and central corneal thickness 
(CCT) with all groups shown (r = -0.005, p = 0.968, 95% CI -0.252 to 0.239).  
 
 
246 
 
8.5 Discussion 
The aim of this study was to determine how tissue-bound AGE levels (SAF) are 
related to retinal vascular parameters and corneal viscoelasticity parameters in 
POAG, NTG, OHT and healthy control participants. It is thought that this is the 
first study to examine SAF levels with retinal parameters and corneal parameters 
in these groups.  
 
8.5.1 Retinal vessel structure and function 
Early stage NTG patients were found to have significantly narrower CRAE in 
comparison to healthy controls. Early stage POAG participants also had a 
narrower CRAE than HC, however this difference was not statistically significant. 
The previous literature agrees that retinal arteriolar narrowing is associated with 
glaucoma (265, 586) and Kawasaki et al. (2013), in addition to concluding that a 
narrower CRAE was associated with higher risk of glaucoma incidence, also 
found that CRVE was not associated with glaucoma risk (587), which is 
consistent with the findings of this study.  
 
The exact mechanism for CRAE narrowing in glaucoma is unknown. One 
hypothesis is that the narrowing may occur as a secondary event to retinal 
ganglion cell loss, as fewer retinal ganglion cells results in reduction in oxygen 
demand (587). An alternative hypothesis is that tissue-bound AGEs are causing 
changes to the retinal vasculature. SAF has been related to the macro-
vasculature, with increased SAF associated with increased maximum IMT of the 
carotid artery in diabetic patients (569). It is thought that the microvasculature is 
affected earlier than the macro-vasculature (304, 577); hence, the finding of a 
247 
 
narrower CRAE may be linked to thickening of the inner layers of the retinal 
microvascular wall. 
 
NTG patients, alongside having a narrower CRAE, also had the highest mean 
value of SAF in this study. A significant correlation between CRAE and SAF, 
however was only evident in the healthy control participants and not in the NTG 
group. This makes it difficult to draw conclusions around whether tissue-bound 
AGEs are part of the mechanism causing retinal arteries to narrow in glaucoma 
patients from this study. It is possible that the lack of a significant relationship 
between SAF and CRAE found here may be a consequence of there being only a 
small number of NTG patients. Exploring CRAE and SAF levels with a larger 
group of NTG patients as well as assessing differing stages of glaucoma 
progression may help to aid understanding of whether this narrowing is indeed 
related to AGE levels within the tissues and whether this carries any pathogenic 
significance. 
 
As well as increased vessel wall thickness it is thought that AGE induced cross-
links alter the mechanical properties of the vessels resulting in increased vessel 
stiffness, and reduced elasticity (38, 71, 72, 75, 136). No relationship however 
was found between the dynamic artery or vein parameters and SAF in the POAG, 
NTG and OHT participants in this study. This result agrees and follows on from 
the dynamic vascular results in Chapter 7 where there was also no significant 
relationship between SAF and retinal dynamic vascular parameters in healthy 
control participants. AGEs are thought to affect systemic vascular function (216), 
and in type 2 diabetic patients SAF readings have been found to be an 
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independent predictor for the development of microvascular complications (588), 
these diabetic patients had a higher mean SAF level (2.74). It may be that since 
the patients in this study were systemically healthy and had a lower SAF level 
that AGE level had not yet influenced microvascular function. It must also be 
considered that since patients continued the use of their IOP lowering medication 
as normal this may have affected retinal vessel function.  However the vascular 
effects of IOP lowering drops on retinal vascular calibre is not fully understood 
(265), a review by Newman et al. (2018) found there was no consistent effect on 
retinal vessel width with the use of IOP lowering drops (585). 
 
8.5.2 Corneal viscoelasticity 
A less viscoelastic cornea has been linked with glaucoma (337, 581, 582), and it 
has been suggested that an increased viscoelasticity of the cornea may have a 
beneficial, protective role against glaucoma (340). As shown in Table 8.8 CCT 
was significantly different between the groups, with NTG and POAG having a 
thinner CCT than HC. It has been previously been shown that a thinner cornea 
experiences increased corneal deformation (589), however there was no 
significant difference in deformation between the groups despite CCT difference. 
This suggests that in this group of patients CCT was not influencing corneal 
deformation. This may be due to there being only a 29 μm difference between 
thinnest and thickest CCT. 
 
In a similar manner to the HC participants, the OHT and POAG patients had no 
significant correlations between SAF and the different corneal viscoelastic 
parameters. In NTG however, velocity and deformation amplitude at the first 
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applanation was found to be reduced with increased SAF. This suggests that in 
NTG patients, SAF is related to corneal viscoelasticity, with increased SAF linked 
to a less viscoelastic cornea. Ocular rigidity although thought to be relevant to 
pathology is not often considered clinically due to the difficulties in acquiring 
accurate measurements (590). The lamina cribrosa is an example of this, as 
rigidity cannot be easily measured. Although differing structures, the stiffening of 
the cornea may be an indicator of overall ocular mechanical rigidity, including 
lamina cribrosa rigidity (338, 339). This is relevant as a lamina cribrosa that is 
more rigid/less viscoelastic is thought to be less able react to changes in IOP 
levels as it is less able to elastically absorb IOP (591). Hence it has been 
hypothesised that a stiffer/less viscoelastic lamina cribrosa is more susceptible to 
damage by increased IOP as well as normal IOP levels (328, 591, 592). This 
links to the results of this study since the relationship with SAF and decreased 
viscoelasticity existed only in the NTG group. These corneal results within the 
NTG group should however be reviewed with caution due to the low participant 
numbers in this group. This relationship should be reviewed and replicated in a 
study with increased numbers of systemically healthy NTG patients.  
 
8.6 Conclusion 
Ageing is a multifactorial process and similarly glaucoma is thought to be 
influenced by multiple factors. The results from Chapter 6 suggest that AGEs 
may be one possible factor influencing glaucoma. The aim of this study was to 
evaluate whether tissue bound AGE level (SAF) related to static and dynamic 
retinal vessel structure and function and corneal viscoelasticity in POAG, NTG 
and OHT patients. The NTG group, who are known to have a higher SAF level in 
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comparison to healthy controls from Chapter 6, were shown in this study to also 
have a significantly narrower CRAE. A direct relationship between SAF and 
CRAE was however not found within this group and it is thought this could relate 
to the small overall number of NTG participants recruited for this study. Indeed, 
the negative relationship shown in the larger HC group could indicate that 
narrower CRAE is related to increased SAF levels in principle. Increased SAF 
levels were found to associate with a less viscoelastic, stiffer cornea in the NTG 
group only. It is possible that increased SAF levels contribute to increased rigidity 
of the ocular structures which leave them more susceptible to damage from more 
‘normal’ IOP levels, or small reductions in arterial blood supply, however larger 
scale studies would be needed before any conclusions could be drawn from 
these findings. There was no significant relationship in the OHT or POAG groups. 
There were no statistically significant relationships between SAF and dynamic 
vascular parameters in any groups, suggesting at the early stages of the disease 
process tissue-bound AGE levels do not significantly influence the vasoactive 
response of the retinal microvasculature to increased metabolic demand from 
flicker light stimulation.  
 
8.7 Limitations 
Participants that were prescribed anti-glaucomatous drops were not excluded. It 
is known that drops can affect the ocular surface, which in turn may have affected 
the Corvis ST measurement (410, 593). In addition some anti-glaucomatous 
drops are known to be vasoactive, this may affect the retinal vasculature and 
hence affect the dynamic and static retinal vascular measurements. 
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The sample size recruited was lower than the target sample size, this potentially 
limits the conclusions drawn from this study. The challenge with recruitment of 
early stage glaucoma participants and OHT participants was due to the strict 
inclusion/exclusion criteria. These criteria however were necessary to avoid any 
other influences on AGE level, e.g. if smokers had been included then this may 
have masked any other relationships. In addition the recruitment between 
glaucoma groups was not even, with fewer NTG patients recruited. The number 
of recruited participants was able to provide statistically significant results, 
however analysis may have been aided by increased participant numbers.  
 
8.8 Future work 
To repeat this study with a larger group of participants and include sub groups of 
varying levels of glaucomatous damage.  
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9.0 The relationship between retinal vessel function and 
corneal viscoelasticity in open angle glaucoma (OAG), OHT 
and healthy patients 
 
9.1 Abstract 
Purpose: To explore whether dynamic retinal vascular parameters are related to 
corneal viscoelastic parameters in HC, OHT and OAG patients.  
 
Methods: 33 healthy control participants, 13 OHT and 36 OAG patients had static 
and dynamic retinal vessel structure and function evaluated using the Dynamic 
Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) and corneal 
viscoelasticity measured using the Corvis ST (Oculus; Optikgeräte GmbH, 
Wetzlar, Germany). 
 
Results: On consideration of retinal artery response, in OAG patients a less 
viscoelastic cornea was related to increased arterial dilation response to flicker 
light (A1 velocity and artery BFR; r = -0.521, p = 0.001, 95% CI -0.236 to -0.757). 
No significant relationships were found between dynamic retinal artery 
parameters and corneal viscoelasticity parameters in HC and OHT groups  
On consideration of retinal venous response, in OAG participants, a less 
viscoelastic cornea was related to a faster venous response and reaction time 
(A2 velocity and vein RT r = 0.484, p = 0.003, 95% CI -0.055 to 0.809; A2 velocity 
and vein CT r = 0.434, p = 0.009, 95% CI -0.070 to 0.736). Similarly, in HC 
participants, a less viscoelastic cornea was found to relate to increased venous 
dilation response (A1 time with venous BFR r = 0.533, p = 0.002, 95% CI 0.112 
to 0.821 and A1 time with vMD; r = 0.497, p = 0.005, 95% CI 0.006 to 0.755). In 
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OHT participants however, a less viscoelastic cornea was found to relate to a 
decreased venous dilation response (A1 time with vein BFR; r = -0.772, p = 
0.002, 95% CI -0.529 to -0.929 and highest corneal deformation amplitude with 
vein BFR r = 0.693, p = 0.009, 95% CI 0.164 to 0.927). 
 
Conclusion: Retinal artery and vein parameters of dynamic retinal function were 
found to be related to viscoelastic corneal properties. However, the results are 
not consistent between parameters, which causes some uncertainty to the 
relationship.  
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9.2 Background 
AGE accumulation can induce direct structural change to cells and tissues, 
through the creation of cross-links with proteins such as extracellular proteins 
collagen and elastin (69, 70). The AGE induced cross-link alters the mechanical 
properties of the protein. In collagen, these cross-links result in increased 
stiffness of tissues and reduction in elasticity (38, 71, 72). Normal collagen and 
elastin function is important for organs, tissues and vascular function throughout 
the body (19, 73), hence modifications are thought to have an adverse effect on 
physiology.  
 
A main site of RGC axonal injury in glaucoma is thought to be the lamina cribrosa 
(591, 594, 595). The lamina cribrosa is known to stiffen with age (592) and on 
becoming less elastic it also becomes less able to respond at high IOP levels and 
therefore more vulnerable to the effects of increased IOP. AGEs have been 
detected in the cribriform plates of optic nerve head (20). Age related stiffening of 
the lamina cribrosa is linked with AGEs and as such AGEs could be encouraging 
the RGC axonal injury seen in glaucoma. It is difficult to measure deformation of 
the lamina cribrosa in living patients (556).  
 
The mechanical properties of the cornea can be indicated by viscoelasticity 
measurement and mechanical properties of retinal blood vessels by dynamic 
vascular measurements. Although differing structures, both are thought to be 
stiffened by AGE collagen cross-linking. This stiffening throughout the structures 
of the eye, could contribute to overall ocular mechanical rigidity, including lamina 
cribrosa rigidity (338, 339). It could be hypothesised therefore that rigidity and 
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dynamic response of the cornea and retinal vasculature may be able to infer if 
there is rigidity of the lamina cribrosa.  
 
Deformation amplitude is considered to be one of the main corneal viscoelastic 
parameters. Deformation amplitude has been linked with glaucoma with Wang et 
al. (2015), Tian et al. (2015) and Jung et al. (2017) each finding that deformation 
amplitude is lower in POAG than HC (596-598), indicating a less viscoelastic, 
stiffer, cornea in these patients. Recent literature has also investigated the 
viscoelastic properties of myopic corneas, Chansangpetch et al. (2017) found 
that myopic participants both with and without glaucoma had an increased 
maximum deformation amplitude compared to emmetropes with and without 
glaucoma (599), similarly He et al. (2017) found that eyes with high myopia (- 
6.00D) had increased deformation amplitude compared to emmetropes (600). 
This suggests that myopic eyes have a more viscoelastic cornea. There is only 
one study which relates Corvis ST measures of deformation amplitude to the 
posterior pole. The results of this were inconsistent compared to other studies 
assessing deformation in glaucoma patients since the results showed that 
increased deformation amplitude significantly correlated with increased 
parapapillary atrophy area and optic disc tilt (601). These results however were 
not found to be significant after multiple regression analysis and should be 
reviewed with caution due to myopia possibly influencing the results (601). 
Exploring if retinal vessels are linked with deformation amplitude and other 
corneal viscoelastic parameters is interesting since both structures largely consist 
of extracellular matrix and both are linked with glaucoma. 
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There is evidence to suggest that AGEs induce structural changes to the 
extracellular matrix of the cornea, lamina cribrosa and the systemic blood vessel 
walls by increasing the stiffness. Exploring if there is any relationship between 
retinal and corneal parameters may reveal if there are links and a general trend 
towards stiffness in the eye at a similar rate, or if the structures are affected 
independently. The elements investigated in this chapter are explorative, based 
on AGE theory. No previous studies have examined the relationship between 
corneal viscoelasticity and vascular dynamic properties. 
 
9.2.1 Aims 
To explore whether dynamic retinal vascular parameters are related to corneal 
viscoelastic parameters in HC, OHT, NTG and POAG patients.  
 
9.2.2 Hypothesis 
A relationship will exist between retinal vascular and corneal parameters.  
 
9.3 Methods 
The methodology used in this study is summarised here; more detailed 
information on the specifics of each technique can be found in Chapter 3. 
 
9.3.1 Participants  
Convenience sampling was used to recruit participants who are eligible according 
to the study’s inclusion and exclusion criteria, the inclusion criteria for participants 
are detailed in section 3.1.3, exclusion detailed in section 3.1.4. Due to the 
established link between diabetes and AGEs (449, 450) participants diagnosed 
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with diabetes or participants found to have a high fasting glucose level were 
excluded from the study, as were current smokers, and previous smokers who 
quit less than 15 years ago due to the link between AGEs and tobacco (10). 
POAG, NTG and OHT participants were identified through their attendance at 
routine outpatient appointments at Derriford REI.  
 
9.3.2 General investigations  
As described in 3.3.2.1, height was measured in meters using a stadiometer, 
weight was measured in kg, and from these measurements BMI was calculated. 
Weight, basal metabolic rate (BMR), and body fat percentage were measured 
using the Tanita body composition analyser (TBF-300 MA). Blood pressure was 
measured, and a fasting venous blood sample was obtained to enable the 
measurement of oxidative stress biomarkers. Three oxidative stress biomarkers 
were used, the non-enzymatic antioxidants ascorbate (vitamin C) and alpha 
tocopherol (a form of vitamin E) and the product of lipid peroxidation 
malondialdehyde (MDA). Each biomarker is described in Section 3.3.2.6. 
As mentioned in Section 9.2 myopia has been linked with deformation amplitude. 
All participants met the inclusion criteria of having a refractive error below +/-
6.00D. 
 
9.3.3 Dynamic Retinal Vessel Analyser (DVA) 
The Dynamic Retinal Vessel Analyser (DVA; IMEDOS GmbH, Jena, Germany) 
was used to assess dynamic retinal vessel function. It is a non-invasive device, 
with high reproducibility (373) and low variability (374). Specific detail on the DVA 
and its protocol for dynamic measurments can be found in Section 3.3.2.2.  
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The dynamic parameters calculated from the raw data included: baseline 
diameter fluctuation (BDF), dilation amplitude (DA), baseline corrected flicker 
response (BFR), maximum percentage dilation (MD%), reaction time (RT), 
minimum percentage constriction (MC%), constriction time (CT) for artery and 
vein. For full list of descriptions of these parameters see Table 3.3 in Section 
3.3.2.2. Pariticpants were asked to maintain normal eating habits before DVA 
measurement as fasting can cause abnormal vascular activity (385).  
 
9.3.4 Corvis ST 
The viscoelastic properties of the cornea were assessed using the Corvis ST 
(Oculus; Optikgeräte GmbH, Wetzlar, Germany). The Corvis ST is a noncontact 
tonometry system, for specific detail see Section 3.3.2.3. The parameters used 
were: first applanation time (time A1), second applanation time (time A2), velocity 
of corneal surface movement at the first applanation (velocity A1), velocity of 
corneal surface movement at second applanation (velocity A2), deformation 
amplitude at first applanation (deformation amplitude A1), deformation amplitude 
at second applanation (deformation amplitude A2), highest deformation 
amplitude, and highest concavity time. Corvis measurements were taken for each 
eye of each participant.  
 
Reduced CCT has been identified as an independent risk factor for GON (331, 
332). Previous studies examining the link between CCT and corneal hysteresis 
have differing results as to if a relationship does or does not exist. Touboul et al. 
(2008) found no significant correlation between CCT and corneal hysteresis 
(602), however Shah et al. (2006) found a moderate positive correlation between 
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increasing CCT and increased corneal hysteresis, and a recent study by Murphy 
et al. (2017) found a strong positive correlation between CCT and corneal 
hysteresis (340). For this reason CCT was measured in addition to viscoelastic 
properties.  
 
9.3.5 Selection of parameters  
Static parameters were not included in the study since it is the responsiveness of 
the structures that is being compared. In addition BDF was not included since it 
describes the vessel in baseline conditions and is also incorporated into the BFR 
result. All other vascular parameters, listed above in Section 9.3.1.3 were 
included and all of Corvis ST viscoelastic properties listed in 9.3.1.4 were also 
included.   
 
9.3.6 Statistical analysis 
Statistical analysis was performed using SPSS version 24 (IBM). The normality of 
data was assessed by the Shapiro–Wilk test and visual inspection of the QQ 
plots.  
P values of less than 0.01 were considered significant for correltions. This stricter 
p-value was adopted for this explorative Chapter in order to correct for multiple 
comparisons taking place, and to minimise any bias towards type II errors. 
 
9.3.6.1 General characteristics between groups 
An ANOVA was used to compare the results of general investigations between 
the groups followed by the post-hoc analysis Scheffe. P values of less than 0.05 
in an ANOVA was considered significant.  
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9.3.6.2 Relationship between arterial retinal vessel and corneal parameters  
Pearson’s correlation was used to analyse the association between the arterial 
parameters: DA, BFR, MD%, RT, MC%, CT with the corneal parameters: time 
A1, time A2, velocity A1, velocity A2, deformation A1, deformation A2, highest 
deformation and highest concavity time. Any significant correlations were entered 
into a stepwise forward and backward multiple linear regression to further assess 
the influence of different variables on one another.  
 
9.3.6.3 Relationship between venous retinal vessel and corneal parameters  
Pearson’s correlation was used to analyse the association between the venous 
parameters: DA, BFR, MD%, RT, MC%, CT with the corneal parameters: time 
A1, time A2, velocity A1, velocity A2, deformation A1, deformation A2, highest 
deformation and highest concavity time. Any significant correlations were entered 
into a stepwise forward and backward multiple linear regression to further assess 
the influence of different variables on one another.  
 
9.3.6.4 Power calculation 
The sample size was determined for Chapters 7 and 8, using data from previous 
research which also measured tissue-bound AGE level using AGE Reader 
between healthy and disease groups (83). In order to achieve 80% power at the 
5% alpha level, a sample size of 37 per group was required (NTG, POAG, OHT 
and controls). To account for unusable data an allowance was made and a 
sample size of 40 participants was chosen per group.  
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9.4 Results  
A total of 28 POAG, 8 NTG, 13 OHT and 33 healthy control participants 
participated in the study. Due to the NTG group having only eight participants the 
NTG and POAG groups were combined into an open angle glaucoma group. 
 
9.4.1 Group characteristics 
There were no significant differences in age, BMI, systemic blood pressure, IOP, 
MABP and OPP between the four groups (p > 0.05). The characteristics of the 
participant group with mean and standard deviation are detailed in Table 9.1.  It 
was expected that there would not be a significant difference in IOP between the 
groups since the OHT, POAG and NTG patients were all taking their prescribed 
IOP lowering treatment as normal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
262 
 
Table 9.1: Summary of mean and standard deviation of participant characteristics for the study 
groups. P<0.05 is considered a significant difference. BMI: body mass index, SBP: systolic blood 
pressure, DBP: diastolic blood pressure, IOP: intraocular pressure, MABP: mean arterial blood 
pressure, OPP: ocular perfusion pressure, was subsequently calculated using MABP and IOP 
values.  
 
 
Corneal viscoelasticity parameters between groups 
The corneal viscoelasticity parameter velocity A1 (m/s) was significantly different 
between groups (p = 0.042) on ANOVA comparison of the means, however on 
post hoc testing this significant difference between the groups was not held. In 
addition no significant difference was found between any of the other corneal 
viscoelasticity parameters between the study groups (p>0.05, Table 9.2). CCT 
however was found to be different between the glaucoma groups and HC, with 
HC having increased CCT.  
Variable HC (1) OHT (2) OAG (3) ANOVA 
p value 
Post 
hoc 
N 33 13 36   
Gender  F:22 M:11 F:5 M:8 F:17 M:19   
Age (years) 65.97 ±9.43 67.23 ±8.10 68.92 ±7.06 0.056  
BMI 25.62 ±3.36 25.77 ±4.56 26.53 ±4.28 0.247  
SBP (mmHg) 134.82 ±16.93 141.15 ±17.60 138.25 ±19.18 0.146  
DBP (mmHg) 80.67 ±10.17 84.85 ±9.50 84.06 ±9.77 0.426  
IOP (mmHg) 16.39 ±2.72 18.25 ±3.13 16.22 ±3.56 0.140  
MABP (mmHg) 98.72 ±11.11 103.62 ±11.13 102.12 ±11.22 0.189  
OPP 49.63 ±7.91 51.08 ±9.87 52.08 ±8.36 0.414  
SAF 2.19 ±0.39 2.39 ±0.44 2.52 ±0.40 0.001 1 < 3 
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Table 9.2: Corneal viscoelastic parameters between groups, mean and standard deviation 
presented. P<0.05 is considered a significant difference. AU: arbitrary units, Time A1: first 
applanation time, Time A2: second applanation time, Velocity A1: velocity of corneal surface 
movement at the first applanation, Velocity A2: velocity of corneal surface movement at second 
applanation, Deformation amp. A1: deformation amplitude at first applanation, Deformation amp. 
A2: deformation amplitude at second applanation, Highest deformation amp: highest deformation 
amplitude, CCT: central corneal thickness. 
 
 
 
 
 
 
 
Corneal 
viscoelasticity 
HC (1) OHT (2) OAG (3) ANOVA 
p value 
Post 
hoc 
N 33 13 36   
Time A1 (ms) 7.33 ±0.37 7.45 ±0.30 7.30 ±0.24 0.225  
Time A2 (ms) 21.95 ±0.44 21.66 ±0.48 21.75 ±0.43 0.063  
Velocity A1 (m/s) 0.15 ±0.02 0.13 ±0.03 0.15 ±0.02 0.042 p>0.05 
Velocity A2 (m/s) -0.26 ±0.03 -0.26 ±0.02 -0.27 ±0.03 0.156  
Deformation amp. 
A1 (mm) 
0.13 ±0.01 0.13 ±0.01 0.13 ±0.01 0.862  
Deformation amp. 
A2 (mm) 
0.44 ±0.07 0.44 ±0.08 0.43 ±0.05 0.699  
Highest 
deformation amp. 
(mm) 
1.09 ±0.11 1.07 ±0.12 1.09 ±0.09 0.530  
Highest concavity 
time (ms) 
16.48 ±0.44 16.42 ±0.54 16.43 ±0.54 0.874  
CCT (μm) 555 ±34.34 550 ±21.22 526.94 ±38.08 0.004 1 > 3 
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9.4.2 Relationship between arterial retinal vessel and corneal parameters 
A more viscoelastic, deformable cornea is thought to have a shorter A1 time, 
faster velocity at A1, increased deformation amplitude at A1, increased maximum 
deformation amplitude and have a longer time A2, and slower velocity at A2 
(410). Vasodilation in response to flicker stimulation relies on the dilation of blood 
vessel walls, which is driven by endothelial function (141, 379). Decreased DA, 
BFR and maximum percentage dilation, slower reaction time and constriction 
time are thought to infer vascular dysfunction.  
 
As shown in Table 9.1 and Table 9.2 SAF and CCT were significantly different 
between the groups. Previous research has suggested that a thinner cornea 
experiences increased corneal deformation (589). For this reason, all correlations 
were run within each group rather than with all participants grouped together. In 
addition, any significant correlations between corneal and vascular parameters 
were entered into a stepwise forward and backward multiple linear regression 
with the variables CCT and SAF included.  
 
9.4.2.1 Healthy controls  
Table 9.3 shows the correlations between the six different retinal artery dynamic 
parameters and the eight different corneal viscoelasticity parameters in healthy 
control participants. No significant correlations existed.   
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 Healthy controls 
 
Artery 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
5.078 
± 3.830 
2.934 
± 3.014 
3.356 
± 2.679 
15.629 
± 5.790 
1.722 
± 1.970 
24.237 
± 8.786 
Time A1 
(ms) 
7.281 
± 0.366 
0.352 
p = 0.057 
 
0.376  
p = 0.041 
0.247 
p = 0.187 
-0.124 
p = 0.514 
0.344 
p = 0.063 
0.227 
p = 0.228  
Time A2 
(ms) 
22.019 
± 0.429 
-0.187 
p = 0.321 
 
-0.208 
p = 0.269 
-0.160 
p = 0.399 
-0.102 
p = 0.594 
-0.145 
p = 0.443 
-0.133 
p = 0.484 
Velocity A1 
(m/s) 
0.152 
± 0.018 
-0.312 
p = 0.093 
 
-0.299 
p = 0.108 
-0.205 
p = 0.277 
-0.066 
p = 0.730 
-0.325 
p = 0.080 
-0.217 
p = 0.249 
Velocity A2 
(m/s) 
-0.263 
± 0.033 
0.422 
p = 0.020 
0.413  
p = 0.023 
 
0.341 
p = 0.066 
0.141 
p = 0.457 
0.354 
p = 0.055 
0.313 
p = 0.092 
Deformation 
amp. A1 
(mm) 
0.135 
± 0.011 
0.286 
p = 0.125 
0.301 
p = 0.106 
0.239 
p = 0.203 
-0.408  
p = 0.025 
0.229 
p = 0.224 
0.136 
p = 0.473 
Deformation 
amp. A2 
(mm) 
0.443 
± 0.076 
0.058 
p = 0.761 
0.039 
p = 0.837 
0.013 
p = 0.947 
0.005 
p = 0.980 
0.094 
p = 0.619 
-0.130 
p = 0.494 
Highest 
deformation 
amp. (mm) 
1.092 
± 0.113 
-0.199 
p = 0.292 
-0.214 
p = 0.257 
-0.202 
p = 0.283 
-0.035 
p = 0.855 
-0.110 
p = 0.562 
-0.302 
p = 0.105 
Highest 
concavity 
time (ms) 
16.480 
± 0.449 
-0.168 
p = 0.376 
-0.108 
p = 0.570 
-0.085 
p = 0.654 
0.120 
p = 0.529 
-0.208 
p = 0.270 
0.068 
p = 0.723 
Table 9.3: Mean, SD and Pearson’s correlations between the six artery parameters and eight 
corneal viscoelasticity parameters. P<0.01* only correlations of P<0.01 were considered 
significant. BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected 
flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: minimum 
percentage constriction, CT: constriction time, Time A1: first applanation time, Time A2: second 
applanation time, Velocity A1: velocity of corneal surface movement at the first applanation, 
Velocity A2: velocity of corneal surface movement at second applanation, Deformation amp. A1: 
deformation amplitude at first applanation, Deformation amp. A2: deformation amplitude at 
second applanation, Highest deformation amp: highest deformation amplitude. 
 
 
Table 9.4 shows the correlations between the six different retinal vein dynamic 
parameters and the eight different corneal viscoelasticity parameters in healthy 
control participants. A significant correlation was found between A1 time and 
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venous BFR (r = 0.533, p = 0.002, 95% bootstrap confidence interval 0.112 to 
0.821) as well as between A1 time and venous MD% (r = 0.497, p = 0.005, 95% 
bootstrap confidence interval 0.006 to 0.755). These correlations suggest that a 
less viscoelastic cornea is related to a greater venous dilation response.  
 
Healthy controls 
 
Vein 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
5.624 
± 2.756 
3.277 
± 1.949 
4.523 
± 2.053 
18.081 
± 2.572 
1.101 
± 1.294 
32.424 
±6.584 
Time A1 
(ms) 
7.281 
± 0.366 
0.402  
p = 0.027 
0.533 * 
p = 0.002 
0.497 * 
p = 0.005 
-0.353 
p = 0.055 
0.072 
p = 0.704 
0.157 
p = 0.409 
Time A2 
(ms) 
22.019 
± 0.429 
-0.291 
p = 0.118 
-0.404  
p = 0.027 
-0.397  
p = 0.030 
0.344 
p = 0.063 
0.006 
p = 0.975 
-0.006 
p = 0.973 
Velocity A1 
(m/s) 
0.152 
± 0.018 
-0.267 
p = 0.154 
-0.434  
p = 0.017 
-0.356 
p = 0.053 
0.349 
p = 0.059 
-0.007 
p = 0.971 
-0.025 
p = 0.897 
Velocity A2 
(m/s) 
-0.263 
± 0.033 
0.366  
p = 0.047 
0.370  
p = 0.044 
0.362  
p = 0.049 
-0.404  
p = 0.027 
0.208 
p = 0.271 
0.053 
p = 0.782 
Deformation 
amp. A1 
(mm) 
0.135 
± 0.011 
0.270 
p = 0.149 
0.449  
p = 0.013 
0.453  
p = 0.012 
-0.166 
p = 0.380 
-0.139 
p = 0.465 
0.175 
p = 0.356 
Deformation 
amp. A2 
(mm) 
0.443 
± 0.076 
-0.061 
p = 0.750 
-0.064 
p = 0.738 
-0.096 
p = 0.614 
0.343 
p = 0.063 
0.022 
p = 0.907 
0.115 
p = 0.544 
Highest 
deformation 
amp. (mm) 
1.092 
± 0.113 
-0.259 
p = 0.166 
-0.347 
p = 0.061 
-0.358 
p = 0.052 
0.460  
p = 0.010 
0.012 
p = 0.951 
-0.024 
p = 0.899 
Highest 
concavity 
time (ms) 
16.480 
± 0.449 
-0.041 
p = 0.830 
-0.025 
p = 0.895 
-0.127 
p = 0.504 
0.206 
p = 0.275 
0.113 
p = 0.552 
0.173 
p = 0.361 
Table 9.4: Mean, SD and Pearson’s correlations between the six vein parameters and eight 
corneal viscoelasticity parameters. P<0.01*, only correlations of P<0.01 were considered 
significant. BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected 
flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: minimum 
percentage constriction, CT: constriction time, Time A1: first applanation time, Time A2: second 
applanation time, Velocity A1: velocity of corneal surface movement at the first applanation, 
Velocity A2: velocity of corneal surface movement at second applanation, Deformation amp. A1: 
deformation amplitude at first applanation, Deformation amp. A2: deformation amplitude at 
second applanation, Highest deformation amp: highest deformation amplitude. 
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Forwards stepwise and backwards multiple linear regression analysis was 
performed to determine the factors that had the most influence corneal time A1. 
The independent variables included were those which had previously correlated, 
vein BFR and vein MD%. In addition CCT, SAF and age were included due to the 
literature suggesting they influence corneal viscoelasticity. 
The variable CCT was the single best predictor (p = 0.005), followed by vein 
MD% (p = 0.020). These findings were also found to be true in the backwards 
model. 
 
9.4.2.2 Ocular hypertension 
Table 9.5 shows the correlations between the six different retinal artery dynamic 
parameters and the eight different corneal viscoelasticity parameters in OHT 
patients. In a similar manner to the healthy control patients no significant 
correlations existed.   
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OHT 
 
Artery 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
5.258 
± 2.928 
2.841 
± 2.104 
2.966 
± 2.529 
15.462 
± 4.860 
2.293 
± 2.121 
26.320 
±7.956 
Time A1 
(ms) 
7.45 
± 0.302 
0.279 
p = 0.357 
0.109 
p = 0.722 
-0.132 
p = 0.668 
-0.052 
p = 0.866 
0.541 
p = 0.056 
0.145 
p = 0.636 
Time A2 
(ms) 
21.656 
± 0.477 
-0.333 
p = 0.266 
-0.111 
p = 0.718 
0.166 
p = 0.589 
0.097 
p =0.752 
-0.657  
p = 0.015 
0.118 
p = 0.701 
Velocity A1 
(m/s) 
0.134 
± 0.027 
-0.289 
p = 0.339 
-0.164 
p = 0.592 
0.057 
p =0.853 
0.189 
p = 0.537 
-0.466 
p = 0.108 
-0.125 
p = 0.684 
Velocity A2 
(m/s) 
-0.257 
± 0.024 
0.149 
p = 0.627 
-0.075 
p = 0.808 
-0.218 
p =0.474 
0.009 
p =0.978 
0.466 
p = 0.109 
-0.048 
p = 0.877 
Deformation 
amp. A1 
(mm) 
0.133 
± 0.009 
-0.329 
p =0.272 
-0.144 
p = 0.639 
-0.177 
p = 0.564 
-0.128 
p = 0.676 
-0.244 
p =0.422 
0.533 
p =0.061 
Deformation 
amp. A2 
(mm) 
0.442 
± 0.077 
-0.123 
p =0.688 
0.074 
p =0.810 
0.209 
p =0.493 
0.405 
p =0.170 
-0.420 
p =0.153 
0.382 
p =0.198 
Highest 
deformation 
amp. (mm) 
1.067 
± 0.118 
-0.290 
p =0.337 
-0.167 
p =0.585 
0.064 
p =0.835 
0.123 
p =0.688 
-0.476 
p =0.100 
0.146 
0.633 
Highest 
concavity 
time (ms) 
16.419 
± 0.537 
-0.173 
p =0.571 
-0.065 
p =0.833 
0.190 
p =0.534 
0.095 
p =0.758 
-0.466 
p =0.109 
0.040 
p =0.897 
Table 9.5: Mean, SD and Pearson’s correlations between the six artery parameters and eight 
corneal viscoelasticity parameters. P<0.01** only correlations of P<0.01 were considered 
significant. BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected 
flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: minimum 
percentage constriction, CT: constriction time, Time A1: first applanation time, Time A2: second 
applanation time, Velocity A1: velocity of corneal surface movement at the first applanation, 
Velocity A2: velocity of corneal surface movement at second applanation, Deformation amp. A1: 
deformation amplitude at first applanation, Deformation amp. A2: deformation amplitude at 
second applanation, Highest deformation amp: highest deformation amplitude. 
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Table 9.6 shows the correlations between the six different retinal vein dynamic 
parameters and the eight different corneal viscoelasticity parameters in OHT 
patients. A negative correlation between corneal A1 time and vein BFR existed (r 
= -0.772, p = 0.002, 95% bootstrap confidence interval -0.529 to -0.929), with a 
shorter A1 time related to increased vein BFR. A positive correlation between 
highest deformation amplitude and vein BFR existed (r = 0.693, p = 0.009, 95% 
bootstrap confidence interval 0.164 to 0.927), as there was increased maximum 
deformation there was increased vein BFR. The results of both of these 
correlations suggest that a less deformable viscoelastic cornea is related to 
reduced venous dilation response.  
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OHT 
 
Vein 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
4.613 
± 2.066 
2.315 
± 2.516 
3.761 
± 2.135 
17.077 
± 4.141 
0.853 
± 0.919 
25.385 
±9.301 
Time A1 
(ms) 
7.45 
± 0.302 
-0.502 
p = 0.080 
-0.772 * 
p = 0.002 
-0.582  
p = 0.037 
-0.640  
p = 0.019 
0.224 
p = 0.462 
-0.524 
p = 0.066 
Time A2 
(ms) 
21.656 
± 0.477 
0.345 
p = 0.248 
0.599  
p = 0.030 
0.474 
p = 0.101 
0.526 
p = 0.065 
-0.326 
p = 0.277 
0.583  
p = 0.036 
Velocity A1 
(m/s) 
0.134 
± 0.027 
0.356 
p = 0.233 
0.621  
p = 0.023 
0.430 
p = 0.142 
0.548 
p = 0.052 
-0.199 
p = 0.513 
0.628  
p = 0.021 
Velocity A2 
(m/s) 
-0.257 
± 0.024 
-0.448 
p = 0.125 
-0.564  
0.044 
-0.440 
p = 0.132 
-0.553  
p = 0.050 
0.017 
p = 0.956 
-0.611  
p = 0.026 
Deformation 
amp. A1 
(mm) 
0.133 
± 0.009 
-0.111 
p = 0.718 
-0.040 
p = 0.897 
-0.085 
p = 0.782 
0.009 
p = 0.977 
-0.052 
p = 0.866 
-0.023 
p = 0.939 
Deformation 
amp. A2 
(mm) 
0.442 
± 0.077 
0.369 
p = 0.215 
0.601  
p = 0.030 
0.419 
p = 0.155 
0.033 
p = 0.914 
-0.143 
p = 0.640 
0.355 
p = 0.235 
Highest 
deformation 
amp. (mm) 
1.067 
± 0.118 
0.399 
p = 0.177 
0.693 * 
p = 0.009 
0.485 
p = 0.093 
0.264 
p = 0.383 
-0.229 
p = 0.452 
0.480 
p = 0.097 
Highest 
concavity 
time (ms) 
16.419 
± 0.537 
0.473 
p = 0.103 
0.595  
p = 0.032 
0.436 
p = 0.137 
0.045 
p = 0.883 
0.050 
p = 0.870 
0.598  
p = 0.031 
Table 9.6: Mean, SD and Pearson’s correlations between the six vein parameters and eight 
corneal viscoelasticity parameters. P<0.01**, only correlations of P<0.01 were considered 
significant.. BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline corrected 
flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: minimum 
percentage constriction, CT: constriction time, Time A1: first applanation time, Time A2: second 
applanation time, Velocity A1: velocity of corneal surface movement at the first applanation, 
Velocity A2: velocity of corneal surface movement at second applanation, Deformation amp. A1: 
deformation amplitude at first applanation, Deformation amp. A2: deformation amplitude at 
second applanation, Highest deformation amp: highest deformation amplitude. 
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Forwards stepwise and backwards multiple linear regression analysis was 
performed to determine the factors that had the most influence corneal time A1. 
The variable vein BFR was included due to the correlation. In addition, CCT, SAF 
and age were included due to the literature suggesting they influence corneal 
viscoelasticity. 
The variable vein BFR was the single best predictor (p = 0.001), followed by SAF 
(p = 0.009). These findings were also found to be true in the backwards model. 
 
Forwards stepwise and backwards multiple linear regression analysis was also 
performed to determine the factors that had the most influence on the corneal 
viscoelastic parameter ‘highest deformation amplitude’. The variable vein BFR 
was included due to the correlation. In addition, CCT, SAF and age were included 
due to the literature suggesting they influence corneal viscoelasticity. 
The variable vein BFR was the single best predictor (p = 0.009), with no other 
significant variables. These findings were also found to be true in the backwards 
model. 
 
9.4.2.3 Open angle glaucoma (NTG and POAG patients) 
Table 9.7 shows the correlations between the six different retinal artery dynamic 
parameters and the eight different corneal viscoelasticity parameters in the open 
angle glaucoma patients. One significant correlation existed between the 
parameters, a faster velocity at A1 related to reduced artery BFR (r = -0.521, p = 
0.001, 95% bootstrap confidence interval -0.236 to -0.757). This relationship 
suggests that in this group of open angle glaucoma patients a more viscoelastic 
cornea is related to a reduced arterial dilation response to flicker light.  
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Glaucoma 
 
Artery 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
5.029 
± 3.379 
1.822 
± 2.184 
3.078 
± 3.148 
14.191 
± 6.279 
2.189 
± 2.804 
22.255 
± 9.244 
Time A1 
(ms) 
7.299 
± 0.240 
0.324 
p = 0.057 
0.324  
p = 0.045 
0.282 
p = 0.101 
-0.011 
p = 0.948 
0.134 
p = 0.444 
0.045 
p = 0.799 
Time A2 
(ms) 
21.749 
± 0.431 
-0.144 
p = 0.410 
-0.322 
p = 0.059 
-0.150 
p = 0.389 
0.096 
p = 0.582 
-0.021 
p = 0.905 
-0.003 
p = 0.989 
Velocity A1 
(m/s) 
0.151 
± 0.020 
-0.264 
p = 0.126 
-0.521 * 
p = 0.001 
-0.268 
p = 0.120 
0.064 
p = 0.715 
-0.039 
p = 0.823 
-0.105 
p = 0.548 
Velocity A2 
(m/s) 
-0.276 
± 0.037 
0.397  
p = 0.018 
0.388  
p = 0.021 
0.334  
p = 0.050 
0.229 
p = 0.187 
0.157 
p = 0.368 
0.281 
p = 0.102 
Deformation 
amp. A1 
(mm) 
0.134 
± 0.009 
0.089 
p = 0.613 
-0.167 
p = 0.337 
0.074 
p = 0.674 
0.151 
p = 0.385 
0.055 
p = 0.753 
0.172 
p = 0.322 
Deformation 
amp. A2 
(mm) 
0.429 
± 0.057 
0.027 
p = 0.877 
-0.131 
p = 0.454 
0.193 
p = 0.266 
0.206 
p = 0.236 
-0.260 
p = 0.132 
-0.016 
p = 0.928 
Highest 
deformation 
amp. (mm) 
1.106 
± 0.096 
-0.317 
p = 0.063 
-0.410  
p = 0.014 
-0.200 
p = 0.248 
0.035 
p = 0.842 
-0.220 
p = 0.204 
-0.049 
p = 0.779 
Highest 
concavity 
time (ms) 
16.421 
± 0.547 
-0.068 
p = 0.698 
-0.172 
p = 0.324 
-0.020 
p = 0.910 
-0.100 
p = 0.567 
-0.063 
p = 0.719 
-0.259 
p = 0.133 
Table 9.7: Mean, SD and Pearson’s correlations between the six artery parameters and eight 
corneal viscoelasticity parameters. P<0.01*. BDF: baseline diameter fluctuation, DA: dilation 
amplitude, BFR: baseline corrected flicker response, MD%: maximum percentage dilation, RT: 
reaction time, MC%: minimum percentage constriction, CT: constriction time, Time A1: first 
applanation time, Time A2: second applanation time, Velocity A1: velocity of corneal surface 
movement at the first applanation, Velocity A2: velocity of corneal surface movement at second 
applanation, Deformation amp. A1: deformation amplitude at first applanation, Deformation amp. 
A2: deformation amplitude at second applanation, Highest deformation amp: highest deformation 
amplitude. 
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Forwards stepwise and backwards multiple linear regression analysis was 
performed to determine the factors that had the most influence on the corneal 
viscoelastic parameter velocity A1. The variable artery BFR was included due to 
the correlation. In addition, CCT, SAF and age were included due to the literature 
suggesting they influence corneal viscoelasticity. Artery BFR was the single best 
predictor (p = 0.006), followed by CCT (p = 0.026). These findings were also 
found to be true in the backwards model. 
 
Table 9.8 shows the correlations between the six different retinal vein dynamic 
parameters and the eight different corneal viscoelasticity parameters in the open 
angle glaucoma patients. As previously mentioned a slower A2 velocity indicates 
a more viscoelastic cornea. A2 velocity was found to correlate with vein reaction 
time (r = 0.484, p = 0.003, 95% bootstrap confidence interval -0.055 to 0.809), 
with a faster A2 velocity related to faster vein reaction time. In a similar manner 
A2 velocity correlated with vein constriction time (r = 0.434, p = 0.009, 95% 
bootstrap confidence interval -0.070 to 0.736), with a faster A2 velocity related to 
a faster vein constriction time. Both of these results indicate that a less 
viscoelastic cornea is related to a faster venous response and recovery time.  
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Glaucoma 
 
Vein 
 
Pearson’s correlation coefficients (R values) 
DA BFR MD% RT (secs) MC% CT (secs) 
 Mean   
± SD 
5.299 
± 2.997 
2.422 
± 2.604 
4.754 
± 2.950 
18.278 
± 5.368 
0.618 
± 1.352 
30.028 
± 9.924 
Time A1 
(ms) 
7.299 
± 0.240 
0.017 
p = 0.922 
0.001 
p = 0.994 
0.003 
p = 0.988 
-0.003 
p = 0.985 
0.082 
p = 0.641 
-0.077 
p = 0.660 
Time A2 
(ms) 
21.749 
± 0.431 
0.110 
p = 0.530 
-0.019 
p = 0.914 
0.114 
p = 0.514 
0.111 
p = 0.525 
-0.018 
p = 0.917 
0.218 
p = 0.209 
Velocity A1 
(m/s) 
0.151 
± 0.020 
0.024 
p = 0.889 
-0.047 
p = 0.788 
0.031 
p = 0.858 
-0.046 
p = 0.795 
-0.049 
p = 0.779 
0.013 
p = 0.942 
Velocity A2 
(m/s) 
-0.276 
± 0.037 
0.319 
p = 0.062 
0.180 
p = 0.300 
0.284 
p = 0.099 
0.484 * 
p = 0.003 
0.141 
p = 0.420 
0.434 * 
p = 0.009 
Deformation 
amp. A1 
(mm) 
0.134 
± 0.009 
0.159 
p = 0.361 
0.019 
p = 0.913 
0.168 
p = 0.334 
0.127 
p = 0.469 
0.013 
p = 0.940 
0.025 
p = 0.887 
Deformation 
amp. A2 
(mm) 
0.429 
± 0.057 
0.380  
p = 0.024 
0.073 
p = 0.678 
0.385 
p = 0.022 
0.193 
p = 0.267 
-0.053 
p = 0.761 
0.145 
p = 0.406 
Highest 
deformation 
amp. (mm) 
1.106 
± 0.096 
0.026 
p = 0.881 
-0.016 
p = 0.929 
0.064 
p = 0.715 
-0.061 
p = 0.726 
-0.136 
p = 0.437 
0.067 
p = 0.702 
Highest 
concavity 
time (ms) 
16.421 
± 0.547 
-0.018 
p = 0.920 
-0.159 
p = 0.361 
-0.058 
p = 0.740 
-0.281 
p = 0.102 
0.081 
p = 0.644 
-0.285 
p = 0.097 
Table 9.8: Pearson’s correlations between the six vein parameters and eight corneal 
viscoelasticity parameters. P<0.01**. BDF: baseline diameter fluctuation, DA: dilation amplitude, 
BFR: baseline corrected flicker response, MD%: maximum percentage dilation, RT: reaction time, 
MC%: minimum percentage constriction, CT: constriction time, Time A1: first applanation time, 
Time A2: second applanation time, Velocity A1: velocity of corneal surface movement at the first 
applanation, Velocity A2: velocity of corneal surface movement at second applanation, 
Deformation amp. A1: deformation amplitude at first applanation, Deformation amp. A2: 
deformation amplitude at second applanation, Highest deformation amp: highest deformation 
amplitude. 
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Forwards stepwise and backwards multiple linear regression analysis was 
performed to determine the factors that had the most influence corneal velocity 
A2. The independent variables included were those which had previously 
correlated, vein RT and vein CT. In addition CCT, SAF and age were included 
due to the literature suggesting they influence corneal viscoelasticity. 
The variable vein RT was the single best predictor (p = 0.003), followed by CCT 
(p = 0.041). These findings were also found to be true in the backwards model. 
 
 
9.5 Discussion 
The aim of this study was to explore if any relationship existed between the 
viscoelastic properties of the cornea and dynamic retinal vessel response to 
flicker stimulation. It is thought that this is the first study to compare these 
parameters. In the population examined, which included healthy, OHT, NTG and 
POAG participants, correlations were found between corneal viscoelasticity and 
retinal vessel responsiveness. There are no previous studies which relate corneal 
viscoelastic properties to the retina or retinal vascular properties. Hence, there is 
no research to directly compare the results of this study to. 
 
A less viscoelastic cornea has been linked with glaucoma (337, 581, 582), and it 
has been suggested that an increased viscoelasticity of the cornea may have a 
protective role against glaucoma (340). In this study, no significant differences in 
corneal viscoelasticity were found between the different groups. The only 
parameter that was significantly different was CCT, with healthy participants 
having a thicker CCT than glaucoma patients. The other measurement different 
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between groups was SAF, with the OAG group having a higher SAF level than 
healthy controls. As potential confounding variables, CCT and SAF were included 
in multiple linear regressions along with the relevant corneal and vascular 
parameters at each stage of the analysis. CCT and SAF were not found to be 
consistent predictors in the different regression analysis. This suggests that the 
relationships found between corneal and vascular parameters were not 
dependent on SAF or CCT levels. 
 
In this study, a less viscoelastic cornea was found to relate to an increased 
arterial dilation response to flicker light in OAG patients only. Based on the 
findings of previous studies that have separately evaluated corneal viscoelasticity 
and retinal artery dilation response in glaucoma patients, this finding is perhaps 
contradictory, as a less viscoelastic cornea and a reduced, rather than increased, 
arterial dilation response has typically been linked to the disease. Previous 
studies using the DVA have however found differing results in relation to arterial 
dilation response to flicker. Garhöfer et al. (2004) found no significant difference 
in arterial flicker response between glaucoma and healthy control groups (305) 
where-as Gugleta et al. (2013) found that response to flicker light was decreased 
in POAG patients compared to controls (603). It is interesting that this 
relationship between arterial dilation response and corneal viscoelasticity was 
only present in the OAG patients and not the HC or OHT patients considering 
there were no significant differences in either corneal viscoelasticity or vascular 
parameters between groups. The result may have been influenced by there being 
a wider variation of results in the OAG group. Due to the small sample sizes, in 
this study, NTG and POAG patients have been grouped together. In Chapter 8 
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altered CRAE was found in our NTG patients, with this group having a 
significantly narrower artery equivalent compared to healthy controls. It may be 
that the relationship found in this study is being driven by a mechanism occurring 
in NTG patients, however more data is needed to better understand this.  
 
With regard to retinal venous response to flicker light and corneal viscoelasticity, 
in this study, a less viscoelastic cornea was found to relate to a faster venous 
response and recovery time in OAG patients and to an increased venous dilation 
response in healthy participants. Somewhat contradictorily to this however, in the 
OHT group a less viscoelastic cornea was found to relate to a reduced venous 
dilation response to flicker light. Retinal venous dilation response following flicker 
light stimulation has been found to be reduced in NTG patients (304) and OAG 
patients (305, 603) compared to healthy controls. A reduced vascular response of 
the tissue is thought to indicate altered endothelial function in these patients. 
There are fewer studies that have assessed retinal venous responses to flicker in 
OHT patients, with studies focusing on response of vessels after IOP rise (282). 
In a recent study the viscoelastic property, corneal hysteresis, was found to be 
higher, i.e. more viscoelastic, in OHT patients compared to glaucoma patients 
however, suggesting that increased viscoelasticity of the cornea may have a 
beneficial, having a protective role against glaucoma (340). This is of interest 
when considered in relation to the OHT results of this study, as a less viscoelastic 
cornea was related to reduced vein dilation response to flicker light. If reduced 
venous reactivity does indeed indicate endothelial function, this could suggest 
that endothelial dysfunction is related to a stiffer, less viscoelastic cornea in OHT 
patients and potentially an increased risk of glaucomatous damage. If this were 
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the case however, it would have been expected that the OAG patients would 
have demonstrated a similar relationship, however no such relationship was 
found. The OAG patients in this study were at the early stages of their disease 
process. There were no significant differences in the vascular parameters 
between OAG and OHT patients in this study, so although it appears 
viscoelasticity and dynamic vascular response of the vein are indeed related, in 
which way is not clear and larger scale studies would be needed to confirm this 
relationship. 
 
It is not known whether the extracellular matrix of the cornea is affected by AGEs 
in a different way to the extracellular matrix in the vessels due to differing ratios of 
elastin and collagen within the structures, and differing types of collagen (604, 
605). It is known that AGE crosslinks form in different types of collagen, however 
collagen type I is thought to be particularly prone to cross-linking (74, 137, 606). 
There is currently no evidence that vessels are more or less prone to AGE cross-
linking than the cornea. This is relevant as differences may help to explain why 
the structures respond differently to one another.  
 
An additional hypothesis important to consider is that the results of this study may 
be unusual and different to what was expected due to the difference in how the 
measurements are achieved. The Corvis ST uses a stimulus that forces the 
cornea to respond in a manner that is not ‘normal’ and would not occur under 
normal conditions. The DVA however relies upon the normal autoregulation 
mechanism to measure response to a stimulus. The response is one which would 
occur under normal conditions. One possible reason for the difference could 
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therefore be how the tissues respond differently when reacting in a recreation of 
‘normal circumstances’, as opposed to those when a forced response is 
prompted. In addition the vascular parameters described here were the result of 
multiple reactions and responses including, myogenic factors, metabolic factors 
and endothelial agents such as NO (607). Whereas the reaction of the cornea is 
a structural response, the corneal deformation and recovery. Hence the vascular 
parameters has more possible factors that could affect the dilation response 
measurements. In addition, one possible factor that could have affected the 
results is that all glaucoma patients continued to use their glaucoma IOP-lowering 
drops as normal. It is known that drops can affect the ocular surface, which in 
turn may have affected the Corvis ST measurement (410, 593).  
 
9.6 Conclusion  
Retinal artery and vein parameters of dynamic retinal function were found to be 
related to viscoelastic corneal properties. In open angle glaucoma patients, a less 
viscoelastic cornea was found to be related to increased arterial dilation response 
to flicker light and a faster venous response and recovery time. The results 
however are not consistent between the groups, which causes some uncertainty 
to the relationships. It is not clear from these results if AGEs cause increased 
stiffness to one structure more than another.  
 
9.7 Limitations  
Participants that were prescribed anti-glaucomatous drops were not excluded. 
This may have impacted the results as these drops can affect the ocular surface, 
which could affect the Corvis ST measurement (410, 593). In addition some anti-
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glaucomatous drops are known to be vasoactive, this may affect the retinal 
vasculature and hence affect the dynamic retinal vascular measurements. 
However the vascular effects of IOP lowering drops on retinal vascular calibre is 
not fully understood (265). 
 
There was an upper limit exclusion criteria for CCT, however due to the lower 
participant numbers in the NTG and OHT groups CCT matching was not possible 
between the groups, in future studies increased numbers of participants would 
allow better matching of patients.  
 
Some results in this study were close to significance. Any larger scale studies 
may help to confirm/deny the findings which are close to significance.  
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10. Summary & conclusions 
 
 
10.1 Summary 
AGEs have the potential to impact both the healthy ageing population and those 
diagnosed with pathology. Enhancing understanding of the role that AGEs may 
play in accelerating the development of age-related conditions, such as open 
angle glaucoma has the potential to offer additional insight into pathogenesis and 
act as a biomarker. Dietary AGE intake represents a potentially modifiable target, 
design of a UK specific AGE FFQ was an aim of this thesis to enable the 
measurement of dietary AGE intake in the UK population. Evaluating the impact 
of AGEs and dietary AGEs on a healthy ageing population as well as patients 
with OHT, NTG and POAG has been a focus of this thesis, as well investigating 
the relationships between AGEs, the retinal vasculature and corneal 
viscoelasticity.  
 
In summary the findings of this work were: 
 
10.1.1 (4.0) Validation of a specifically designed semi-quantitative food frequency 
questionnaire  
The known links between dAGE and pathology and the concept that they are a 
potentially modifiable factor makes assessment of dAGE intake an area of great 
interest. The aim of this study was to design and validate a UK-specific FFQ for 
use in AGE research. In addition, this study aimed to assess the reliability of the 
newly developed FFQ and to compare the dAGE outputs calculated using the 
three different databases. 
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The comparisons between databases suggested that they are more in line with 
each other than previously thought. The choice of database should therefore be 
based upon which is most relevant to the population, and has enough foods 
measured to ensure minimal instances of assigning ‘assumed values’ to foods 
with no assigned measured value. The strong correlations found between the 
three different types of AGEs measured by Schejien (CML, CEL and MG-H1) 
suggests that when considering diet as a whole, an individual dAGE may be 
sufficient to give a representation as to if a person has a high or low AGE diet. 
 
The UK-specific semi-quantitative FFQ developed to measure dAGE was found 
to produce valid results when compared to a 4-day FR and to be reliable across 
two completions; this indicates that it is a useful tool for estimating dAGE in a UK 
population. We were however unable to validate the FFQ against the objective 
plasma CML-AGE measurement and the reasons behind this require further 
research, but could relate to the measurement technique used.  
 
10.1.2 (5.0) The relationship between skin autofluorescence, dietary AGE intake 
and circulating oxidative stress levels in a healthy ageing population 
Questions remain as to if dAGEs accumulate in tissues or if they cause biological 
consequence. As such, the aim of this study was to determine whether dAGE 
intake is associated tissue-bound AGE levels (SAF) in a healthy ageing 
population.  If addition, due to oxidative stress having strong links with AGEs the 
study aimed to determine whether circulating oxidative stress levels relate to 
tissue-bound AGE levels (SAF) and dAGE in this same population.  
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The results of this study suggest that the contribution of dAGE to tissue-bound 
AGE levels may be minimal. This however requires further investigation. New 
AGE databases, and different AGEs are being measured which will aid further 
research. The relationship between oxidative stress and AGEs was investigated, 
no significant associations between oxidative stress biomarkers and dAGE were 
found. The oxidative stress biomarker alpha tocopherol correlated with SAF, this 
was however in the opposite way to that hypothesised and therefore requires 
further investigation before the relevance and insight that could be gained from 
this finding can be determined. The results also suggest that tissue-bound AGEs 
measured by SAF and the circulating oxidative stress biomarkers measured in 
this study are not closely related. For this reason the AGE reader, SAF, should 
not simply be used as a marker for oxidative stress and instead the two 
measures should be used alongside each other, rather than interchangeably in 
place of each other. 
 
10.1.3 (6.0) AGE levels in early stage POAG, NTG and OHT patients 
The results of Chapter 5 indicated that the contribution of dAGE to tissue-bound 
AGE levels is minimal, and requires further investigation to understand which, if 
any, types of AGEs are impacting tissue-bound levels in a healthy ageing 
population. Previous research however has shown that diets higher in dAGE are 
linked with pathology, for this reason it was decided that dAGE would be included 
in this study to allow the assessment of dAGE intake between HC and pathology 
groups.   
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It has been hypothesised that increased accumulation of AGEs could be the 
underlying causative factor for a number of the known pathological associations 
of GON and ultimately contribute towards its development in some individuals 
through acceleration of the ageing process. The aim of this study was to 
determine whether tissue bound and dAGE levels are elevated in POAG and 
NTG in comparison to age-matched OHT patients and healthy controls. Oxidative 
stress levels were compared as a possible influencing factor. No previous studies 
had examined SAF in these three groups in conjunction with each other. 
 
Tissue-bound AGE, SAF level, was significantly higher in NTG and POAG 
compared to healthy controls. This finding adds to the evidence that SAF, as an 
accessible measure, may be a suitable long-term biomarker of glaucoma. 
Understanding if AGEs influence vascular parameters more than structure of 
tissues is not yet established. Dietary AGE intake was found to be similar 
between healthy controls, OHT, NTG and POAG patients. Patients with POAG 
exhibited lower levels of the antioxidants ascorbate and alpha tocopherol 
compared to OHT and healthy controls, suggesting oxidation inhibition. There 
was however no increased level of MDA. 
 
10.1.4 (7.0) The relationship between tissue-bound AGE levels (SAF), retinal 
vessel structure and function and corneal viscoelastic properties in a healthy 
ageing population 
Age-related changes in the eye have been linked with pathology. There are no 
previous studies that have explored whether tissue-bound AGE levels are directly 
associated with retinal vessel structure and function, or corneal viscoelasticity, 
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hence the aim of this study was to determine how tissue-bound AGE levels are 
associated with static and dynamic retinal vessel parameters and corneal 
viscoelasticity in a healthy ageing population.   
 
Higher levels of tissue-bound AGE (SAF), were associated with narrower retinal 
arteries in a healthy population. This finding adds to the evidence that AGEs are 
an accessible marker of vascular health. Increased levels of ascorbate were 
associated with wider retinal arteries, this supports previous literature that diet 
derived antioxidants may have a protective effect. In this healthy population SAF 
was not found to be associated with dynamic vessel parameters or corneal 
viscoelastic parameters, however this may be due to the healthy group recruited 
as mean SAF was lower than expected.  
 
10.1.5 (8.0) The relationship between tissue bound AGE levels, static and 
dynamic retinal vessel structure and function, and corneal viscoelasticity in 
POAG, NTG and OHT patients 
In Chapter 6 SAF was significantly higher in NTG and POAG compared to 
healthy controls. This finding adds to the evidence that SAF, as an accessible 
measure, may be a suitable long-term biomarker of glaucoma. Understanding if 
AGEs influence vascular parameters in glaucoma is not yet established. 
Therefore, the aim of this study was to evaluate whether level of tissue bound 
AGEs (SAF) relates to static and dynamic retinal vessel structure and function 
and corneal viscoelasticity in POAG, NTG and OHT patients. It was shown in 
Chapter 6 that dAGE level is not significantly different between HC, OHT, NTG 
and POAG groups. For this reason, dAGEs were not assessed in this study. 
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The NTG group, who were shown to have a higher SAF level in comparison to 
healthy controls in Chapter 6, were found to have a significantly narrower CRAE. 
A direct relationship between SAF and CRAE was however not found within this 
group and it is thought this could relate to the small overall number of NTG 
participants recruited for this study. Indeed, the negative relationship shown in 
the larger HC group in Chapter 7 could indicate that narrower CRAE is related to 
increased SAF levels in principle.  
 
Increased SAF levels were found to associate with a less viscoelastic, stiffer 
cornea in the NTG group only. It is possible that increased SAF levels contribute 
to increased rigidity of the ocular structures which leave them more susceptible to 
damage from more ‘normal’ IOP levels, or small reductions in arterial blood 
supply, however larger scale studies would be needed before any conclusions 
could be drawn from these findings. There was no significant relationship in the 
OHT or POAG groups. The lack of statistically significant relationships between 
SAF and dynamic vascular parameters in any groups suggests that at the early 
stages of the disease process tissue-bound AGE levels do not significantly 
influence the vasoactive response of the retinal microvasculature to increased 
metabolic demand from flicker light stimulation.  
 
10.1.6 (9.0) The relationship between retinal vessel function and corneal 
viscoelasticity in OAG, NTG, OHT and healthy patients 
Although differing structures, both retinal vessels and the cornea are thought to 
be stiffened by AGE collagen cross-linking. This stiffening throughout the 
structures of the eye could contribute to overall ocular mechanical rigidity. The 
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aim of this study was to explore whether dynamic retinal vascular parameters are 
related to corneal viscoelastic parameters in HC, OHT, OAG patients.  
 
Retinal artery and vein parameters of dynamic retinal function were found to be 
related to viscoelastic corneal properties. In open angle glaucoma patients, a less 
viscoelastic cornea was found to be related to increased arterial dilation response 
to flicker light and a faster venous response and recovery time. The results 
however are not consistent between the groups, which causes some uncertainty 
to the relationships. It is not clear from these results if mechanical rigidity occurs 
at an equal rate throughout the eye, or if structure is affected more than another. 
Larger scale studies may help to identify which way relationships exist in different 
patient groups.  
 
10.2 Overall limitations 
The studies outlined in this thesis are subject to potential limitations.  
The sample size recruited for OHT and NTG was lower than the target sample 
size, this potentially limits the conclusions drawn from this study. The challenge 
with recruitment of early stage glaucoma participants and OHT participants was 
due to the strict inclusion/exclusion criteria. These criteria however were 
necessary to avoid any other influences on AGE level, e.g. if smokers were 
included then this may have masked any other relationships. As a result of this 
strict criteria and exclusion of other disease linked to AGEs the resultant group of 
participants were particularly healthy and as a result had a lower SAF level than 
was expected for mean age.  
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The AGE-reader (DiagnOptics B.V., Groningen, The Netherlands) as explained in 
previous Chapters, is a device which utilises the fluorescent properties of tissue-
bound AGEs in the skin to provide a measurement of skin autofluorescence 
(SAF). A limitation of the device is that it can only assess Fitzpatrick skin colour 
classes 1-4 (419). Fitzpatrick skin colour classes 5 and 6 (Skin reflectance <6%) 
do not give the required reflectance for a reliable measurement (416, 417, 419). 
As described in Chapter 6, SAF has been found to be significantly higher in NTG 
and POAG compared to healthy controls. A problem arises here in that ethnicity 
is a risk factor for glaucoma, with people of African descent more at risk of 
developing glaucoma (608-611). It is this same ethnicity group that has the 
darkest skin and would not be able to have a reliable SAF measurement taken.  
 
The Plasma AGE-CML ELISA kit used was not validated and produced results 
which did not agree with the previous research. The standards given with this kit 
were not in the same range as the measurements found, this will have impacted 
the results. In future research plasma AGE-CML will be carried out using the 
UPLC–MS/MS method. 
 
Participants that were prescribed anti-glaucomatous drops were not excluded. 
This may have impacted the results as these drops can affect the ocular surface, 
which could affect the Corvis ST measurement (410, 593). In addition some anti-
glaucomatous drops are known to be vasoactive, this may affect the retinal 
vasculature and hence affect the dynamic retinal vascular measurements. 
However the vascular effects of IOP lowering drops on retinal vascular calibre is 
not fully understood (265). 
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10.3 Clinical implications 
 
10.3.1 Implications in regard to dAGE 
The UK-specific semi-quantitative FFQ developed for this thesis offers a method 
of dAGE intake measurement that could be used in both future research and a 
clinical setting.  
 
10.3.2 Implications in regard to open angle glaucoma patients 
The results of this study found that SAF, as a measure of tissue-bound AGE 
level, may be a suitable long-term biomarker of glaucoma. SAF is an easily 
accessible fast measurement. The introduction of AGE readers to measure SAF 
could be something seen in a clinical setting either in a hospital or ‘high street’ 
setting and may be a useful tool as part of glaucoma screening.   
 
 
10.4 Future directions 
 
10.4.1 Further FFQ validation 
Despite the results of this thesis suggesting that the newly developed UK specific 
AGE FFQ is repeatable and a useful tool for estimating dAGE in a UK population, 
further validation and review should take place. This validation should use UPLC-
MS/MS to measure CML in the plasma. 
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10.4.2 Assessment of AGE-reader capabilities 
Since the AGE reader was able to successfully measure SAF readings in 
participants whose characteristics would be linked to Fitzpatrick class 5 further 
research is required to better understand the capabilities of the AGE reader and 
establish which ethnicity groups can be measured accurately. In addition further 
investigation into how body fat percentage and fat mass impact SAF 
measurements is of interest.  
  
10.4.3 Larger scale studies  
Despite statistically significant results being demonstrated in this thesis any larger 
scale studies may help to confirm/deny the findings which are close to 
significance. In addition to this, including sub-groups with varying levels of 
glaucomatous damage would be of interest as to AGEs influence on glaucoma 
progression.  
 
10.4.4 AGE levels influence on the rate of glaucoma progression 
Assessing if baseline AGE (SAF) levels are associated with an increased rate of 
progression in NTG and POAG patients as well as determine whether SAF levels 
are associated with OHT progression to develop POAG. This would be a long-
term follow up study assessing early stage glaucoma patients and following the 
changes in visual field mean deviation and OCT retinal nerve fibre layer. These 
parameters are measured routinely in the glaucoma follow-up clinics and would 
therefore be easily accessible. The literature suggests that a follow-up period of 
between 3-5 years is preferential for determining the potential role of influencing 
factors on rate of progression in glaucoma. 
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15/12/16 
 
Dear Leanne,   
 
Further to the below, I am pleased to confirm that HRA Approval has been issued for the 
referenced amendment, following assessment against the HRA criteria and standards.  
 
The sponsor should now work collaboratively with participating NHS organisations in England to 
implement the amendment as per the below categorisation information.  This email may be 
provided by the sponsor to participating organisations in England to evidence that the 
amendment has HRA Approval. 
 
Please contact hra.amendments@nhs.net  for any queries relating to the assessment of this 
amendment. 
 
Yours sincerely, 
 
 
Kind Regards 
Steph Macpherson 
HRA Senior Assessor 
  
 
Health Research Authority 
HRA, Ground Floor, Skipton House, 80 London Road, London, SE1 6LH 
E: hra.approval@nhs.net  
www.hra.nhs.uk 
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nt information sheet  
 
 
 
Participant information sheet   
Project title: Advanced glycation end products as a biomarker for accelerated 
ageing  
We would like to invite you to participate in a research study being conducted by Miss 
Leanne Smewing, Optometrist and PhD researcher, in conjunction with Dr Stephanie 
Mroczkowska, Dr Desley White and Professor Paul Artes from Plymouth University.  
Before deciding if you would like to participate it is important for you to understand why 
the research is being undertaken and what it will involve. This information sheet explains 
the background and aims of the study. Please take time to read it carefully and discuss it 
with others if you wish. If anything is unclear, or if you would like more information, 
please ask us. Your participation in this study is entirely voluntary.  
 
Information related to your participation 
1. What is this study about? 
Glaucoma is a disease of the eye which affects over 60 million people worldwide. The 
exact cause of glaucoma is still relatively poorly understood, however one of the most 
significant risk factors for its development is thought to be advancing age.  This study 
aims to explore whether ageing products that accumulate naturally within the body over 
time (called advanced glycation end-products (AGEs)) influence the function of the blood 
vessels at the back of the eye in healthy individuals. It also aims to explore whether the 
accumulation of these ageing products occurs to a higher level in those with glaucoma 
and/or in those with high pressure in the eye. 
2. Why have I been invited to participate? 
To allow measurement of ‘normal ageing’ and to allow the comparison of ‘normal’ results 
to those of our participants diagnosed with glaucoma or high eye pressure, this study 
requires the participation of healthy volunteers, like yourself, who do not suffer from 
either eye condition.  
3. What does the study involve? 
Data collection for the study will be carried out across 2 sessions. Session 1 will be 
carried out at Peninsula Allied Health Centre (PAHC), Derriford, PL6 8BH or the 
Wellbeing Centre, Endsleigh Place, Plymouth University, Drake Circus, PL4 8AA. 
 
 
 
Appendix 2.1 – Healthy control information sheet  
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Session 2 will be carried out at Human Metabolism laboratory, Food and Nutrition Unit, 
Link Building, Drake Campus, Plymouth University. 
Session 1 procedures: 
- Completion of a short questionnaire 
- Measurement of vision 
- Examination of the health of your eyes and insertion of drops 
- Measurement of eye pressure 
- Have a scan taken of the front of your eye (cornea) 
- Have a scan taken of the back of your eye (retinal vessel function) 
Total visit time approximately 2.5 hours  
Session 2 procedures: 
- Height and weight measured 
- Measurement of blood pressure 
- Measure AGE level with skin reader 
- Finger prick blood sugar test 
- Obtain a blood sample 
- Complete a food questionnaire  
Total visit time approximately 2 hours  
 
4. What is expected of me at these sessions? 
Session 1: Carried out at Peninsula Allied Health Centre (PAHC), Derriford, PL6 8BH or 
Wellbeing Centre, Endsleigh Place, Plymouth University, Drake Circus, PL4 8AA 
Before session 1: 
 Leanne Smewing (chief investigator) will call you and remind you of your 
appointment time and remind you that as drops will be inserted into one of your eyes 
at this visit you will not be able to drive for 4 hours after the appointment 
(alternative travel arrangements will need to be made). 
 Due to their possible effect on your blood vessel measurement, you will be asked to 
avoid the following in the 12 hours before your appointment: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
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- caffeine containing products (tea/coffee) 
- taking any dietary supplements or vitamins (especially vitamin C)  
 
However, you will be asked to maintain your normal eating habits on this day i.e. you are 
NOT required to fast. 
On the day of session 1: 
 If you decide to participate in this study you will be asked to sign a consent form. A 
copy of this consent form can be found at the end of this information pack 
 
 You will be asked to complete a quick questionnaire to allow us to collect information 
about your age, ethnicity and any medication you are taking etc. This will aid us with 
the analysis of our results and also ensure that there are no unforeseen medical 
factors that would prevent you being included in our study. 
  
 You will have your vision measured and a short health exam to ensure your eyes 
won’t have any allergic reaction to the drops used.  
 
 A machine will be used to take measurements of your cornea at the front of your eye. 
This procedure requires you to sit down with your head on a comfortable support. 
You will be required to look straight ahead at a target.  
 
 A drop and some fluorescein eye dye will be put into each of your eyes so that your 
eye pressure can be measured. This drop is an anaesthetic drop called 
proxymetacaine. The drops take about 60 seconds to work and the anaesthetic effect 
can last for up to 20 minutes. You will be advised not to rub your eyes and avoid 
getting dust or grit in your eye during this 20 minute period.  
 
 So that good images of the back of your eye can be obtained with the retinal camera 
another drop will be put into one of your eyes only. This drop, called tropicamide, 
increases the size of your pupil so that we can get a full view of the back of your eye. 
Having big pupils can reduce your quality of vision temporarily and you may 
experience some dazzling in bright sunlight or artificial light for a few hours after 
you’ve had the drops in. You may therefore benefit from bringing some sunglasses 
with you and will be advised not to drive a motor vehicle, ride a bicycle or operate 
moving machinery for 4 hours after the appointment.  
 
 The pupil dilating drops take approximately 20 minutes to work, while the drops are 
working we will decide a suitable date for part 2 and you will be provided with a 
campus map. You will also have the opportunity to ask any further questions. 
 
 Once the drops have dilated your pupil the retinal camera will be used to take 
measurements of the blood vessels at the back of your eye. This procedure requires 
you to sit down with your head on a comfortable support. You will be required to look 
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straight ahead and you will see a flickering light for short periods of time. This will not 
harm your eyes but may leave you with an afterimage for a few seconds. 
 
Due to the flickering light it is important that you tell us if you have a known history 
of epilepsy. Although the camera poses very little harm, there is a small risk of 
triggering an episode of epilepsy in those not diagnosed. 
 
At the end of session 1: 
 You will be advised not to drive a motor vehicle, ride a bicycle or operate moving 
machinery for at least 4 hours after the appointment due to the insertion of the eye 
drop. 
 Your appointment for session 2 will be confirmed 
 
Session 2:  
Before session 2: 
 You will be required to fast (i.e. not eat anything) for 12 hours before this 
appointment. This is because eating food can affect the outcome of your blood test 
During the 12 hours before your appointment you will also be asked to avoid: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
- caffeine containing products  
- taking any dietary supplements or vitamins (especially vitamin C)  
This is because these factors can also affect the outcome of the results.   
 We recommend that you wear comfortable, loose fitting clothing on the day of this 
appointment. This is to allow us to easily access your upper arm for both blood 
pressure measurement and blood sample.  
 Self-tanning agents must not have been used for at least 2 days before this 
appointment as they can affect the AGE reading taken from your skin. 
 
On the morning of session 2: 
At Plymouth University main campus Link building Leanne Smewing will meet you at the 
main entrance.  
 Basic measurements will be taken first. These will include your; height, weight and 
blood pressure. Your BMI will be calculated from these measurements. 
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 If you have any sun blockers or skin creams on your forearm this will be removed as 
it can influence the AGE measurement. 
 Next, your tissue bound AGE level will be measured using a non-invasive device 
called the AGE Reader. You will place your forearm on the machine a light from the 
machine will be used to take the AGE measurement. The measurement will take 
approximately 20-30 seconds and will be repeated 3 times.  
 A finger prick blood sugar test will be taken prior to your blood sample.   
 A blood sample will be taken by a researcher trained in phlebotomy in a specialist 
blood laboratory. This will be carried out with you sitting up and will involve taking 
blood in a similar way to that which you may have experienced at your GP’s surgery 
or at the hospital. This is a routinely performed procedure and the risks associated 
with this procedure are minimal. 
 You will be asked to complete a questionnaire relating to your diet. The researcher 
will go through the questions with you. This allows us to collect information about the 
foods you eat and your methods of cooking.  
 
After session 2: 
 It is recommended that you avoid alcohol for 4 hours after the study and also 
avoid any unnecessary hazardous/strenuous/physical activity. 
 As we require you to fast for 12 hours prior to the appointment a light snack will be 
provided after the study is completed. Alternatively you may wish to bring some 
refreshments with you  
 
5. What are the risks of taking part in this study? 
All the devices used in this study are commercially available and CE marked to ensure 
they comply with European Health and Safety requirements. We have worked hard to 
limit the risks associated with this study and all participants will be selected carefully. 
Despite this it is still important that you are aware of the possibility of adverse effects.   
Leanne Smewing is a qualified optometrist and is fully trained in the techniques being 
performed. In addition first aiders will be present on both sites. 
Use of Proxymetacaine 0.5% and fluorescein  
This is a drop that is used when measuring eye pressure. It is a drop routinely used by 
Optometrists and Eye Hospitals so it possible you may have had it before. You may 
experience mild stinging when the drop is first put into your eyes, but this will subside 
very quickly.  The drops are a type of local anaesthetic and take about 60 seconds to 
work and the effect may last for up to 20 minutes. You must not rub your eyes and try to 
avoid getting dust or grit in your eye as the anaesthetic would prevent you feeling any 
effect of this until after the drops wear off. 
In the unlikely event that you experience any unusual symptoms such as pain and 
soreness in or around your eyes or your vision seems blurred after the appointment, 
contact a member of the research team, your optometrist or seek medical advice as you 
might be experiencing an adverse reaction to the drops. 
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Use of Tropicamide 0.5% 
This is the drop that is used with the retinal camera to make your pupils larger. It takes 
approximately 15 to 30 minutes to work and up to 6 hours to wear off. Again, it is a drop 
routinely used by Optometrists and Eye Hospitals so it possible you may have had it 
before.  
As mentioned previously, the enlargement of the pupil may cause a reduced quality of 
vision temporarily and you may experience some glare in bright sunlight or artificial light 
for a few hours afterwards. You are therefore advised not to drive a motor vehicle, ride a 
bicycle or operate moving machinery for at least 6 hours after the appointment. You may 
also wish to use sunglasses during this time to alleviate any increased light sensitivity. 
You may experience mild stinging when the drop is first put into your eyes, but this will 
subside very quickly.   
There is a very small chance that using this drop can trigger unusual symptoms such as 
pain and redness around the eyes or ‘misty’ vision, usually immediately after drop 
insertion. This is very unlikely but if any of these symptoms do occur you are advised to 
speak to the research team and seek medical advice immediately as you may be 
experiencing an adverse reaction to the drops. 
Use of the retinal camera 
The retinal camera is a non-invasive device that poses very little harm. As it uses a 
flickering light it is important to be aware that there is a small risk of it triggering an 
episode of epilepsy in those not diagnosed. 
Taking a blood sample 
There can be a mild short irritation when taking a blood sample. Only a small amount of 
blood is taken during this study so you shouldn't feel any significant after-effects. 
However some people may feel dizzy and faint during and after the test. If this has 
happened to you in the past, or happens during the test please tell the person carrying 
out the test so they’re aware and can help you feel more comfortable. After the test, you 
may have a small bruise where the needle went in. Bruises can be painful, but are 
usually harmless and fade over the next few days. 
A small blood sample of 9mL will be taken. This blood sample will provide us with 
information about oxidative stress. The sample we store will not contain any of your DNA 
and will be stored and destroyed following the human tissue act procedures. The sample 
will be kept in the -80 degree C freezer in the locked laboratory in the Human 
Metabolism Laboratory at the Food and Nutrition Unit, Link Building, Plymouth 
University. They will be stored until all analysis is completed, stored for maximum of 2 
years. Only the research team and technical staff will have access to the samples.  
Any abnormal findings found from this study would be sent in a letter to your GP and a 
copy would also be sent to you.   
6. Are there any benefits of participating in this study? 
This study is not likely to benefit you directly, but it will help researchers at Plymouth 
University evaluate whether AGE levels influence the function of the blood vessels in 
302 
 
your eye or contribute to the development of the eye disease glaucoma. In the future it 
may open up the possibility of new diagnostic and treatment options in the form of 
dietary, lifestyle or targeted therapeutic interventions.  
7. Who has reviewed the study? 
All research is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and approved by the 
Health Research Authority and Plymouth University’s Faculty Research Ethics 
Committee by the ‘Central Office of the Research Ethics Committee (REC) for the NHS 
and the Plymouth University Research Ethics Committee.  
8. Do I have to take part? 
No. You are free to decide whether or not to participate in this study. You should take 
time to consider your participation in this research and ask questions if there are aspects 
which you do not understand or if you need further information. If you decide to take part 
you will be asked to sign two copies of a consent form in the presence of an appropriate 
member of the research team. You will be given a signed copy of the consent form and 
an information sheet for your own records. You may decide not to participate or withdraw 
at any time without giving a reason or without it affecting your relationship with Plymouth 
University, or your current or future treatment in any way. If you decide to withdraw from 
the study all identifiable data and samples collected from you would be withdrawn. The 
samples would be destroyed as per human tissue authority guidelines. The lead 
investigator may also remove you from the study if they believe it to be in your best 
interest.  
9. Is there remuneration for participation?  
Unfortunately, you will not get paid to participate in this project. 
10. Is taking part confidential? 
If you decide to participate in the study we will inform your GP you are doing so. 
All of the information you provide as a participant and any data collected as a result of 
your participation in this study will remain confidential. Your records may be looked at by 
the research team involved in this study and the monitoring or audit team approved by 
the university.  All information will be stored electronically on a computer which is 
password protected, in a document file that is also password protected. All information 
will be handled in compliance with the Data Protection Act (1998).  
Your name and address (which we need in order to contact you) will be stored 
separately from the other information you supply during the study so that you cannot be 
identified from your study records. After 10 years, all of your records will confidentially be 
disposed of in accordance with the guidelines laid out by Plymouth University. 
Any data collected in this investigation may be submitted for publication or used in 
presentations. Neither your name nor information disclosing your identity will be released 
or published without your explicit consent to the disclosure.  
11. What will happen to the results of the research study?  
The results will be available through University of Plymouth, if you require a copy of the 
final report please write to the address given below. 
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12. What if I have any further questions or require further information? 
If you have any questions about our project, either now or in the future, please feel free 
to contact:  
Leanne Smewing; 
Email: leanne.smewing@plymouth.ac.uk   
Phone: (0)1752 587541      
 
13. What if I have a complaint?  
Should you have reason to complain about the way you have been treated at any stage 
during the study you can contact; 
 
Dr Stephanie Mroczkowska;  
Email: stephanie.mroczkowska@plymouth.ac.uk 
Telephone: 01752 587549 
 
Alternatively, you can make your complaint directly to Leanne Smewing, (contact details 
as above).  
 
In the unlikely situation that you experience any unusual side effects to any of the 
procedures carried out you are advised to seek immediate medical advice. You will be 
issued with a list of any drugs administered to you and this should be shown to any 
medic that you consult. 
If you have any concerns about the way in which the study has been conducted, please 
contact the Secretary of the Health & Human Sciences University Research Ethics 
Committee Sarah C Jones by email, or telephone (details below) as well as contacting 
the Patient Advice and Liaison Service (PALS) on 0800 328 3205. 
Sarah C Jones;  
Email: hhsethics@plymouth.ac.uk  
Telephone: 01752 585339 
If there is negligent harm during the clinical trial, Plymouth University owes a duty of care 
to the person harmed. 
If you decide to participate in this study you will be asked to sign a consent form. A copy 
of this consent form can be found at the end of this information pack.  
 
Thank you for taking the time to read this information sheet 
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Appendix 2.2 – Healthy control consent form  
 
 
 
 
Declaration of informed consent 
 
Title of Project:  Advanced glycation end products as a biomarker for accelerated 
ageing in glaucomatous optic neuropathy 
Name of researcher: Leanne Smewing 
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Appendix 2.3 – POAG and NTG information sheet  
 
 
 
 
 
 
 
Participant information sheet  
Project title: Advanced glycation end products as a biomarker for accelerated 
ageing in glaucomatous optic neuropathy 
We would like to invite you to participate in a research study being conducted by Miss 
Leanne Smewing, Optometrist and PhD researcher, in conjunction with Dr Stephanie 
Mroczkowska, Dr Desley White and Professor Paul Artes from Plymouth University.  
Before deciding if you would like to participate it is important for you to understand why 
the research is being undertaken and what it will involve. This information sheet explains 
the background and aims of the study. Please take time to read it carefully and discuss it 
with others if you wish. If anything is unclear, or if you would like more information, 
please ask us. Your participation in this study is entirely voluntary. 
 
Information related to your participation 
1. What is this study about? 
Glaucoma is a disease of the eye which affects over 60 million people worldwide. The 
exact cause of glaucoma is still relatively poorly understood, however one of the most 
significant risk factors for its development is known to be advancing age.  With this in 
mind, this study aims to explore whether certain ageing products, (called advanced 
glycation end-products, (AGEs), that accumulate naturally within the body over time, are 
present in higher amounts in those with glaucoma and/or in those with high pressure in 
the eye compared to those without glaucoma. This study will also aim to explore whether 
the level of these ageing products in your body at the start relates to how much your 
glaucoma progresses over a 5 year period 
2. Why have I been invited to participate? 
The study requires the participation of individuals who have been diagnosed with or are 
suspected of having early glaucoma and are otherwise healthy, like yourself.  
3. What does the study involve? 
Data collection for the study will be carried out across 2 sessions. Session 1 will be 
carried out at The Royal Eye Infirmary, level 3 Derriford Hospital, Derriford Road, 
Plymouth, PL6 8DH. Session 2 will be carried out at Human Metabolism laboratory, Food 
and Nutrition Unit, Link Building, Drake Campus, Plymouth University. There is an 
optional 3rd visit which will be carried out at Peninsula Allied Health Centre (PAHC), 
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Derriford, PL6 8BH or Wellbeing Centre, Endsleigh Place, Plymouth University, Drake 
Circus, PL4 8AA 
 
Session 1 procedures: 
- Normal NHS appointment procedures 
- Given this information sheet and a short questionnaire 
 
Session 2 procedures: 
- Height and weight measured 
- Measurement of blood pressure 
- Measure AGE level with skin reader 
- Finger prick blood sugar test 
- Obtain a blood sample 
- Complete a food frequency questionnaire  
Total visit time approximately 2 hours  
Optional session 3: 
- Examination of the health of your eyes and insertion of drops 
- Measurement of eye pressure 
- Have a scan taken of the back of your eye (retinal vessel function) 
After completion of session 1 and 2 and with your consent, your NHS eye records will be 
reviewed yearly for 5 years by a member of the research team. The results of your visual 
field test and optic nerve scan will be noted from your eye records and used as a way of 
monitoring the progression of your glaucoma.  You will not need to be present for this 
section of data collection. 
4. What is expected of me at these sessions? 
Session 1:  
If you decide to participate in this study you will be asked to sign a consent form. A copy 
of this consent form can be found at the end of this information pack.  
Once you have given your consent you will be asked to complete a quick questionnaire 
which will allow us to collect information about your age, ethnicity and any medication 
you are taking. This will aid us with the analysis of the results and also ensure that there 
are no unforeseen medical factors that would prevent you being included in our study. 
Following this we will arrange a date that is suitable for you to visit Plymouth University 
main campus for your second data collection session. You will be provided with a 
campus map and given full instructions on how to locate the required building in 
preparation for this second session.  
Session 2:  
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Before session 2: 
 You will be required to fast (i.e. not eat anything) for 12 hours before this 
appointment. This is because eating food can affect the outcome of your blood 
test 
During the 12 hours before your appointment you will also be asked to avoid: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
- caffeine containing products  
- taking any dietary supplements or vitamins (especially vitamin C)  
This is because these factors can also affect the outcome of the results.   
 We recommend that you wear comfortable, loose fitting clothing on the day of this 
appointment. This is to allow us to easily access your upper arm for both blood 
pressure measurement and blood sample.  
 Self-tanning agents must not have been used for at least 2 days before this 
appointment as they can affect the AGE reading taken from your skin.  
 
On the morning of session 2: 
At Plymouth University main campus Link building Leanne Smewing will meet you at the 
main entrance.  
 Basic measurements will be taken first. These will include your; height, weight and 
blood pressure. Your BMI will be calculated from these measurements. 
 If you have any sun blockers or skin creams on your forearm this will be removed as 
it can influence the AGE measurement. 
 Next, your tissue bound AGE level will be measured using a non-invasive device 
called the AGE Reader. You will place your forearm on the machine and a light from 
the machine will be used to take the AGE measurement. The measurement will take 
approximately 20-30 seconds and will be repeated 3 times.  
 A finger prick blood sugar test will be taken prior to your blood sample.   
 A blood sample will be taken by a researcher trained in phlebotomy in a specialist 
blood laboratory. This will be carried out with you sitting up and will involve taking 
blood in a similar way to that which you may have experienced at your GP’s surgery 
or at the hospital. This is a routinely performed procedure and the risks associated 
with this procedure are minimal. 
 You will be asked to complete a questionnaire relating to your diet. The researcher 
will go through the questions with you. This allows us to collect information about the 
foods you eat and your methods of cooking.  
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After session 2: 
 It is recommended that you avoid alcohol for 4 hours after the study and also 
avoid any unnecessary hazardous/strenuous/physical activity. 
 As we require you to fast for 12 hours prior to the appointment a light snack will 
be provided after the study is completed. Alternatively you may wish to bring 
some refreshments with you  
 Should you be interested, we can arrange an optional 3rd session where we can 
take measurements of the blood vessels at the back of your eye. The drops used 
at this 3rd session are the same as the drops used for your hospital visits.  
 
Optional Session 3: Carried out at Peninsula Allied Health Centre (PAHC), Derriford, 
PL6 8BH or Wellbeing Centre, Endsleigh Place, Plymouth University, Drake Circus, PL4 
8AA 
Before session 3: 
 Leanne Smewing (chief investigator) will call you and remind you of your 
appointment time and remind you that as drops will be inserted into one of your eyes 
at this visit you will not be able to drive for 4 hours after the appointment (alternative 
travel arrangements will need to be made). 
 Due to their possible effect on your blood vessel measurement, you will be asked to 
avoid the following in the 12 hours before your appointment: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
- caffeine containing products (tea/coffee) 
- taking any dietary supplements or vitamins (especially vitamin C)  
However, you will be asked to maintain your normal eating habits on this day i.e. you are 
NOT required to fast. 
On the day of session 3: 
 You will have your vision measured and a short health exam to ensure your eyes 
won’t have any allergic reaction to the drops used.  
 
 A drop and some fluorescein eye dye will be put into each of your eyes so that your 
eye pressure can be measured. This drop is an anaesthetic drop called 
proxymetacaine. The drops take about 60 seconds to work and the anaesthetic effect 
can last for up to 20 minutes. You will be advised not to rub your eyes and avoid 
getting dust or grit in your eye during this 20 minute period.  
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 So that good images of the back of your eye can be obtained with the retinal camera 
another drop will be put into one of your eyes only. This drop, called tropicamide, 
increases the size of your pupil so that we can get a full view of the back of your eye. 
Having big pupils can reduce your quality of vision temporarily and you may 
experience some dazzling in bright sunlight or artificial light for a few hours after 
you’ve had the drops in. You may therefore benefit from bringing some sunglasses 
with you and will be advised not to drive a motor vehicle, ride a bicycle or operate 
moving machinery for 4 hours after the appointment.  
 
 The pupil dilating drops take approximately 20 minutes to work. 
 
 Once the drops have dilated your pupil the retinal camera will be used to take 
measurements of the blood vessels at the back of your eye. This procedure requires 
you to sit down with your head on a comfortable support. You will be required to look 
straight ahead and you will see a flickering light for short periods of time. This will not 
harm your eyes but may leave you with an afterimage for a few seconds. 
 
Due to the flickering light it is important that you tell us if you have a known history of 
epilepsy. Although the camera poses very little harm, there is a small risk of 
triggering an episode of epilepsy in those not diagnosed. 
 
At the end of session 3: 
 You will be advised not to drive a motor vehicle, ride a bicycle or operate moving 
machinery for at least 4 hours after the appointment due to the insertion of the 
eye drop. 
 
5. Are any risks associated with this project? 
All the devices used in this study are commercially available and CE marked to ensure 
they comply with European Health and Safety requirements. We have worked hard to 
limit the risks associated with this study and all participants will be selected carefully. 
Despite this it is still important that you are aware of the possibility of adverse effects.   
Leanne Smewing is a qualified optometrist and is fully trained in the techniques being 
performed. In addition first aiders will be present on both sites. 
Use of Proxymetacaine 0.5% and fluorescein  
This is a drop that is used when measuring eye pressure. It is a drop routinely used by 
Optometrists and Eye Hospitals so it possible you may have had it before. You may 
experience mild stinging when the drop is first put into your eyes, but this will subside 
very quickly.  The drops are a type of local anaesthetic and take about 60 seconds to 
work and the effect may last for up to 20 minutes. You must not rub your eyes and try to 
avoid getting dust or grit in your eye as the anaesthetic would prevent you feeling any 
effect of this until after the drops wear off. 
In the unlikely event that you experience any unusual symptoms such as pain and 
soreness in or around your eyes or your vision seems blurred after the appointment, 
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contact a member of the research team, your optometrist or seek medical advice as you 
might be experiencing an adverse reaction to the drops. 
Use of Tropicamide 0.5% 
This is the drop that is used with the retinal camera to make your pupils larger. It takes 
approximately 15 to 30 minutes to work and up to 6 hours to wear off. Again, it is a drop 
routinely used by Optometrists and Eye Hospitals so it possible you may have had it 
before.  
As mentioned previously, the enlargement of the pupil may cause a reduced quality of 
vision temporarily and you may experience some glare in bright sunlight or artificial light 
for a few hours afterwards. You are therefore advised not to drive a motor vehicle, ride a 
bicycle or operate moving machinery for at least 6 hours after the appointment. You may 
also wish to use sunglasses during this time to alleviate any increased light sensitivity. 
You may experience mild stinging when the drop is first put into your eyes, but this will 
subside very quickly.   
There is a very small chance that using this drop can trigger unusual symptoms such as 
pain and redness around the eyes or ‘misty’ vision, usually immediately after drop 
insertion. This is very unlikely but if any of these symptoms do occur you are advised to 
speak to the research team and seek medical advice immediately as you may be 
experiencing an adverse reaction to the drops. 
Use of the retinal camera 
The retinal camera is a non-invasive device that poses very little harm. As it uses a 
flickering light it is important to be aware that there is a small risk of it triggering an 
episode of epilepsy in those not diagnosed. 
Taking a blood sample 
There can be a mild short irritation when taking a blood sample. Only a small amount of 
blood is taken during this study so you shouldn't feel any significant after-effects. 
However some people may feel dizzy and faint during and after the test. If this has 
happened to you in the past, or happens during the test please tell the person carrying 
out the test so they’re aware and can help you feel more comfortable. After the test, you 
may have a small bruise where the needle went in. Bruises can be painful, but are 
usually harmless and fade over the next few days. 
A small blood sample of 9mL will be taken. This blood sample will provide us with 
information about oxidative stress. The sample we store will not contain any of your DNA 
and will be stored and destroyed following the human tissue act procedures. The sample 
will be kept in the -80 degree C freezer in the locked laboratory in the Human 
Metabolism Laboratory at the Food and Nutrition Unit, Link Building, Plymouth 
University. They will be stored until all analysis is completed, stored for maximum of 2 
years. Only the research team and technical staff will have access to the samples.  
Any abnormal findings found from this study would be sent in a letter to your GP and a 
copy would also be sent to you.   
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6. What are the benefits of participation? 
This study is not likely to benefit you directly, but it will help researchers at Plymouth 
University evaluate whether AGE levels influence the function of the blood vessels in 
your eye or contribute to the development of the eye disease glaucoma. In the future it 
may open up the possibility of new diagnostic and treatment options in the form of 
dietary, lifestyle or targeted therapeutic interventions.  
7. Who has reviewed the study? 
All research is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and approved by the 
Health Research Authority and Plymouth University’s Faculty Research Ethics 
Committee. 
8. Do I have to take part? 
No. You are free to decide whether or not to participate in this study. You should take 
time to consider your participation in this research and ask questions if there are aspects 
which you do not understand or if you need further information. If you decide to take part 
you will be asked to sign three copies of a consent form in the presence of an 
appropriate member of the research team. You will be given a signed copy of the 
consent form and an information sheet for your own records. You may decide not to 
participate or withdraw at any time without giving a reason or without it affecting your 
relationship with Plymouth University, or your current or future treatment in any way. If 
you decide to withdraw from the study all identifiable data and samples collected from 
you would be withdrawn. The samples would be destroyed as per human tissue authority 
guidelines. The lead investigator may also remove you from the study if they believe it to 
be in your best interest.  
9. Is there remuneration for participation?  
Unfortunately, you will not get paid to participate in this project. 
10. Is taking part confidential? 
If you decide to participate in the study we will inform your GP you are doing so. 
All of the information you provide as a participant and any data collected as a result of 
your participation in this study will remain confidential. Your records may be looked at by 
the research team involved in this study and the monitoring or audit team approved by 
the university.  All information will be stored electronically on a computer which is 
password protected, in a document file that is also password protected. All information 
will be handled in compliance with the Data Protection Act (1998).  
Your name and address (which we need in order to contact you) will be stored 
separately from the other information you supply during the study so that you cannot be 
identified from your study records. After 10 years, all of your records will confidentially be 
disposed of in accordance with the guidelines laid out by Plymouth University. 
Any data collected in this investigation may be submitted for publication or used in 
presentations. Neither your name nor information disclosing your identity will be released 
or published without your explicit consent to the disclosure.  
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11. What will happen to the results of the research study?  
The results will be available through University of Plymouth, if you require a copy of the 
final report please write to the address given below. 
12. What if I have any further questions or require further information? 
If you have any questions about our project, either now or in the future, please feel free 
to contact:  
Leanne Smewing; 
Email: leanne.smewing@plymouth.ac.uk   
Phone: (0)1752 587541      
 
 
13. What if I have a complaint?  
Should you have reason to complain about the way you have been treated at any stage 
during the study you can contact; 
Dr Stephanie Mroczkowska;  
Email: stephanie.mroczkowska@plymouth.ac.uk 
Telephone: 01752 587549 
Alternatively, you can make your complaint directly to Leanne Smewing, (contact details 
as above).  
 
In the unlikely situation that you experience any unusual side effects to any of the 
procedures carried out you are advised to seek immediate medical advice. You will be 
issued with a list of any drugs administered to you and this should be shown to any 
medic that you consult. 
If you have any concerns about the way in which the study has been conducted, please 
contact the Secretary of the Health & Human Sciences University Research Ethics 
Committee Sarah C Jones by email, or telephone (details below) as well as contacting 
the Patient Advice and Liaison Service (PALS) on 0800 328 3205. 
Sarah C Jones;  
Email: hhsethics@plymouth.ac.uk 
Telephone: 01752 585339 
If there is negligent harm during the clinical trial, Plymouth University owes a duty of care 
to the person harmed. 
If you decide to participate in this study you will be asked to sign a consent form. A copy 
of this consent form can be found at the end of this information pack. 
 
Thank you for taking the time to read this information sheet 
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Appendix 2.4 – POAG and NTG consent form  
 
 
 
 
Declaration of informed consent 
 
Title of Project:  Advanced glycation end products as a biomarker for accelerated 
ageing in glaucomatous optic neuropathy 
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Appendix 2.5 – OHT information sheet  
 
 
 
 
 
 
Participant information sheet  
Project title: Advanced glycation end products as a biomarker for accelerated 
ageing in glaucomatous optic neuropathy 
We would like to invite you to participate in a research study being conducted by Miss 
Leanne Smewing, Optometrist and PhD researcher, in conjunction with Dr Stephanie 
Mroczkowska, Dr Desley White and Professor Paul Artes from Plymouth University.  
Before deciding if you would like to participate it is important for you to understand why 
the research is being undertaken and what it will involve. This information sheet explains 
the background and aims of the study. Please take time to read it carefully and discuss it 
with others if you wish. If anything is unclear, or if you would like more information, 
please ask us. Your participation in this study is entirely voluntary. 
 
Information related to your participation 
1. What is this study about? 
Glaucoma is a disease of the eye which affects over 60 million people worldwide. The 
exact cause of glaucoma is still relatively poorly understood, however one of the most 
significant risk factors for its development is known to be advancing age.  With this in 
mind, this study aims to explore whether certain ageing products (called advanced 
glycation end-products, AGEs), that accumulate naturally within the body over time, are 
present in higher amounts in those with glaucoma and/or in those with high pressure in 
the eye compared to those without glaucoma or high pressure. This study also aims to 
explore whether the level of these ageing products in your body at the start relates to the 
progression of your eye condition over a 5 year period 
2. Why have I been invited to participate? 
The study requires the participation of those who have been diagnosed with or are 
suspected of having ocular hypertension and are otherwise healthy, like yourself.  
3. What does the study involve? 
Data collection for the study will be carried out across 2 sessions. Session 1 will be 
carried out at The Royal Eye Infirmary, level 3 Derriford Hospital, Derriford Road, 
Plymouth, PL6 8DH. Session 2 will be carried out at Human Metabolism laboratory, Food 
and Nutrition Unit, Link Building, Drake Campus, Plymouth University. There is an 
optional 3rd visit which will be carried out at Peninsula Allied Health Centre (PAHC), 
Derriford, PL6 8BH or Wellbeing Centre, Endsleigh Place, Plymouth University, Drake 
Circus, PL4 8AA 
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Session 1 procedures: 
- Normal NHS appointment procedures 
- Given this information sheet and a short questionnaire 
 
Session 2 procedures: 
- Height and weight measured 
- Measurement of blood pressure 
- Measure AGE level with skin reader 
- Finger prick blood sugar test 
- Obtain a blood sample 
- Complete a food frequency questionnaire  
Total visit time approximately 2 hours  
Optional session 3: 
- Examination of the health of your eyes and insertion of drops 
- Measurement of eye pressure 
- Have a scan taken of the back of your eye (retinal vessel function) 
After completion of session 1 and 2 and with your consent, your NHS eye records will be 
reviewed yearly for 5 years by a member of the research team. The results of your visual 
field test and optic nerve scan will be noted from your eye records and used as a way of 
monitoring the progression of your glaucoma.  You will not need to be present for this 
section of data collection. 
4. What is expected of me at these sessions? 
 
Session 1:  
If you decide to participate in this study you will be asked to sign a consent form. A copy 
of this consent form can be found at the end of this information pack.  
Once you have given your consent you will be asked to complete a quick questionnaire 
which will allow us to collect information about your age, ethnicity and any medication 
you are taking. This will aid us with the analysis of the results and also ensure that there 
are no unforeseen medical factors that would prevent you being included in our study. 
Following this we will arrange a date that is suitable for you to visit Plymouth University 
main campus for your second data collection session. You will be provided with a 
campus map and given full instructions on how to locate the required building in 
preparation for this second session.  
Session 2:  
Before session 2: 
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 You will be required to fast (i.e. not eat anything) for 12 hours before this 
appointment. This is because eating food can affect the outcome of your blood 
test 
During the 12 hours before your appointment you will also be asked to avoid: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
- caffeine containing products  
- taking any dietary supplements or vitamins (especially vitamin C)  
This is because these factors can also affect the outcome of the results.   
 We recommend that you wear comfortable, loose fitting clothing on the day of this 
appointment. This is to allow us to easily access your upper arm for both blood 
pressure measurement and blood sample.  
 Self-tanning agents must not have been used for at least 2 days before this 
appointment as they can affect the AGE reading taken from your skin.  
 
On the morning of session 2: 
At Plymouth University main campus Link building Leanne Smewing will meet you at the 
main entrance.  
 Basic measurements will be taken first. These will include your; height, weight and 
blood pressure. Your BMI will be calculated from these measurements. 
 If you have any sun blockers or skin creams on your forearm this will be removed as 
it can influence the AGE measurement. 
 Next, your tissue bound AGE level will be measured using a non-invasive device 
called the AGE Reader. You will place your forearm on the machine and a light from 
the machine will be used to take the AGE measurement. The measurement will take 
approximately 20-30 seconds and will be repeated 3 times.  
 A finger prick blood sugar test will be taken prior to your blood sample.   
 A blood sample will be taken by a researcher trained in phlebotomy in a specialist 
blood laboratory. This will be carried out with you sitting up and will involve taking 
blood in a similar way to that which you may have experienced at your GP’s surgery 
or at the hospital. This is a routinely performed procedure and the risks associated 
with this procedure are minimal. 
 You will be asked to complete a questionnaire relating to your diet. The researcher 
will go through the questions with you. This allows us to collect information about the 
foods you eat and your methods of cooking.  
 
After session 2: 
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 It is recommended that you avoid alcohol for 4 hours after the study and also 
avoid any unnecessary hazardous/strenuous/physical activity. 
 As we require you to fast for 12 hours prior to the appointment a light snack will 
be provided after the study is completed. Alternatively you may wish to bring 
some refreshments with you  
 Should you be interested, we can arrange an optional 3rd session where we can 
take measurements of the blood vessels at the back of your eye. The drops used 
at this 3rd session are the same as the drops used for your hospital visits.  
 
Optional Session 3: Carried out at Peninsula Allied Health Centre (PAHC), Derriford, 
PL6 8BH or Wellbeing Centre, Endsleigh Place, Plymouth University, Drake Circus, PL4 
8AA 
 
Before session 3: 
 Leanne Smewing (chief investigator) will call you and remind you of your 
appointment time and remind you that as drops will be inserted into one of your eyes 
at this visit you will not be able to drive for 4 hours after the appointment (alternative 
travel arrangements will need to be made). 
 Due to their possible effect on your blood vessel measurement, you will be asked to 
avoid the following in the 12 hours before your appointment: 
- alcohol  
- tobacco/nicotine  
- extreme exercise  
- unnecessary sleep deprivation  
- caffeine containing products (tea/coffee) 
- taking any dietary supplements or vitamins (especially vitamin C)  
However, you will be asked to maintain your normal eating habits on this day i.e. you are 
NOT required to fast. 
On the day of session 3: 
 You will have your vision measured and a short health exam to ensure your eyes 
won’t have any allergic reaction to the drops used.  
 
 A drop and some fluorescein eye dye will be put into each of your eyes so that your 
eye pressure can be measured. This drop is an anaesthetic drop called 
proxymetacaine. The drops take about 60 seconds to work and the anaesthetic effect 
can last for up to 20 minutes. You will be advised not to rub your eyes and avoid 
getting dust or grit in your eye during this 20 minute period.  
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 So that good images of the back of your eye can be obtained with the retinal camera 
another drop will be put into one of your eyes only. This drop, called tropicamide, 
increases the size of your pupil so that we can get a full view of the back of your eye. 
Having big pupils can reduce your quality of vision temporarily and you may 
experience some dazzling in bright sunlight or artificial light for a few hours after 
you’ve had the drops in. You may therefore benefit from bringing some sunglasses 
with you and will be advised not to drive a motor vehicle, ride a bicycle or operate 
moving machinery for 4 hours after the appointment.  
 
 The pupil dilating drops take approximately 20 minutes to work. 
 
 Once the drops have dilated your pupil the retinal camera will be used to take 
measurements of the blood vessels at the back of your eye. This procedure requires 
you to sit down with your head on a comfortable support. You will be required to look 
straight ahead and you will see a flickering light for short periods of time. This will not 
harm your eyes but may leave you with an afterimage for a few seconds. 
 
Due to the flickering light it is important that you tell us if you have a known history of 
epilepsy. Although the camera poses very little harm, there is a small risk of 
triggering an episode of epilepsy in those not diagnosed. 
 
At the end of session 3: 
 You will be advised not to drive a motor vehicle, ride a bicycle or operate moving 
machinery for at least 4 hours after the appointment due to the insertion of the 
eye drop. 
 
5. Are any risks associated with this project? 
All the devices used in this study are commercially available and CE marked to ensure 
they comply with European Health and Safety requirements. We have worked hard to 
limit the risks associated with this study and all participants will be selected carefully. 
Despite this it is still important that you are aware of the possibility of adverse effects.   
Leanne Smewing is a qualified optometrist and is fully trained in the techniques being 
performed. In addition first aiders will be present on both sites. 
Use of Proxymetacaine 0.5% and fluorescein  
This is a drop that is used when measuring eye pressure. It is a drop routinely used by 
Optometrists and Eye Hospitals so it possible you may have had it before. You may 
experience mild stinging when the drop is first put into your eyes, but this will subside 
very quickly.  The drops are a type of local anaesthetic and take about 60 seconds to 
work and the effect may last for up to 20 minutes. You must not rub your eyes and try to 
avoid getting dust or grit in your eye as the anaesthetic would prevent you feeling any 
effect of this until after the drops wear off. 
In the unlikely event that you experience any unusual symptoms such as pain and 
soreness in or around your eyes or your vision seems blurred after the appointment, 
319 
 
contact a member of the research team, your optometrist or seek medical advice as you 
might be experiencing an adverse reaction to the drops. 
Use of Tropicamide 0.5% 
This is the drop that is used with the retinal camera to make your pupils larger. It takes 
approximately 15 to 30 minutes to work and up to 6 hours to wear off. Again, it is a drop 
routinely used by Optometrists and Eye Hospitals so it possible you may have had it 
before.  
As mentioned previously, the enlargement of the pupil may cause a reduced quality of 
vision temporarily and you may experience some glare in bright sunlight or artificial light 
for a few hours afterwards. You are therefore advised not to drive a motor vehicle, ride a 
bicycle or operate moving machinery for at least 6 hours after the appointment. You may 
also wish to use sunglasses during this time to alleviate any increased light sensitivity. 
You may experience mild stinging when the drop is first put into your eyes, but this will 
subside very quickly.   
There is a very small chance that using this drop can trigger unusual symptoms such as 
pain and redness around the eyes or ‘misty’ vision, usually immediately after drop 
insertion. This is very unlikely but if any of these symptoms do occur you are advised to 
speak to the research team and seek medical advice immediately as you may be 
experiencing an adverse reaction to the drops. 
Use of the retinal camera 
The retinal camera is a non-invasive device that poses very little harm. As it uses a 
flickering light it is important to be aware that there is a small risk of it triggering an 
episode of epilepsy in those not diagnosed. 
Taking a blood sample 
There can be a mild short irritation when taking a blood sample. Only a small amount of 
blood is taken during this study so you shouldn't feel any significant after-effects. 
However some people may feel dizzy and faint during and after the test. If this has 
happened to you in the past, or happens during the test please tell the person carrying 
out the test so they’re aware and can help you feel more comfortable. After the test, you 
may have a small bruise where the needle went in. Bruises can be painful, but are 
usually harmless and fade over the next few days. 
A small blood sample of 9mL will be taken. This blood sample will provide us with 
information about oxidative stress. The sample we store will not contain any of your DNA 
and will be stored and destroyed following the human tissue act procedures. The sample 
will be kept in the -80 degree C freezer in the locked laboratory in the Human 
Metabolism Laboratory at the Food and Nutrition Unit, Link Building, Plymouth 
University. They will be stored until all analysis is completed, stored for maximum of 2 
years. Only the research team and technical staff will have access to the samples.  
Any abnormal findings found from this study would be sent in a letter to your GP and a 
copy would also be sent to you.   
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6. What are the benefits of participation? 
This study is not likely to benefit you directly, but it will help researchers at Plymouth 
University evaluate whether AGE levels influence the function of the blood vessels in 
your eye or contribute to the development of the eye disease glaucoma. In the future it 
may open up the possibility of new diagnostic and treatment options in the form of 
dietary, lifestyle or targeted therapeutic interventions.  
7. Who has reviewed the study? 
All research is looked at by an independent group of people, called a Research Ethics 
Committee, to protect your interests. This study has been reviewed and approved by the 
Health Research Authority and Plymouth University’s Faculty Research Ethics 
Committee. 
8. Do I have to take part? 
No. You are free to decide whether or not to participate in this study. You should take 
time to consider your participation in this research and ask questions if there are aspects 
which you do not understand or if you need further information. If you decide to take part 
you will be asked to sign three copies of a consent form in the presence of an 
appropriate member of the research team. You will be given a signed copy of the 
consent form and an information sheet for your own records. You may decide not to 
participate or withdraw at any time without giving a reason or without it affecting your 
relationship with Plymouth University, or your current or future treatment in any way. If 
you decide to withdraw from the study all identifiable data and samples collected from 
you would be withdrawn. The samples would be destroyed as per human tissue authority 
guidelines. The lead investigator may also remove you from the study if they believe it to 
be in your best interest.  
9. Is there remuneration for participation?  
Unfortunately, you will not get paid to participate in this project. 
10. Is taking part confidential? 
If you decide to participate in the study we will inform your GP you are doing so. 
All of the information you provide as a participant and any data collected as a result of 
your participation in this study will remain confidential. Your records may be looked at by 
the research team involved in this study and the monitoring or audit team approved by 
the university.  All information will be stored electronically on a computer which is 
password protected, in a document file that is also password protected. All information 
will be handled in compliance with the Data Protection Act (1998).  
Your name and address (which we need in order to contact you) will be stored 
separately from the other information you supply during the study so that you cannot be 
identified from your study records. After 10 years, all of your records will confidentially be 
disposed of in accordance with the guidelines laid out by Plymouth University. 
Any data collected in this investigation may be submitted for publication or used in 
presentations. Neither your name nor information disclosing your identity will be released 
or published without your explicit consent to the disclosure.  
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11. What will happen to the results of the research study?  
The results will be available through University of Plymouth, if you require a copy of the 
final report please write to the address given below. 
12. What if I have any further questions or require further information? 
If you have any questions about our project, either now or in the future, please feel free 
to contact:  
Leanne Smewing; 
Email: leanne.smewing@plymouth.ac.uk   
Phone: (0)1752 587541      
 
13. What if I have a complaint?  
Should you have reason to complain about the way you have been treated at any stage 
during the study you can contact; 
 
Dr Stephanie Mroczkowska;  
Email: stephanie.mroczkowska@plymouth.ac.uk 
Telephone: 01752 587549 
Alternatively, you can make your complaint directly to Leanne Smewing, (contact details 
as above).  
 
In the unlikely situation that you experience any unusual side effects to any of the 
procedures carried out you are advised to seek immediate medical advice. You will be 
issued with a list of any drugs administered to you and this should be shown to any 
medic that you consult. 
If you have any concerns about the way in which the study has been conducted, please 
contact the Secretary of the Health & Human Sciences University Research Ethics 
Committee Sarah C Jones by email, or telephone (details below) as well as contacting 
the Patient Advice and Liaison Service (PALS) on 0800 328 3205. 
Sarah C Jones;  
Email: hhsethics@plymouth.ac.uk  
Telephone: 01752 585339 
If there is negligent harm during the clinical trial, Plymouth University owes a duty of care 
to the person harmed. 
If you decide to participate in this study you will be asked to sign a consent form. A copy 
of this consent form can be found at the end of this information pack. 
 
 
Thank you for taking the time to read this information sheet 
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Appendix 2.6 – OHT consent form  
 
 
 
 
Declaration of informed consent 
 
Title of Project:  Advanced glycation end products as a biomarker for accelerated 
ageing in glaucomatous optic neuropathy 
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Appendix 3 – Demographic questionnaire 
 
 
 
 
 
 
PERSONAL INFORMATION QUESTIONNAIRE 
All information contained within this questionnaire is strictly confidential. Please complete all of the questions on both 
sides of this questionnaire as accurately as possible. Please tick (✓) all of the boxes that apply to you  
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Appendix 4.1 – Specifically designed FFQ  
 
 
Dietary questionnaire 
 
Questions about what you eat, how you cook and what you drink 
Throughout this questionnaire the cooking method will also be described such as; frying, 
grilling, boiling and roasting. If you are unsure of the exact meaning of these terms 
please let the person going through this questionnaire with you aware and they can 
explain further.  
 
When frying/roasting foods what type of oil/cooking fat would you use? 
……………………………………………………………………………………………………………………………… 
For the first section you will be shown images of different portion sizes of food. Please 
put a (X) in the box which best describes (on average) how much you would usually 
have eaten at a main meal in the last 12 months.  
The images will be of a food pictured on its own, although this may not be the way you 
usually eat this food please try to answer as best you can. 
For example: 
Breaded fish 
Which option best describes what you ate? 
 
 
 
 
 
 
 
 
Less than A A Between A 
& B 
B Between B 
& C 
C More than C 
    x   
A 
-  
B C 
60g 110g 170g 
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If you have eaten any of these foods which option best describes what you ate?  
1. Breaded fish 
 
 
 
 
 
 
 
2. Thin crust pizza 
 
 
 
 
 
 
 
3. Sausages 
 
 
 
 
 
 
 
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
A B C 
A B C 
A B C 
60g 110g 170g 
50g 200g 400g 
45g 90g 135g 
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Continued, which option best describes what you ate? 
4. Fried skinless chicken 
 
 
 
 
 
 
 
5. Breaded oven chicken 
 
 
 
 
 
 
 
6. Roast beef 
 
 
 
 
 
 
 
 
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
Less than A A Between A & 
B 
B Between B & 
C 
C More than C 
       
A B C 
A B C 
A B C 
75g 135g 210g 
75g 150g 225g 
60g 120g 180g 
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This questionnaire will ask you about your usual eating habits over the last 12 
months. Examples of food portion sizes can be found on the final page. 
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Appendix 4.2 – FFQ prompt flow chart 
 
FFQ prompt flow chart for clinician 
 
Explain the principle of the FFQ and remind the participant to be as honest as possible 
 
Ask if there has been a significant change to their diet in the last 12 months 
 
Ask the participant to read the instructions  
 
Prompt the first question, ‘What sort of cooking fat would you use?’ 
 
Talk the participant through the worked example for the portion questions and show the 
plate used to take the photographs. If they would never eat a food photographed put a 
line through the foods name.  
 
Show the FFQ itself and remind the participant that it covers foods eaten over the last 12 
months. Explain that this is to encompass foods eaten in different seasons e.g. more 
salads in the summer.  
 
Talk the participant though the worked example (feta cheese) 
 
Explain that if a portion size isn’t written next to the food it should be at the top of its 
‘group’ e.g. all cheese 30g unless otherwise stated, such as cream cheese 1tbsp.  
 
There are rows within the questionnaire which say ‘other’, explain that this is intended to 
allow the recording of foods they eat often that haven’t been listed in the questionnaire 
 
Note all drinks are 250ml and show the reference page at the end of the FFQ. Show the 
cups which amount to 250ml. 
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Begin the FFQ, allow the participant to fill in the questionnaire themselves and offer 
assistance if required.  
 
When beginning cheese section show the 30g portion of cheddar on the reference page. 
If their portion is larger than this adjust the portion to account for this.  
 
When reaching ‘other cheese’ provide prompt ‘e.g. stilton?’ 
 
Explain timing’s on soft/hard boiled eggs is from when they go into cold water 
(Americanism) 
 
‘Other egg’ provide prompt ‘e.g. scrambled? Omelette?’ 
 
Bacon portion ‘one rasher or more?’ 
 
Sausages portion, 2 sausages = 1 portion, therefore if they eat 3 sausages record as 1.5 
 
‘Other pork’ prompt ‘e.g. roast pork?’ 
 
‘Other lamb’ prompt ‘e.g. roast lamb?’ 
 
If they are uncertain between ‘chicken breast cubed and pan fried’ and ‘chicken breast 
cubed, pan fried and boiled’ explain that the second would be where the chicken once 
cooked is added to a sauce and boiled e.g. sweet & sour chicken. 
 
If they put never to battered cod prompt ‘do you think you have had fish and chips at all 
in the last 12 months?’ it may be they have a different type of battered fish.  
 
‘Other fish’ provide prompt ‘e.g. mackerel (tinned or fresh) 
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When beginning the ‘Carb’s’ section remind the participant each slice of bread = 1 
portion.  
 
When beginning ‘cereals’ remind the participant to look at the reference page for what 
30g ‘looks like’ 
 
When reaching fruits and vegetables address the fact that not many fruits and 
vegetables are listed in the FFQ. Reiterate that they should fill the ‘other’ sections with 
fruits/veg they eat often.  
 
‘Raw veg’ prompt ‘for example this would include salad – what raw vegetables would go 
into your salad?’ 
 
‘Other condiments’ prompt ‘e.g. jam, marmalade?’  
 
  
 
Finally, make sure to add the date the FFQ was completed and the participant’s code to 
the FFQ. 
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Appendix 5 – 4 day weighed food diary 
 
 
 
 
 
4 - Day Weighed Food Diary 
 
Use this diary to record everything you eat and drink for 4 days – 3 weekdays 
and 1 weekend day. The purpose of filling out these food records is to help better 
understand the foods you eat, when you eat and your portion size.  
 Please record your food items and portions in a real time, do not wait until 
the end of the day, as you may forget some items and the analysis will be 
unreliable. 
 Do not try to modify your dietary habits and the food choices just because 
you are recording, as it will not represent your usual diet. Similarly, please 
avoid recording during feasts such as Birthdays for the same reason.  
 If you eating out, please try to estimate portion and best list the meals 
ingredients. Record the place of eating (name of the restaurant) and the 
foods eaten. 
 
You will be loaned a set of digital kitchen scales to allow you to weigh your foods. 
Drinks can be measured either by pouring into a measuring jug, or by ‘zeroing’ 
your mug/cup on the digital scales and weighing the fluid, in international units (1 
gram (g) = 1 millilitre (ml)). 
 
Example 
Lunch 
 
Place eaten 
 
Time 
 
Item, portion, description 
 
 Weight (g/ml) 
 
Home 
 
 
 
 
OR 
example if 
out 
 
 
Out 
shopping 
 
2pm 
 
 
 
 
 
 
 
 
2pm 
 
Ham sandwich : 
2 slices of hovis granary 
bread, 1 tsp of butter, 3 wafer 
thin slices of ham 
 
 
OR example if out 
 
 
Boots shapers ham sandwich 
 
Total weight: 
110g 
Bread = 35g 
per slice 
Ham = 35g 
 
 
 
 
110g 
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Before beginning the food diary please can you fill out the table below 
 
What do you regularly eat for…. 
 
 
 
Breakfast 
 
 
 
 
 
 
 
 
 
Lunch 
 
 
 
 
 
 
 
 
 
Evening meal 
 
 
 
 
 
 
 
 
 
Snacks 
 
 
 
 
 
 
 
 
 
Kitchenware sizes  
Dinner plate across (cm)  
Side plate across (cm)  
Bowl across (cm)   
Bowl down (cm)   
Bowl (ml) full capacity   
Mug/cup (ml)  full capacity  
Glass (ml) full capacity  
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Appendix 6 – Lab analysis methods 
 
 
6.1  ASCORBATE MEASUREMENT  
 
HPLC electrochemical detection of ascorbate 
 
 
SOLUTIONS 
 
Standard Ascorbate – make fresh on the day 
 
Ascorbate: 0.018 g ascorbic acid/100 ml [0.009 g/50 ml] in H2O gives a 1.0 mM stock 
solution. 
Dilute in PBS to standards 10M, 30M and 50M. 
 
10% Metaphosphoric acid [MPA] containing 2mM EDTA 
 
Make up a solution of 2 mM EDTA in H2O.  e.g 0.186 g EDTA disodium salt made up in 
250 ml H2O.  Use this to make up the MPA solution. 
16 g of MPA (33.5 – 36.5%) diluted with 50 ml of HPLC H2O containing 2 mM EDTA. 
 
5% MPA containing 1 mM EDTA 
 
A 1:2 dilution of the above in H2O 
 
Tris (2-carboxyethyl)phosphine hydrochloride [TCEP] 350 mM in 5% MPA 
containing 1 mM EDTA (Reducing agent). 
 
0.100 g made up in 1.0 ml of 5% MPA in 1 mM EDTA.  Make up e.g. 0.025g plus 250l 
5% MPA in 1mM EDTA.  
* Make this first as needs to dissolve * 
 
 
 
MOBILE PHASE 
 
50 mM Phospate buffer containing 540 μM EDTA and 2% Methanol. 
 
Weigh out 3.9 g of sodium dihydrogen orthophosphate HPLC grade [MW 156.01] and 
place in a 500 ml flask. 
 
Weigh out 0.1 g EDTA disodium salt [MW 372.2] and add to the flask. 
 
Make up to about 300 ml with HPLC grade H2O. 
 
Add 10 ml of methanol. 
 
Make up to 500 ml with HPLC grade H2O. 
 
Take to pH 2.8 with 6.0 M HCl. 
 
Filter and degas (Millipore glassware) 
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ASCORBATE MEASUREMENT PROCEDURE 
 
 
1. Take 200 l of plasma and add to 200 l of 10% MPA containing 2.0 mM 
EDTA. Mix well and centrifuge at 20,000 x g at 4oC for 10 minutes. 
 
2. Take 2 x 90 l aliquots of supernatant.  
 
3. To one add 10 l of 5% MPA containing 1 mM EDTA.  Add a further 200 l 
of 5% MPA containing 1 mM EDTA.  Mix well. This is for measurement of 
reduced ascorbate.  From this sample remove 50 l and add to a tube 
containing 450 l 5% MPA containing 1 mM EDTA.  Mix well.  This is for 
measurement of urate. 
 
4. To the other sample add 10l 350 mM TCEP in 5% MPA containing 1 mM 
EDTA.  Incubate for 20 minutes at room temperature.  This is to reduce 
the oxidised dehydroascorbate back to ascorbate.  Add a further 200 l of 
5% MPA containing 1 mM EDTA.  Mix well. This sample is for 
measurement of total ascorbate  
 
Suggested procedure: Inject the reduced sample, and the sample for 
urate while the total ascorbate sample is incubating. Then inject the total 
sample. 
 
 
Standards:   Prepare standards as follows:  
 Take 200 l of standard and add to 200 l of 10% MPA containing 2 
mM EDTA & ‘Buzz’ 
 Take a 90 l aliquot and add 10 l of 350 mM TCEP in 5% MPA 
containing 1 mM EDTA. 
 Incubate for 20 minutes at room temperature. 
 Add a further 200 l of 5% MPA.  Mix well. 
 Inject into HPLC system 
 Use HPLC H2O to wash between each standard and samples 
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6.2  MEASUREMENT OF MALONDIALDEHYDE 
 
Remember! – Don’t put the weighed out crystals back in the tub!! 
 
SOLUTIONS 
 
1) Butylated hydroxytoluene [BHT] (found in top cupboard) 0.05% in 95% 
ethanol (kept in yellow cupboard). To be made up on the day. 
Weigh out 0.05 g in 100 ml HPLC water, for this study used 0.0025 g (with small 
amounts measure with test tube on the scales) in 5 ml of 95% ethanol. i.e 4.750ml 
in 250 µl water. 
 
2) Phosphoric acid (0.44 M) 
Take 1.0 ml of concentrated orthophpsphoric acid and make up to 100 ml with 
distilled water  
 
3) TBA (42 mM) 
Weigh out 0.303 g of TBA and make up to 50 ml with water. Heat at 50-55 C to 
ensure that it dissolves. 
 
4) Stock solution of MDA (1mM) 
Weigh out 0.00313 g of MDA and make up to 10 ml with distilled  
water store at (-80c).  Dilute down in pbs to a range of standards from 500 nM to 
10 M 
 
5) Phosphate buffered saline [PBS] PH 7.4  
[137 mM Nacl; 2.7 mM Kcl; 8 mM Na2HPO4; 1.46 mM KH2PO4] 
Using a 250 ml volumetric flask weight out the following:  
2.0 g of Nacl (MW 58.44), 0.05 g of Kcl (74.56),0.716 g of Na2HPO4 (MW 358.14), 
0.05 g of KH2PO4 (MW 136.09) dissolved in about 200 ml distilled water, adjust PH 
to 7.4 make up to 250 ml storage in Keep this solution at 4℃. 
 
6) Mobile phase – the solution that carried the sample through the machine  
Potassium dihydrogen orthophosphate [KH2PO4] (50 mM)/MeOH 80/20 v/v 
Weigh out 3.403 g KH2PO4 and dissolve in 500 ml HPLC grade water.  Add 125 ml 
MeOH. Adjust to pH 6.8 using 5 M sodium hydroxide.  Filter and degass. 
HPLC wavelengths: Excitation 515 nm, Emission 553 nm 
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MEASUREMENT OF MALONDIALDEHYDE PROCEDURE 
In 2.0 ml centrifuge tube with screw caps, put 50 µl of Plasma or standard or 
blank add 50µl of BHT solution then add 400 µl of phosphoric acid and 100 µl of 
TBA solution. 
1) Cap the tubes, mix well on a vortex mixer. Heat for 1 hour at 100o C in a 
dry block. 
2) Remove tubes and place on ice to cool. 
3) Add 300 µl of n-1- butanol. Mix well using the vortex mixer. 
4) Centrifuge the mixture for 5 minute at 13,000 × g. to separate the aqueous 
and butanol phases. 
5) Carefully remove 200 µl of the butanol extract and place in tubes inject 
the butanol extract direct into HPLC system 
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6.3  MEASUREMENT OF ALPHA-TOCOPHEROL (VITAMIN E) IN PLASMA  
 
SOLUTIONS 
Mobile phase: 6% tetrahydrofuran (THF) in methanol 
15 ml THF made up to 250 ml with MeOH. Don’t pH or filter. 
Vit E standards, make up in methanol: 5, 10, 20, 50 ug/ml, in MeOH. 
Weigh out a tiny blob and add MeOH to mix, e.g:  
0.0215 g vitamin E + 215 ul MeOH = 100 mg/ml 
 
Sample preparation 
To 100 ul plasma, standards and blank (use MeOH for blank) add 200 ul 
acetronitrile-THF [3 parts acetronitrile : 2 parts THF]. 
Vortex each sample for 2 minutes to get the full extraction. 
Centrifuge 12,800 g for 20 mins, 4 degrees C using refridgerated centrifuge. 
Remove supernatant for injection. 
 
HPLC set up 
THf destroys some plastics (though seems OK with our Eppendorf tubes), and so 
the rheodyne and tubing need to be changed prior to measuring vitamin E. The 
column and guard column are also changed. 
Absorbance is read at 292 nm  
1 ml/min pump setting. Comes off at ~ 5 min, do a 7 min run. 
Use MeOH for between injection washes. 
Use a programmed wash after standards and after each batch of samples. 
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Appendix 7 – Full list of parameters measured by the Corvis ST 
 
 
 
 
 
 
 
 
Parameter 
 
Description 
IOP (mmHg) Intraocular pressure (based on A1) 
CCT (µM) Central corneal thickness by optical pachymetry 
Time A1 (ms) Measures the time from the initiation of the air puff to the 
first inward corneal movement 
Time A2 (ms) Measures the time to second applanation / outward 
corneal movement 
Length A1 (mm) Length of the applanated flat cornea surface at 
first applanation 
Length A2 (mm) Length of the applanated flat cornea surface at  
second applanation 
Velocity A1 (m/s) Velocity of corneal surface movement at the first 
applanation 
Velocity A2 (m/s) Velocity of corneal surface movement at the second 
applanation 
Deformation 
amplitude A1 (mm) 
The magnitude of the movement of the corneal surface 
at the first applanation 
Deformation  
amplitude A2 (mm) 
The magnitude of the movement of the corneal apex at 
the second applanation 
Highest deformation 
amplitude (mm) 
The magnitude of the movement of the corneal surface 
at the highest concavity 
Highest concavity 
time (ms) 
Time from the initiation of the air puff to the highest 
concavity of the deformation of cornea 
HC radius (mm) The radius of curvature at highest concavity of the 
deformation of the cornea. 
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Appendix 8 – Table summary of AGEs and ocular disease literature 
 
Summary of AGE and Ocular disease studies 
 
Diabetic retinopathy (DR) 
 
Study Participants  Findings 
Ghanem et 
al. (2011) 
30 HC 
Type 2 DM: 
35 mild NPDR 
30 severe NPDR 
25 PDR 
Serum levels of pentosidine and CML are 
related to severity of DR. In addition, aqueous 
humor level of CML increased with progression 
of DR. 
Choudhuri 
et al. (2013) 
 
95 HC 
Type 2 DM: 
70 NPDR 
105 PDR 
102 DNR 
Serum and vitreous CML levels were 
significantly elevated in PDR and NPDR 
subjects compared to DNR. ROS production 
was higher in NPDR and PDR compared to the 
DNR group. 
Al-
Mesallamy 
et al. (2011) 
20 HC 
Type 2 DM: 
14 DNR 
14 NPDR 
9 PDR 
Soluble RAGE levels were significantly lower in 
patients NPDR and PDR compared to HC and 
DNR patients.   
Anitha et al. 
(2008) 
188 HC 
Type 2 DM: 
188 DNR 
153 NPDR 
41 PDR 
Advanced glycation index, an assay to detect 
serum AGEs was significantly associated with 
severity of DR. 
 
Boehm et 
al. (2004) 
HC 792 
Type 2 DM:  
81 DNR 
56 DR 
Higher serum CML levels were associated with 
advanced stages of DR. 
Beisswenge
r et al. 
(1995) 
29 HC  
48 type 1 DM  
 
Levels of collagen-linked AGEs, measured by 
ELISA, were correlated with preclinical stages 
of DR (not indicated by other methods).  
Miura et al. 
(2003) 
Type 1 DM: 
35 DNR 
22 NPDR 
28 PDR 
Elevation of serum CML and non-specified 
AGE were associated with the severity of 
diabetic retinopathy in patients with Type 1 
diabetes. 
Murata et 
al. (1997) 
(Immunohistoche
mi-stry) 
9 HC 
27 DR 
Increased CML was associated with increased 
vascular endothelial growth factor. CML also 
found to be located in the thickened vascular 
wall. 
Yao et al. 
(2009) 
 
Cultured human 
aortic endothelial 
cells 
Evaluated RAGE and its ligands in human 
aortic endothelial cells. Proposed that ROS as 
well as being formed at the end of RAGE 
activation, ROS also create a positive 
feedback of RAGE facilitated pro-inflammatory 
signalling. 
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Zong et al. 
(2011) 
Animal study: rats 
(n = 10) 
Hyperglycaemia in vivo and in vitro induces 
upregulation of RAGE and its ligands, leading 
to RAGE signalling. This links to pro-
inflammatory responses by retinal Müller glia.  
Laiet et al. 
(2017) 
Animal study: 
diabetic rodents.  
Inhibiting the CML-induced tumor progression 
locus 2 axis prevented DR. 
Hirano et al. 
(2014) 
111 HC 
Type 2 DM: 
36 DNR 
71 NPDR 
31 PDR 
SAF was increased in patients with DM to HC.  
SAF correlated with severity of DR, whereas 
single measured HbA1c did not.  
Age-related macular degeneration (AMD) 
 
Study Participants  Findings 
Ni et al. 
(2009) 
32 HC 
58 AMD 
Higher levels of CML and pentosidine in AMD 
plasma protein. 
Ishibashi et 
al. (1998) 
Human donor 
eyes 
8 AMD 
12 aged HC  
2 young HC 
Soft, macular drusen and/or basal laminar and 
basal linear deposits showed CML 
accumulation. In choroidal neovascular 
membranes RPE cells showed CML 
accumulation in their cytoplasm.  
Schutt et al. 
(2003) 
Human donor 
eyes 
10 pairs of donor 
eyes 
Lipofuscin associated proteins were damaged 
by covalent modifications of MDA and AGEs in 
human RPE 
Howes et al. 
(2004) 
Donor macula 
retinas: 
2 Early AMD 
3 GA 
1 with drusen 
7 normal  
Presence of AGE and RAGE in RPE and 
photoreceptors corresponded with macular 
disease in aged, early AMD, and GA retinas. 
Glenn et al. 
(2011) 
RPE 
recovered from 7 
aged donor eyes 
AGE-induced modifications to the basement 
membrane alters the RPE proteome. 
Hollyfield et 
al. (2003) 
Human donor 
eyes 
18 HC 
5 AMD 
Protein cross-links and AGEs were observed in 
drusen and Bruch's membrane. 
Mulder et al. 
(2009) 
31 HC 
73 neovascular 
AMD 
SAF was increased in patients with 
neovascular AMD 
AGEs and diabetic keratopathy 
 
Study Participants  Findings 
Sato et al. 
(2001) 
13 HC 
Type 2 DM: 
8 DNR 
6 NPDR 
12 PDR 
The corneal AGE fluorescence values were 
significantly higher in the PDR group compared 
with HC 
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Mori et al. 
(2009) 
8 HC 
17 PDR 
Corneal and lens autofluorescence significantly 
increased in PDR, compared with HC. 
Hyperglycemia associated with increasing 
corneal autofluorescence in PDR. 
Sady et al. 
(1995) 
Human donor 
eyes 
11 HC 
8 DM 
Fluorescence and pentosidine were present at 
higher levels in DM corneas compared to age-
matched HCcorneas. 
Kaji et al. 
(2000) 
Human donor 
eyes 
8 HC 
8 DM 
CML present in epithelial basement membrane 
of all DM corneas, only in one of 8 HC 
corneas. 
Kim et al. 
(2010) 
Animal study: rats 
8 control rats 
8 DM rats 
Corneal thickness was increased in DM rats 
compared to controls. Increased AGE in 
corneal tissues of DM rats 
AGEs and Glaucoma 
 
Study Participants  Findings 
Tezel at al. 
(2007) 
Human donor 
eyes 
30 HC 
38 Glaucoma 
Higher levels of AGEs and RAGE were 
detectable in the glaucomatous retina and 
ONH. In glaucomatous eyes AGE was 
predominantly extracellular in laminar 
cribriform plates in the ONH, RAGE was was 
predominant on glial cells. 
Amano et 
al. (2001) 
Human donor 
eyes 
(all elderly 
6 HC 
7 DM 
Pyrraline detected in sclera, pia mater, 
cribriform plates, connective tissues in the optic 
nerve. Also found around vessels in the optic 
nerve and pia mater. 
Albon et al. 
(1995) 
Human donor 
eyes 
Age range 3 to 92 
Age-related changes included an increase in 
total collagen and a decrease in the proportion 
of type III collagen in the lamina cribrosa. Age-
related increase of pentosidine. 
Spoerl et al. 
(2005) 
80 porcine eyes 
24 pairs of human 
donor eyes 
Glyceraldehyde and methylglyoxal increase 
the stiffness of the lamina cribrosa and the 
peripapillary sclera in human and in porcine 
eyes. 
Park et al. 
(2012) 
Cultured human 
trabecular 
meshwork cells 
AGE enhances cellular deterioration with age 
in human trabecular meshwork cells, 
accompanied with increased oxidative stress.  
Tezel et al. 
(1997) 
HC 24 
POAG 31 
Small increase in aqueous humor endothelin 
levels in patients with POAG versus controls 
Doganay et 
al. (2002) 
14 HC 
16 POAG 
Decreased aqueous humor NO levels in 
patients with POAG compared to HC 
Galassi et 
al. (2004) 
46 HC 
38 POAG 
NO plasma levels and aqueous humor levels 
were decreased in POAG compared to HC 
Himori et al. 
(2016) 
36 HC 
71 POAG 
176 NTG 
SAF negatively correlated with MD in the 
youngest subjects, not in the older subjects. 
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Himori et al. 
(2015) 
20 HC 
73 NTG 
SAF higher in NTG patients than HC (but not 
significantly different). SAF and 8-OHdG were 
negatively correlated with tissue-area mean 
blur rate in NTG patients 
Schweitzer 
et al. (2018) 
424 HC 
31 POAG 
Higher SAF and smoking were independently 
associated with increased risk of glaucoma 
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Appendix 9 – Table summary of dietary AGE literature 
 
Summary of dietary AGE studies 
 
Study Participants  Findings 
Hofmann et 
al. (2002) 
16 HC mice 
20 DM mice 
Mice fed a low dAGE diet had lower CML and 
MG levels compared with high dAGE fed mice.  
Vlassara et 
al. (2002) 
 
24 type 2 DM: 
11 in 2wk 
13 in 6wk 
Participants on reduced dAGE diet had a 
reduction in circulating AGE level and 
reduction in both TNF-and VCAM1. 
Uribarri et 
al. (2003) 
18 non-DM renal 
failure patients: 
9 high dAGE 
9 low dAGE 
dAGE contributes to the elevated AGE levels 
in renal failure patients. Correlation between 
circulating AGE and dietary intake. 
Uribarri et 
al. (2007) 
10 HC 
44 DM 
 
Dietary oral AGE-rich liquid beverage (free 
from lipids) results in a rise in AGE serum 
levels. The AGE-rich beverage caused 
impairment of endothelial function. 
Vlassara et 
al. (2009) 
 
325 HC  
66 chronic kidney 
disease patients 
Reduction of dAGE lowers oxidative stress and 
inflammation in both healthy and chronic 
kidney disease patients.  
Birlouez-
Aragon et 
al. (2010) 
62 healthy 
volunteers 
A diet based on high-heat-treated foods 
increases markers associated with an 
enhanced risk of type 2 diabetes and 
cardiovascular diseases in healthy people. 
Uribarri et 
al. (2011) 
18 HC  
18 type 2 DM  
 
Restriction of dAGE may preserve natural 
defences and insulin sensitivity by maintaining 
lower basal oxidative stress. 
Piroddi et 
al. (2011) 
10 HC 
10 chronic kidney 
disease patients 
10 hemodialysis 
patients 
Dietary intake of CML did not affect circulating 
levels in these groups of patients.  
Luevano-
Contreras et 
al. (2013) 
34 type 2 DM 
 
Restriction of dAGEs significantly decreased 
TNFα and malondialdehyde levels. 
Semba et 
al. (2014) 
 
24 healthy 
volunteers 
12 high dAGE 
12 low dAGE 
No significant changes in serum and urinary 
CML concentrations from baseline to follow-up 
in the high-AGE diet group. A high- or low- 
dietary AGE had no significant impact on 
inflammatory mediators or peripheral arterial 
tonometry after 6wk intervention. 
Mark et al. 
(2014) 
74 overweight 
women 
37 high dAGE 
37 low dAGE 
The low-AGE diet decreased urinary AGEs, 
fasting insulin concentrations, and 
Homeostasis model assessment of insulin 
resistance, compared with the high-AGE diet. 
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Macias-
Cervantes 
et al. (2015) 
43 overweight 
15 low dAGE and 
exercise 
14 low dAGE  
14 exercise (with 
habitual food 
intake) 
AGE-restricted diet reduces serum. The 
addition of exercise to the restricted diet has 
the same effects but also improves lipid profile. 
 
Barbora de 
Courten et 
al. (2016) 
20 healthy 
volunteers 
A diet that is low in AGEs may reduce the risk 
of type 2 diabetes by increasing insulin 
sensitivity. 
Scheijen et 
al. (2018) 
450 volunteers Higher intake of dAGEs is associated with 
higher levels of AGEs in plasma and urine. 
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Appendix 10 - Statistical tests 
 
 
Appendix 10.1 – Median and IQR for non-parametric data in Chapter 4 
 
Table 10.4.2: Median, IQR and Spearman’s correlations between plasma CML and dAGEs 
calculated with each database. Interquartile range: IQR. *p < 0.05  
 
 
Table 10.4.4: Medians, IQR and Spearman’s correlations between dAGEs for each database 
measured with FFQ1 (n = 70). Interquartile range: IQR. *p < 0.05. **p < 0.01.  
 
 
 
 
 
Median IQR Spearman’s correlation coefficients (R values) 
 Uribarri 
(average 
CML 
kU/day) 
Hull CML 
(average 
mg 
CML/day
) 
ScheijenCM
L 
(average mg 
CML/day) 
ScheijenCE
L 
(average 
mg 
CEL/day) 
ScheijenMG-
H1 
(average mg 
MG-H1/day) 
Plasma 
CML  
(ng/ml) 
91.40 77.42, 
124.05 
-0.256 
p = 
0.038* 
0.079 
p = 0.526 
0.080 
p = 0.523 
-0.029 
p = 0.817 
0.068 
p = 0.590 
    Spearman’s correlation coefficients (R) 
 
 
Median IQR 1 2 3 4 5 
1. Uribarri  
(average CML kU/day) 
18841.08 13820.49, 
25068.05 
 0.274* 0.337** 0.525** 0.176 
2. Hull CML  
(average mg CML/day) 
5.34 4.45, 5.34   0.745** 0.705** 0.771** 
3. Scheijen-CML  
(average mg CML/day) 
3.60 2.91, 4.93    0.740** 0.731** 
4. Scheijen-CEL   
(average mg CEL/day) 
2.99 2.19, 3.67     0.764** 
5. Scheijen-MGH1   
(average mg MG-
H1/day) 
29.43 22.28, 
36.73 
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Appendix 10.2 – Median and IQR for non-parametric data in Chapter 5 
 
Table 10.5.1: Median, IQR and Spearman’s correlations between SAF (AU) and dAGEs 
calculated with each database. *p<0.05  
 
 
 
Table 10.5.2: Median, IQR and Spearman’s correlations between SAF (AU) and each oxidative 
stress biomarker: ascorbate (vitamin C), malondialdehyde (MDA) and alpha tocopherol (form of 
vitamin E). *p<0.05  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median IQR Spearman’s correlation coefficients (R values) 
 Uribarri 
(averag
e CML 
kU/day) 
Hull 
CML 
(averag
e mg 
CML/da
y) 
Scheijen 
CML 
(average 
mg 
CML/day) 
Scheijen 
CEL 
(average 
mg 
CEL/day) 
Scheijen 
MG-H1 
(average mg 
MG-H1/day) 
SAF  2.10 2.00, 
2.47 
0.075  
p = 
0.545 
0.210 
p = 
0.085 
0.190 
p = 0.120 
0.175 
p = 0.153 
0.319 
p = 0.008* 
 
 
Median IQR Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
Ascorbate (µM) 44.89 36.83, 62.65 -0.207,  p = 0.093 
MDA (µM) 0.59 0.48, 0.72 0.072,  p = 0.570 
Alpha tocopherol 
(µM) 
40.41 31.81, 50.37 0.252,  p = 0.044*  
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Table 10.5.3: Median, IQR and Spearman’s correlations between all parameters which correlated 
with SAF. 
 
 
 
 
 
 
Appendix 10.3 – Median and IQR for non-parametric data in Chapter 7 
Table 10.7.1: Artery dynamic parameters, median, IQR and spearman’s correlation with SAF. AU: 
arbitrary units, BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline 
corrected flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: 
minimum percentage constriction, CT: constriction time.  
 
 
Variable 
 
 
Median 
 
IQR 
 
Spearman’s correlation coefficients 
R values P values 95% bootstrap 
confidence 
interval 
Age (years) 57.00 53.00, 
67.50 
0.435 p<0.001 0.205 to 0.620 
Dietary AGE MG-H1  
(average mg MG-
H1/day) 
29.43 22.28, 
36.55 
0.333 0.007 0.105 to 0.550 
Alpha tocopherol  
(µM) 
40.41 31.81, 
50.37 
0.252 0.044 0.034 to 0.461 
Artery  
 
Median IQR Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
BDF 2.11 1.49, 3.02  0.007,  p = 0.956 
DA 3.51 2.21, 5.71 0.144,  p = 0.272 
BFR 1.30 0.49, 3.20 0.165,  p = 0.207  
MD % 2.23 1.26, 3.76 0.131,  p = 0.319 
RT (secs) 15.00 12.42, 19.00 -0.033,  p = 0.803 
MC % 1.31 0.63, 2.01 0.123,  p = 0.349 
CT (secs) 22.00 17.25, 28.50 0.215,  p = 0.098 
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Table 10.7.2: Vein dynamic parameters, median, IQR and spearman’s correlation with SAF. AU: 
arbitrary units, BDF: baseline diameter fluctuation, DA: dilation amplitude, BFR: baseline 
corrected flicker response, MD%: maximum percentage dilation, RT: reaction time, MC%: 
minimum percentage constriction, CT: constriction time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vein 
 
Median IQR Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
BDF 1.82 1.51, 3.04 -0.140,  p = 0.287 
DA 4.82 3.44, 7.36 -0.075,  p = 0.570 
BFR 2.82 1.94, 4.17 0.008,  p = 0.950  
MD % 3.98 2.95, 6.16 -0.098,  p = 0.458 
RT (secs) 18.00 16.75, 25.83 -0.004,  p = 0.978 
MC % 0.71 0.31, 1.45 0.015,  p = 0.912 
CT (secs) 33.25 25.83, 37.25 -0.147,  p = 0.262 
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Table 10.7.3: Corneal viscoelastic parameters, median, IQR and spearman’s correlation with 
SAF. AU: arbitrary units, Time A1: first applanation time, Time A2: second applanation time, 
Velocity A1: velocity of corneal surface movement at the first applanation, Velocity A2: velocity of 
corneal surface movement at second applanation, Deformation amp. A1: deformation amplitude 
at first applanation, Deformation amp. A2: deformation amplitude at second applanation, Highest 
deformation amp: highest deformation amplitude.  
 
 
 
 
 
 
 
 
Corneal 
parameters 
 
Mean Standard 
deviation 
Spearman’s correlation 
coefficients (R values) 
 SAF (AU) 
Time A1 (ms) 7.27 7.09, 7.59 0.140,  p = 0.394 
Time A2 (ms) 21.99 21.66, 22.26 -0.105,  p = 0.526 
Velocity A1 (m/s) 0.15 0.14, 0.17 -0.227,  p = 0.165  
Velocity A2 (m/s) -0.27 -0.29, -0.24 0.290,  p = 0.074 
Deformation amp. 
A1 (mm) 
0.13 0.13, 0.14 0.033,  p = 0.840 
Deformation amp. 
A2 (mm) 
0.44 0.41, 0.49 0.113,  p = 0.492 
Highest 
deformation amp. 
(mm) 
1.09 0.99, 1.15 -0.265,  p = 0.103 
Highest 
concavity time 
(ms) 
16.40 16.17, 16.86 0.012,  p = 0.942 
374 
 
 
 Year 1 Year 2 Year 3 
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 
Introduction to 
study and 
training (DVA, 
SAF, Bloods) 
                  
Literature  
Review 
                  
Protocol/Ethics 
development 
                  
Recruitment 
 
                  
Data collection 
 
                  
Blood analysis     
 
              
Data analysis            
 
       
Thesis writing 
 
                  
 
 
 
- Introduction to end note seminar 
- Introduction to ethical approval seminar 
- Library services seminar 
- ITL – Introduction to learning  
- Good clinical practice (GCP) training 
- Research writing session 
- Human tissue training session 
- Phlebotomy training (Derriford hospital) 
- Basic laboratory training  
- Pipette training 
- Preparing for the transfer seminar 
- Lab analysis training 
- Postgraduate statistics course – multiple seminar sessions 
- Post-graduate writing workshop 
- Preparing for the viva seminar 
 
 
Appendix 11 – Gantt chart 
Appendix 12 – Research training activities 
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